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Abstract 
 
Treatment with the taxanes, docetaxel and paclitaxel, can result in the emergence of 
multi-drug resistance (MDR) mediated by P-gp (MDR-1, ABCB1), which is an effective 
cellular efflux pump for both agents. This thesis was undertaken to examine the 
contribution of drug transport mechanisms to chemotherapeutic drug resistance, 
focussing on docetaxel. Sensitive and resistant NSCLC cell lines were used to model 
docetaxel transport and examine the ability of three tyrosine kinase inhibitors (TKIs), 
gefitinib, erlotinib and lapatinib, to circumvent resistance to docetaxel, and other 
chemotherapeutic agents, arising from P-gp over-expression.  
A HPLC – based method was initially employed to quantify docetaxel levels in cells. The 
very high taxane levels required rendered this method unreliable for prediction of 
pharmacologically relevant effects. A more sensitive radiolabel-based technique was then 
developed to examine lower, pharmacologically achievable concentrations (100-500 nM) 
of docetaxel. The radiolabel-based assay was then applied to examining docetaxel uptake 
in the DLKP and A549 NSCLC cell lines and docetaxel accumulation and efflux in the P-
gp over-expressing A549-Taxol and DLKP-A cell lines.  
Passive diffusion is believed to be the mechanism of uptake for docetaxel in most cancer 
cells due to its lipophilic characteristics. However, evidence was found for an energy-
dependent docetaxel uptake mechanism in DLKP and a non-P-gp energy-dependent 
efflux mechanism in A549. The contribution of the OATP (organic anion transporting 
polypeptides) family of transporters to docetaxel uptake in A549 could not be discounted. 
The existence of transporter-mediated docetaxel uptake in NSCLC cells represents an 
important new factor in determining the sensitivity of cancer cells to docetaxel. 
Studies on the TKIs revealed that lapatinib interacted with the ATPase function of P-gp 
in a manner distinct from gefitinib and erlotinib at clinically achievable concentrations. 
Lapatinib is most likely a slowly-transported substrate with high affinity for P-gp while 
erlotinib and gefitinib are most likely transported P-gp substrates. As a result of this, P-gp 
over-expression may contribute to erlotinib and gefitinib, but not lapatinib, resistance at 
pharmacological concentrations. Results suggest the three TKIs, particularly lapatinib, 
have potential clinical utility as MDR modulators capable of augmenting the cytotoxic 
activity of P-gp substrate chemotherapeutic agents against P-gp positive tumour cells. In 
addition, each TKI altered EGFR and P-gp protein expression levels. 
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1.1 Lung cancer 
 
Lung cancer is the most frequent occurring malignancy in western countries with an 
incidence of 60 in 100,000 [1]. Smoking is responsible for 80 to 90% of lung cancers. 
Small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) are the two 
major types of lung cancer. Classification is made based on histological features of 
the tumour cells. In Europe, an overview of trends since 1960 has shown there has 
been a levelling off or general fall of lung cancer mortality in men in the last decade 
excluding Portugal and Romania, while there has been a general increase in cancer 
mortality in women except in Ireland, the U.K., Denmark and Iceland. The Russian 
Federation is the only country to register an overall decrease in female lung cancer 
mortality [2].  
 
1.1.1 SCLC 
 
Small cell lung cancer is an aggressive disease with a median survival of 3 months if 
left untreated. The proportion of lung cancers that are of the small cell type has 
decreased in the United States to 13.8% from 17.4% between 1986 and 1998[3]. 
Tumour extent is described as limited-stage disease (LD) or extensive stage disease 
(ED) with both stages responding to treatment. LD median survival is 14-20 months 
with a 20-40% 2-year survival and a 10% 5-year survival rate. ED median survival is 
7-10 months and 2-year survival is rare [2]. SCLC has a significant response to 
chemotherapeutic agents and radiation. 80-90% of LD patients respond to 
combination chemotherapy with or without radiation [4]. 
 
1.1.2 NSCLC 
 
Non-small cell lung cancer accounts for approximately 80% of lung cancers. NSCLC 
is categorised according to the TNM system (T- Primary tumour size and location, N- 
regional lymph node invasion status, M- presence of metastases). Depending on its 
TNM score, the lung cancer is then categorised into stages, Stage I (A or B), Stage II 
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(A or B), Stage III (A or B) or Stage IV (Table 1) [5].   Patients presenting with early 
stage, localised disease are considered curatively resectable even though the five year 
survival rate is 61% for stage IA and 24% for stage IB [1]. The majority of patients 
therefore suffer a relapse. Unfortunately, 65% present with inoperable stage IIIB or 
stage IV disease, and the average age is 68 years old, presenting greater problems 
when trying to minimise treatment related symptoms [6].  
The disease stage of NSCLC is of utmost importance in the consideration of 
treatment, with surgically resectable, locally advanced and metastatic tumours usually 
considered separately [7].  
 
1.1.3 SCLC treatment 
 
The standard combination therapies for SCLC treatment have been 
cyclophosphamide- doxorubicin vincristine (CAV), cyclophosphamide, doxorubicin 
and etoposide (CDE), ifosphamide, carboplatin and etoposide with or without 
vincristine (ICE±V) and, the increasingly used, and favoured platinum 
(cisplatin/carboplatin) and etoposide (PE) combinations [2]. Cisplatin-irinotecan is a 
promising new combination in SCLC treatment [8]. 
Paclitaxel has been used in a number of trials. A paclitaxel-etoposide-carboplatin 
(TEC) regimen tested against carboplatin-etoposide-vincristine (CEV) in LD and ED-
SCLC patients resulted in a one month increase in median survival for LD-SCLC 
patients only [9]. Two other trials testing paclitaxel-etoposide-cisplatin (TEP) against 
platinum (cis or carboplatin)-etoposide (PE) and failed to show enough advantages of 
this paclitaxel regimen over the existing PE standard to favour its adoption [10]. 
 
1.1.4 NSCLC treatment 
 
The platinum drugs, particularly cisplatin, are a mainstay of the chemotherapeutic 
regimen for NSCLC. Surgery is the best option for (medically operable) early stage 
NSCLC. The high incidence of recurrence following resection may be attributable to 
undetectable metastases at diagnosis. This theory has led to numerous trials involving 
adjuvant chemotherapy and radiotherapy treatments. The efficacy of postoperative 
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radiotherapy (PORT) in early stage disease is controversial but may still have 
potential with improved delivery systems [11]. Combined sequential 
chemoradiotherapy (CTRT) is also being looked at as an adjuvant therapy, a neo-
adjuvant therapy (RT following CT and surgery) and in inoperable advanced Stage III 
disease [12]. Stage IIIA is generally considered to be the highest stage for which 
surgery is employed. Unresectable Stage III cancer has traditionally been treated with 
radiation alone but recently the bi-modal approach of CTRT has been adopted [13]. 
Surgical resection and adjuvant platinum-containing chemotherapy has become the 
optimal treatment strategy for early stage NSCLC [14]. Paclitaxel and carboplatin,  
and vinorelbine (vinca alkaloid) and cisplatin are two combinations that have shown 
much promise in this setting [15].  There are a myriad of used, tested and proposed 
regimens for treating advanced NSCLC. They differ in CT agents combined 
(although there is constant platinum drug involvement) and use of radiotherapy. 
Timing options include induction chemotherapy (CT before surgery), adjuvant 
therapies and sequential or concurrent therapies (adjuvant or neo-adjuvant). 
Recent and ongoing clinical trials involving the taxanes are creating a significant role 
for this class of drug in NSCLC treatment. Chu et al., give a comprehensive overview 
of the taxanes as first line therapy in NSCLC, including a comprehensive review of 
the major clinical trials and practice guidelines [16].  
 
Recommendations include:  
- Paclitaxel and docetaxel combined with cisplatin as one of a number of first 
line chemotherapy treatment options in NSCLC patients with good 
performance status 
- Carboplatin can be combined with a taxane if cisplatin is not an option. 
- A taxane-gemcitabine may be considered in patients with contraindication to 
both cisplatin and carboplatin. 
- Single agent taxane treatment may be considered if combination 
chemotherapy is deemed inappropriate. 
 
In a study of 52 patients with poor prognosis Stage IIIA N2 NSCLC, the authors 
concluded that the combination of paclitaxel, carboplatin and gemcitabine was a 
safe and active regimen [17]. 
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1.1.5 Chemotherapeutic agents 
 
A wide variety of chemotherapeutic agents are used in the treatment of malignancies. 
They vary in their cellular targets, mechanism of action and types of cancer they are 
used to treat. The major compounds are classified in Table 1.1.5.1, along with some 
of the major-ABC resistance proteins they are associated with. The key for the 
diseases that the chemotherapeutic agents are used to treat listed in Table 1.1.5 is as 
follows: 
 
ALL/CLL- Acute/Chronic lymphocytic leukaemia 
AGL- acute granulocytic carcinoma  
BC- breast cancer 
BLC- bladder cancer  
CC- colon cancer 
CVC- cervical cancer 
GC- genitourinary cancer 
HD-Hodgkin’s disease  
nHD- non Hodgkin’s disease 
HN- head and neck cancer 
KS- Kaposi’s sarcoma  
LC- lung cancer 
MM- multiple myeloma 
NB- neuroblastoma 
OC- ovarian cancer 
OS- osteogenic sarcoma 
PC- pancreatic cancer 
SC- stomach cancer 
TC- testicular cancer 
THC- thyroid cancer. 
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Table 1.1.5.1 Neoplasms are carcinomas unless otherwise stated. Compiled from [18], [19], [20], [21], [22], [23], [24], [25], [26], [27], [28] and 
[29]. 
Class Type of agent Name Mechanism of action Disease Associated MDR 
transporter(s) 
Cyclophosphamide
Ifosfamide 
DNA cross linkage ALL, CLL, HD, nHD, MM, 
BC, OC, LC, NB, CVC, TC 
MRP-2, MRP-4 Alkylating 
Agents 
Nitrogen Mustard 
Melphalan DNA cross linkage MM, BC, OC  
Folic Acid 
Analogues 
Methotrexate Folate synthesis 
inhibition 
ALL, BC, HN, LC, OS MRP-3, MRP-4, MRP-5 
Fluorouracil (5-
Fu) 
DNA destabilisation BC, CC, SC, PC, OC, HN MRP-5, MRP-8 
Antimetabolites 
Pyrimidine 
Analogues 
Gemcitabine DNA destabilisation PC, OC MRP-5 
Vinblastine Microtubulintargetted 
antimitotic 
HD, nHD, BC, TC P-gp, MRP-1, MRP-3 Vinca Alkaloids 
Vincristine Microtubin-targetted 
antimitotic 
ALL, NB, HD, nHD, LC P-gp, MRP-1, MRP-2, 
MRP-3 
Taxanes Docetaxel 
Paclitaxel 
Microtubule-targetted 
antimitotics 
OC, BC, LC, HN P-gp, MRP-2, MRP-7 
Epipodophyllotoxins Etoposide 
Teniposide 
Topoisomerase II 
inhibitors 
TC, LC, BC, HD, nHD, 
AGL, KS 
P-gp, BCRP, MRP-1, 
MRP-2, MRP-3 
Camptothecins Topotecan 
Irinotecan 
Topoisomerase I 
inhibitors 
OC, LC, CC BCRP, P-gp (T), MRP-1 
(I),  
Daunorubicin Topoisomerase II 
inhibitor 
AGL, ALL P-gp, BCRP, MRP-1 
Doxorubicin Topoisomerase II 
inhibitor 
OS, HD, nHD, AL, BC, GC, 
THC, LC, SC, NB 
P-gp, BCRP, MRP-1 
Natural Products 
Antibiotics 
Epirubicin Topoisomerase II 
inhibitor 
BC, OC, SC, LC P-gp, BCRP, MRP-1 
Platinum Complexes Carboplatin 
Cisplatin 
DNA cross linkage TC, OC, BLC, HN, LC, 
THC, CVC, NB, OS 
MRP-2 (Cis), ATP7A, 
ATP7B 
Miscellaneous 
Anthracenedione Mitoxantrone Topoisomerase II 
inhibitor 
AGL, BC, PC P-gp, BCRP 
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1.2 The Taxanes 
 
Docetaxel and paclitaxel are the most prominent members of the taxane family. 
Paclitaxel was originally isolated from the bark of the Pacific Yew (Taxus brevifolia) 
while docetaxel is derived from the European Yew (Taxus baccata). Both compounds 
target the microtubules, components of the cell cytoskeleton and essential to the 
production of the mitotic spindle. Treatment with taxanes results in stabilisation of the 
microtubules leading to cell cycle arrest in the G2/M phase [30].  
Both paclitaxel and docetaxel are widely used in the treatment of ovarian and breast 
carcinomas and are being adopted as standard therapies for lung, digestive and 
prostate cancers. Other solid tumours that these drugs have been effective in treating 
include carcinomas of the head and neck and bladder.  
Docetaxel and paclitaxel are similar in structure (Figure 1.2.1), but do have noticeable 
pharmacological differences. Gligorov and Lotz [31], summarise the major 
differences.  
 
Docetaxel: 
 
- Exhibits greater uptake into, and slower efflux from, tumour cells (P388, 
murine leukemia cell line). 
- Exhibits greater affinity to the beta-tubulin subunit of microtubules. 
- Targets centrosome organisation. 
- Acts on cells in the S/G2/M stages of the cell cycle. 
- Demonstrates linear pharmacokinetics and no cardiotoxic effects in 
combination with anthracyclines. 
 
Paclitaxel: 
 
- Targets the mitotic spindle. 
- Acts on cells in the G2/M phase of the cell cycle. 
- Demonstrates non-linear pharmacokinetics and enhanced cardiotoxicity, 
especially in combination with the anthracyclines. 
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The slower efflux of docetaxel could be associated with its greater affinity for beta-
tubulin. This affinity also leads to higher intra-cellular concentrations contributing to 
docetaxels greater cytotoxicity. There is no definitive evidence explaining the greater 
uptake of docetaxel in P388 murine leukaemia cells. The ability of the taxanes to 
arrest cells in the G2/M phase is exploited clinically. This is the cell cycle stage that is 
most sensitive to radiation. Docetaxel has been used as a radiosensitiser in the clinic 
and  incidentally, the same study also reported anti-tumour immune stimulatory 
activity of docetaxel, another positive aspect of the use of this drug [32]. 
Both taxanes cause Bcl-2 phosphorylation leading to apoptosis but the concentration 
of docetaxel needed to cause apoptosis through Bcl-2 is 100 times less than paclitaxel 
[33]. Bcl-2 is an anti-apoptotic protein over-expressed in a number of tumours. 
Paclitaxel increases Raf 1, a serine/threonine protein kinase involved in the MAPK 
pathway and Bcl-x, leading to decreased levels of Bcl-2 [34]. 
 
Figure 1.2.1 Docetaxel and paclitaxel structure [30] 
 
 
 
Given the advantages of docetaxel over paclitaxel listed earlier in this section, it 
would be assumed that docetaxel is the more potent anti-cancer drug. A head to head 
study between paclitaxel and docetaxel in metastatic breast cancer did prove that 
docetaxel was superior to paclitaxel in terms of median overall survival (15.4 vs. 12.7 
months), median time to progression (5.7 months v 3.6 months and overall response 
rate (32% vs. 25%) [35]. Although the incidence of treatment-related hematologic and 
nonhematologic toxicities was greater for docetaxel than for paclitaxel, the quality-of-
life scores were not statistically different between treatment groups over time [35].  
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The clinical use of docetaxel is more prevalent in Europe than in the U.S., probably 
related to the geographical location of the development of each drug (docetaxel in 
Europe, paclitaxel in the U.S.) and the earlier approval of paclitaxel in cancer 
treatment.  Pre-clinical studies of paclitaxel in vitro also heavily outway those 
involving docetaxel, also most likely a function of the aforementioned reasons. The 
search for factors, such as uptake mechanisms, that would influence docetaxel 
sensitivity and/or resistance in tumour cells is a major area of study. The existence of 
such factors and would have important implications for the treatment of cancers like 
NSCLC with docetaxel. 
 
1.2.1 Taxane mechanism of action 
 
The taxanes are microtubule-interfering agents. Pellegrini and Budman provide a 
general overview of tubulin dynamics [36]. Tubulin molecules are made up of a 
heterodimer consisting of alpha- and beta-tubulin subunits. The subunits are arranged 
head to tail as are the molecules when they join together to form protofilaments. Each 
microtubule consists of 12 or 13 protofilaments aligned in parallel with the same 
polarity. There are at least 6 alpha- and beta-tubulin isotypes, differing in their 
intracellular localisation.  
Microtubules have a plus (+) end where there tends to be rapid tubulin assembly and a 
minus (-) end with slow assembly or even disassembly. The minus end is often 
anchored at the microtubule-organising centres (MTOCs) with the plus end free in the 
cytoplasm. GTP and magnesium are required for assembly. Microtubules are 
continually in a state of dynamic instability, both ends having the ability to switch 
spontaneously from a growing to a shortening state, dependent on a cycle of GTP 
hydrolysis and exchange. 
Microtubule associated proteins (MAPs) modulate the dynamics at the end of the 
microtubules. Stabilising MAPs include Tau, MAP1, MAP2, MAP4 and XMAP215 
while stathmin, XKCM1, XKIF2 and katanin are regulatory molecules that favour 
disassembly [36]. Some of these proteins are targets for microtubule interfering agents 
and may be potential targets for drugs in sensitive or resistant cancers. MAP4, for 
instance, is phosphorylated by paclitaxel leading to loss of tubulin binding and altered 
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tubulin function [37]. Paclitaxel resistant cells do not generate phosphorylated MAP4 
in response to the drug. 
Concentrations of GTP (promotes assembly) and Ca2+ (inhibits assembly) are other 
factors that influence the degree of tubulin polymerisation [38]. 
Docetaxel and paclitaxel share a mutual binding site on the beta tubulin subunit [39]. 
Docetaxel has a higher affinity for this site and is a more potent tubulin assembly 
promoter and tubulin stabiliser than paclitaxel [40]. The resulting mitotic arrest 
triggers the mitotic spindle checkpoint, that  induces the mitochondrial permeability 
transition, releasing pro-death molecules into the cytosol resulting in caspase-
dependent apoptosis [38]. 
 
As with any other class of drugs, research is ongoing into improving the efficacy of 
the existing members of the taxane family and producing new more efficacious 
analogues.  
New formulations of paclitaxel and docetaxel are under development to improve 
delivery, pharmacokinetic properties and reduce drug resistance. Abraxane is 
paclitaxel formulated as an albumin-bound nanoparticle. This eliminates the cytotoxic 
solubiliser cremophor EL used in Taxol® improving paclitaxel activity [41]. A 
formulation of paclitaxel encapsulated in cationic liposomes, to overcome transport 
associated drug resistance, is now in clinical trials [42]. EGF-conjugated paclitaxel 
has been generated to provide selectivity for EGFR-expressing tumours is still at the 
development stage [42]. Enhancement of docetaxel toxicity towards tumour 
vasculature is being pursued by combination with a monoclonal antibody (3G4). The 
combination was no more harmful than docetaxel alone and has demonstrated a 
superior activity in mice bearing orthotopic MDA-MB-435 human breast tumours 
[43].  
BMS-188797 is a new taxane under development. It differs from paclitaxel at the C4 
side chain only but it is more active in pre-clinical tumour models. It is now 
undergoing clinical development [44]. TL-130 is another taxane analogue that was 
reported to have activity against P-gp-over-expressing cell lines and those containing 
beta-tubulin mutations [45]. 
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1.2.2 Taxane metabolism and pharmacokinetics 
 
The taxanes undergo hepatic oxidative metabolism by the cytochrome P450 family. 
The majority of the metabolites are excreted in the bile with only 5% excreted renally. 
Docetaxel is metabolised by the CYP3A4 and CYP3A5 isoenzymes to 
hydroxydocetaxel and three other minor metabolites. All metabolites are less active 
than docetaxel [46]. CYP2C8 is the main enzyme involved in metabolising paclitaxel, 
producing 6-alpha-hydroxy-paclitaxel. CYP2C8 also oxidises troglitazone and 
arachidonic acid [47]. Production of the minor secondary metabolite 3-para-
hydroxyphenyl-paclitaxel is by CYP3A4. Both species can be metabolised further to 
the dihydroxyl product 6-alpha-hydroxyl-3-para-hydroxyphenyl paclitaxel. The 
paclitaxel metabolites are less potent than the parent compound, in the case of 6-alpha 
hydroxyl paclitaxel 30 times less so [46].  
 
The taxanes are insoluble in aqueous solution. Paclitaxel is formulated in 50% alcohol 
and 50% cremophor EL while docetaxel is formulated in polysorbate 80 to improve 
solubility. The drugs are diluted in saline or 5% dextrose-saline for administration. 
 
Docetaxel and paclitaxel are highly bound by plasma proteins (95% paclitaxel, > 95% 
docetaxel in the bloodstream). The pharmacokinetics of paclitaxel are more 
complicated than that of docetaxel. It’s non-linear disposition and saturable 
distribution means that dose changes can lead to disproportionate toxicity duration 
and severity [30]. This leads to difficulties defining the optimal delivery schedule for 
monotherapy and combinations. 
Cremophor EL may contribute to the non-linear kinetics [48]. In contrast, the linear 
kinetics of docetaxel makes for easier dose optimisation. Toxicity is proportionate to 
the dose changes and its clearance rate is relatively constant [30]. 
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1.2.3 Taxane resistance 
 
Inherent or acquired, taxane resistance has major clinical consequences. Extensive 
research has been undertaken in the area and many molecules (and pathways) have 
been implicated but much of our knowledge remains incomplete. The main 
contributors to taxane resistance are: 
 
1) Changes in regulation of the apoptosis related Bcl-2 family.  
2) Tubulin mutations. 
3) Differential expression of tubulin isotypes. 
4) Changes in other cellular pathways. 
5) Increased drug efflux by membrane transporters. 
 
1.2.3.1 Apoptosis and taxane resistance 
 
One of the major characteristics of all resistant cells is their ability to avoid apoptosis. 
A number of apoptosis-related proteins have been examined as potential mediators of 
taxane resistance. There are two main pathways to apoptosis, extrinsic and 
mitochondrial. Figure 1.2.3.1.1 gives a basic graphical representation of the two 
pathways. 
Figure 1.2.3.1.1 Graphical representation of apoptosis pathways, taken from [49]. 
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Death ligands, such as Apo-2L/TRAIL, trigger the extrinsic pathway by binding the 
cell membrane death receptors DR4 and DR5. This results in the recruitment and 
assembly of FADD and caspase 8 into a death inducing signalling complex (DISC). 
Caspase 8 is processed and activated and induces downstream caspases and apoptosis 
directly or by recruitment of mitochondria related factors[38]. Active caspase 8 
cleaves p22BID producing the pro-apoptotic p15 tBID that targets the mitochondria, 
binding proapoptotic Bax or Bak to trigger mitochondrial loss of prodeath molecules, 
also known as the mitochondrial permeability transition [38]. 
Mitotic arrest caused by the taxanes also leads to mitochondrial permeability 
transition. During this process, the mitochondria secrete pro-death molecules like 
cytochrome (cyt) c, SMAC, Omi/HtrA2, apoptosis-inducing factor (AIF) and 
endonuclease G. The released cyt c and dATP bind to Apaf-1 causing its 
multimerisation. This allows the recruitment of procaspase 9 and procaspase 3 and the 
processing and activation of caspases 9 and 3 [38]. The Apaf-1/Pro-caspase 9/Pro-
caspase 3 complex is termed the “apoptosome”. 
Loss of Apaf-1 expression in Apaf-1 -/- mouse embryonic fibroblasts has been shown 
to confer resistance to paclitaxel- (and etoposide-) induced resistance while ectopic 
over-expression of Apaf-1 sensitised HL-60 cells to paclitaxel [50].  
 
Bcl-2 family 
 
Many other apoptosis-related proteins have been shown to have a part to play in 
taxane resistance. The Bcl-2 family has become a much studied therapeutic target in 
recent times. The anti-apoptotic Bcl-2 is over-expressed in 70% of breast cancers, 
90% of colo-rectal adenocarcinomas and in many other cancers [51]. In the clinic, 
Bcl-2 expression has correlated with improved response to docetaxel and improved 
survival [52], [53]. In the oestrogen receptor-expressing breast cancer cell line, MCF-
7, Bcl-2 levels were increased after exposure to oestrogen, conferring resistance to 
paclitaxel-induced apoptosis [54]. An increase of the Bcl-2 to pro-apoptotic Bax ratio 
was found but there was no increase in the anti-apoptotic Bcl-xL or levels of the drug 
transport pump P-gp (P-gp, Section 1.3.2.1). Increased Bcl-2 and Bcl-xL levels were 
also found in paclitaxel-and vincristine- selected HL-60 leukemia cells in addition to 
P-gp [55].  
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High expression levels of the pro-apoptotic protein Bim, correlated with susceptibility 
to paclitaxel-induced apoptosis in a panel of NSCLC cell lines [56]. SiRNA 
knockdown of Bim has conferred taxane resistance to breast cancer cell lines [38]. 
This would suggest that down-regulation of Bim could be a factor in NSCLC taxane 
resistance.  
 
Inhibitors of apoptosis (IAP) family 
 
The inhibitors of apoptosis (IAP) family include XIAP, cIAP1, cIAP2 and survivin. 
These proteins inhibit caspase processing and proteolytic activity [38].  
Paclitaxel induces apoptosis through down-regulation of XIAP (X-linked inhibitor of 
apoptosis) and Bcl-2 phosphorylation in NSCLC H460 cells [57]. Inhibition of 
MEK1/2 potentiates this effect. Docetaxel resistance in epithelial ovarian cancer cells 
is XIAP-dependent and reversible by phenoxodiol [58]. XIAP is the most potent 
member of the IAP family considering its ability to suppress apoptosis and inhibit 
caspases.  
Survivin is over-expressed in most human cancers but is not expressed in normal, 
terminally differentiated adult tissues [59]. Over-expression of survivin inhibits 
apoptosis and increased survivin levels have been linked to paclitaxel resistance in 
ovarian cancer cells in vitro and in the clinic [60]. Flavopiridol inhibits multiple 
cyclin dependent kinases including cyclin B-cdk1. This prevents the phosphorylation 
and accumulation of survivin, enhancing apoptosis. Flavopiridol is in clinical trials 
combined with the taxanes for treatment of late stage NSCLC [61]. Survivin is of 
interest in taxane resistance as there is a pronounced upregulation in expression at the 
G2/M transition of the cell cycle and it forms complexes with centromeres [62]. 
 
p53 
 
p53 is a tumour suppressor protein that acts as a major defence against cancer but has 
been found to be mutated in 50% of all human cancers [63]. Patients with p53 mutant 
cancers respond to paclitaxel treatment as well as patients with wild type p53 in 
NSCLC [64]. Complete loss of p53 function  has lead to paclitaxel sensitisation in 
fibroblasts and cisplatin-resistant and -sensitive ovarian cancer cell lines [64], [65]. A 
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number of indirect explanations have been put forward. Cells with non-functional or 
mutated p53 no longer have the G1 checkpoint and accumulate in the G2/M phase, a 
target of mitotic arrest by the taxanes. p21WAF1/CIP1 which facilitates exit from mitotic 
arrest is up-regulated by p53. Cells left in mitotic arrest undergo apoptosis. 
Microtubule associated protein 4 (MAP4), essential for microtubule dynamics is 
down-regulated by activation of wild-type p53.  
MAP4 is down-regulated by activation of wild type p53 [66]. In the absence of 
functional p53, high levels of MAP4 stabilise microtubules, sensitising cells to 
paclitaxel. In paclitaxel-resistant A549 cancer cells (found to contain an alpha-tubulin 
mutation), the stabilising function of MAP4 is inhibited by phosphorylation while the 
levels of active non-phosphorylated stathmin are increased [67].  
 
1.2.3.2 Tubulin mutations 
 
Mutations in beta-tubulin resulting in resistance to paclitaxel and decreased 
microtubule assembly have been described in paclitaxel resistant ovarian cell lines 
[68]. These mutations cause resistance through altering microtubule dynamics, 
binding of MAP and motor proteins, rather than through inactivation of the taxane 
binding site. Beta-tubulin mutations have correlated with poor paclitaxel response and 
prognosis in stage III and IV NSCLC patients [69]. 
An increase in microtubule dynamics has been shown to confer paclitaxel resistance 
to A549 cells selected in paclitaxel. Microtubule dynamics and instability increased 
with withdrawal of low levels of paclitaxel, blocking A549 cells at the 
metaphase/anaphase transition [70]. 
Post-translational modifications to the C-terminal of alpha- and beta- tubulins can also 
affect binding of structural and motor MAPs including tau, MAP2 and kinesin. The 
ability of these proteins to interact with the microtubule skeleton in vitro is regulated 
by the levels of polyglutamylation of the alpha- and beta-tubulins [71]. 
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1.2.3.3 Tubulin isotype expression 
 
Alterations to beta-tubulin isotypes have been found in docetaxel resistant oestrogen-
receptor-positive MCF-7 and oestrogen-receptor negative MDA-MB-231 breast 
cancer cell lines [72]. The MCF-7 docetaxel-resistant cell line exhibited an increase in 
protein expression of class I, II, II and IV beta-tubulins but there was a different 
pattern in the MDA-MB-231 docetaxel resistant cells. Only class IV beta tubulin 
protein levels were increased with class I, II, and III isotype expressions decreasing 
[72]. Once the IVa and IVb isotypes could be distinguished using RT-PCR, 
experiments revealed that it was class IVb beta-tubulin not class IVa beta-tubulin, that 
increased significantly in the docetaxel resistant cells [72]. 
 
Paclitaxel-resistant A549 cells showed mRNA increases in beta-tubulin isotypes III 
and IVa while paclitaxel-resistant ovarian tumour samples showed mRNA increases 
in isotypes I, III, and IVa [73]. Types III and IVa were barely detectable at the mRNA 
level in the parent A549 cell lines. A 40-50% downregulation of class III beta tubulin 
in the paclitaxel resistant A549-T24 cell line was achieved by antisense 
oligonucleotide treatment and this was associated with a 39% increase in sensitivity to 
paclitaxel [74]. Two other paclitaxel-selected cell lines, NCIH460 and H69/Txl 
showed protein increases in alpha-tubulin and actetylated alpha-tubulin respectively 
[71]. High expression of class III tubulin has been associated with poor prognosis in 
NSCLC patients receiving a taxane-based therapy [75]. 
 
1.2.3.4 Cell pathways associated with taxane resistance 
 
A number of cell signalling pathway factors continue to emerge in relation to taxane 
action and resistance. 
The MAPKs are a family of serine-threonine kinases activated by diverse stimuli. The 
three major types are ERK1/2 (extracellular signal-regulated kinases 1/2), the c-JNKs 
and the p38 kinase [38]. Paclitaxel induces ERK1/2 activities and the downstream 
transcription factor ELK1. This shows cytotoxic benefit when paclitaxel is combined 
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with a MAPK kinase inhibitor, especially in tumour cells expressing high levels of 
Erk1/2 [76]. 
JNK is activated by paclitaxel in cancer cells through the activation of Ras and/or 
ASK1 and its involvement in Bcl-2 phosphorylation has been observed [77].  
Inhibition of the transcription factor NFkappaB (by parthenolide) [78] and the heat 
shock protein, Hsp-90, has been found to sensitise breast cancer cells to paclitaxel 
[79]. The inhibition of Hsp-90 by LAQ824 also lead to down-regulation of c-Raf, Akt 
and Her-2. NF-kappaB has been shown to activate MDR1, a well established taxane 
membrane transporter [80] and regulates expression of the taxane resistance 
associated proteins, MMP9, Survivin, XIAP, Bcl-2 and COX-2 among others [81]. 
Constitutively active PI3K/Akt pathway signalling is described in a number of 
malignancies and has been linked to the multi-drug resistant phenotype [82]. 
 
1.2.3.5 Drug efflux by membrane transporters 
 
The reduction of intracellular taxane concentrations by membrane transporters is 
another source of taxane resistance. Three members of the ATP-binding cassette 
protein (ABC) superfamily of transporters have been implicated in taxane transport 
and resistance: P-gp (MDR-1, ABCB1), MRP-2 (ABCC2) and MRP-7 (ABCC10). 
The multi-drug resistance phenomenon and the aforementioned proteins are explored 
in greater detail in Section 1.3.2. 
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1.3 Multi-drug resistance 
 
Clinical drug resistance is a major obstacle in the treatment of all types of cancer. It 
may be intrinsic, present from first diagnosis and unresponsive to first line 
chemotherapy, or it may be acquired. Acquired resistance often arises in recurrence of 
tumours that responded well initially but then display resistance to a broad range of 
structurally and functionally diverse agents as well as to the drugs they were 
originally exposed to.  
The causes of drug resistance can be divided into two groups, inadequate drug 
exposure and changes in the cancer cells themselves. 
Tumour exposure to chemotherapeutic agents is dependent on a number of factors, 
mostly physiological. Poor drug bioavailability and distribution, insufficient dosage, 
increased metabolism and excretion and poor tumour vascularisation all contribute to 
resistance development. 
Transformations within the cancer cell itself include increased drug efflux, decreased 
drug influx, altered drug distribution, changes in drug detoxification systems and 
alterations to genes and proteins involved in apoptosis. Other mechanisms include 
increased tolerance to drug-induced damage to DNA, proteins and/or membranes, 
altered drug targets and cell cycle regulation [83],[84] . 
The increased understanding of cellular resistance mechanisms is leading to the 
development of new targeted cancer therapies. 
 
1.3.1 ABC superfamily 
 
The ATP-binding cassette (ABC) family of transporters play a major role in the 
pharmacological behaviour of most drugs in use today. They are the largest family of 
proteins that bind ATP and use the energy created from ATP hydrolysis to drive 
transport of various compounds across the cell membrane [85]. The sequence and 
organisation of a proteins ATP-binding domain (nucleotide-binding domain – NBD) 
determines its ABC classification and it is central to the ATPase function of the 
protein. All ATP-binding proteins contain the characteristic Walker A and Walker B 
motifs in their NBDs. A Walker C motif located upstream of Walker B is the 
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additional signature element of ABC transporters [86]. The functional protein 
generally consists of two cytoplasmic NBDs and two transmembrane domains 
consisting of 6-11 alpha-helices. Substrate specificity is provided by the 
transmembrane domains and the NBDs transfer energy for substrate transport. 
 
ABC transport is usually uni-directional and involves compounds being moved from 
the cytoplasm to outside the cell or from the cytoplasm into intracellular bodies. 
Eukaryotic ABC genes are separated into full transporters, containing two NBDs and 
two transmembrane domains or half transporters that need to form homo- or 
heterodimers to function [85]. 
ABC transporters are highly expressed in intestinal and renal epithelia, hepatocytes, 
the blood-brain barrier, the blood-CSF (Cerebro-Spinal Fluid) barrier and the blood 
placental barrier, limiting drug and xenobiotic penetration into the body and into 
specific cell and tissue compartments [87].  
This has major implications for chemotherapeutic agent pharmacokinetics, with drug 
absorption, distribution, clearance and interactions being influenced strongly by ABC 
protein expression, affecting the efficacy of these drugs. 
 
1.3.2 ABC proteins and MDR 
 
While altered drug pharmacology is problematic, ABC proteins play a more 
malevolent role in drug resistance. 
Cells exposed to toxic compounds can develop resistance to these agents through a 
number of mechanisms including changes in intracellular target proteins, increased 
detoxification and excretion and decreased uptake [19]. 
In some cases a multi-drug resistant (MDR) phenotype develops, where a cell not 
only becomes resistant to the initial drug it was exposed to but also a host of other 
structurally un-related compounds. This is often the case for agents used in cancer 
chemotherapy, including the taxanes. A number of ABC proteins play a role in MDR 
by reducing intracellular drug accumulation and increasing drug efflux. Table 1.1.5 
gives an account of chemotherapeutic agents and the ABC protein associated with 
drug resistance for each.  
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1.3.3 ABC proteins associated with taxane resistance 
 
1.3.3.1 P-gp (ABCB1, MDR-1) 
 
P-gp is a 170kDa membrane glycoprotein that is the most studied and best 
characterised efflux pump in cancer cells.  P-gp was first discovered by Juliano and 
Ling. in 1976 [88]. Chinese Hamster Ovary cells selected for colchicine resistance 
exhibited cross resistance to a number of amphiphilic compounds. The discovery of 
increased levels of a membrane bound glycoprotein, named P-glycoprotein, in cells 
expressing the MDR phenotype followed. The reduced cytotoxicity of these drugs 
was shown to be related to reduced drug accumulation due to enhanced drug efflux 
[89].  
 
P-gp has two pairs of six transmembrane alpha-helical domains and two NBDs [90]. 
The gene maps to chromosome 7 (7q 21.1). P-gp is expressed in many excretory cell 
types such as kidney, liver, intestine and adrenal gland and in cells at the blood-brain 
barrier [91, 92]. 
It is also localised on the apical surface of bronchial and bronchiolar epithelium and 
the plasma membrane of alveolar macrophages where it is suggested it removes 
environmental compounds to the lung lumen [93]. 
 
P-gp has the capacity to transport the major classes of anti-cancer chemotherapeutic 
agents out of tumour cells and to affect the pharmacokinetics of these drugs. A 
summary of the anti-cancer compounds transported by P-gp in their native form is 
provided in Table 1.3.3.1.1. 
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Table 1.3.3.1.1 P-gp substrates transported in native form, taken from [94]. 
Class Drug 
Taxanes Docetaxel 
 Paclitaxel 
Vinca Alkaloids Vinblastine 
 Vincristine 
Anthracyclines Daunorubicin 
 Doxorubicin 
 Epirubicin 
Epipodophyllotoxins Etoposide 
 Teniposide 
Anthracenes Mitoxantrone 
 
 
P-gp Inhibitors 
 
Since its discovery, P-gp has been a prime therapeutic target. First generation P-gp 
inhibitors, such as the calcium channel blocker verapamil and the immunosuppressant 
cyclosporin A, displayed useful MDR reversal activities in vitro and in murine 
models. The concentrations required, however, were high and often accompanied by 
increased cytotoxicity [95]. Second generation inhibitors comprise newer analogues 
of the first generation agents like dexverapamil (less cardiotoxic r-enantiomer of 
verapamil) and PSC 833 (valspodar), the non-immunosuppressive analogue of 
cyclosporin A. These compounds were less cytotoxic and in some cases more potent 
P-gp modulators but still required micromolar concentrations to be effective. PSC 833 
was also an inhibitor of cytochrome P450 3A4, one of the main drug metabolising 
enzymes in the body  [96]. Third generation P-gp modulators have been developed 
based on structure-activity relationships that exhibit effective MDR reversal 
concentrations in the nanomolar range. These include GF120918- Elacridar [97], LY 
335979- Zosuquidar [98], XR9576- Tariquidar [99], XR9051  [100], OC144-093- 
Ontogen (ONT-093) [101] and the bi-specific (P-gp and ABCC1) inhibitors, VX-710- 
Biricodar [102] and VX-853- Timcodar [103]. 
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Combinations of the taxanes and third generation P-gp inhibitors have been 
promising. Elacridar improved the oral absorption of paclitaxel in mice [104] and has 
significantly increased systemic exposure to paclitaxel in humans [105]. The 
combination was well tolerated [105]. A phase I trial has shown zosuquidar to have 
no adverse effects in combination with docetaxel and a Phase II trial in metastatic 
breast cancer has been undertaken [106]. Evidence has come to light identifying the 
tyrosine kinase inhibitors gefitinib and erlotinib as P-gp and BCRP inhibitors [107], 
[108]. This is covered further in Section 1.5.6.  
 
The clinical significance of P-gp expression is well documented. P-gp expression has 
been associated with poor clinical response to neo-adjuvant chemotherapy in locally 
advanced breast cancer and intrinsic P-gp overexpression at diagnosis in acute 
myeloid leukemia has been found to be a strong predictor of survival [109], [110]. 
Using immunohistological detection methods, P-gp was found to be present in 11-
14% of breast cancer tumours pre-treatment and 30 -43 % of tumours post-treatment 
[111]. 
Efforts are under way to find more effective and less cytotoxic MDR modulators. 
 
Cellular Signalling Pathways involved in P-gp regulation 
 
P-gp expression has been studied extensively in normal and malignant tissues. P-gp is 
a stress-induced protein and has been shown to be activated by heat shock,  
irradiation, genotoxic stress, hormones, oncogenes, inflammatory mediators and 
growth factors such as EGF (epidermal growth factor) [112]. The exact pathway 
mechanisms involved have yet to be elucidated but many of the taxane-related 
signalling pathways, such as MAPK, phospholipase c and PI3K, are involved in P-gp 
regulation.  
Activation of phopholipase c (PLC) by a variety of cellular stimuli (doxorubicin 
exposure, EGF, PDGF) regulates the expression of P-gp and the transcriptional 
modulation of P-gp by PLC is modulated by the Raf-MAPK (ERK1/ERK2) pathway 
[113]. JNK, also a member of the MAPK cascade, is activated in response to many 
stress stimuli and are sometimes referred to as Stress Activated Protein Kinases 
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(SAPK) [114]. JNK is activated in carcinoma cells by vinblastine, adriamycin and 
VP-16 resulting in up-regulation of P-gp [115].   
A possible mechanism for the involvement of the third MAPK family member has 
also been suggested. SB203580, a specific inhibitor of the p38-MAPK pathway, 
reversed P-gp-mediated resistance in murine leukemic L1210/VCR cells [116].  The 
authors remarked that the mechanism would have to be further investigated but it 
could be related to P-gp down-regulation.  
 
1.3.3.2  MRP-2 (ABCC2) 
 
MRP-2 (ABCC2, cMOAT) plays an important role in the membrane transport of a 
variety of compounds. It is believed to be one of the major transporters determining 
the pharmacokinetic profile of drugs (involved in hepatic and renal excretion) [117] 
and plays a role in anti-cancer resistance [118]. 
Given its importance in drug detoxification it is no surprise that MRP-2 is 
predominantly expressed at the hepatocyte canalicular membrane [119] and at the 
apical membrane of human gall bladder epitheial cells [120]. In addition, rat studies 
have shown low levels of MRP-2 mRNA in the lung, stomach [121] and peripheral 
blood cells [122]. Loss of MRP-2 activity in humans is responsible for Dubin-Johnson 
syndrome, a rare hereditary disorder resulting in hyperbilirubinemia [123]. 
 
MRP-2 and drug resistance in cancer 
 
MRP-2 mediates the ATP-dependent transport of various organic anions, including 
glucuronate, sulfate and glutathione conjugates of endogenous compounds and 
xenobiotics out of cells. The substrate specificity of MRP-2 (Table 1.3.3.2.1) is very 
similar to MRP-1 (Section 1.3.4.1), and MRP-2 may also require free glutathione to 
allow co-transport of some compounds such as vinblastine [124]. Unlike MRP-1, 
MRP-2 may be capable of transporting glutathione alone without the need for 
simultaneous co-transport or binding of other compounds [125]. 
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MRP-2 expression in sensitive cell lines has conferred resistance to number of 
cytotoxic agents, methotrexate, cisplatin, etoposide, vincristine and doxorubicin 
[124]. Cisplatin-selected (head and neck KB cancer cell line) cancer lines over-
express MRP-2 [126] as do hepatocarcinoma cell lines [127] and anti-sense DNA 
transfected into hepatic cancer cells enhanced drug sensitivity [128]. MRP-2 
expression has been found in a range of cancers in vivo including breast cancer, lung 
cancer and acute myeloid leukemias [129], [130], [131]. In a panel of lung cancer cell 
lines, MRP-2 and MRP-3 expression was almost exclusively found in NSCLC cell 
lines rather than SCLC cell lines but it was MRP-1 and MRP-3 expression that 
correlated with resistance to doxorubicin and VP-16 [130].  
 
Docetaxel and paclitaxel are transported by MRP-2 in MRP-2-transfected MDCKII 
cells and the transport is stimulated by probenecid [132]. This marks MRP-2 as a 
potential taxane resistance mediator and must increase awareness of possible 
drug:drug interactions in trials given its role in detoxification.  
A role for MRP-2 in NSCLC taxane resistance in vivo has not been established as yet. 
 
 
 
Table 1.3.3.2.1 MRP-2 substrates (native or conjugated form), taken from [124]. 
Class Drug 
Anti-Cancer Drugs Taxanes [132] 
 Cisplatin 
 Vinblastine 
 Irinotecan 
 Topotecan 
 Methotrexate 
Endogenous Compounds Bilirubin 
 Leukotrienes C4, D4 and E4 
 Bile Salts 
 Estradiol 
 Glutathione 
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MRP-2 inhibitors 
 
MRP-2 inhibitors are not particularly specific with many of them inhibiting other 
transporters such as MRP-1 [133], P-gp [134] or organic anion-transporting 
polypeptides (OATPs) (rifampicin) (Table 1.3.3.2.2) [135]. Inhibitor interactions are 
made all the more complicated when you consider their drug dependent effects. 
Probenecid is an inhibitor of MRP-2-mediated methotrexate transport but it can also 
stimulate taxane transport [136]. 
 
 
Table 1.3.3.2.2 MRP-2 inhibitors [124] 
 
Inhibitors 
Probenecid 
Rifampicin 
Cyclosporin A 
Glibenclamide 
Flavonoids – luteolin, quercetin 
Indomethacin 
MK571 
Azithromycin 
Sulindac [137] 
 
 
1.3.3.3  MRP-7 (ABCC10) 
 
MRP-7 (ABCC10) is a very recently described addition to the MRP family. It was 
identified by data-base screening for sequences related to human ABC transporters 
originally identified by EST analysis [138]. RT/PCR analysis of a number of human 
tissues revealed the highest transcription levels were in colon, skin and testis [138]. 
Northern blot experiments failed to produce results in the same tissues inferring low 
expression rates. Subsequent expression profiling found a splice variant, MRP7A, 
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expressed in most human tissues with MRP-7 located only in the spleen [139]. 
Expression of the original MRP-7 [138] and two other unique variants were reported 
in the human hepatoblastoma cell line HepG2 and prostate cancer cell line 
CWR22Rv1 [140]. In mice, the highest levels of MRP-7 RNA were found in small 
intestine, kidney, ovary and testis tissues and there was also lung tissue expression 
[141].  
Membrane vesicle studies have demonstrated transport of the endogenous substrates 
17beta-estradiol-(17-beta-D-glucuronide (E217betaG) and leukotriene C4 by MRP-7 
[142]. HEK293 cells ectopically expressing MRP-7 have been used to determine the 
drug resistance profile of the transporter [143]. MRP-7 confers moderate resistance 
(2-3 fold) to the vinca alkaloids (vincristine and vinblastine), the anthracycline 
doxorubicin and paclitaxel. It exhibits its highest activity towards docetaxel (9-13 fold 
increase). This marks MRP-7 as a potential taxane resistance mediator in cancer. 
 
1.3.4 Other ABC proteins involved in MDR 
 
1.3.4.1 MRP-1 (ABCC1) 
 
The multi-drug resistance protein (MRP, ABCC) group is a subset of the ABC family. 
Other members of ABCC subfamily include the cystic fibrosis transmembrane 
conductance regulator (CFTR), the sulfonylurea receptors SUR1 and SUR2 and yeast 
cadmium resistance factor 1 (YCF1) [124]. 
MRP-1 (ABCC1) was the founding member of the MRP family, first isolated in 1992 
[144]. The MRP-1 is a 190 kDa protein consisting of two NBDs and three 
transmembrane domains, a feature it shares with the MRP-2 (ABCC2), MRP-3 
(ABCC3), MRP-6 (ABCC6) and MRP-7 (ABCC10). Other members of the MRP 
family (MRP-4, MRP-5, MRP-8 and MRP-9) contain two NBDs and two 
transmembrane domains similar to P-gp [124].  
MRP1 is ubiquitously expressed throughout the body, although there are certain 
organs such as the lungs, kidneys and testes that express relatively high levels of the 
protein [145].  It is generally localised to the baso-lateral membrane of epithelial cells, 
which results in MRP1 pumping its substrates into the interstitial space rather than 
 27
into an excretory pathway such as the gut or into urine [146], [147].  In the lungs, 
MRP1 has been implicated in the reaction of this organ lungs to toxicological insult, 
being expressed at high levels in alveolar macrophages, bronchial epithelium and in 
cells produced specifically in response to xenobiotics, such as reactive type II 
pneumocytes [145]. High expression in human and murine testes may point to a 
possible role in the maintenance of low oestrogen levels in these organs [145].  
It has since been characterised as a glutathione and glucuronate pump and resistance 
factor for anthracyclines, vinca alkaloids, epipodophyllotoxins and camptothecins 
[148].  
Although it has a broad substrate specificity that overlaps with P-gp, it only shares 
approximately 15% amino acid homology. While P-gp substrates are neutral or mildly 
positive lipophilic compounds,  MRP-1 can transport lipophilic anions and the 
structurally diverse products of phase II cellular detoxification of hydrophobic 
xenobiotics (glutathione, sulphate, glucuronate conjugates) and endogenous 
compounds [148]. This is the major difference between P-gp and MRP-1. 
 
Along with the transport of conjugates, MRP1 can actively co-transport GSH and 
unmodified vincristine and vinblastine [149]. It is hypothesised that daunorubicin and 
etoposide are transported in a similar manner [150], [151]. GSH (glutathione) and 
glucuronate by themselves are not substrates for MRP [152]. The situation where both 
the GSH-conjugated substrate and the free substrate can be transported can also occur 
as in the case of the potent cancer carcinogen, aflatoxin B1 [153]. Manipulation of 
GSH levels can reverse MRP-mediated drug resistance. Depletion of GSH by 
exposure to buthionine sulfoxamine (BSO) restores drug sensitivity in MRP-
expressing cell lines, for example the reversal of a daunorubicin accumulation defect 
caused by GSH depletion by restoring previous GSH levels [154], [155]. It is possible 
that drugs that are positively charged or neutral, such as daunorubicin and vincristine, 
may need GSH to be transported but anionic molecules may not. Evidence for this 
comes from studies showing the transport of anionic molecules to not be affected by 
GSH depletion [156]. Methotrexate has been shown to be transported in its native 
form by MRP-1 [136].  
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1.3.4.1.1 MRP-1 inhibitors 
 
Given the similarity between MRP-1 and MRP-2 substrate sets, competitive inhibition 
by high affinity substrates like leukotriene C4, S-decylglutathione and MK571  occurs 
in both MRP-1 and MRP-2 [157], [158]. More MRP-1 inhibitors include 
sulfinpyrazone, benzbromerone and probencid [146]. The same inhibitors don’t 
always work for both MRP-1 and MRP-2, even though they have similar substrate 
specificities. For instance, sulfinpyrazone, an MRP1 inhibitor, does not inhibit the 
transport of dinitrophenyl S-glutathione by MRP-2 [159]. 
Non-steroidal anti-inflammatory drugs (NSAIDs) have in recent times become 
players in the drug resistance arena.  A study of the effects of a group of these drugs 
(indomethacin, sulindac, tolmetin, acemetacin, zomepirac and mefenamic acid) at 
non-toxic levels illustrated their ability to increase the cytotoxicity of 
chemotherapeutic agents such as the anthracyclines, VP16 and vincristine in the cell 
lines HL-60ADR, Cor L23R, DLKP and COR L23P [160]. Sulindac, as a competitive 
MRP-1 inhibitor, has been the subject of a recent Phase I clinical and pharmacokinetic 
study in combination with epirubicin in advanced cancer conducted by our group 
[161]. 
 
 
1.3.4.2 MRP-3 (ABCC3) 
 
MRP-3, like MRP-1 and MRP-2, is an organic anion transporter [162]. MRP-3 is 
reported to be expressed mainly in the pancreas, kidney, liver, colon, intestine and 
adrenal gland [162]. Studies of cloned rat mrp-3, suggests it displays a preference for 
glucuronate conjugates as substrates over glutathione conjugates [163]. Cells 
expressing the protein are resistant to etoposide, teniposide and short term 
methotrexate exposure but not other MDR linked drugs [162]. Studies on a murine 
fibroblast-like cell line retrovirally transduced with MRP-3 cDNA and lacking 
mdr1a/b and mrp1 showed that when over-expressing MRP-3 these cells were 
resistant to etoposide and teniposide but not vincristine, doxorubicin and cisplatin 
[164]. The etoposide resistance was not affected by glutathione depletion. Membrane 
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vesicles expressing MRP-3 mediated the ATP-dependent transport of etoposide 
glucuronide, estradiol 17-β-D-glucuronide, leukotriene C4, dinitrophenyl S-
glutathione but not glutathione itself [164]. 
1.3.4.3  MRP-4 (ABCC4) 
 
MRP-4 has been found to be expressed in the prostate, testis, ovary, intestine, 
pancreas and lung tissues [165]. Studies on membrane vesicles prepared from insect 
cells infected with MRP-4 baculovirus have shown MRP-4 to be specifically 
associated with the MgATP-dependent transport of cGMP, cAMP, DHEAS and 
estradiol 17-β-D-glucuronide [166]. It was also found that MRP4 is involved in 
resistance to the anti-cancer purine analogues 6-thioguanine and 6-mercaptopurine 
and methotrexate [166], [167]. The ability of MRP-4 to transport prostaglandins E1 
and E2, mediators of the inflammatory response and over-expressed in some tumours, 
may suggest a role for MRP-4 in prostaglandin regulation in normal and neoplastic 
tissue [167].  MRP-4 has been much studied recently as it can function as a cellular 
efflux pump for the HIV drugs 9-(2-phosphonylmethoxyethyl) adenine PMEA and 
Azidothymidine monophosphate (AZTMP) in PMEA resistant cells [168]. 
 
1.3.4.4  MRP5 (ABCC5) 
 
MRP-5 is expressed in most normal tissues and is over-expressed in lung, breast colon 
and pancreatic cancers [169]. Drug transfection studies in drug sensitive cells have 
shown MRP-5 confers resistance to antifolate drugs such as methotrexate and 
pemetrexed and to nucleoside –based drugs such as 6- mercaptopurine, 6-thioguanine 
PMEA, 5-FU and gemcitabine [169]. MRP5 has been shown to be inhibited by 
sulfinpyrazone and benzbromarone but not by probenecid [170]. 
MRP5 overexpression has produced no prominent resistance to other anti-cancer 
drugs such as the anthracyclines, vinca alkaloids and epipodophyllotoxins [146].  
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1.3.4.5  MRP-6 (ABCC6) 
 
Expression of MRP-6 has been found in the liver and the kidney [165]. Mutations in 
the MRP-6 gene have been associated with the rare hereditary connective tissue 
disorder Pseudoxanthoma elasticum [171]. The 3’ end of the MRP-6 protein is almost 
identical to the anthracycline resistance-associated (ARA) protein previously 
identified in epirubicin-selected leukaemia cells [172]. Studies in membrane vesicles 
transfected with MRP-6 expression vector have shown that expression of MRP-6 is 
specifically associated with the transport of glutathione S-conjugates but not 
glucuronate conjugates while MRP-6 transfected cells have shown low levels of 
resistance to etoposide, tenoposide, doxorubicin and daunorubicin [172]. 
 
1.3.4.6  MRP-8 (ABCC11) 
 
MRP-8 is a lipophilic anion exchanger capable of transporting with a substrate 
specificity that overlaps with MRP-4 and MRP-5. [142]. A single nucleotide 
polymorphism in MRP-8 has been shown to determine wet versus dry earwax and is 
the only known  physiological role that has been found for MRP-8 [23]. Endogenous 
transported compounds include LTC4, E217BG, DHEAS, and the cyclic nucleotides 
cAMP, cGMP [142]. MRP-8 mediates resistance to fluoropyrimidines through 
transport of 5-fluoro-2-deoxyuridine monophosphate, the cytotoxic metabolite of 5-
fluorouracil, 5- fluoro-2-deoxyuridine and capecitabine [173].  
 
The substrate range of MRP-9 (ABCC12) is not characterised to date [23].  
1.3.4.7  Breast Cancer Resistance Protein (BCRP, ABCG2) 
 
BCRP is a 70 kDa protein and a more recent addition to MDR transport molecules 
and is also referred to as MXR (mitoxantrone resistance associated protein), ABCP 
(Placenta-specific ABC gene) and ABCG2. Identification of the molecule in the 
anthracycline-selected breast cancer cell line MCF-7/AdrVp led to it being named 
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BCRP [174]. It later emerged as the prime suspect in the search for a mediator of high 
mitoxantrone resistance.  
The BCRP gene has been mapped to chromosome 4q22 [175]. It seems to be localised 
mainly to the plasma membrane rather than any intracellular membranes [176]. This 
does not rule out the possible existence of intracellular BCRP as drug sequestering 
cytoplasmic vesicles have been observed in the BCRP-over-expressing gastric 
carcinoma cell line EPG85-257RNOV [177], [178]. 
 
BCRP is described as an ABC half-transporter with six transmembrane helices, with 
the active BCRP transport complex consisting of two half transporters [179]. The 
phenotype of BCRP resistant cells overlaps with that of classical MDR but is distinct 
from it. The breast carcinoma cell line MCF-7/BCRPclone8, a BCRP-transfected cell 
line showed cross-resistance to daunorubicin, doxorubicin, mitoxantrone, SN-38 
(active metabolite of irinotecan) and topotecan while retaining sensitivity to cisplatin, 
paclitaxel and vincristine [174], [180]. 
 
The normal physiological role of BCRP is still unknown. In a recent study using two 
monoclonal antibodies, BXP-34 and BXP-21, high BCRP expression was observed in 
placental syncytiotrophoblasts, the epithelium of the small intestine and colon, the 
liver canalicular membrane and in ducts and lobules of the breast [181]. These results 
point to a role in the placental barrier and a further protective role against xenobiotics 
in the intestine and liver. There is further evidence that BCRP is involved in cellular 
homeostatic mechanisms, hypoxic responses and systemic access [182]. This last 
association is being exploited to improve the pharmacokinetic profiles of BCRP-
substrate chemotherapeutic agents when co-administered with a BCRP modulator 
such as elacridar [182].  
 
The original, specific agent for the reversal of BCRP-dependent is fumitremorgin C 
[183]. It was isolated from Asperillus fumigatus and does not reverse resistance 
associated with MRP and P-gp [183], [184]. Elacridar, a dual P-gp and BCRP 
inhibitor, is able to resensitise mitoxantrone-resistant BCRP-expressing cells and is 
reported as a potent reversal agent of BCRP-mediated resistance to 
camptothecins[185], [186]. Other modulators of BCRP include tamoxifen, imatinib 
and the fumitremorgin C analogues, Ko132, Ko134 and Ko143 [182]. 
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1.3.5 ABC protein expression in lung tissue 
 
Many of the ABC transporters, including P-gp, MRP-1 and BCRP, show elevated 
levels of expression expressed in normal bronchial epithelium [187]. The airways 
form the first line of defence against inhaled pathogens, pollutants and other toxic 
agents. The prominent expression of ABC transporters in the lung suggests that they 
may be central in the protection of the lungs from harmful endogenous and exogenous 
compounds. There has been conflicting reports for the expression of MRP-2, MRP-3, 
MRP-4 and MRP-5 in primary bronchial and peripheral epithelial cells [187]. Two 
studies that examined the levels of P-gp and MRP-1 by RT-PCR in NSCLC cancers 
revealed 100% expression of MRP-1 in all tumours and 27-43% expression of P-gp 
[111]. A correlation between current smoking and doxorubicin resistance of NSCLC 
has been reported, with 42 out of 72 NSCLC smokers expressing P-gp, whereas only 
2 out of 22 tumours of non-smokers were P-gp positive [187]. 
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1.4 Drug uptake mechanisms 
 
Energy-dependent efflux of chemotherapy drugs is well characterised through the role 
of the MRP family and P-gp in multi-drug resistance. There are a number of 
chemotherapy drugs that do not rely solely on passive diffusion for drug entry into 
cells. Melphalan, the nitrogen mustard derivative of L-phenylalanine, is transported 
by the L-type amino acid transporter 1 (LAT 1/SLC7A5) system in breast cancer cells 
[188]. Cisplatin and carboplatin kinetics are linked to human copper transporter 1 
(CTR1/SLC31A1) and ATP7B, transporters involved in cellular copper homeostasis 
[189]. Methotrexate is an anti –metabolite that is transported into the cell by a number 
of mechanisms, most notably the reduced folate carrier (RFC/SLC19A1) [190]. Anti-
cancer nucleoside analogues, such as mercaptopurine and thioguanine, are transported 
by the equilibrative nucleoside transporter (ENT/SLC29) and concentrative 
nucleoside transporter (CNT/SLC28) gene groups. [191]. In most cases, as 
exemplified by melphalan and methotrexate, the existence of an influx mechanism is 
down to the similarity of the chemotherapy agent to naturally occurring endogenous 
compounds. 
 
1.4.1 Taxane uptake mechanisms 
 
The mechanism by which docetaxel and paclitaxel enter the cell has received 
relatively little attention as it has been assumed that the lipophilic taxanes enter cells 
by passive diffusion. Two recent studies have provided evidence for carrier mediated 
taxane transport. OATP1B3 (organic anion transporting polypeptide 1B3/ 
SLCO1B3/OATP8) is a member of the solute carrier family 21 (SLC21/SLCO) that 
has exhibited paclitaxel and docetaxel transport in transfected oocytes, a standard 
approach for analysing a transporter’s substrate selectivity [192].  
[192]. Using the same experimental procedure, Kobayashi et al., have shown that 
OAT2 (organic anion transporter 2/SLC22A7), also expressed in the liver, is capable 
of stimulating uptake of paclitaxel into oocytes [193].  
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Many of the influx mechanisms identified, including those associated with taxane 
transport to date, are members of the solute carrier (SLC) superfamily of transporters.  
As well as the important physiological role as transporters of endogenous substrates, 
the SLC superfamily plays a major role in systemic drug disposition and mediation of 
the chemosensitivity and -resistance of cancer cells. Approximately 300 SLC genes 
have been cloned and organised into 43 families to date [194]. The only documented 
member of the SLC superfamily shown to transport docetaxel, OATP1B3, is part of 
the SLCO family [192]. For this reason, the SLCO family became a focus of the 
investigation into a putative docetaxel uptake mechanism in NSCLC cell lines. 
 
1.4.2 SLCO family 
 
The traditional SLC21 gene and OATP (-A, - B, -C, -8) protein classifications has 
recently been replaced with a new nomenclature system, OATP/SLCO, based on 
phylogenetic relationships and chronology of identification [195]. SLCO is used to 
denote the gene while OATP is used to denote the related protein product. Of the 52 
members of the SLCO superfamily found in the human, rat and mouse, 36 have been 
identified in humans thus far [195]. Their transport mechanism appears to be by 
sodium-independent anion exchange [196]. This facilitated transport antiporter 
activity involves coupling the cellular uptake of organic componds with the efflux of, 
for example, bicarbonate, glutathione or glutathione-S-conjugates [195]. This system 
does not directly require or utilise ATP hydrolysis.  
OATPs were originally characterised as uptake transporters but some may function 
primarily as efflux pumps in certain parts of the body [197]. It is likely that the OATP 
family can mediate bi-directional organic substrate, with the overall directionality of 
transport dependent on the prevailing substrate gradients [195]. Bidirectional 
transmembrane BSP transport has been observed in rat Oatp1-expressing HeLa cells 
and Oatp1-mediated taurocholate/HCO3 exchange [196]. 
 
Expression of a number of OATP family members has been documented in lung 
tissue. Some OATPs are expressed exclusively in one tissue, such OATP1B1 and 
OATP1B3 in the liver, while others are expressed in multiple organs, like OATP2B1 
(heart, lung, small intestine, kidney, ovary) or the ubiquitously expressed OATP3A1, 
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OATP2A1 and OATP4A1 [196]. OATP1A2 mRNA expression has been reported in 
the lung, testis, brain, kidney and liver [196]. While the normal physiological 
expression of the taxane-transporting OATP1B3 is in the liver, it has been shown to 
be expressed in various human cancer tissues and cell lines derived from lung, colon, 
gastric, pancreas, gallbladder and brain cancers [198].  
 
The OATPs mediate the membrane transport of a wide variety of amphipathic organic 
compounds including bile salts, organic dyes, steroid conjugates, thyroid hormones, 
numerous drugs and xenobiotic compounds [196]. Endogenous compounds include 
bile salts (cholate, glycocholate), eicosanoids (prostaglandine E2, leukotriene C4), 
hormones and their conjugates (estrone-3-sulfate, E217BG) and bilirubin. Xenobiotic 
compounds transported include fexofenedine (also a P-gp substrate [199]), 
methotrexate, pravastatin, digoxin, rifampicin and bromosulfophthalein [196]. The 
MRP-2 flavonoid substrate epigallocatechin-3-gallate is also an OATP-C substrate 
[200]. 
 
The overlapping of ABC transporter and OATP substrates is no coincidence. OATPs 
are involved in drug vectoring, transcellular drug transport based on the apical or 
basolateral expression of transporters. This occurs at areas such as the blood-brain 
barrier, intestinal and renal epithelia and hepatocytes where the OATPs expressed 
basolaterally, take drugs into epithelial cells with exporters such as MRP-2 expressed 
apically to excrete the drug into the lumen [87].  
 
The effect of OATPs on drug disposition and excretion is unquestionable. A role for 
OATPs in taxane influx (or efflux) in tumours is not implausible due to substrate 
similarities to recognised taxane transporters, co-expression with these established 
transporters (MRP-2) in some tissues and documented expression in cancer cells. 
 
1.4.3 SLC22 family  
 
The SLC22 family is divided into two subcategories, OATs (organic anion 
transporters) and OCTs (organic cation transporters). The OCTs are broad specificity 
transporters involved in the uptake, excretion and distribution of endogenous organic 
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cations and cationic xenobiotics [201]. The involvement of OCTs in drug resistance is 
unknown but they have been shown to transport nucleoside analogues in vitro [202].  
Although structurally similar, the OATs, in contrast, are involved in the uptake, 
elimination and distribution of endogenous and exogenous organic anions. There are 
five human OAT members  OAT1 (SLC22A6), OAT2 (SLC22A7), OAT3 
(SLC22A8), OAT4 (SLCA11) and URAT1 (SLCA12) [203]. Expression of all 
members is found in the kidneys except for OAT2, with OAT3 and OAT4 expression 
also reported in the brain and placenta, respectively [204]. Methotrexate is a substrate 
for OAT1, OAT3 and OAT4 but not the paclitaxel transporting OAT2 [204], [193]. 
OAT3 and OAT4 can transport DHEAS while OAT1 can handle NSAID transport 
[204]. There is no evidence that the OAT family contributes to cancer cell 
chemosensitivity or resistance in vivo. 
 
 37
1.5 EGFR inhibitors in lung cancer  
 
1.5.1 Epidermal growth factor receptor (c-ErbB) Family 
 
The type I receptor tyrosine kinases are a family of transmembrane proteins involved 
in various aspects of cell growth, survival, and differentiation [205]. Members of the 
family include the EGFR (epidermal growth factor receptor, c-ErbB1), Her-2/neu, (c- 
ErbB-2), Her-3 (c-ErbB-3), and Her-4 (c-ErbB-4). 
The c-ErbB family have been investigated as potential therapeutic targets due to over-
expression in a broad variety of cancers. EGFR has been shown to be over-expressed 
in bladder, breast, head and neck, kidney, non-small cell lung, and prostate cancers, 
Her-2 in over-expressed in breast, cervix, colon, endometrial, oesophageal, lung, and 
pancreatic cancers. Her-3 over-expression has been reported in breast, colon, prostate, 
and stomach malignancies while Her-4 over-expression has been detected in breast 
cancer and granulosa cell tumours of the ovary [206], [207], [208].  
 
All four proteins share a similar structure; the extracellular domain contains two 
regions involved in ligand binding and two cysteine rich regions, the transmembrane 
domain involved in dimerisation between c-ErbB family members and the 
intracellular domain which contains the tyrosine kinase domain that phosphorylates 
tyrosine residues on substrate proteins. The cytoplasmic domain also contains a 
carboxy-terminal tail with tyrosine autophosphorylation sites which link these 
receptors to proteins containing Src homology and phosphotyrosine-binding domains 
[209]. Her-2 and Her-3 are exceptions to the rule containing an inactive ligand 
binding site and an inactive tyrosine kinase domain, respectively.  
 
There are six known endogenous ligands for EGFR: epidermal growth factor (EGF), 
transforming growth factor-a, amphiregulin, betacellulin, heparin-binding EGF, and 
epiregulin. Betacellulin, heparin-binding EGF, and epiregulin are also ligands for 
Her-4. The neuregulin isoforms NRG1 and NRG2 are ligands of Her-3 and Her-4, 
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low and high affinity receptors respectively, and the NRG3 and NRG4 isoforms are 
Her-4 ligands [210]. 
 
The members of the c-ErbB family can form four homodimers and six heterodimers. 
Studies show that certain combinations of dimers are preferred.  The Her-2/Her-3 
dimer, for instance is reported as being a preferred dimer in breast cancer [211]. Her-3 
has an active ligand binding domain but requires heterodimerisation with another 
family member to activate a signalling cascade due to its inactive tyrosine kinase 
domain. The Her-2 receptor is an orphan receptor with an inactive ligand binding 
domain that requires heterodimerisation for activation of its tyrosine kinase domain. 
Heterodimerisation increases the number of cell signalling pathways that can be 
activated by various ligands. 
 
1.5.2 EGFR signalling pathways 
 
There are some common signalling pathways activated by all c-ErbB family 
members. All four members of the family have the potential to stimulate the 
Ras-Raf-MAPK protein kinase signalling cascade.  Phospholipase Cγ, however binds 
to specific phosphotyrosines of EGFR but not to the other c-ErbB family members, 
mediating the formation of diacylglycerol and inositol 1,4,5-trisphosphate second 
messengers. This leads to downstream activation of Akt [212]. Other factors activated 
by the c-ErbB family include the cytoplasmic tyrosine kinase c-Src, MAP kinase, c-
Jun kinase, and signal transducers and activators of transcription (STATs) [210]. 
The importance of the signalling pathways activated by the EGFR family of receptor 
tyrosine kinases can be seen by the key role these pathways play in the regulation of 
normal cellular development as well the critical part they play in a variety of 
pathophysiological phenomena [210].  
The Ras-Raf-MAPK pathway is a major signalling pathway of EGFR and the other 
members of the c-ErbB family [212], [213]. Activation of Ras initiates a 
phosphorylation cascade that leads to the activation of the p44/42 mitogen-activated 
protein kinases (MAPK’s), consisting of the extracellular signal-regulated kinases, 
Erk1 and Erk2, by dual phosphorylation. Erk1/2 then translocates to the nucleus and 
regulates transcription and cell proliferation. EGF is also capable of activating the 
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PI3-Kinase/Akt signalling pathway. Akt is involved down-stream of activated PI3-
kinase and supervises the balance of apoptosis and cell survival by inhibition of 
proapoptotic proteins [212]. The Rac/JNK/p38 MAPK signalling cascade is another 
important EGFR activated pathway [214]. The stress-activated protein kinase (SAPK) 
p38 MAPK, is induced by growth factors, pro-inflammatory cytokines and non-
steroidal anti-inflammatory drugs [215]. EGF signalling through p38 MAPK can exert 
apoptotic or mitogenic effects dependent on the cell type [216], [217]. The activity 
ratio of Erk/p38 MAPK may predict whether tumour cells proliferate or enter a state 
of dormancy in vivo. A high Erk/p38 MAPK ratio favours tumour growth, whereas a 
high p38 MAPK/Erk ratio induces growth arrest indicating that Erk is negatively 
regulated by p38 MAPK [218]. EGFR-regulated pathways have been extensively 
implicated in taxane resistance (Section 1.2.3.4) and P-gp regulation (Section 1.3.2). 
 
1.5.3 c-ErbB regulation 
 
Along with activating downstream signalling pathways, ligand binding to plasma 
membrane receptor tyrosine kinases (RTKs) such as EGFR and Her-2 promotes 
cellular internalisation of the proteins. Internalisation leads to downregulation of the 
signal via degradation of the ligand/receptor complex or in the case of EGFR, to 
further signalling from endosomes [219]. Most RTKs are predominantly localised in 
regions of the plasma membrane called lipid rafts that may or may not be associated 
be associated with caveolins [219]. Lipid rafts are more rigid patches of plasma 
membrane containing a concentration of cholesterol, sphingolipids and phospholipids 
that are compositionally identical to vesicles known as caveolae but for the absence of 
a set of proteins known as caveolins [220]. Ligand activation promotes internalisation 
of RTKs through clathrin-dependent (EGFR, PDGFR (platelet-derived growth factor 
receptor), IGF-1R (Insulin growth factor-1 receptor)) or –independent (VEGF-R 
(vascular endothelial growth factor receptor)) pathways [219]. Internalisation 
commences with the recruitment of vesicular trafficking molecules and the formation 
of clathrin-coated membrane invaginations around the RTK. Further adapter proteins 
facilitate the budding of the clathrin-coated vesicle (CCV) and subsequent release 
from the plasma membrane [219]. The CCV sheds the clathrin coat and fuses with 
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early endosomes that either recycle the receptors back to the cell surface or  sort them 
to late endosomes for lysosomal and/or proteosomal degradation [219]. 
1.5.4 c-ErbB and cancer 
 
The c-ErbB family was first implicated in carcinogenesis in 1984 with the discovery 
that the transforming element of an oncogenic avian erythroblastosis retrovirus 
encoded a truncated ortholog of human EGFR [221]. Two years later, Her-2 was 
isolated from rat glioblastomas as a carcinogen-induced oncogene (neu) with a point 
mutation in its transmembrane domain resulting in ligand-independent 
homodimerisation and constitutive activation [222]. Irregular activation of the c-ErbB 
network can occur through a number of mechanisms including receptor 
overexpression, autocrine production of ligand, gene amplification and mutation. 
All four mechanisms have also been documented for the EGF-receptor, EGFR. EGFR 
over-expression has been documented in a number of cancers including breast cancer, 
lung cancer and particularly high frequency of over-expression due to gene 
amplification in gliomas [223], [224, 225]. Recent retrospective analyses have 
reported EGFR overexpression in 62% of NSCLC cases with its expression correlated 
to a poor prognosis [226]. 
Several mutations in EGFR have been reported. EGFRvIII involves the loss of coding 
sequence for amino acids 6-273 (exons 2-7) and expression has been shown in 39% of 
NSCLC tumours and 78% of breast cancer tumours [225]. Further somatic EGFR 
mutations have been identified in NSCLC that lead to hyperactivation of the kinase 
domain and over-dependence of the cell on the EGFR pathway for survival. In-frame 
deletions of amino-acids 747–750 in exon 19 account for 45% of these mutations, 
exon 21 mutations resulting in L858R substitutions account for 40–45% of mutations, 
and the remaining 10% of mutations involve exon 18 and 20 [226]. 
The majority of these mutations have been associated with sensitivity to the tyrosine 
kinase inhibitors gefitinib and erlotinib (see Section 1.5.5.2) but some are associated 
with acquired tyrosine kinase inhibitor resistance. 
Her-2 is found to be over-expressed in a variety of cancers including 20-30% of breast 
and ovarian cancers due to over-amplification [225]. Her-2 over-expression correlates 
with therapeutic resistance and poor prognosis in breast cancer [227]. Trastuzumab 
(Herceptin ®) is a Her-2-targetted monoclonal antibody that has achieved significant 
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success for the treatment of Her-2 positive metastatic breast cancer improving 
survival by 25% [228]. Over-expression of Her-2 in NSCLC is reported to be between 
4 and 27% in NSCLC, depending on the detection method used [229]. A study by 
Gatzemeier et al., recently showed that 17% of NSCLC patients presented with Her-2 
levels of 2+/3+ using the Herceptest method of Her-2 detection and consequent 
combination therapy with cisplatin/gemcitabine and trastuzumab versus 
cisplatin/gencitabine alone did not improve any efficacy endpoint [230]. The 
Herceptest® is a standard method for determining tumour Her-2 levels that uses a 
immunohistochemical scoring system (0 (no expression) to 3+ (high expression) to 
rate Her-2 expression relative to known Her-2 over-expressing cell lines. Her-2 
overexpression may still provide a target in NSCLC as there is evidence that Her-2 
co-operation is required by EGFR and Her-3 in lung tumourigenesis and Her-2 over-
expression is related to cisplatin resistance therefore, Her-2 may have potential in 
combination with EGFR therapies and as a platinum-sensitiser in NSCLC [229]. 
Less is known about the involvement of Her-3 and Her-4 in NSCLC. Her-3 over-
expression has been found in breast, colon, prostate, bladder, oral and gastric cancers 
while Her-4 has been found to be a target of mutation in lung, gastric, breast and 
colorectal carcinoma [225]. Activation of Her-3, and subsequently the PI3K/Akt 
signalling pathway, by the over-expressed MET tyrosine kinase receptor, rather than 
EGFR, has been associated with TKI inhibition in NSCLC lung cancer cell lines 
[231].  
 
1.5.5 Targetted c-ErbB therapies 
 
Two approaches have been adopted for inhibition the c-ErbB family, monoclonal 
antibodies and small molecule tyrosine kinase inhibitors (TKIs). There are 
disadvantages and advantages to both types of inhibitor. Monoclonal antibodies are 
highly specific and they block EGFR ligand binding, receptor internalisation and 
dimerisation and in some cases (IgG1 isotype), stimulate the immune response [232]. 
Although TKIs provide a less robust inhibition of EGFR by preventing activation of 
EGFR signalling pathways by inhibition of c-ErbB kinase activity only, TKIs have 
better tumour penetration due to their size and they are effective against constitutively 
active EGFR [232]. 
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1.5.5.1 Monoclonal antibodies 
 
Cetuximab (Erbitux®) is a monoclonal human-murine chimeric antibody against 
EGFR that has been approved for colorectal cancer treatment [232]. Binding of the 
antibody causes EGFR internalisation and prevents ligand mediated tyrosine kinase 
phophorylation resulting in up-regulation of p27KIP1, a decrease in CDK2, cyclins A 
and E and G1 cell cycle arrest [233]. Phase II trials have been carried out in 
combination with docetaxel in recurrent NSCLC. This achieved a partial response rate 
of 28% and a stable disease rate of 17%, survival analysis is ongoing. In 
chemotherapy naïve, stage IV NSCLC patients, carboplatin and paclitaxel combined 
with cetuximab produced a response rate of 29%. Both trials were carried out in 
patients with EGFR positive tumours [234]. 
 
Other monoclonal antibodies that are in Phase II and III trials for NSCLC treatment 
include panitumumab (Vectibix ®), matuzumab, nimotuzumab (TheraCIM®) and 
zalutumumab (HuMax-EGFr ®).  
 
1.5.5.2 Small molecule TKIs 
 
The major EGFR inhibitors approved in the treatment of NSCLC are gefitinib 
(Iressa®, ZD1839) and erlotinib (Tarceva®, OSI-774).  
 
Gefitinib  
 
Gefitinib is a quinazoline derivative and reversible inhibitor of EGFR [232]. Gefitinib 
inhibits EGFR phosphorylation with an IC50 of 27 to 33 nmol/l [235]. Gefitinib also 
has the ability to inhibit Her-2 phosphorylation but at higher concentrations (Her-2 
phosphorylation IC50 of 3.7 µmol/l) [235].  
Gefitinib is approved as a third line monotherapy for the treatment of advanced 
NSCLC [232]. Gefitinib has achieved modest success as a single agent therapy in 
lung cancer. It has shown close to a 25% response rate (stable disease, partial and 
complete responses together) in advanced disease [236]. In one particular study where 
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gefitinib monotherapy resulted in 15% partial response, those that responded were 
most likely to have adenocarcinomas of the broncheoalveolar subtype (25% of 
NSCLC) and to be never-smokers [237]. It was discovered that gefitinib-sensitive 
patients had EGFR mutations [238], [239]. Analysis of eight trials (86 patients) in this 
particular sub-population with EGFR mutations found they had produced response 
rates of between 76 and 92% [240]. One of these studies compared the median 
survival time of wild type EGFR and mutated EGFR patients and found them to be 7 
months and 31 months respectively [241]. The same study also compared responses to 
gefitinib between never-smokers and smokers in six trials. Never-smokers showed 
response rates of between 18 and 63% with a 5-18% range in smokers. Mutations of 
EGFR occur in two major hotspots, multinucleotide in-frame deletions that eliminate 
four amino acids in exon 19 and point mutations in exon 21 that result in a specific 
amino acid substitution at position 858 (L858R) [242]. Squamous cell carcinomas can 
often express higher levels of EGFR than adenocarcinomas but may not have 
mutations associated with EGFR inhibitor sensitivity [242]. These results suggest 
gefitinib efficacy can be improved by patient selection based on tumour phenotype 
and patient history. 
Combination studies with gefitinib and chemotherapy agents have been disappointing. 
Trials of gefitinib combined with gemcitabine and cisplatin with late stage NSCLC, 
showed no benefit over the gemcitabine and cisplatin alone [243]. A number of 
reasons have been suggested for this lack of benefit in combination studies. 
Suboptimal target modulation due to inadequate dosing, antagonism between gefitinib 
and the chemotherapeutic agents, the same tumour population being sensitive to 
chemotherapy and gefitinib, and the benefit to some patients being hidden within in 
the larger population of patients with insensitive tumours have been purported as 
possible explanations [244].   
 
Erlotinib 
 
Erlotinib is another quinazoline-derived reversible EGFR inhibitor that has similar 
activity to gefitinib [232]. Erlotinib inhibits EGFR phosphorylation with an IC50 of 2 
nM in kinase assays and an IC50 of 20 nM in intact cells [245]. Erlotinib is capable of 
inhibiting Her-2 phosphorylation but at higher concentrations IC50 1 µM [246]. 
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Erlotinib was found to have a more favourable hazard ratio than gefitinib and has 
improved median survival of never-smoker patients in combination with 
chemotherapy (23 months) over chemotherapy and placebo (10 months) [240]. Pao et 
al.,  strongly correlated the mutations with never-smoking patients with 
adenocarcinoma histology, usually with bronchioalveolar carcinoma features and 
sensitivity to erlotinib as well as to gefitinib [242]. In a phase II trial of erlotinib in 
bronchioalveolar carcinomas, it achieved 48% response rates in never smoking 
patients versus 18% in smokers. This has prompted the initiation of a neo-adjuvant 
erlotinib trial in combination with docetaxel and cisplatin in operable NSCLC [240]. 
 
Lapatinib 
 
Lapatinib (Tykerb ®, GW2016) is the first dual EGFR and Her-2 inhibitor and is 
currently in phase III clinical trials in breast cancer [247]. Lapatinib is a potent 
inhibitor of the tyrosine kinase domains of both c-ErbB family members with IC50 
values against purified EGFR and Her-2 of 10.2 and 9.8 nM, respectively [248]. It has 
shown biologic and clinical activity in EGFR and/or Her-2- overexpressing tumors 
[249]. Lapatinib-bound EGFR has a unique structure compared to erlotinib-bound 
EGFR and lapatinib has a slower off-rate of dissociation from EGFR than erlotinib or 
gefitinib, producing a longer lasting effect on EGFR phosphorylation [250]. Lapatinib 
is being studied primarily in breast cancer. A phase III trial of lapatinib in 
combination with capecitabine versus capecitabine alone in Her-2 over-expressing 
refractory advanced or metastatic breast cancer was stopped after the interim analysis 
such was the favourable increase in median time to progression (8.5 months vs. 4.5 
months) [232].  
  
1.5.6 TKIs and ABC transporters 
 
The ability of gefitinib to interact with members of the ABC family of transporters is 
well established [107], [108], [251], [252]. Studies of gefitinib using in vitro assay 
systems found that gefitinib is most likely a transported substrate of P-gp but an 
inhibitor of MRP-1 [251]. Gefitinib has been shown to moderately reverse the P-gp-
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mediated resistance to paclitaxel and docetaxel in P-gp over-expressing cells [107]. 
Data suggest that gefitinib is a transported substrate of BCRP at low physiological 
levels but may act as an inhibitor at higher concentrations [253]. Gefitinib has 
reversed resistance to topotecan and mitoxantrone in BCRP-over-expressing cell lines 
[108], [252]. Gefitinib affinity towards BCRP is ten times higher than that for P-gp 
[251]. Evidence is available from cell transfection studies that erlotinib is also a 
BCRP substrate [254].  The interaction of erlotinib and lapatinib with other ABC 
transporters has not been reported.  
 
Modulation of ABC transporters by TKIs has a number of important pharmacokinetic 
implications for co-administration of ABC protein cytotoxic drugs and TKIs. 
Inhibition of ABC proteins involved in the absorption and excretion of drugs could 
lead to increased exposure levels and reduced clearance levels. This can be exploited 
to increase oral availability of ABC substrate drugs as demonstrated by the increase in 
the oral bioavailability of BCRP substrate, irinotecan effected by gefitinib in mice 
[255]. Elevated systemic levels of chemotherapeutic agents could also lead to 
increased toxicity levels that have to be compensated for by reduction in dosing 
levels. 
The interactions of TKIs with BCRP in particular are further complicated by the 
existence of more than 40 naturally occurring single-nucleotide polymorphisms 
(SNPs) in BCRP [182]. HEK293 cells transfected with BCRP containing one of these 
SNPs, C241A (Q141K), had impaired ability to transport gefitinib and erlotinib [256]. 
The frequency of this particular allele was also found to vary between ethnic 
populations with 46% of the Japanese population found to be carriers, with levels in 
Caucasians averaging 10% and sub-Saharan Africans 1% meaning genotype may 
influence chemotherapeutic outcome [182].  
The ability of TKIs to modulate the major ABC proteins involved in MDR may also 
signify a role for TKIs in the circumvention of multi-drug resistance in tumours.  
 
This project was undertaken to look at the resistance to docetaxel mediated by 
transport proteins in NSCLC cell lines. The mechanism of docetaxel uptake in cancer 
is a poorly studied subject. A docetaxel uptake mechanism, active or passive, could be 
an important determinant of the sensitivity of tumour cells to this agent. The P-gp-
mediated cellular efflux of docetaxel, and many other chemotherapy drugs, greatly 
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reduces the efficacy of these cytotoxics. The identification of novel, effective and low 
toxicity compounds to overcome P-gp-mediated drug resistance is a major goal in 
cancer research. The abilty of TKIs, gefitinib, erlotinib and lapatinib to fulfill such a 
role has not been fully assessed to date. 
 
1.6 Aims of the thesis 
 
The aims of this thesis were to: 
 
 
A)         Examine docetaxel uptake in NSCLC cell lines to determine if it is carrier 
        mediated, and if so, if it is active or passive in nature. 
  
 
B)  (i)   Examine the potential of the tyrosine kinase inhibitors, lapatinib, gefitinib 
        and erlotinib, as modulators of P-gp-mediated docetaxel efflux in NSCLC 
        cell lines. 
 
 (ii)  Examine the interaction of lapatinib with BCRP and MRP-1. 
 
 (iii) Examine any link between TKI inhibition of EGFR and P-gp expression 
        levels. 
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Chapter 2. Materials and Methods 
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2.1 Ultrapure Water 
Ultrapure water, (UHP) was used for the preparation of all media and solutions. This 
water was purified to a standard of 12-18 MΩ / cm resistance by a reverse osmosis 
system (Millipore Milli-RO 10 Plus, Elgastat UHP).  
 
2.2  Glassware 
The solutions utilised in the various stages of cell culture were stored in sterile glass 
bottles. All sterile bottles and other glassware required for cell culture related 
applications were prepared as follows: glassware and lids were soaked in a 2% 
solution of RBS-25 (AGB Scientific) for 1 hour. They were cleaned and rinsed in tap 
water. The glassware was then washed in an industrial dishwasher, using Neodisher 
detergent and rinsed twice with UHP. The materials were finally sterilised by 
autoclaving as described in Section 2.3. 
 
2.3  Sterilisation Procedures 
All thermostable solutions, water and glassware were sterilised by autoclaving at 
1210C for 20 minutes at 15 p.s.i.. Thermolabile solutions were filtered through 0.22 
μm sterile filters (Millipore, Millex-GV SLGV025BS). Large volumes, (up to 10 
litres) of thermolabile solutions were filter sterilised through a micro-culture bell filter 
(Gelman, 12158). 
 
2.4  Preparation of cell culture media 
The basal media used for cell culture were prepared as follows: 10X medium was 
added to sterile UHP water, buffered with HEPES (N-(2-Hydroxyethyl) piperazine-N-
(2-ethanesulfonic acid)) and NaHCO3 as required and adjusted to pH 7.5 using sterile 
1.5 N NaOH or 1.5 N HCL. The media was then filtered through sterile 0.22 μm bell 
filters (Gelman, 12158) and stored in sterile 500 ml bottles at 4°C. Sterility checks 
were performed on each bottle of media by inoculating samples of the media on to 
Colombia blood agar plates (Oxoid, CM217), Thioglycollate broths (Oxoid, CM173) 
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and Sabauraud dextrose (Oxoid, CM217) and incubating the plates at 370C and 250C. 
These tests facilitated the detection of bacteria, fungus and yeast contamination. 
Basal medium was then stored at 40C for up to three months. The HEPES buffer was 
prepared by dissolving 23.8 g HEPES in 80 ml UHP water and this solution was 
sterilised by autoclaving. 5 ml of sterile 5N NaOH was then added to give a final 
volume of 100 ml. NaHCO3 was prepared by dissolving 7.5 g in 100 ml UHP water 
followed by autoclaving. Complete media was then prepared as follows: supplements 
of 2 mM L-glutamine (Gibco, 11140-0350) and 5% foetal calf serum (Sigma, F-7524) 
were, in the majority of cases, added to volumes of 100 ml basal media. 1ml 100X 
non-essential amino acids (Gibco, 11140-035) and 100 mM sodium pyruvate (Gibco, 
11360-035) were also added to MEM. Complete media were maintained at 40C for a 
maximum of 1 week. 
 
2.5 Cells and Cell Culture 
 
All cell culture work was carried out in a class II laminar air-flow cabinet. All 
experiments involving cytotoxic compounds were conducted in a cytogard laminar 
air-flow cabinet (Gelman Sciences, CG series). Before and after use the laminar air-
flow cabinet was cleaned with 70% industrial methylated spirits (IMS). Any items 
brought into the cabinet were also cleaned with IMS. At any time, only one cell line 
was used in the cabinet and upon completion of work with any given cell line the 
cabinet was allowed to clear for at least 15 minutes so as to eliminate any possibilities 
of cross- contamination between the various cell lines. The cabinet was cleaned 
weekly with industrial disinfectants (Virkon or TEGO) and these disinfectants were 
alternated every month. Details pertaining to the cell lines used for the experiments 
detailed in this thesis are provided in Table 2.5.1.  All cells were incubated at 370C 
and, where required, in an atmosphere of 5% CO2.  Cells were fed with fresh media or 
subcultured (see section 2.5.1) every 2-3 days in order to maintain active cell growth. 
All of the cell lines listed in Table 2.5.1, except for HL-60 and HL60-ADR, are 
adherent cell lines. HL-60 and HL60ADR cells were grown in suspension in vented 
75cm2 flasks (Costar, 3276) at 37°C in an atmosphere of 5% CO2 in RPMI 1640 
media (Gibco, 52400-025) containing 10 % serum. 
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2.5.1 Subculturing of cell lines 
 
The waste cell culture medium was removed from the tissue culture flask and 
discarded into a sterile bottle. The flask was then rinsed out with 1 ml of 
trypsin/EDTA solution (0.25% trypsin (Gibco, 043-05090), 0.01% EDTA (Sigma, 
E9884) solution in PBS (Oxoid, BRI4a)) to ensure the removal of any residual media. 
5 ml of trypsin was added to the flask, which was then incubated at 370C, for 
approximately 5 minutes, until all of the cells detached from the inside surface of the 
flask. The trypsin was neutralised by adding an equal volume of complete media to 
the flask. The cell suspension was removed from the flask and placed in a sterile 
universal container (Sterilin, 128a) and centrifuged at 1000 r.p.m. for 5 minutes. The 
supernatant was then discarded from the universal and the pellet was suspended in 
complete medium. A cell count was performed and an aliquot of cells was used to 
reseed a flask at the required density. Medium requirements for each cell line used in 
the project are given in Table 2.5.1.1. 
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Table 2.5.1.1 Description, medium requirements and source of cell lines. ATCC = 
American Tissue Culture Collection, NCTCC = National Cell and Tissue Culture 
Centre and ECACC= European Collection of Cell Cultures 
Cell line Medium FCS(%) Cell type Source 
A549  DMEM/Ham’s 
F12 1:1  
5 Human lung adenocarcinoma 
NSCLC cell line 
ATCC 
A549-Taxol DMEM/Ham’s 
F12 1:1 
5 Taxol-resistant variant of A549 
selected by Dr. Laura Breen 
NCTCC 
DLKP  DMEM/Ham’s 
F12 1:1 
5 Human lung squamous carcinoma 
NSCLC 
NCTCC 
DLKP-A DMEM/Ham’s 
F12 1:1 
5 Adriamycin-resistant variant of 
DLKP selected by Alice 
Redmond 
NCTCC 
DLKP-TXT DMEM/Ham’s 
F12 1:1 
5 Taxotere-resistant variant of DLKP 
selected by Dr. Yizheng Liang 
NCTCC 
DLKP-
Mitox 
DMEM/Ham’s 
F12 1:1 
5 Mitoxantrone-resistant variant of 
DLKP selected by Dr. Yizheng 
Liang 
NCTCC 
DMS 53 RPMI 1640 10 Human lung SCLC cell line ECACC 
DMS-Taxol RPMI 1640 10 Taxol-resistant variant of DMS-53 
selected by Dr. Lisa Murphy 
NCTCC 
DMS-
Taxotere 
RPMI 1640 10 Taxotere-resistant variant of DMS-
53 selected by Dr. Lisa Murphy 
NCTCC 
HL-60 RPMI 1640 10 Human leukemic cell line Melvin 
Centre, KSU 
HL-60ADR RPMI 1640 10 Adriamycin-resistant variant of HL-
60 
Melvin 
Centre, KSU 
SK-MES-1 MEM  
 
10 Squamous cell lung carcinoma cell 
line 
ATCC 
SK-Taxol MEM  
 
10 Taxol-resistant variant of SK-MES-
1 selected by Dr. Lisa Murphy 
NCTCC 
SK-Taxotere MEM  
 
10 Taxotere-resistant variant of SK-
MES-1 selected by Dr. Lisa 
Murphy 
NCTCC 
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2.5.2 Assessment of cell number and viability 
 
Cells were trypsinised, pelleted and resuspended in medium. An aliquot of the cell 
suspension was then added to trypan blue (Gibco, 525) at a ratio of 5:1. 
The mixture was incubated for 3 minutes at room temperature. A 10 μl aliquot of the 
mixture was then applied to the chamber of a glass coverslip enclosed 
haemocytometer. 
Cells in the 16 squares of the four grids of the chamber were counted. The average 
cell numbers per 16 squares were multiplied by a factor of 104 and the relevant 
dilution factor to determine the number of cells per ml in the original cell suspension. 
Non-viable cells stained blue, while viable cells excluded the trypan blue dye as their 
membrane remained intact, and remained unstained. On this basis, % viability could 
be calculated. 
 
2.5.3 Cryopreservation of cells 
 
Cells for cryopreservation were harvested in the log phase of growth and counted as 
described in Section 2.5.2. 
Cell pellets were resuspended in a suitable volume of serum. An equal volume of a 10 
% DMSO/serum solution was added dropwise to the cell suspension resulting in a 
final DMSO concentration of 5%. 
A total volume of 1ml of this suspension (which should contain approximately 7x106 
cells) was then placed in cryovials (Greiner, 122278). 
These vials were then placed in the vapour phase of a liquid nitrogen container, which 
was equivalent to a temperature of –800C. 
After a period of three hours, vials were removed from the vapour phase and 
transferred to the liquid phase for storage (-1960C). 
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2.5.4 Thawing of cryopreserved cells  
 
A volume of 9 ml of fresh growth medium was added to a sterile universal. The 
cryopreserved cells were removed from the liquid nitrogen and rapidly thawed at 
370C. The cells were removed from the vials and transferred to the aliquoted media. 
The resulting cell suspension was centrifuged at 1,000 r.p.m. for 5 minutes. The 
supernatant was removed and the pellet resuspended in fresh culture medium. 
An assessment of cell viability on thawing was carried out (Section 2.5.2). 
Thawed cells were then added to an appropriately sized tissue culture flask with a 
suitable volume of growth medium and allowed to attach overnight. 
 
2.5.5 Monitoring of sterility of cell culture solutions 
 
Sterility testing was performed in the case of all cell culture media and cell culture-
related solutions. Samples of prepared basal media were inoculated on to Colombia 
blood agar plates (Oxoid, CM331), thioglycollate broths (Oxoid, CM173) and 
Sabauraud dextrose (Oxoid, CM217) and the plates incubated at 370C and 250C. 
These tests facilitated the detection of bacteria, fungus and yeast contamination. 
Complete cell culture media were sterility tested at least four days prior to use, using 
Columbia blood agar. 
 
2.5.6 Serum batch testing 
 
Batch to batch variation of FCS can result in alterations to cell growth characteristics. 
In extreme cases this may result in a lack of cell growth or retarded cell growth in 
more moderate cases. To minimise the impact of FCS inter-batch variability, growth 
of the cell lines in a range of FCS samples was screened. The FCS most suitable for 
each cell line was then purchased in bulk to maintain continuity of cell culture 
conditions. The screening process involved a comparison of the growth of cells in 
each FCS sample as a percentage of growth of serum with known acceptable growth 
rate. Logarithmically growing cells were seeded in a 96-well plate (Costar; 3599) 
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from a single cell suspension at a density of 103 cells/well in 100 µl of medium 
without FCS. 100 µl volumes of medium containing 10% or 20% FCS was added to 
the 96-well plate, resulting in final dilutions of the FCS to 5% or 10%, respectively. 
One column of each plate provided a control containing FCS with a known acceptable 
growth rate. Plates were placed at 370C in 5% CO2, for 5 days, after which growth 
was assessed by the acid phosphatise method, see Section 2.7.2. 
 
2.6 Mycoplasma analysis of cell lines 
 
Cell lines were tested for possible Mycoplasma contamination every three months 
approximately. The protocol used is detailed in the following Sections 2.6.1 and 2.6.2.  
 
2.6.1 Indirect staining procedure for Mycoplasma analysis 
 
Mycoplasma negative NRK (normal rat kidney fibroblast) cells were used as indicator 
cells for this analysis. The cells were incubated with a sample volume of supernatant 
from the cell lines in question and then examined for Mycoplasma contamination. A 
fluorescent Hoechst stain was used in this analysis. The stain binds specifically to 
DNA and so stains the nucleus of the cell in addition to any Mycoplasma present. 
Mycoplasma infection was indicated by fluorescent bodies in the cytoplasm of the 
NRK cells. 
 
2.6.2 Direct culture procedure for Mycoplasma analysis 
 
Direct staining for Mycoplasma analysis involved inoculating samples on to a 
Mycoplasma culture broth (Oxoid, CM403). This was supplemented with 16% serum, 
0.002% DNA (BDH, 42026), 2 μg/ml fungizone (Gibco, 042 05920), 2x103 units 
penicillin (Sigma, Pen-3) and 10 ml of a 25% yeast extract solution. Incubation was 
carried out at 370C for a period of 48 hours. Samples of this broth were then streaked 
onto plates of Mycoplasma agar base (Oxoid, CM401), which had been supplemented 
as described above. The plates were incubated for three weeks at 370C while exposed 
to C02. The plates were examined microscopically every 7 days. The appearance of 
small oval shaped colonies indicated the presence of Mycoplasma infection. 
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2.7 Miniaturised in vitro proliferation assays 
 
2.7.1 In-vitro proliferation assay experimental procedure  
 
Cells in the exponential phase of growth were harvested by trypsinisation as described 
in Section 2.5.1. 
Cell suspensions containing 1 X 104cells/ml were prepared in cell culture medium. 
Volumes of 100 μl/well of these cell suspensions were added to 96-well plates 
(Costar, 3599) using a multichannel pipette. Plates were agitated gently in order to 
ensure even dispersion of cells over a given well. Cells were then incubated overnight 
at 370C in an atmosphere containing 5% CO2.  
For IC50 determinations drug dilutions were prepared at 2X their final concentration in 
cell culture medium and 100 µl volumes of the drug dilutions were added to each well 
using a multichannel pipette. For combination assays 50 µl of the two compounds to 
be examined were added at a 4X concentration. Plates were then mixed gently.  
Cells were incubated for a further 6 days at 370C and 5% CO2. At this point the 
control wells would have reached approximately 80-90% confluency. 
Assessment of cell survival in the presence of drug was determined by the acid 
phosphatase assay (Section 2.7.2). The concentration of drug which inhibited 50% of 
cell growth (IC50 of the drug) was determined from a plot of the % survival (relative 
to the control cells) versus cytotoxic drug concentration using the Calcusyn ® 
software package. 
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Table 2.7.1 The drugs used in this thesis and their sources. 
 
Drug MW (g/mol) Source 
Sulindac 356.4 Sigma 
Sulindac sulfide 340.4 Sigma 
Elacridar (GF120918) 600.1 GSK 
Gefitinib 446.9 Sequoia Chemicals 
Erlotinib (HCl) 429.9 Sequoia Chemicals 
Lapatinib (Ditosylate 
Monohydrate) 
943.5 GSK 
Epirubicin* 579.9 SVUH 
Adriamycin (Doxorubicin)* 543.5 SVUH 
Paclitaxel (Taxol)* 853.9 SVUH 
Docetaxel (Taxotere)* 807.8 SVUH  
Vincristine* (sulfate) 923.1 SVUH 
Oregon-green paclitaxel 1319.3 Molecular Probes 
 [14C] docetaxel 807.8 American Radiolabelled 
Chemicals 
Cisplatin* 300.1 SVUH 
MK571 537.1 Calbiochem 
Mitoxantrone* 517.4 SVUH 
Verapamil 491.1 Sigma 
 
* = Clinical formulation 
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2.7.2 Assessment of cell number - Acid Phosphatase assay 
 
Following the incubation period of 6 days, media was removed from the plates. 
Each well on the plate was washed with 100 μl PBS. This was then removed and 100 
μl of freshly prepared phosphatase substrate (10 mM p-nitrophenol phosphate (Sigma 
104-0) in 0.1 M sodium acetate (Sigma, S8625), 0.1% triton X-100 (BDH, 30632), 
pH 5.5) was added to each well. 
The plates were incubated in the dark at 370C for 2 hours. 
The enzymatic reaction was stopped by the addition of 50 μl of 1N NaOH. 
The plate was read in a dual beam plate reader at 405 nm with a reference wavelength 
of 620 nm. 
 
2.7.3 Assessment of cell number - XTT assay 
 
The XTT Assay is a non-radioactive means to measure cell viability in non-adherent 
cell lines. It is based on the fact that viable cells cleave the yellow tetrazolium salt 
XTT to form an orange formazan dye. Reading with a spectrophotometer then 
determines differences in cell survival. 
75 µl of non-adherent cells are seeded at 5 X 104 cells/ml in a 96-well plate.  
24 hours later, 75 µl of drug containing media is added at 2X concentrations to each 
well for IC50 determinations. For combination assays using two drugs, drugs are 
plated at 4X concentrations with 37 µl of each drug dilution being added. Every well 
should contain 150 µl. 
After 48 hours, 75 µl of the XTT labelling mixture is added to each well.  
This mixture consists of 5 ml XTT labelling reagent and 100 µl of the electron-
coupling reagent.  
Following 24 hours, the plates are read @ 460 nm on a spectrophotometer. 
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2.7.4 Proliferation assays examining docetaxel accumulation assay 
conditions 
 
Cells were trypsinised from the flask in the exponential phase of growth as described 
in Section 2.5.1. 
Cell suspensions containing 1 X 104 cells/ml were prepared in cell culture medium. 
Volumes of 100 μl/well of this cell suspension were added into 96-well plates 
(Costar, 3599) using a multichannel pipette. Plates were agitated gently in order to 
ensure even dispersion of cells over a given well. Cells were then incubated overnight 
at 370C in an atmosphere containing 5% CO2. 
The plates were removed from the incubator and the media was removed from each 
well. Cells were incubated with either verapamil or docetaxel alone or in combination 
for 90 minutes at 370C in an atmosphere containing 5% CO2.  
Following the 90 minute incubation, the media was removed from each plate and each 
well was washed twice with 100 µl warm PBS.  
Cells were incubated for a further 6 days at 370C in an atmosphere containing 5% 
CO2. At this point the control wells would have reached approximately 80-90% 
confluency. Cell number was assessed using the acid phosphatase assay (Section 
2.7.2). 
 
2.7.5 Statistical Evaluation 
Experimental in vitro data are presented as a mean ± S.D. from three experiments. 
Levels of significance from these data were calculated using student’s t test (two-
tailed) (Excel ®, Microsoft). A p-value of less than 0.05 was considered significant in 
all statistical testing. 
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2.8 Protein Extraction and Quantification 
 
2.8.1 Protein Extraction 
 
Cells were seeded at 0.5 – 1 X 106 cells per petridish in 10 ml of medium.  
Cells were grown to 80% confluency and fed every 2-3 days if necessary.  
Medium was removed and the cells washed with cold PBS, making sure that as little 
of the PBS as possible was left in the petri-dish.  
500 µl cold RIPA buffer (R0278, Sigma), 10X protease inhibitors (P2714, Sigma) 
(50µl per 500 µl of buffer) and 100X PMSF (Sigma) (2.5 µl per 500 µl buffer) were 
added to the cells.  
Following 20 minutes incubation on ice, the lysed cells were removed using a cell 
scraper if necessary and transferred to a sterile eppendorf.  
The sample was passed through a 21-gauge needle a number of times to shear DNA. 
The samples were then centrifuged at 14,000 r.p.m. for 5 minutes at 40C.  
The resulting supernatant was transferred to sterile eppendorfs in 100 µl aliquots and 
stored at - 200C. Protein concentration was then determined using the BCA assay 
(Pierce, Cat# 23227). 
NOTE: Once the lysis buffer was added to the cells, all steps were carried out on ice. 
 
RIPA Buffer Components:                                          
150 mM NaCL 
1% Igepal CA-630 
0.5% sodium deoxycholate 
0.1% SDS 
50 mM Tris, pH 8.0 
 
 
 
Protease inhibitors (10X): 
20 mM AEBSF 
10 mM EDTA 
1.3 mM Bestatin 
140 µM E-64 
10 µM Leupeptin 
3 µM Aprotinin 
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2.8.2 Protein Quantification 
 
Protein concentration of samples was determined using the BCA assay kit (Pierce 
Cat# 23227). 
The Pierce BCA protein assay is a detergent-compatible formulation based on 
bicinchoninic acid (BCA) for the colorimetric detection and quantitation of total 
protein. The method combines the reduction reaction of Cu+2 to Cu+1 by protein in an 
alkaline medium (the Biuret reaction) with highly sensitive and selective colorimetric 
detection of the cuprous cation (Cu+1) using a reagent containing bicinchoninic acid. 
The purple coloured reaction product of this assay is formed by the chelation of two 
molecules of BCA with one cuprous ion. The water-soluble complex exhibits a strong 
absorbance at 562 nm that is close to linear with increasing protein concentration over 
a broad working range (20 -2000 μg/ml). 
Assay procedure: 
A 2 mg/ml bovine serum albumin (BSA) solution was prepared freshly in protease 
inhibitor. A protein standard curve was prepared from the BSA stock with dilutions 
made in protease inhibitor. 
The working reagent was prepared by mixing 50 parts of BCA reagent A with 1 part 
of BCA reagent B. 200 μl of working reagent is required for each well of a 96-well 
plate used. 
25 μl of each standard or unknown sample was pipetted in duplicate onto a 96-well 
plate. 200 μl of working reagent was added to each well and the plate was mixed 
thoroughly on a plate shaker for 30 seconds. 
The plate was covered and incubated at 370C for 30 minutes and absorbance was read 
at 562 nm. 
The average 562 nm absorbance of the blank was subtracted from the 562 nm 
measurements of all other individual standard and unknown replicates 
A standard curve was prepared by plotting the average blank corrected 562 nm 
absorbance for each BSA standard versus its concentration in μg/ml. The standard 
curve was then used to determine the protein concentration of each unknown sample. 
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2.9 Western Blotting 
 
2.9.1 Gel electrophoresis 
Proteins for analysis by Western blotting were resolved using SDS-polyacrylamide 
gel electrophoresis (SDS-PAGE). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2.9.1.1: Preparation protocol for SDS-PAGE gels (2 x 0.75 mm gels). 
 
A running gel of required % was prepared according to Table 2.9.1.1.  
The running gel was poured gently into a gel cassette and overlayed with a layer of 
isopropanol.  
The gel was allowed to set for approximately 1 hour at room temperature. 
A stacking gel was prepared according to Table 2.9.1.1.  
The isopropanol was removed from the running gel and the stacking gel poured. A 
comb was inserted and the stacking gel was allowed to set for an hour. The gel rig 
was assembled and the tank filled with 1X SDS running buffer. The gel cassette was 
inserted in the rig and the well comb removed. The wells were washed with running 
Component 
7.5% Gel 10% Gel Stacking 
Gel 
Acrylamide/bis-acrylamide 30% 
solution (Sigma A-3574) 
3.8 ml 5.07 ml 840 μl 
Ultra Pure Water 7.3 ml 5.94 ml 2.84 ml 
1.5M Tris/HCl buffer pH 8.8 
(Biorad 161-0977) 
3.75 ml 3.75 ml N/A 
0.5M Tris/HCl Buffer pH 6.8 
(Biorad 161-0978) 
N/A N/A 1.25ml 
SDS solution 10% (w/v) 
(Biorad 161-0416) 
150 μl 150 μl 50 μl 
Ammonium persulphate 10% 
solution (Sigma A-3678) 
60 μl 60 μl 20 μl 
TEMED (Sigma T-9281) 10 μl 10 μl 5 μl 
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buffer Samples were loaded and the gel was run at a constant voltage of 100-150V for 
approximately 90 minutes or until the dye was about 80% of the way down the gel. 
 
2.9.2 EGFR  
A 7.5% running gel and stacking gel was prepared as in Section 2.9.1. 
Using the data obtained from the protein quantification step, protein samples were 
prepared with 10-30 μg protein in 15 μl plus 15 μl loading buffer (Sigma S-3401)). 
Samples were denatured by heating at 950C for 5 minutes then centrifuged briefly and 
loaded with 30 μl of each sample including 5 μl of standards and molecular weight 
markers (New England Biolabs P-7708S). 
 
2.9.3 P-gp/MRP-1  
A 10% running gel and a stacking gel were prepared as in Section 2.9.1. Protein 
samples were prepared with 25-50 µg protein in 15 µl plus 15 µl of 2X loading buffer. 
Positive controls were included by including 25 µg of P-gp-positive control cell 
extract or 50 µg MRP-1 positive control cell extract. Samples were NOT denatured. 
The gel cassette was inserted in the rig and the well comb removed. The wells were 
washed with running buffer and loaded with 30 μl of each sample including 5 μl of 
pre-stained standards and molecular weight markers (New England Biolabs P-7708S). 
Gel was run as in Section 2.9.1. 
.  
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2.9.4 Blotting protocol 
Once electrophoresis was completed, the gel cassette removed from the tank. The 
glass plates were carefully separated and the stacking gel removed. The gel, PVDF 
membrane (Boehringer Mannheim, 1722 026)) were equilibrated in transfer buffer 
(Biorad 161-0734) for 5-10 minutes.  
12 pieces of 3 mm filter paper (Whatman) were also soaked in 1X transfer buffer. 
The components were then arranged as follows on the cathode of the semi-dry blotter 
(Bio-Rad): 6 pieces of filter paper, PVDF membrane, gel and the remaining 6 pieces 
of filter paper. The stack was then rolled gently to remove any air bubbles that would 
affect transfer. 
Protein transfer was carried out at 250 mA for 60 minutes. After completion of the 
transfer, the position of the standards was marked and the transfer stack disassembled.  
The transfer process was verified by treating the PVDF membrane with 1% Ponceau 
solution for approximately 1 minute. Ponceau was then removed through rinsing in 
water. 
The membrane was incubated in 10 ml of blocking solution (5% Marvel) for 2 hours 
at room temperature. On removal of the blocking solution, the blot was incubated in 
10 ml of TBS (Sigma T5912) containing 1% Marvel and primary antibody overnight 
at 40C on an agitator (Table 2.9.4.1). Primary antibody was removed and three 10 
minute washes in 1X TBS containing 0.5% Tween (Sigma, P7949) were carried out at 
room temperature while shaking.  
 
Table 2.9.4.1  
Antibody Cat # Dilution Storage 
EGFR (Ab-12) 
 
Lab-Vision-MS-
400 
1:1000 4 0C 
P-gp (MDR-1 G-1) Santa Cruz SC-
13131 mouse 
monoclonal 
1:200 4 0C 
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Secondary antibody (1 in 1000 dilution of anti-mouse IgG peroxidase conjugate 
(Dako, P0447) in TBS) was then applied for 1 hour at room temperature with 
agitation. A further three 10 minute washes in 1X TBS-Tween were carried out while 
shaking. 
2.9.5 Enhanced chemiluminescence detection 
 
Note: This procedure was carried out in a darkroom. 
 
The Blot was incubated in ECL solution (Amersham, RPN2109) (1.5 ml solution A + 
1.5 ml solution B) to detect bound peroxidise-conjugated secondary antibody for 1 
minute. 
The membrane was then placed under a sheet of transparent film in a cassette, 
ensuring all air bubbles were removed.   
A sheet of X-ray film (Kodak, X-OMATS) was placed over the membrane and 
exposed for 5-15 minutes (depending on the signal).  
The exposed autoradiographic film was developed for 3 minutes in developer (Kodak, 
LX-24) then washed in water for 15 seconds and transferred to a fixative (Kodak, FX-
40) for 5 minutes.  
The film was washed with water for 5-10 minutes and left to dry at room temperature. 
The membrane was exposed for a longer or shorter time based on initial signal. 
 
2.10 Immunoprecipitation 
 
500 µg of protein lysate was added to ~ 700-800 µl RIPA buffer, ~900 µl in total in 
eppendorfs.  
3 µg of EGFR IP antibody (EGFR Ab-15 (Neomarkers, MS-665-P)) was then added 
to each tube and mixed thoroughly by pipetting. Samples are then shaken at 40C for 
30 minutes.  
50 µl of protein G-agarose beads were added to each tube and mixed thoroughly. 
Tubes were mixed overnight on a blood mixer at 40C overnight.  
Samples were centrifuged at maximum speed for 25 seconds to pellet the protein/bead 
complex. The majority of the supernatant was aspirated leaving ~ 5 µl. Pellets were 
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washed with ~ 500-600 µl wash buffer (1X cell lysis buffer prepared from 10X cell 
lysis buffer (Cell Signalling cat #9803) with added 1X PI cocktail, 1X PMSF and 1X 
sodium orthovanadate) and mixed by inverting 5 times. Samples were centrifuged at 
maximum speed for 25 seconds and the supernatant removed. The wash step was 
repeated twice.  
The last centrifugation lasted 35 seconds and as much supernatant as possible was 
removed. 50 µl 1.2X sample buffer was added to each sample, followed by a vortex to 
mix.  
The samples were then denatured at 950C for 5 minutes. Samples were stored at -200C 
and run on gels according to Section 2.9.1. 
 
 
2.11 Laser Scanning Confocal Microscopy (LSCM) 
 
LSCM was carried out in conjunction with Dr. Finbarr O’Sullivan. Cells were seeded 
at 1 X 105 cells/well on glass coverslip chamber slides (NUNC) 24 hours prior to the 
experiment and cultured at 37ºC and 5% CO2. Medium was removed and for 
epirubicin studies, cells were exposed to 2 µM epirubicin alone or in combination 
with test compound for 120 minutes. Cells containing drug were  
examined by confocal laser scanning microscopy using a Leica TCS AOBS. 
A spectral scan was performed to obtain the optimum excitation and  
emission wavelengths. The spectral scan was performed for excitation at  
458 nm, 476 nm, 488 nm, 496 nm, 514 nm, and 543 nm. Spectral stacks were  
obtained with a 5 nm step size. Using the stack profile tool in the LSC  
software the intensity and spectral profile was obtained. Based on this  
data, epirubicin fluorescence was examined in situ by exciting at 514 nm and emitted 
light between 531-667 nm collected (Em(max) 600 nm). 
For study of tubulin, cells were exposed to 1 µM Oregon-green paclitaxel (Molecular 
Probes) for 120 or 180 minutes. Drug was then removed and replaced with medium. 
Oregon-green paclitaxel was excited at 493 nm with emission at 520 nm. 
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2.12 Time course treatments in A549-Taxol 
 
2.12.1 EGF treatments 
 
8 ml of a cell suspension containing 5 X 105 cells per ml was plated in petridishes and 
incubated at 370C for 24 hours. Medium was then removed and protein extracted from 
one of the petridishes according to the protocol in Section 2.8.1 as a T0 control. The 
petridishes were divided into four sets of three dishes. Each set of three received 8 ml 
of FCS-free medium or 10 ng/ml, 50 ng/ml or 100 ng/ml EGF in FCS-free medium 
and were incubated at 370C. At 12, 24 and 48 hour timepoints, medium was removed 
from one of the petridishes in each group of concentrations and the cells washed in ice 
cold PBS. Protein was extracted according to Section 2.8.1. Samples were stored at -
200C. 
 
 
2.12.2 TKI treatments 
 
8 ml of a cell suspension containing 5 X 105 cells per ml was plated in petridishes and 
incubated at 370C for 24 hours. Medium was then removed and protein extracted from 
one of the petridishes according to the protocol in Section 2.8.1 as a T0 control. The 
petridishes were divided into five sets of three dishes. Each set of three dishes 
received 8 ml of medium, medium and 0.1% DMSO or 2.5, 5 or 10 µM 
lapatinib/erlotinib (or medium and 0.2% DMSO or 5, 10 or 20µM gefitinib) and were 
incubated at 370C. At 12, 24 and 48 hour timepoints, medium was removed from one 
of the petridishes in each group of three and the cells washed in ice cold PBS. Protein 
was extracted according to Section 2.8.1. Samples were stored at -200C. 
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2.13 HPLC-based taxane transport assays 
 
The optimum cell number for these assays was found to be a 75 cm2 flask at 80% 
confluency or a final cell number of 3 X 106 cells. Each data point was carried out in 
triplicate flasks. 
10 µM docetaxel or 10 µM paclitaxel were determined as the concentrations that gave 
a sufficient peak/reading through HPLC measurement. 
 
2.13.1 Taxane accumulation assay in adherent cell lines 
 
Cells were seeded in 75 cm2 flasks at 1 X 105 cells per ml in 10 ml of medium. The 
assay was carried out once the cells have reached 80% confluency (24-48 hours). The 
medium was removed and replaced with 370C medium containing 10 µM docetaxel or 
10 µM paclitaxel for 90 minutes. After incubation, the drug containing medium was 
removed and the cells were washed in cold PBS. After removal of the PBS, 3 ml 
trypsin was added to the flasks. When the cells had detached, 3 ml medium was added 
and the cells transferred to extraction tubes. Samples were then centrifuged at 1000 
r.p.m. for 5 minutes. The supernatant was aspirated and 8 ml cold PBS added. 10 µl of 
each sample was taken for a cell count. Samples were again centrifuged at 1000 r.p.m. 
for 5 minutes. The supernatant was removed with as much as possible being removed 
using lint-free wipes. The resulting pellets were frozen and stored at -200C for 
extraction.  
 
2.13.2 Taxane accumulation profiles 
A set of three flasks was set up as in 2.1.1 for each of the timepoints to be examined. 
Cells were exposed to 10 µM docetaxel for 15, 45, 75, 105 and 135 minutes and the 
procedure described in 2.1.1 followed. 
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2.13.3 Taxane efflux profiles 
 
A set of three flasks was set up as in 2.1.1 for each of the timepoints to be examined. 
Cells were incubated with 10 µM docetaxel for 90 minutes. After 90 minutes the drug 
containing medium was removed from the cells, the cells were washed with 370C PBS 
and fresh 370C medium applied. After 15, 45, 75, 105 and 135 minutes medium was 
removed from a set of three flasks and the cells washed in cold PBS. The cells were 
then trypsinised, washed and counted as in 2.1.1.  
 
2.13.4 Taxane accumulation assays involving MDR modulators 
 
Cells were prepared as in 2.1.1. A set of three flasks was set up for each MDR 
modulator to be tested. These flasks were incubated with 10 µM docetaxel or 10 µM 
paclitaxel combined with each MDR modulator. A control containing 10 µM 
docetaxel or 10 µM paclitaxel alone was also carried out.  The procedure in 2.1.1 was 
followed. The addition of drug to each set of flasks was staggered by 20 minutes to 
allow time for each set of flasks to be taken down. 
 
2.13.5 Taxane accumulation assays in non-adherent cell lines 
 
Triplicate flasks containing 10ml of cell suspension with 1 X 105 cells per ml were set 
up as in 2.1.1. The assay commenced 48 hours after cells were seeded.  To initiate the 
assay, a 10ml solution containing a 2X concentration of 10 µM docetaxel or 10 µM 
paclitaxel plus the compound to be examined was added to the flasks. A 2X 
concentration of 10 µM docetaxel or 10 µM paclitaxel alone was added to a set of 
flasks as a control. The addition of drug to each set of flasks was staggered by 20 
minutes to allow time for each set of flasks to be taken down. After 90 minutes the 
cells were pipetted in to a 30 ml sterilin and centrifuged at 1000 r.p.m. for five 
minutes. The drug containing medium was aspirated and 10 ml cold PBS added to the 
cells and this suspension transferred to an extraction tube. The cells were centrifuged 
again and resuspended in 8 ml cold PBS. 10 µl of this suspension was taken to 
 69
perform a cell count. Following centrifugation, the PBS was carefully removed and 
the pellets stored at -200 C for extraction.  
  
2.13.6 Taxane efflux assay in adherent cell lines 
 
Cells were seeded as described in 2.1.1. Once the cells reached 80% confluency (24-
48 hours), the medium was aspirated and replaced with 10 ml pre-warmed 10 µM 
docetaxel or 10 µM paclitaxel and incubated for 90 minutes. The addition of drug to 
each set of flasks was staggered by 20 minutes to allow time for each set of flasks to 
be taken down. The drug containing medium is then removed. At this stage a set of 
control flasks were taken down for extraction. The remaining flasks were washed with 
pre-warmed PBS and incubated for a further 40 minutes in pre-warmed medium or a 
concentration of test compound. This medium is then removed and the procedure to 
produce a cell pellet for extraction as described in 2.1.1 is followed. 
 
2.13.7 HPLC analysis of taxanes 
 
All reagents used were ultrapure and only HPLC-clean glassware and compatible 
plastics were used. 
 
2.13.7.1 Reagents used 
 
HPLC mobile phase:  
600 ml of taxane mobile phase containing acetonitrile, 35 mM ammonium acetate 
buffer (pH 5) and THF (45:50:5) was carried out as follows as follows: 
0.809 g of ammonium acetate was weighed out and transferred to a cleaned mobile 
phase bottle.  300 ml of water was then added and the pH adjusted to 5 with acetic 
acid. 
270 ml of acetonitrile and 30 ml of THF were then added.  Mobile phase was used 
within one week. 
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Ammonium acetate buffer. pH 5.0 0.1M: 
To make 50 ml 0.0385 g of ammonium acetate was weighed out.  Add 50 ml of water 
were added and the pH adjusted to 5 with acetic acid. The solution was aliquotted and 
kept frozen at -200C.  
 
Internal standard (IS) 
 
A solution of 10 μg/ml paclitaxel (Taxol ®) or docetaxel (Taxotere ®) was prepared 
in methanol for each analysis.  Docetaxel and paclitaxel can both be analysed by this 
method and since both give peaks on the HPLC, one is used as the internal standard 
for the other. 
 
2.13.8 HPLC extraction method for the taxanes 
 
The extraction process and HPLC method were adapted from Ciccolini et al., 2001. 
The frozen pellet of cells was thawed and resuspended in 200 μl of UHP water.  
Each sample had 100 μl of internal standard (I.S.), 2 ml of ethyl acetate (using a glass 
pipette) and 100 μl of 0.1% formic acid added. The internal standard for docetaxel 
was 10 ng/ml paclitaxel made up in methanol and vice versa for taxol. The samples 
were mixed on a blood tube mixer for 5 minutes and then centrifuged at 4000 r.p.m. 
for a further 5 minutes. The samples separated into two layers, the top layer 
containing the extracted taxane. 
The necessary number of glass autosampler tubes was labelled. A glass Pasteur 
pipette was used to remove approximately 1.1 ml to the appropriate autosampler tube. 
The autosampler tubes were then transferred to the evaporation apparatus that had 
already been pre-warmed to 400C.  A few drops of water were added into each of the 
evaporator wells to aid thermal transfer. The extraction solvents were evaporated with 
a stream of nitrogen gas. Once the solvents were completely evaporated, the 
autosampler tubes were covered with septae and plastic lids. The samples were then 
stored at -200C until required for HPLC analysis. 
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2.13.9 Preparation of taxane HPLC standards. 
 
Standards and samples must be prepared at the same time using the same reagents. 
A broad or narrow range of standards was prepared depending on the range of 
samples required. 100 μl of a solution of blank cells was added to an extraction tube. 
All drug samples were made up at 10 X their final concentration in methanol. 100 μl 
of the 10 X drug concentration was transferred to duplicate extraction tubes already 
containing the 100 μl of cells.  The usual broad range of standards used were 50, 250, 
500, 1000, 2500, 5000 and 25000 ng/ml (10 X concentrations). 100 µl of I.S., 100 µl 
of 0.1% formic acid and 2 ml of ethyl acetate were added to each of the duplicate 
standard tubes. A control containing 100 µl UHP instead of a 10X concentration of 
drug and a blank that substituted 200 µl UHP for the I.S. and a 10X concentration of 
drug were also prepared. 
 
 
2.13.10 HPLC analysis of the taxanes 
 
The HPLC analysis was carried out on a Beckman System Gold consisting of a 125 
Solvent Module, a 166 Detector, a 508 Autosampler, a Prodigy reverse phase column 
(ODS3 100A 150 x 4.6mm 5 micron) (Phenomenex, UK) and analysed using the 32 
Karat Software package. The mobile phase consisted of 0.809g ammonium acetate, 
pH 8.8 (acetic acid), 300 ml UHP, 270 ml acetonitrile and 30 ml THF and was 
prepared as in Section 2.13.7.1. The amount of mobile phase required was calculated 
from the number of samples, the flow rate and the analysis time per sample (10-15 
minutes). When ready to analyse the samples, the HPLC was prepared in advance. 
Mobile phase was run at a flow rate of 1.8 ml/minute for approximately 20 minutes 
prior to the start of analysis. The UV detector was set to 227 nm. 
A system check was performed by injecting a taxane sample in methanol and 
demonstrating a suitable peak around the expected retention time. A second injection 
of just mobile phase was run to washout any residue in the needle. 
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Once the system was ready, the autosampler vials were reconstituted with 80 μl of 
mobile phase and fully mixed. 50 μl of each sample was injected onto the column 
using the autosampler. 
 
Analysis started with the standards from lowest concentration to highest, the 
extraction blank and the control (I.S.) should also be included at the start. A wash vial 
of mobile phase was inserted between the standards and the samples to avoid cross 
over. 
 
2.14 HPLC-based epirubicin transport assays 
 
2.14.1 Epirubicin accumulation assays in adherent cell lines 
Cells were seeded into 25 cm2 flasks (Costar, 3375) at 0.5 X 106 cells per flask. Cells 
were incubated for 48 hours, after which time medium was removed and fresh medium 
containing epirubicin (2 μM) or combinations of both epirubicin and compound of 
interest were added. Flasks were incubated at 370C for a period of two hours. 
 
2.14.2 Epirubicin efflux assays in adherent cell lines 
For efflux studies, the media was removed from all flasks and replaced with fresh media, 
or media containing test compound as the experiment required after the two-hour 
incubation. The flasks were returned to the 370C incubator. 
At relevant time points the media was removed from the flasks and the flasks washed 
twice with PBS. Cells were trypsinised as described in Section 2.5.1 and counted as 
described in Section 2.5.2. Pellets were washed with PBS and frozen at -200C. 
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2.14.3 Quantification of epirubicin by HPLC 
 
Reagents used: 
 
Epirubicin mobile phase 
0.854 ml of formic acid was added to 400 ml of ultrapure water. The pH was brought 
to 3.2 using 1M ammonium formate. 200 ml of acetonitrile was added and the 
solution was mixed and left to settle for a few hours with the lid tightly closed. 
1M Ammonium Formate Buffer 
15.76 g of Formic acid ammonium salt was added to 200 ml of water in a volumetric 
flask. The pH was adjusted to 8.5 with concentrated ammonia. The volume of the 
solution was brought to 250 ml with ultra pure water. The solution was aliquoted into 
20 ml stocks and frozen at –200C in order to keep it fresh. 
 
33% Silver Nitrate (w/v) 
3.3 g of silver nitrate powder was added to a 10 ml universal. Water was then added 
to the 10 ml mark. The universal was covered in tin foil, as it is light sensitive and 
kept frozen at –200C.  
Daunorubicin internal standard 
A 1 μg/ml solution of daunorubicin was made in ultra pure water and covered in tin 
foil as it is light sensitive. 
Epirubicin standards 
Epirubicin standards were made in ultra pure water at 50, 250, 500, 1000, 2,500, 
5,000, and 25,000 ng/ml. (these were 10 X concentrations). 
 
2.14.4 Epirubicin extraction procedure 
 
The frozen pellets of cells were thawed and re-suspended in 200 μl of ultra pure 
water. The cells were transferred to a polypropylene extraction tube. In the case of the 
epirubicin standards 100 μl of blank cells were added to the extraction tubes. 100 μl 
of the each 10 X epirubicin standard was added to duplicate tubes. 
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20 μl of silver nitrate solution, 100 μl of daunorubicin internal standard, 700 μl of ice-
cold isopropanol, 100 μl of 1M ammonium formate buffer (pH 8.5) and 1400 μl of 
chloroform were added to each tube. 
The tubes were mixed on a blood mixer for 5 minutes 
Following centrifugation at 4000 r.p.m. for 5 minutes, the liquid clarified to two 
separate layers. The bottom organic layer contained the drug. 
1.1 ml of the bottom layer from each tube was removed using a glass Pasteur pipette 
to an auto sampler tube. 
An evaporation apparatus was set up and pre-warmed to 400C. A few drops of water 
were added into each evaporating well. 
The auto sampling vials were placed into the evaporating wells. 
The liquid in each auto sampling tube was evaporated with a stream of nitrogen gas. 
When all liquid had evaporated the vials were covered with septae and lids and frozen 
at –200C. 
 
2.14.5 Preparation of epirubicin HPLC standards. 
 
100 μl of a solution of blank cells was added to duplicate extraction tubes. 100 μl of 
the each 10 X epirubicin standard was added to the tubes containing the 100 μl of 
cells. 
The usual range of standards used were 50, 250, 500, 1000, 2500, 5000 and 25000 
ng/ml (10 X concentrations). 20 μl of silver nitrate solution, 100 μl of daunorubicin 
internal standard, 700 μl of ice-cold isopropanol, 100 μl of 1M ammonium formate 
buffer (pH 8.5) and 1400 μl of chloroform were added to each tube. 
The tubes were mixed on a blood mixer for 5 minutes 
Following centrifugation at 4000 r.p.m. for 5 minutes, the liquid clarified in to two 
separate layers, the bottom layer containing the drug. 
A control containing 100 µl UHP instead of a 10 X concentration of drug and a blank 
that substituted 200 µl UHP for the I.S. and a 10 X concentration of drug were also 
prepared. 
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2.14.6 HPLC analysis of epirubicin.  
 
The HPLC was left at a flow rate of 0.5 ml/minute of mobile phase (see Section 
2.14.3.1), flowing over a Prodigy reverse phase column (ODS3 100A, 150 × 4.60 
mm, 5 micron) (Phenomemex, UK) for 20 minutes prior to beginning analysis.  
The same Beckman System Gold HPLC system with integrated pump, autosampler 
and UV detector as used with the taxanes was utilised with a Hitachi LaChrom 
fluorescence detector (L-7480) coupled to the system. 
UV measurement was performed at 253 nm and fluorescence measurement at 480 nm 
excitation and 560 nm emission wavelengths. 
Analysis continued as per Section 2.13.10, starting with a system check sample of 
epirubicin and then doxorubicin.  
 
2.14.7 HPLC data analysis 
 
The HPLC produced measurements of the areas of each peak in a sample.  The area 
calculation of the software was double checked to make sure that they were accurate. 
Once the docetaxel and paclitaxel peaks were identified, the data was exported in to 
Microsoft Excel. A peak area ratio (P.A.R.) was generated for all the samples.  This is 
the area of the paclitaxel, docetaxel or epirubicin peak (whichever is being measured) 
divided by the area of the I.S. The P.A.R. results for the standards are used to generate 
a concentration versus P.A.R. curve. The concentrations used were 1 X as only 100 μl 
of the standard had been included. The reverse plot is used to generate the equation of 
the line. The formula of the line was then used to convert the P.A.R. of each unknown 
sample to mass paclitaxel, docetaxel or epirubicin measured in nanograms. The cell 
counts obtained during the assay were then used to express the result as ng of drug per 
million cells. 
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2.14.8 Quantification of epirubicin by mass spectrometry 
 
Cellular levels of epirubicin were quantitated using LC-MS analysis as previously 
reported [257].  Briefly, 5 ml of cell suspension was seeded into 25cm2 flasks at 1 X 
105 cells per ml in triplicate and incubated at 370C for 24 hours. 2 µM epirubicin was 
added to the medium and the cells were incubated for 2 hours in the presence or 
absence of test compound. Cells were then washed with ice-cold PBS, trypsinised and 
cell counts performed. Epirubicin was extracted from the cells using a liquid-liquid 
extraction method and epirubicin levels were quantitated on an LC –MS system 
consisting of MDLC (GE Healthcare Life Sciences, Bucks., U. K.) coupled to an LTQ 
hybrid ion trap mass spectrometer (Thermo Scientific, MA, U.S.A.). 
 
2.15 14C docetaxel radiolabel assays 
 
2.15.1 Standard curve 
 
Dilutions of 14C docetaxel at 0.01, 0.05, 0.1, 0.25, 0.5, 1, 2 and 5 µM were made in 
0.1M NaOH. 250 µl of each dilution was added to a scintillation vial containing 3 ml 
of scintillation fluid. A blank containing 250 µl 1M NaOH was also included. All 
points were carried out in duplicate. The samples were read on the scintillation 
counter, producing C.P.M. values.  
To examine the effect of cell debris on docetaxel radioactivity, the same standards 
were prepared in 0.1 M NaOH. Cells were seeded at 1 X 105 cells per ml per well in a 
24 well-plate. Medium was removed from the cells followed by two washes with cold 
PBS. Ensuring all PBS was removed from the wells, 250 µl of each duplicate 14C 
docetaxel concentration was added to a cell-containing well. The 14C docetaxel 
concentrations were mixed thoroughly, transferred to a scintillation vial containing 3 
ml scintillation fluid and read on the scintillation counter. 
 77
 
2.15.2 Saturation assay 
 
Each well in a 24-well plate was seeded with 1 ml of cell suspension containing 1 X 
105 cells per ml. Following a 24 hour incubation at 370C, medium was removed from 
the cells. 500 µl of pre-warmed 14C docetaxel at concentrations of 5, 15, 25, 50, 75, 
100, 200, 300, 400 and 500 nM were added to duplicate wells in medium containing 
5% FCS. Warm media was added to the four remaining wells that were to be used for 
cell counts. The cells were incubated with the 14C docetaxel concentrations for 90 
minutes at 370C. Drug containing medium was aspirated and the cells washed twice in 
cold PBS. 250 µl of 1M NaOH was added to each well and then transferred to 
scintillation vials containing 3 mL scintillation fluid to be analysed. Medium was 
removed from the four remaining wells on the plate, the cells trypsinised and a cell 
count performed. 
 
 
2.15.3 Serum accumulation assay 
 
21 wells of four 24-well plates (A, B, C, and D) were seeded with 1 ml of cell 
suspension containing 1X105 cells per ml. Following a 24 hour incubation at 370C, 
medium was removed from the cells. 100 nM concentrations of 14C docetaxel were 
prepared in 0, 1, 5, 50 and 100% FCS with medium. All samples were pre-warmed. 
500 µl of these concentrations were applied to each of the plates in triplicate wells. 
500 µl of medium was applied to the three wells to be used for cell counts. Drug was 
removed from plate A after 30 minutes, plate B after 60 minutes, plate C after 90 
minutes and plate D after 120 minutes. Each well was washed twice with cold PBS 
and 250 µl of 1M NaOH was added. Samples were then transferred to scintillation 
vials containing 3 ml scintillation fluid to be analysed. Medium was removed from the 
three remaining wells on each plate, the cells trypsinised and a cell count performed. 
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2.15.4 Accumulation assay 
 
Each well in a 24-well plate was seeded with 1 ml of cell suspension containing 1 X 
105 cells per ml. Following a 24 hour incubation at 370C, medium was removed from 
the cells. A solution of 2X 100 nM (or 500 nM) 14C docetaxel was prepared. Three 
wells received 250 µl medium, 15 wells received the test compound at various 
concentrations and three wells received the vehicle control. 500 µl medium was 
placed in the remaining three wells required for cell counts. Triplicate wells allows for 
a maximum of 5 test compound concentrations. 250 µl 2X 100 nM 14C docetaxel was 
then added to the 21 test wells. Drug was removed after 90 minutes and each well was 
washed twice with cold PBS and 250 µl of 1M NaOH was added. Samples were then 
transferred to scintillation vials containing 3 ml scintillation fluid to be analysed. 
Medium was removed from the three remaining wells on each plate, the cells 
trypsinised, and a cell count performed. All medium used in the assay was pre-
warmed to 370C. 
 
2.15.5 Time accumulation profile  
 
Each well in a 24-well plate was seeded with 1 ml of cell suspension containing 1 X 
105 cells per ml. Following a 24 hour incubation at 370C, medium was removed from 
the cells. 500 µl of 100 nM 14C docetaxel was added to 20 wells and 500 µl medium 
to the remaining 4 wells used for cell counts. The plate was incubated at 370C. At the 
10, 30, 50, 70, 90, 110, 130, 150, 170 and 190 minute timepoints, drug was removed 
from duplicate wells, the cells washed twice in cold PBS and 250 µl 1M NaOH 
added. Samples were then transferred to scintillation vials containing 3 ml 
scintillation fluid to be analysed. After the 190 minute timepoint, medium was 
removed from the three remaining wells on each plate, the cells trypsinised, and a cell 
count performed. All medium used in the assay was pre-warmed to 370C. 
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2.15.6 Efflux profile  
 
Each well in a 24-well plate was seeded with 1 ml of cell suspension containing 1 X 
105 cells per ml. Following a 24 hour incubation at 370C, medium was removed from 
the cells. 500 µl of 100 nM 14C docetaxel was added to 21 wells and 500 µl medium 
to the remaining 3 wells to be used for cell counts. After 90 minutes, the drug 
containing medium was aspirated from all 21 wells, 14C docetaxel levels were 
examined in 3 of the wells as a control and 500 µl fresh medium was placed on 18 of 
the wells. At the 10, 20, 40, 60, 80 and 100 minute timepoints drug was removed from 
triplicate wells, the cells washed twice in cold PBS and 250 µl 1M NaOH added. 
Samples were then transferred to scintillation vials containing 3 ml scintillation fluid 
to be analysed. After the 100 minute timepoint, medium was removed from the three 
remaining wells on each plate, the cells trypsinised, and a cell count performed. All 
medium used in the assay was pre-warmed to 370C. 
 
2.15.7 Temperature accumulation assay 
 
Four wells of twenty 24-well plates were seeded with 1 ml of cell suspension 
containing 1 X 105 cells per ml. Following a 24 hour incubation at 370C, medium was 
removed from the cells. 500 µl was added to 3 of the wells in each plate and 500 µl 
medium to the remaining well to be used for a cell count. Four plates were placed in 
an incubator at 0, 27, 37, 41 and 460C. A plate was taken from each incubator at the 
30, 60, 90 and 120 minute timepoints. At each timepoint, drug was removed from 
triplicate wells, the cells washed twice in cold PBS and 250 µl 1M NaOH added. 
Samples were then transferred to scintillation vials containing 3 ml scintillation fluid 
to be analysed. Medium was removed from the remaining well on each plate, the cells 
trypsinised, and a cell count performed. All medium used in the assay was pre-
warmed to 370C. 
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2.16 ELISAs 
Samples were extracted and quantified as in Section 2.8.  EGFR levels were examined 
using developmental sandwich ELISA assay kits, DY231 and DY1854 while Her-2 
levels were determined using a rapid format sandwich ELISA kit, QIA10. 
 
2.16.1 EGFR 
 
Extracellular EGFR domain (R&D Systems, DY231) 
 
This kit utilised antibodies against an extracellular domain of EGFR. The capture 
antibody (Part 840830) was diluted to the working concentration of 0.8 µg/ml in PBS 
without carrier protein. A treated 96-well plate (Nunc, 467466 F16 Maxisorp) was 
coated with 100 µl per well of the diluted capture antibody. The plate was sealed and 
incubated overnight at room temperature. The following day, each well was aspirated 
and washed with wash buffer (0.05% Tween in PBS, pH 7.2-7.4), repeating the 
process two times for a total of three washes. To wash, each well was filled with 400 
µl wash buffer using a squirt bottle. Complete removal of liquid at each step was 
essential for good performance. After the last wash, any remaining wash buffer was 
removed by inverting the plate and blotting it against clean paper towels. Plates were 
then blocked by adding 300 µl of reagent diluent to each well (1% BSA in PBS, pH 
7.2 to 7.4). The plate was then incubated at room temperature for a minimum of 1 
hour, followed by three washes with wash buffer. The plate was then ready for sample 
addition. 
 
100 µl of sample containing 50 µg of protein or standards (Part 840832, recombinant 
human EGFR) was added in reagent diluent per well. A seven point standard curve 
using 2-fold serial dilutions from 2000 pg/ml was used. An adhesive strip was used to 
cover the plate and it was then incubated for 2 hours at room temperature. Three 
washes were then repeated as before. 100 µl of the detection antibody (Part 840831, 
biotinylated goat anti-human EGFR) diluted in reagent diluent to 200 ng/ml was then 
added to each well. The plate was covered with an adhesive strip and incubated for 2 
hours at room temperature. Three washes with wash buffer were carried out as before. 
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100 µl of the working dilution of Streptavidin-HRP (Part 890803) was added to each 
well. The plate was covered again and left to incubate for 20 minutes at room 
temperature, avoiding direct light. Wash buffer was used to perform three washes as 
before. 100 µl of substrate solution (R&D Systems, DY999) was added to each well, 
followed by incubation for 20 minutes at room temperature avoiding direct light. To 
terminate the reaction, 50 µl of stop solution (R&D Systems, DY994) was dispensed 
to each well. Gentle agitation mixed the solutions and the optical density of each well 
was read immediately, using a microplate reader set to 450 nm. Wavelength 
correction was set to 540 nm or 570 nm. EGFR levels were determined from a 
standard curve plotting absorbance versus concentration EGFR (ng/ml). Final EGFR 
concentration (pg/µg total protein) was calculated from the sample concentration (50 
µg/100 µl). 
 
Intracellular EGFR domain (R&D Systems, DY1854) 
 
This kit used antibodies detecting the intracellular domain of EGFR. The procedure 
was the same as that for DY1854 with a number of variations. Samples and standards 
were diluted in IC Diluent #12 (1% NP-40, 20 mM Tris (pH 8.0), 137 mM NaCl, 10% 
glycerol, 2 mM EDTA, 1 mM activated sodium orthovanadate). Detection antibody 
was diluted to a working concentration of 200 ng/ml with IC Diluent # 14 (R&D 
Systems, DY995), as was the Streptavidin-HRP conjugate. EGFR levels were 
determined from a standard curve plotting absorbance versus concentration EGFR 
(ng/ml). Final EGFR concentration (pg/µg total protein) was calculated from the 
sample concentration (50 µg/100 µl). 
 
2.16.2 Her-2  
 
C-erbB2/c-neu rapid format ELISA kit (Cat# QIA10) 
 
Samples were prepared as in Section 2.8. The appropriate number of capture antibody 
pre-coated wells were removed and placed in the well holder. A working solution of 
wash buffer was prepared by adding 25 ml of the 20 X concentrated solution 
(provided), to 475 ml of deionized water and mixed well. Lyophilised standard was 
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reconstituted in dH2O to give a concentration of 3 ng/ml by carefully. The 
reconstituted standard was left sit for 15 minutes at room temperature, with occasional 
swirling. Excessive agitation of the standard was avoided. Two fold serial dilutions of 
the standard were made in sample diluent (supplied) to provide the following 
concentrations: 3, 1.5, 0.75, 0.375, 0.188, and 0 ng/ml. Reconstituted standards were 
discarded after one use. Samples were diluted with sample diluent (provided) to 
contain 50 µg protein per 100 µl. 
Samples and each of the standard concentrations were added in duplicate by pipetting 
100 μl into the appropriate wells using clean pipette tips for each sample. 
Wells were covered with a plate sealer and incubated at room temperature for 2 hours. 
Wells were washed 3 times with 1 X wash buffer making sure each well was filled 
completely. 100 μl of the detector antibody (provided) was pipetted into each well, 
covered with a plate sealer and incubated at room temperature for 1 hour. 
Wells were washed 3 times with 1 X wash buffer, again making sure each well was 
filled completely. 500 X Conjugate 1:500 was diluted in conjugate diluent to provide 
100 μl of 1 X solution for each sample and standard well The solution was filtered 
with a 0.2 μm syringe filter prior to use. 
100 μl of the 1 X Conjugate was pipetted into each well, covered with a plate sealer 
and incubated at room temperature for 30 minutes. Wells were washed 3 times with 
wash buffer making sure each well was filled completely. 
The entire plate was flooded with dH2O. Contents of the wells were removed by 
inverting over a sink and residual dH2O by tapping on paper towels. 
100 μl of substrate solution (provided) was added to each well and incubated in the 
dark at room temperature for 30 minutes. The reaction was terminated by addition of 
100 μl of stop solution to each well in the same order as the previously added 
substrate solution. 
Absorbance was measured in each well using a spectrophotometric plate reader at 
dual wavelengths of 450/595 nm (or 450/540 nm). Wells were read within 30 minutes 
of adding the stop solution. Her-2 levels were determined from a standard curve 
plotting absorbance versus concentration Her-2 (ng/ml). Final Her-2 concentration 
(pg/µg total protein) was calculated from the sample concentration (50 µg/100 µl). 
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2.17 Determination of cellular ATP levels 
 
Cellular ATP levels were determined using the bio-luminescent luciferase-based 
Enliten ® ATP assay system (Promega, FF2000). The light producing reaction which 
is catalysed by the luciferase enzyme is given below: 
 
 
luciferin + O2 + ATP                             oxyluciferin + AMP + PPi + C O2 + light@562nm 
 
A concentration of 1% trichloroacetic acid (TCA) was used to extract ATP from cells. 
Application of TCA to living cells disrupts the cell membranes allowing release of 
cell contents (including ATP) and TCA irreversibly inactivates the enzymes which 
catalyse ATP conversion reactions. For maximum ATP yield, the pH must be acidic 
(pH < 1.2) during the extraction procedure. The indicator xylenol blue is included 
during the extraction procedure to give a visual indication of the pH. A red colour is 
representative of a pH of less than 1.2.  TCA concentrations greater than 0.1% inhibit 
the luciferase reaction and so samples must be diluted in tris-acetate buffer before 
determination of the ATP content. This also raised the pH to ~ 7.5, the optimal 
conditions for the luciferase reaction (xylenol blue- yellow, pH 2.8-8.0).  A final 
concentration of < 0.002% xylenol blue was required for negligible 
spectrophotometric interference. 
 
Note: all efforts were made to ensure minimum contamination by external sources of 
ATP. Autoclaved tips and glassware, sterile plastics and gloves were used throughout. 
 
2.17.1 Reagents  
 
0.1 M Tris Acetate buffer (with 2 mM EDTA):  0.372 g of EDTA (Sigma, E6758) 
was dissolved in 75 ml of dH2O by heating. 6.06 g of tris acetate (Sigma, T1258) was 
then added and dissolved by heating. The solution was allowed to cool and the pH 
adjusted to 7.75 with acetic acid and made up to 500 ml.  
 
luciferase
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10% TCA solution (including 4 mM EDTA with 0.002% xylenol blue): 0.149 g 
EDTA was dissolved in 50 ml dH2O by heating. 2 mg of xylenol blue (Sigma, 
114561) was added and dissolved by heating. Addition of 10 g of trichloroacetic acid 
(Sigma, T4885) followed and the volume made up to 100 ml with dH2O. 
 
2.17.2 Procedure 
1 ml of a 1 X 105 cells/ml solution were seeded per well of a 24-well plate and 
incubated overnight at 370C. Medium was removed and replaced with pre-warmed 
fresh medium or medium containing ATP depleting agents (sodium azide (Sigma, 
S8032), 2-deoxyglucose (Sigma, D3179) or antimycin A (Sigma, A8674)). Medium 
was replaced in wells included for cell counts also. Following incubation, medium 
was aspirated from the plate and all wells washed with ice-cold PBS. 100 µl of a 1% 
TCA solution (10 ml 10% TCA solution and 90 ml dH2O) was added to each well for 
5 minutes, except the wells providing cell counts, to which 500 µl trypsin was added. 
The presence of a red colour gave confirmation of acidic pH required for ATP 
extraction. 900 µl of 0.1M Tris Acetate buffer was added to each test well producing a 
yellow colour (pH~ 8 as required for luciferase reaction). 500 µl medium was added 
to the cell count wells and the number of cells present determined as in Section 2.5.2. 
10 µl of each sample was then transferred to a 96-well luminescence plate already 
containing 90 µl Tris Acetate buffer per well. Two-fold serial dilutions of the 100 nM 
ATP standard (Promega FF2000, F203A) to 3.125 nM were prepared in ATP-free 
water (Promega FF2000, F201A). 100 µl of each standard was pipetted into the 96-
well luminescence plate in duplicate. The Enliten luciferase/luciferin agent (Promega 
FF2000, F120A) was reconstituted in reconstitution buffer (Promega FF2000, 
F180A). 100 µl of the reconstituted luciferase/luciferin agent was added to each well 
and the luminescence measured on a Bio-Tek II Synergy HT with a sensitivity setting 
of 125 and utilising KC4 Synergy software. A plot of luminescence (RLU, relative 
luminescence units) versus the concentration of the known standards (ng/ml) provided 
the concentration of the samples. The cell counts were used to convert the values to 
ng/10,000 cells once the dilution factor was taken into account.  
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2.18 ATPase Assays 
The ATPase activity of the human multidrug resistance (MDR) transporter proteins P-
gp, MRP-1 and BCRP, was determined using purified membrane vesicles transfected 
to express high levels of the selected human MDR transporter proteins. The ATPase 
activity for measuring human P-gp (SB-MDR1-Sf9-ATPase) and MRP-1 (SB-MRP1-
Sf9-ATPase) ATPase activities were performed in membrane vesicles prepared from 
insect Sf9 (Spodoptera frugiperda) cells, while the wild type BCRP membrane 
vesicles (SB-MXR-M-ATPase) were prepared from selected mammalian cells. The 
membrane vesicles and assay protocols related herein were supplied by Solvo 
Biotechnology (Hungary). The protocol for the BCRP ATPase assay differs slightly 
from the P-gp and MRP-1 ATPase assay and these differences will be noted 
throughout. 
MDR transporters pump substrates out of the cell by using ATP hydrolysis as an 
energy source. ATP hydrolysis yields inorganic phosphate (Pi), which can be detected 
by a simple colorimetric reaction. The amount of Pi liberated by the transporter is 
proportional to the activity of the transporter. 
In the presence of a transported substrate the ATPase activity of the MDR-transporter 
increases. If a compound is an inhibitor of the transporter, or a slowly transported 
compound, it will inhibit the MDR-ATPase activity measured in the presence of a 
stimulating agent. The BCRP ATPase membrane preparations have a higher intrinsic 
baseline ATPase activity that is activated by some compounds and inhibited by others 
allowing activation and inhibition studies to be performed directly without the need 
for a stimulating agent. 
The ATPase assays are a modification of the method of Sarkadi et al. [258].  
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2.18.1 ATPase assay materials 
A list of the compounds required for the ATPase assays, and the individual storage 
conditions are shown in Table 2.18.1.1 
 
Table 2.18.1.1 Materials required for the ATPase assays. 
Substance Cat. Number Storage 
Tris-Base (Tris[hydroxymethyl]aminomethane) Sigma T-1503 RT, >1year 
MOPS (3-[N-Morpholino]propanesulfonic acid) Sigma M-1254 RT, >1year 
EGTA Sigma E-3889 RT, >1year 
KCl Sigma P-9333 RT, >1year 
Na-azide Sigma S-8032 RT, >1year 
DTT Serva 20710 4 0C, >1 year 
Ouabain Sigma O-3125 RT, >1year 
SDS Sigma L-6026 RT, >1year 
KH2PO4 Sigma P-5379 RT, >1year 
Verapamil Sigma V-4629 RT, >1year 
N-ethylmaleimide (NEM), (for MRP1 studies) Sigma E-1271 4 0C, >1 year 
Glutathione (for MRP1 studies) Sigma G-4251 4 0C, >1 year 
Sulfasalazine (BCRP studies) Sigma P-7791 RT, >1 year 
Hoechst 33342 (BCRP studies) Sigma B-2261 -20 0C, >1 year 
Na-Orthovanadate (Na3VO4) Sigma S-6508 RT, >1year 
ATP (disodium salt) Sigma A-2383 -20 0C, >1 year 
MgCl2 (hexahydrate) Sigma M-2670 RT, >1year 
Zinc acetate (dihydrate) Sigma Z-4540 RT, >1year 
Ammonium-molybdate (tetrahydrate) Sigma A-7302 RT, >1year 
Ascorbic acid Pharaceutical 
grade 
4 0C, >1 year 
DMSO Sigma D-2650 RT, >1year 
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2.18.2 ATPase assay stock solutions 
The stock solutions for use in ATPase activation and inhibition assays are given in 
Table 2.18.2.1 and Table 2.18.2.2. UHP water was used for all dilutions. 
Table 2.18.2.1 Stock solutions for use in the ATPase assays.  
 
Solution Storage 
1.7 M Tris 
20.587 g of Tris was dissolved in 100 ml distilled water. 
4 0C, >1 year 
0.1 M MOPS-Tris 
2.09 g of MOPS was dissolved in 90 ml distilled water; the pH was 
adjusted to 7.0 with 1.7 M Tris (about 2 ml). The solution was brought 
to 100 ml with distilled water. 
4 0C, >1 year 
100 mM EGTA-Tris pH 7.0 
38.04 mg of EGTA was dissolved in about 10 ml of 1.7 M Tris. 80 ml 
of distilled water was added and the pH was adjusted to 7.0 with 1.7 M 
Tris. The solution was brought to 100 ml with distilled water. 
4 0C, >1 year 
1 M KCl 
7.46 g of KCl was dissolved in 100 ml distilled water. 
4 0C, >1 year 
0.1 M Na-azide 
0.65 g of Na-azide was dissolved in 100 ml distilled water. 
4 0C, >1 year 
0.1 M DTT 
0.3086 g of DTT was dissolved in 20 ml distilled water. 
-20 0C in small 
aliquots  
10 mM Ouabain 
14.6 mg of Ouabain was dissolved in 2 ml distilled water in a glass tube. 
It was stirred with a glass rod until dissolved. 
Prepare fresh 
5% SDS 
5 g of SDS was dissolvIC100 ml of distilled water. 
RT, > 1 year 
100 mM KH2PO4 
0.1361 g of KH2PO4 was dissolved in 10 ml distilled water. 
-20 0C in small 
aliquots 
Phosphate standard solutions 
0.5 mM, 1 mM, 2 mM, 4 mM and 8 mM KH2PO4 were prepared from 
the 100 mM stock in distilled water. 
-20 0C in small 
aliquots 
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Table 2.18.2.2 Stock solutions for use in the ATPase assays.  
Solution Storage 
0.2 M MgATP 
2.2 g of ATP and 0.8 g MgCl2 were dissolved in 10 ml of distilled water 
and the pH was adjusted to 7.0 with 1.7 M Tris. The solution was 
brought to 20 ml with distilled water. 
-20 0C in small 
aliquots 
2 mM Verapamil (for MDR1 studies) 
A 2 mM stock of Verapamil was made in DMSO. 
-20 0C in small 
aliquots 
0.5 mM Hoechst 33342 (for MXR studies) 
0.5 mM Hoechst 33342 in DMSO 
 
0.5 mM Sulfasalazine (for MXR studies) 
0.5 mM Sulfasalazine in DMSO 
-20 0C in small 
aliquots 
60 mM Na-Orthovanadate 
A 60 mM stock of Na-Orthovanadate was made in distilled water. 
-20 0C in small 
aliquots 
300 mM NEM (for MRP1 studies) 
0.375 g of NEM was dissolved in 10 ml of 0.1 M MOPS-Tris. 
-20 0C in small 
aliquots 
300 mM Glutathione (for MRP1) 
0.922 g of Glutathione was dissolved in 8 ml distilled water and the pH 
was adjusted to 6.8 with 10 M NaOH. The solution was brought to 10 
ml with distilled water. 
-20 0C in small 
aliquots 
150 mM NEM-GS (for MRP1) 
300 mM NEM was mixed with 300 mM glutathione in 1:1 ratio. 
Prepare fresh 
15mM Zinc Acetate 
330 mg of Zinc Acetate was dissolved in 100 ml of distilled water. 
4 0C, 2 weeks 
35 mM Ammonium Molybdate in 15 mM Zinc Acetate pH 5.0 
0.864 g of Ammonium Molybdate was dissolved in 15 ml of Zn Acetate 
and the pH was adjusted to 5.0 with HCl solution. The solution was 
brought to 20 ml with 15 mM Zn Acetate. This solution was stored in a 
container wrapped with aluminum foil in the dark. 
4 0C, 1 week, 
dark 
10% Ascorbic Acid pH 5.0 
1 g Ascorbic Acid was dissolved in 10 ml distilled water and the pH 
was adjusted to 5.0 with NaOH (prepared freshly). 
Prepared 
freshly 
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2.18.3 ATPase assay mix 
The ATPase assay mix was prepared as per Tables 2.18.3.1 and 2.18.3.2. Ouabain and 
DTT were added freshly before use. The rest of the solutions were pre-mixed and 
stored at 40C. 
DMSO was used as the general solvent in these assays with a final concentration of 
2% during the assay. The assays are designed to tolerate up to 2 % of a wide variety 
of solvents (ethanol, acetonitrile, and methanol) that should be included in all controls 
instead of DMSO if used. 
Some molecules require the presence of glutathione to be transported by MRP-1 and 
to modulate the ATPase activity of MRP-1 in ATPase assays. For this reason, 
glutathione was included in the assay mix at a concentration of 2 mM in both MRP-1 
activation and inhibition studies in this project. 
 
Table 2.18.3.1 P-gp and MRP-1 assay mix 
Ingredient Volume (μl) Final concentration 
0.1 M MOPS-TRIS, pH 7.0 5,000 50 mM 
1 M KCl 500 50 mM 
0.1 M Na-azide 500 5 mM 
0.1 M DTT 200 2 mM 
100 mM EGTA-TRIS, pH 7.0 10 0.1 mM 
Distilled Water 3,790  
Total volume 10,000  
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Table 2.18.3.2 BCRP Assay-mix 
Ingredient Volume (μl) Final concentration 
0.1 M MOPS-TRIS, pH 7.0 5,000 50 mM 
1 M KCl 500 50 mM 
0.1 M Na-azide 500 5 mM 
0.1 M DTT 200 2 mM 
100 mM EGTA-TRIS, pH 7.0 10 0.1 mM 
10 mM Ouabain 1,000 1 mM 
Distilled Water 2,790  
Total volume 10,000  
 
2.18.4 Composition of signal 
 
As a result of the relatively complex composition of the assay, transporter activities 
from OD (optical density/absorbance) values can only be calculated with adequate 
controls. Therefore, it was important to understand how the different experimental 
conditions modify the read out (OD, reflecting Pi concentration). The total Pi 
measured is composed of the following elements: 
 
1. There is some Pi present in the final assay suspension (containing the membranes 
and ATP). This is mainly due to the contamination of the membranes and ATP 
with Pi, and some non-enzymatic ATP hydrolysis. 
2. Some of the ATPase activities in the membranes are sodium orthovanadate 
(Na3VO4)-insensitive. This is important to determine since the transporter-
specific, sodium vanadate-sensitive activity can only be calculated by subtracting 
this background sodium orthovanadate-insensitive activity. This activity may 
somewhat vary with membrane stocks, thus including this control in the 
calculations also decreases inter-assay variability 
3. There is a small amount of sodium orthovanadate-sensitive ATPase activity 
present in the membranes not related to transporter ATPase. This can be assayed 
 91
by measuring the sodium orthovanadate-sensitive ATPase activity of a control 
membrane. This was not done for the ATPase assays in this thesis. 
4. The rest of the signal is the transporter specific ATPase activity of the membrane 
suspension, which is sodium orthovanadate-sensitive. Transporters show some 
baseline ATPase activity that varies for different transporters and different 
membrane preparations. Substrates of the transporter stimulate the baseline 
ATPase activity while inhibitors or slowly transported compounds inhibit the 
baseline ATPase activity. 
5. Some drugs are coloured or might interfere with the assay in any other non-
specific way. In order to separate any non-specific effects, test drugs with and 
without 1.2M sodium orthovanadate were included as control wells. 
 
2.18.5 ATPase assay controls 
 
In order to accurately define the Pi liberated due to sodium orthovanadate-sensitive 
transporter activity, a number of controls were set up for measuring different elements 
of the signal. All controls were performed in duplicate. 
 
Control 1: Assay background control: 40 μl membrane in assay mix and 40 μl 5% 
SDS were added to the wells. DMSO (1 μl DMSO/well) was also added because the 
compounds tested were dissolved in DMSO. The plate was preincubated at 370C for 5 
minutes (P-gp and MRP-1) or 320C for 5 minutes (BCRP). 10 μl of 25 mM MgATP 
was added to the wells and the plate was incubated at 370C (P-gp or MRP-1) or 320C 
(BCRP) for the requisite time. The colour reaction for inorganic phosphate was 
developed. This control showed the Pi present in the well without any enzymatic ATP 
hydrolysis. Control 1 served as a quality check of the components of the assay mix, 
solvents and the ATP and membrane used. 
 
Control 2: Sodium orthovanadate-insensitive ATPase activity: 40 μl membrane in 
assay mix and 1 μl of 60 mM sodium orthovanadate were added to the wells (final 
sodium orthovanadate concentration is 1.2 mM). DMSO (1 μl DMSO/well) was 
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added as the compounds tested were dissolved in DMSO. The plate was preincubated 
at 370C for 5 minutes (P-gp and MRP-1) or 320C for 5 minutes (BCRP). The reaction 
was started by adding 10 μl of 25 mM MgATP to the wells and the plate was 
incubated at 370C (P-gp or MRP-1) or 320C (BCRP) for the requisite time. The 
reaction was stopped by adding 40 μl 5% SDS/well at the end of the incubation period 
and the colour reaction for inorganic phosphate was developed. This control showed 
the ATPase activity not sensitive to sodium orthovanadate. 
 
Control 3: Baseline ATPase activity: 40 μl membrane in assay mix and DMSO (1 
μl DMSO/well) were added as the compounds tested were dissolved in DMSO. The 
plate was preincubated at 370C for 5 minutes (P-gp and MRP-1) or 320C for 5 minutes 
(BCRP). The reaction was started by adding 10 μl of 25 mM MgATP to the wells and 
the plate was incubated at 370C (P-gp or MRP-1) or 320C (BCRP) for the requisite 
time. The reaction was stopped by adding 40 μl 5% SDS/well at the end of the 
incubation period and the colour reaction for inorganic phosphate was developed. 
This control showed the basic level of Pi liberation in the presence of a given 
membrane, transporter and solvent for the drugs. For obtaining the vanadate-sensitive 
baseline ATPase activity, Control 2 was subtracted from this value. 
 
Ctrl 4: Fully activated ATPase activity: 40 μl membrane in assay mix was added. 
For the P-gp ATPase assay, 40 μM verapamil was added (1 μl of 2 mM 
verapamil/well), for the MRP-1 assay, 10 mM NEM-GS was added (3.3 μl of 150 
mM NEM-GS/well), and for the BCRP assay, 10 µM sulfasalazine (1 μl of 0.5 mM 
sulfasalazine/well),   to obtain maximum ATPase activity. The plate was preincubated 
at 370C for 5 minutes (P-gp and MRP-1) or 320C for 5 minutes (BCRP). The reaction 
was started by adding 10 μl of 25 mM MgATP to the wells and the plate was 
incubated at 370C (P-gp or MRP-1) or 320C (BCRP) for the requisite time. The 
reaction was stopped by adding 40 μl 5% SDS/well at the end of the incubation period 
and the colour reaction for inorganic phosphate was developed. This control showed 
the maximum level of Pi liberation in the presence of a given membrane and 
transporter. For obtaining the full vanadate-sensitive ATPase activity Control 2 was 
subtracted, for obtaining the drug-stimulated ATPase activity fraction, Control 3 was 
subtracted. 
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Control 5: Inhibited ATPase activity (BCRP only): 40 μl membrane in assay mix 
was added. 10 μM of Hoechst 33342 was added (1 μl of 0.5 mM Hoechst 
33342l/well) to obtain maximum ATPase activity. The plate was preincubated at 320C 
for 5 min. The reaction was started by adding 10 μl of 25 mM MgATP to the wells 
and the plate was incubated at 320C. The reaction was stopped by adding 40 μl 5% 
SDS/well at the end of the incubation period and the colour reaction for inorganic 
phosphate was developed. This control showed ATPase activity in the presence of a 
specific inhibitor of BCRP.  
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2.18.6 MDR-transporter ATPase activation assay procedure 
The assay mix was assembled as per Table 2.18.3.1 or Table 2.18.3.2 and kept on ice. 
The assay components were added to a 96-well plate that was also kept on ice at all 
times as follows. 
A Pi (KH2PO4) calibration series was prepared by adding 10 μl of the phosphate 
standard solutions (Table 2.18.2.1) per well to 40 μl assay mix (to obtain 5-80 nmoles 
of Pi/well). 40 μl 5% SDS was added to these wells. These were performed in 
duplicates. 
The predetermined membrane protein concentration (5 mg/ml) was used to prepare a 
1 mg/ml membrane suspension in the case of P-gp and MRP-1, and a 0.5 mg/ml 
membrane suspension for BCRP by diluting membranes in the assay mix and mixed 
well. 
40 μl of membrane suspension was added to the desired wells of a 96-well plate 
(samples and controls) according to Table 2.18.6.1. 
Control wells were set up according to Section 2.18.5.  
1 µl of 60 mM sodium orthovanadate was added. 1 μl of the required test 
reagents/drugs in DMSO per well were then added to the membrane suspension. 
The plates were then transferred to a 370C (P-gp/MRP-1) or 320C (BCRP) incubator 
and preincubated for 5 minutes. 
A 25 mM MgATP solution was made by diluting the stock ATP solution (0.2 M) in 
assay mix. 
The ATPase reaction was started by the addition of 10 μl of 25 mM MgATP (final 
MgATP concentration was 5 mM). 
The plates were incubated at 370C in an incubator for 20 minutes in the P-gp ATPase 
assays or 60 minutes for the MRP1 ATPase assay. The plates for the BCRP ATPase 
assay were incubated at 320C for 40 minutes. The ATPase reaction was stopped by 
adding 40 μl 5% SDS to each well. 
The detection reagent was prepared by adding 5 ml of 35 mM ammonium molybdate 
in 15 mM zinc acetate to 15 ml of the freshly prepared 10% ascorbic acid. This 
solution was mixed by inverting. 200 μl of detection reagent was added to each well. 
The plate was mixed well by shaking the plates thoroughly. The plates were incubated 
at 370C for 25 minutes, and the OD was read between 630 and 850 nm.  
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Table 2.18.6.1 Standard 96-well plate layout used for ATPase assays 
 1 2 3 4 5 6 7 8 9 10 11 12 
 Calibration Controls Test drug 
A 
Test drug 
A + 
vanadate 
Test drug 
B 
Test drug 
B + 
vanadate 
A 0 Control 1 30 µM 30 µM 30 µM 30 µM 
B 5 nmol Pi Control 2 15 µM 15 µM 15 µM 15 µM 
C 10 nmol Pi Control 3 5 µM 5 µM 5 µM 5 µM 
D 20 nmol Pi Control 4 2.5 µM 2.5 µM 2.5 µM 2.5 µM 
E 40 nmol Pi  1 µM 1 µM 1 µM 1 µM 
F 80 nmol Pi  0.25 µM 0.25 µM 0.25 µM 0.25 µM 
G       
H       
 
 
2.18.7 MDR transporter ATPase inhibition assays 
 
P-gp and MRP-1 inhibition assays were carried out as in Section 2.18.6 with minor 
adjustments to the protocol. 
An excess of an established activator of each MDR transporter was added to provide 
maximum ATPase activity to study the ATPase inhibitory effects of test compounds. 
For P-gp inhibition assays, 25 µl of 2 mM verapamil per ml (40 µM final 
concentration) was added to the membrane suspension AFTER a volume of 
membrane suspension was removed for the Controls.  
For MRP-1 inhibition assays, 82.5 µl of 150 mM NEM-GS per ml (10 mM final 
concentration) was added to the membrane suspension AFTER a volume of 
membrane suspension was removed for the Controls. The assay then proceeded as for 
the activation assays. 
A BCRP inhibition assay was not performed as inhibition of the naturally active basal 
level of BCRP ATPase activity could be determined directly without the use of a 
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stimulating agent. However, a fifth control (Section 2.18.5) was included to determine 
the maximal inhibited ATPase activity and the assay carried out as in Section 2.18.6. 
2.18.8 Calculation of the specific (sodium orthovanadate-sensitive) 
MDR transporter ATPase activities 
 
The average OD values of the duplicate calibration curve and controls were 
calculated. A calibration curve using the calibration curve OD values and the amount 
of Pi (KH2PO4) used (nmol/well) was set up. 
The average OD values of the samples tested were also calculated. The nanomoles of 
Pi liberated in the controls and in the samples were calculated by using the calibration 
curve.  
The Pi liberated in Control 2 was subtracted from Pi liberated in Control 3. This gave 
the baseline sodium orthovanadate-sensitive ATPase activity. 
The Pi liberated in Control 2 from was subtracted from the Pi liberated in Control 4. 
This gave the fully activated sodium orthovanadate-sensitive transporter ATPase 
activity. 
The Pi values determined in the presence of sodium orthovanadate were subtracted 
from the Pi values measured without sodium orthovanadate for each compound 
examined. This gave the sodium orthovanadate-sensitive transporter ATPase activity 
for each drug and drug concentration assayed. 
The Na3VO4-sensitive transporter ATPase activity was calculated in terms of Pi 
liberated/mg membrane protein/min. To do this the nmol/well were divided by the 
amount of membrane protein in each well and the time of incubation in minutes. 
 
2.18.9 Expected MDR transporter ATPase parameters 
 
The expected parameters for ATPase activity as supplied by Solvo Biotechnology 
were as follows. The typical sodium orthovanadate-sensitive ATPase activity of P-gp-
containing Sf9 cell membranes (measured under the above described conditions) was 
8-16 nmoles Pi/mg membrane protein/min. This activity increased to 35-60 nmoles 
Pi/mg membrane protein/min in the presence of 20-40 μM verapamil. The nmoles 
Pi/mg membrane ATPase activity of the MRP-1 membranes was significantly lower 
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for MRP-1. The basal ATPase activity was 3-6 nmoles Pi/mg membrane protein/min, 
stimulated to 9-18 nmoles Pi/mg membrane protein/min in the presence of 10 mM 
NEM-GS. The BCRP membranes were expected to have a baseline activity of 5-10 
nmoles Pi/mg membrane protein/min, a maximal activity of 15-25 nmoles Pi/mg 
membrane protein/min and an inhibited activity of 0-3 nmoles Pi/mg membrane 
protein/min. 
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Chapter 3. HPLC- determined taxane accumulation 
and efflux in MDR and sensitive human lung and 
leukemic cell lines 
 99
3.1 Introduction 
 
To study taxane transport effectively, a sufficiently sensitive method to measure 
changes in taxane levels in multi-drug resistant and sensitive cell lines was required. 
Our group had used high performance liquid chromatography (HPLC) to measure 
levels of the anthracyclines successfully in the past [160]. On developing a HPLC-
based procedure for taxane measurement, a number of issues were identified.  
To establish the basic parameters of taxane transport, docetaxel and paclitaxel 
accumulation were examined in a panel of non-small cell lung cancer (NSCLC) cell 
lines. The sensitive adenocarcinoma cell line, A549, and squamous cell, DLKP, cell 
line were chosen along with the drug resistant DLKP-A (high P-gp over-expression) 
and DLKP-TXT (low P-gp expression).  
The HL-60s cell line was utilised to compare docetaxel and paclitaxel transport in a 
cell line devoid of major efflux transporter activity. Taxane transport was also 
examined in the drug-resistant, MRP-1 over-expressing, variant, HL-60 ADR, to 
investigate if MRP-1 expression changed taxane accumulation. 
The effects of potent P-gp inhibitors on taxane transport in drug resistant cell lines 
was assessed to define the range of measurement facilitated by the HPLC method 
within which potential new P-gp inhibitors could be ranked. The assays were also 
carried out in the sensitive cell lines to provide a negative control and discount the 
possibility of other taxane efflux mechanisms in these cell lines. 
Sulindac was found to be an MRP-1 inhibitor by our group [160]. To explore any 
possible interactions between sulindac and P-gp and other putative taxane 
transporters, sulindac was studied in taxane transport assays in all cell lines. 
Preliminary studies in A549 and DLKP utilising compounds known to deplete ATP 
levels were performed to provide an insight into the plausibility of an energy-
dependent influx mechanism in lung cancer cells and assess the potential of the HPLC 
method for quantifying such changes accurately. 
 100
HPLC-based analysis was used to examine taxane accumulation and efflux in non-
small cell lung cancer (NSCLC) cell lines and two leukaemia cell lines, HL-60 and 
HL-60ADR. Time-points, cell number and drug concentration were optimised and the 
assay was then used to examine the influence of P-gp and MRP-1 expression on 
taxane accumulation. Cyclosporin A, verapamil and the third generation inhibitor, 
elacridar (GF120918), were used to examine the involvement of P-gp in taxane 
transport.  
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3.2 Drug selection and P-gp expression 
 
P-gp expression was analysed in the panel of cell lines by western blot (Figure 3.1.1). 
P-gp was detected in the taxane selected cell lines, DLKP-TXT (selected with 
docetaxel by Dr. Yizheng Liang) and A549-Taxol (selected with paclitaxel by Dr. 
Laura Breen). Significantly elevated levels of P-gp were detected in the doxorubicin 
(adriamycin)-selected DLKP-A. The DLKP and A549 parent cell lines and the 
mitoxantrone-selected DLKP-Mitox did not express measurable levels of P-gp by 
Western blot. 
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A 
 
 
  
B 
 
 
  
 
Figure 3.2.1 Western blot for P-gp (A) in two NSCLC cell lines and drug selected 
variants. DLKP-TXT was selected with docetaxel, DLKP-Mitox was selected with 
mitoxantrone and A549-Taxol was selected with paclitaxel (® Taxol). Samples were 
also blotted for alpha-tubulin expression (B). 
 
170 kDa   
P-gp 
50 kDa  
α-tubulin 
1        2        3        4        5          6        7 
1        2        3        4        5          6        7 
1 - DLKP-TXT 
2 - DLKP-Mitox 
3 - Blank 
4 - DLKP  
5 - A549-Taxol 
6 - A549 
7 - DLKP-A (+ control) 
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3.3 Optimisation of drug exposure for HPLC analysis 
 
Cellular docetaxel accumulation levels were measured in A549 cells exposed to 10 
μM docetaxel for various durations up to 140 minutes (Figure 3.3.1). Docetaxel 
accumulation was found to be gradual. 90 minutes was chosen as a practical time-
point that resulted in a measurable mass of docetaxel and would allow observation of 
differences in docetaxel accumulation.  
The efflux profile for docetaxel in A549 cells was measured after exposure to 10 μM 
docetaxel for 90 minutes (Figure 3.3.2). After the 90 minutes exposure the drug was 
removed and replaced with fresh medium and efflux was measured at various time-
points, up to 140 minutes. 40 minutes was chosen as the time-point for measurement 
of efflux as the level of docetaxel plateaued within this time. 
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Figure 3.3.1 HPLC accumulation profile of 10 μM docetaxel over time in A549, 
measured as the mass of docetaxel (ng) accumulated in 106 cells. Data are mean +/- 
SD calculated on experiments performed in triplicate. 
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Figure 3.3.2 Profile of docetaxel efflux from A549 cells after treatment with 10 µM 
docetaxel for 90 minutes. After 90 minutes, the drug was removed and replaced with 
fresh medium (T0) and the mass of docetaxel retained in the cells was measured at 
various time-points up to 135 minutes. Data are mean +/- SD calculated on 
experiments performed in triplicate. 
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3.4 Effects of sulindac on docetaxel accumulation and efflux in the 
A549 cell line. 
 
A549 cells were incubated with 10 μM docetaxel and various concentrations of the 
MRP-1 inhibitor sulindac for 90 minutes (Figure 3.4.1). 5, 10 and 20 μM sulindac are 
clinically relevant concentrations. All three concentrations of sulindac had no effect 
on docetaxel accumulation in this cell line. 
To examine the effect of sulindac on docetaxel efflux in the A549 cell line, cells were 
incubated with 10 μM docetaxel for 90 minutes. The drug was then removed and 
replaced with medium or varying concentrations of sulindac for 40 minutes (as 
determined from Figure 3.4.2). 5, 10, and 20 μM sulindac had no significant effect on 
docetaxel efflux from A549 cells. 
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Figure 3.4.1 Effect of the MRP-1 inhibitor sulindac on the mass of docetaxel (ng) 
accumulated per million cells in the A549 cell line. Cells were incubated with 10 µM 
docetaxel alone or in combination with 5, 10, or 20 µM sulindac for 90 minutes. The 
control contains the concentration of DMSO vehicle present in 20 µM sulindac. Data 
are mean +/- SD calculated on experiments performed in triplicate. † not significantly 
different from control values, P > 0.05 relative to the control (10 µM docetaxel alone). 
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Figure 3.4.2 The effect of sulindac on docetaxel efflux in A549. Cells were exposed 
to 10 μM docetaxel for 90 minutes (control, T0). Docetaxel was removed and 
replaced with medium or medium containing sulindac or DMSO control for 40 
minutes (T40). The control contained the equivalent amount of DMSO present in 20 
μM sulindac. Data are mean +/- SD calculated on experiments performed in triplicate. 
† not significantly different from the T40 medium control, P > 0.05 relative to the T40 
medium control. 
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3.5 Effect of the P-gp inhibitor Elacridar (GF120918) on docetaxel 
accumulation in A549. 
 
The mass of docetaxel accumulated in the P-gp-negative A549 cell line was examined 
in the presence of the P-gp inhibitor elacridar. Cells were incubated with 10 μM 
docetaxel for 90 minutes. The addition of 2.5, 5 and 10 μM elacridar had no affect on 
cellular docetaxel levels after 90 minutes (Figure 3.5.1).  
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Figure 3.5.1 A549 cells were incubated with 10 µM docetaxel or 10 µM docetaxel 
and a range of elacridar concentrations for 90 minutes. A 0.3% DMSO control was 
included with an equivalent amount of vehicle as found in 10 µM elacridar. Data are 
mean +/- SD calculated on experiments performed in triplicate * significantly 
different from control (10 µM docetaxel).  P < 0.05 relative to the control.  
 
 
 
*
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3.6 The effect of sodium azide on taxane transport in A549. 
 
One of the aims of this project was to examine the possibility of the existence of an 
energy-dependent taxane influx mechanism in lung cancer cells. Sodium azide is 
widely used to deplete ATP levels in cell systems. The effect of a wide range of azide 
concentrations on docetaxel accumulation was examined in the A549 cell line using 
glucose-free medium and dialysed serum (serum filtered to remove small molecules < 
10,000 MW) , Figure 3.6.1. The presence of sodium azide did not reduce the amount 
of docetaxel accumulated significantly. A docetaxel accumulation, Figure 3.6.2, and 
efflux assay, Figure 3.6.3, was then carried out in the presence of 10 mM sodium 
azide, glucose free medium and dialysed serum to assess the effects of sulindac on 
taxane transport in conditions with reduced ATP-levels.  Sulindac did not 
significantly affect docetaxel accumulation or efflux in the presence of sodium azide 
in the A549 cell line. 
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Figure 3.6.1 A549 cells were incubated with 10 µM docetaxel or 10 µM docetaxel 
and a range of sodium azide concentrations for 90 minutes. The assay was carried out 
in glucose-free DMEM medium containing 5% dialysed serum. Data are mean +/- SD 
calculated on experiments performed in duplicate. Sodium azide was dissolved in 
water. † no significant difference relative to the control (10 µM docetaxel), P > 0.05 
relative to the control. 
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Figure 3.6.2 The effect of sulindac on docetaxel accumulation in A549 in the 
presence of 10 mM sodium azide. A549 cells were incubated with 10 µM docetaxel or 
10 µM docetaxel and a range of sulindac concentrations for 90 minutes. The assay 
was carried out in glucose-free DMEM medium containing 5% dialysed serum and 10 
mM sodium azide. Sulindac was dissolved in DMSO. Control contained 0.7% 
DMSO. Data are mean +/- SD calculated on experiments performed in triplicate. † no 
significant difference relative to the control (10 µM docetaxel), P > 0.05 relative to 
the control. 
† 
† †
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Figure 3.6.3 The effect of sulindac on docetaxel efflux in A549 in the presence of 10 
mM sodium azide. Cells were exposed to 10 μM docetaxel in glucose-free medium 
(DMEM) for 90 minutes (control, T0). Docetaxel was removed and replaced with 
glucose-free medium or glucose-free medium containing sulindac for 40 minutes 
(T40). The DMSO control was omitted as it was shown to have no effect, Figure 
3.3.2. Data are mean +/- SD calculated on experiments performed in triplicate. 
† no significant difference relative to the control (T40 Medium), P > 0.05 relative to 
the control. 
 
 
 
T 0 T 40 
† †
† 
 115
3.7 The effect of P-gp inhibitors on taxane transport in DLKP. 
 
The DLKP cell line expresses the drug resistance associated MRP-1 efflux pump 
[160]. Cyclosporin A and verapamil are classic P-gp modulators while elacridar is a 
third generation non-reversible P-gp inhibitor. A comparison of taxane accumulation 
in the presence of these inhibitors is shown in Figure 3.7.1. DLKP does not express 
detectable levels of P-gp (Figure 3.2.1). Approximately four times more docetaxel 
than paclitaxel was accumulated in this cell line. None of the P-gp inhibitors affected 
paclitaxel accumulation.  
DLKP cells were loaded with docetaxel for 90 minutes. The drug was then removed 
and the cells were incubated with medium or the P-gp modulators cyclosporin A and 
verapamil. Cyclosporin A had no effect on docetaxel retention while the effect of 
verapamil was minute but significant, Figure 3.7.2. Elacridar and sulindac had no 
significant effect on docetaxel retention, Figure 3.7.3.  
A trypan blue cell viability study was carried out in DLKP to ensure the extreme 
levels of taxanes used in the HPLC assay did not cause direct toxic insult to the cancer 
cells resulting in necrosis within the time frame of the experiment. Docetaxel, rather 
than paclitaxel, was chosen for the experiment given its greater toxicity. Cells were 
grown according to procedure and the percentage cell death determined by the trypan 
blue method (Section 2.5.2). 10 µM docetaxel did not cause a significant increase in 
dead cells in the accumulation and efflux assays compared to the accumulation assay 
control (Table 3.7.1). 
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Figure 3.7.1 Comparison of docetaxel and paclitaxel accumulation in DLKP. Cells 
were exposed to 10 µM docetaxel or paclitaxel for 90 minutes in the presence or 
absence of inhibitor. The ethanol control is specifically for cyclosporin A. Verapamil 
is dissolved in water. Elacridar was delivered in DMSO. Data are mean +/- SD 
calculated on experiments performed in triplicate. † no significant difference relative 
to the control (No inhibitor), P > 0.05 relative to the control. 
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Figure 3.7.2 Docetaxel efflux assay in DLKP. T0 represents the mass of docetaxel 
accumulated in DLKP cells exposed to 10 μM docetaxel for 90 Min. T40 represents 
the mass of docetaxel remaining in the cells 40 minutes after drug removal and in the 
presence of P-gp inhibitors or medium. DLKP does not express P-gp.  Data are mean 
+/- SD calculated on experiments performed in triplicate. * significantly different 
from the control (T40 Medium), P < 0.05 relative to the control.  
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Figure 3.7.3 Docetaxel efflux assay in DLKP. T0 represents the mass of docetaxel 
accumulated in DLKP cells exposed to 10 μM docetaxel for 90 minutes. T40 
represents the mass of docetaxel remaining in the cells 40 minutes after drug removal 
and in the presence of elacridar, sulindac or medium. DLKP does not express P-gp. 
Data are mean +/- SD calculated on experiments performed in triplicate. † no 
significant difference relative to the control (T40 Medium), P > 0.05 relative to the 
control. 
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Table 3.7.1 Measurement of % dead DLKP cells using the trypan blue method. Four cell 
counts were taken from duplicate flasks and the total viable and non-viable cell counts 
averaged to determine % of cells that were dead. † no significant difference, P > 0.05 
relative to the control values. 
 
Conditions % Dead Cells 
Accumulation assay control- 
Medium for 90 minutes 
 
2.96 +/- 0.46 
10 µM docetaxel in medium 
for 90 minutes 
 
4.63 +/- 2.09 † 
Efflux assay control – loaded with 10 µM 
docetaxel for 90 minutes, drug removed 
and replaced with medium for 40 minutes 
 
2.68 +/- 0.61 † 
Loaded with 10 µM docetaxel for 90 
minutes, drug removed and replaced with 
medium containing 0.25 µM elacridar for 
40 minutes 
 
2.96 +/- 2.06 † 
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3.8 The effect of ATP inhibitors on docetaxel accumulation in 
DLKP. 
 
Docetaxel accumulation was examined in the presence of 10 mM sodium azide, 5 
mM 2-deoxyglucose and elacridar in the DLKP cell line, Figure 3.8.1. Sodium azide 
and 2-deoxyglucose are standard agents used to deplete cellular ATP levels. Elacridar 
was included as a negative control for P-gp activity. Addition of 10 mM sodium azide 
in glucose-free medium reduced docetaxel accumulation from 284 ng/million cells in 
the presence of glucose to 148 ng/million cells. The inclusion of 5 mM 2-
deoxyglucose with sodium azide did not significantly decrease docetaxel 
accumulation further compared to sodium azide alone, P = 0.18. The presence of 
elacridar had no significant effect on docetaxel accumulation in DLKP. 
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Figure 3.8.1 DLKP cells were incubated with 10 µM docetaxel or 10 µM docetaxel 
and various combinations of sodium azide, 2-deoxyglucose and elacridar for 90 
minutes. (G) denotes glucose containing DMEM/Ham’s F12 supplemented with 5% 
FCS. (NG) denotes glucose-free DMEM containing 5% dialysed FCS. Sodium azide 
and 2-deoxyglucose were dissolved in water, elacridar was dissolved in DMSO. Data 
are mean +/- SD calculated on experiments performed in triplicate. * significantly 
different from the control (10 µM docetaxel (G)), P < 0.05 relative to glucose 
containing control. 
*
*
*
* 
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3.9 Taxane accumulation and efflux in the multi-drug resistant cell line 
DLKP-A 
 
 
DLKP-A is a resistant variant of DLKP created by increasing exposure to adriamycin 
by Dr. Mary Heenan [259]. The DLKP-A cell line over-expresses P-gp (Figure 3.2.1) 
and is highly resistant to the taxanes. A comparison of docetaxel and paclitaxel 
accumulation in this cell line is shown in Figure 3.9.1. Four times more docetaxel 
than paclitaxel was accumulated in this P-gp over-expressing cell line. Elacridar 
increased docetaxel and paclitaxel retention 4-fold and 2-fold, respectively. 
Cyclosporin A increased accumulation of both taxanes approximately 2-fold. 
Verapamil has no effect on docetaxel levels but a similar affect to cyclosporin A on 
paclitaxel levels. 
Docetaxel and paclitaxel efflux in DLKP-A is shown in Figure 3.9.2. There was 
approximately six times more docetaxel than paclitaxel accumulated in this cell line 
after 90 minutes. Elacridar was the only inhibitor that increased docetaxel retention 
after 40 minutes. Cyclosporin A and verapamil had no effect on docetaxel efflux. 
Sulindac increased docetaxel efflux but not significantly relevant to the control. All 
three P-gp inhibitors successfully maintained control levels (T0) of paclitaxel. 
Cyclosporin A and verapamil are well established P-gp inhibitors. Their poor ability 
modulating docetaxel accumulation and efflux in the DLKP-A cell line (Figures 3.9.1 
and 3.9.2) was not reflected in proliferation assays carried out in this cell line. 
Verapamil had no effect on docetaxel accumulation or efflux but the combination of 
docetaxel (37 nM) with verapamil (1, 2 and 10 μM) resulted in a concentration-
dependent and synergistic increase in toxicity (Figure 3.9.3). All concentrations of 
verapamil used were below 100 μM, the concentration that fails to affect docetaxel 
and paclitaxel accumulation in the HPLC-based assays in this cell line. Verapamil 
also potentiated the toxicity of paclitaxel in DLKP-A (Figure 3.9.4), consistent with 
the HPLC-determined paclitaxel accumulation assay in DLKP-A (Figure 3.9.1). 
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DLKP-A is highly resistant to the taxanes due to high levels of P-gp over-expression. 
Verapamil had little effect on docetaxel accumulation and efflux but did modulate 
paclitaxel levels in these assays. This is reflected in the proliferation assay in Figure 
3.9.4. The combination of 10 μM verapamil (ten-fold less than the 100 μM verapamil 
concentration used in the HPLC assays) and 58 nM paclitaxel is synergistic in this 
seven day proliferation assay. The lower levels of verapamil (1 and 2 μM) did not 
potentiate paclitaxel toxicity. 
DLKP-A cells were exposed to the HPLC assay conditions of 10 µM docetaxel and 
100 µM verapamil for 90 minutes and then allowed to proliferate for six days. The 
three concentrations of verapamil used did not increase docetaxel levels over 90 
minutes as there was only an additive increase in docetaxel toxicity (Figure 3.9.5).  
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Figure 3.9.1 Comparison of docetaxel and paclitaxel accumulation in DLKP-A over 
90 minutes. The DLKP-A cell line was exposed to 10 μM docetaxel or 10 μM 
paclitaxel alone or in the presence of the P-gp modulators, elacridar, cyclosporin A 
and verapamil. Ethanol is the cyclosporin A delivery vehicle. Verapamil and elacridar 
were dissolved in water and DMSO respectively. Data are mean +/- SD calculated on 
experiments performed in triplicate. * significantly different from the control (No 
inhibitor), P < 0.05 relative to control. 
*
* 
* 
*
*
*
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Figure 3.9.2 Comparison of docetaxel and paclitaxel efflux assays in DLKP-A. The 
control, T0, represents DLKP-A cells exposed to either 10 μM docetaxel or 10 μM 
paclitaxel for 90 minutes. The T40 values represent the mass of each taxane 
remaining in the cells 40 minutes after the taxane was removed and various P-gp 
inhibitors or sulindac were added. DLKP-A over-expresses P-gp. The DMSO control 
relates to elacridar. Cyclosporin A, sulindac and verapamil were dissolved in ethanol, 
DMSO and water, respectively. T40 values for 10 µM sulindac and paclitaxel or a 
DMSO control for docetaxel were not obtained. Data are mean +/- SD calculated on 
experiments performed in triplicate. * significantly different from the control (T40 
Medium), P < 0.05 relative to control. 
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Figure 3.9.3 Proliferation assay combining 37 nM docetaxel and 1, 2 and 10 μM 
verapamil in DLKP-A. Cells were seeded in 96-well plates 24 hours before 
application of the drugs and were then allowed to proliferate for a further 6 days. Data 
are mean +/- SD calculated on experiments performed in duplicate. * significantly 
different from the control (37 nM docetaxel alone), P < 0.05 relative to control. 
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Figure 3.9.4 Proliferation assay combining 58 nM paclitaxel and verapamil in 
DLKP-A. Cells were seeded in 96-well plates 24 hours before application of the 
drugs and were then allowed to proliferate for a further 6 days. Data are mean +/- SD 
calculated on experiments performed in duplicate. * significantly different from the 
control (58 nM paclitaxel alone), P < 0.05 relative to control. 
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Figure 3.9.5 Proliferation assay exposing DLKP-A to 10 µM docetaxel and 
verapamil for 90 minutes. Cells were seeded in 96-well plates 24 hours before 
application of the drugs for 90 minutes. The drugs were removed and the cells 
washed. Fresh medium was applied and the cells allowed to proliferate for a further 6 
days. Data are mean +/- SD calculated on experiments performed in duplicate.  
* significantly different from the control (10 µM docetaxel alone), P < 0.05 relative to 
control. 
 
 
 
* 
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3.10 The effect of ATP inhibitors on docetaxel transport in 
DLKP-A 
Docetaxel accumulation was examined in the presence of 10 mM sodium azide, 10 
mM 2-deoxyglucose and elacridar in the DLKP-A cell line, Figure 3.10.1. The 
combination of sodium azide and 2-deoxyglucose is frequently used to deplete 
cellular ATP levels. Elacridar was included as a positive control for inhibition of P-gp 
activity. Addition of 10 mM sodium azide in glucose-free medium increased 
docetaxel accumulation presumably due to inhibition of P-gp efflux activity by 
partially decreasing ATP levels. Concurrent treatment with sodium azide and 
elacridar increased the levels of docetaxel retained further, suggesting a residual P-gp 
activity inhibited by elacridar. The inclusion of 10 mM 2-deoxyglucose with sodium 
azide or elacridar with 2-deoxyglucose and sodium azide did not significantly 
decrease docetaxel accumulation compared to the glucose containing control.
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Figure 3.10.1 DLKP-A cells were incubated with 10 µM docetaxel or 10 µM docetaxel and various combinations of sodium azide, 2-deoxy 
glucose and elacridar for 90 minutes. (G) denotes glucose containing DMEM/Ham’s F12 supplemented with 5% FCS. (NG) denotes glucose-
free DMEM containing 5% dialysed FCS. Sodium azide and 2-deoxyglucose were dissolved in water, elacridar was dissolved in DMSO. Data 
are mean +/- SD calculated on experiments performed in triplicate. * significant, P < 0.05 relative to glucose containing control.
**
*
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3.11 Taxane accumulation in the taxotere-selected cell line DLKP-
TXT. 
 
DLKP-TXT is a docetaxel-selected variant of DLKP that was found to express P-gp 
(Figure 3.2.1), MRP-1 and BCRP (N.I.C.B. culture collection information, [260]). 
The amount of paclitaxel accumulated in DLKP-TXT was approximately one third of 
the amount of docetaxel (Figure 3.11.1). The ratio was closer to 1:4, 
paclitaxel:docetaxel in DLKP and DLKP-A. In this cell line, cyclosporin A > 
elacridar > verapamil at increasing docetaxel accumulation but cyclosporin A was the 
only compound to produce a significant increase (Figure 3.11.1). Although DLKP-
TXT expresses P-gp, elacridar did not have as great an effect on taxane accumulation 
as it did in the DLKP-A cell line. This supports the fact that lower levels of P-gp 
protein are expressed in DLKP-TXT. Interestingly, sulindac decreased paclitaxel 
accumulation in this cell line. Elacridar and verapamil minutely increased paclitaxel 
accumulation, but not significantly. 
Verapamil had little effect on paclitaxel and docetaxel accumulation in the P-gp-
expressing DLKP-TXT. Verapamil did, however, exhibit a synergistic, concentration-
dependent potentiation of docetaxel and paclitaxel toxicity in DLKP-TXT 
proliferation assays. The toxicity of 1 nM docetaxel (Figure 3.11.2) and 5 nM 
paclitaxel (Figure 3.11.3) was significantly potentiated by 5, 10 and 20 μM 
verapamil.  Higher concentrations of verapamil did not increase docetaxel or 
paclitaxel retention in DLKP-TXT over 90 minute accumulation assays.  
Elacridar is a potent P-gp inhibitor and it increased docetaxel and paclitaxel 
accumulation in DLKP-TXT by a small margin (Figure 3.11.1). Proliferation assay 
results show that the lowest concentration tested (0.25 μM), the same concentration 
used in the 90 minute accumulation assay exhibited synergy when combined with 
docetaxel (Figure 3.11.4) and paclitaxel (Figure 3.11.5). 
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Figure 3.11.1 Comparison of docetaxel and paclitaxel accumulation in DLKP-TXT. 
The DLKP-TXT cell line was exposed to 10 μM docetaxel or 10 μM paclitaxel alone, 
or in combination with the P-gp modulators, elacridar, cyclosporin A and verapamil. 
Ethanol is the cyclosporin A delivery vehicle. Verapamil and elacridar were dissolved 
in water and DMSO respectively Data are mean +/- SD calculated on experiments 
performed in triplicate. * significantly different from the control (No inhibitor), P < 
0.05 relative to respective control. 
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Figure 3.11.2 Proliferation assay combining docetaxel (1 nM) and verapamil (5, 10, 20 
μM) in DLKP-TXT. DLKP-TXT expresses P-gp. Verapamil was dissolved in water. 
This result was obtained from a single determination of eight replicates.  Verapamil 
increased docetaxel toxicity in a concentration-dependent manner. 
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Figure 3.11.3 Combination toxicity assay 5 nM paclitaxel and verapamil in DLKP-
TXT. DLKP-TXT expresses P-gp. Verapamil was dissolved in water. This result was 
obtained from a single determination of eight replicates.  Verapamil increased 
paclitaxel toxicity in a concentration-dependent manner. 
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Figure 3.11.4 Proliferation assay combining 5 nM docetaxel and elacridar in DLKP-
TXT. DLKP-TXT expresses P-gp. Elacridar was dissolved in DMSO. This result was 
obtained from a single determination of eight replicates. The combination of 5 nM 
docetaxel and elacridar at all concentrations examined was highly synergistic. 
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Figure 3.11.5 Proliferation assay combining 5 nM paclitaxel and elacridar in DLKP-
TXT. DLKP-TXT expresses P-gp.  This result was obtained from a single determination 
of eight replicates. Elacridar was dissolved in DMSO. The combinations of 5 nM 
paclitaxel and elacridar at all concentrations examined was highly synergistic. 
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3.12 Taxane accumulation in HL-60 and HL-60 ADR 
 
HL-60 is a non-adherent human leukemic cell line [261]. HL-60 accumulated 
approximately 1.2 times the mass of docetaxel than paclitaxel which is much less than 
the ratio observed in any of the other cell lines examined using the HPLC method, 
Figure 3.12.1. DLKP-TXT accumulated approximately three times more docetaxel 
(Figure 3.11.1) and DLKP-A (Figure 3.9.1) and DLKP (Figure 3.7.1), approximately 
four times more docetaxel than paclitaxel. A direct comparison of the mass of taxanes 
retained in the HL-60 vs. the DLKP cell lines cannot be made as there is a considerable 
size difference between these cell lines, the HL-60 cells being smaller than DLKP. The 
results shown support evidence that HL-60 do not express P-gp. The effect of elacridar 
on docetaxel accumulation was not significant. More surprising was the significant 
reduction of accumulation of both taxanes by verapamil. Verapamil is a much less 
specific pump inhibitor than elacridar and cyclosporin A to a lesser extent. 10 µM 
sulindac, an inhibitor of MRP-1, had no significant effect with either taxane. 
A paclitaxel efflux assay in HL-60 reaffirms that this cell line does not express P-gp 
(Figure 3.12.2). 9.6% of the accumulated paclitaxel was retained following 40 minutes 
in drug-free medium. The only significant change in the mass of paclitaxel effluxed 
was a decrease related to 0.25 µM elacridar. Paclitaxel efflux was unaffected by 
verapamil or cyclosporin A. 
The HL-60ADR cell line is a drug resistant variant of HL-60 created by exposure to 
adriamycin (doxorubicin), HL-60ADR over-express the MRP-1 drug efflux pump 
[262]. There was decreased retention of both taxanes in comparison with the HL-60 cell 
line Figure 3.12.3). P-gp inhibitors did not have a significant effect on retention of 
either taxane, bar cyclosporin A, which increased docetaxel accumulation, although not 
significantly. The MRP-1 inhibitor, sulindac, also had no effect on docetaxel or 
paclitaxel accumulation. As with HL-60, approximately 1.4 times the amount of 
docetaxel than paclitaxel was accumulated in this cell line. 
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Figure 3.12.1 Comparison of docetaxel and paclitaxel accumulation in HL-60 over 90 
minutes. HL-60 cells were incubated with 10 μM docetaxel or 10 μM paclitaxel alone 
and in combination with the P-gp modulators elacridar, cyclosporin A and verapamil and 
the MRP-1 inhibitor sulindac for 90 minutes. Elacridar and sulindac were dissolved in 
DMSO. Ethanol is the cyclosporin A delivery vehicle. Verapamil was dissolved in water. 
Vehicle controls have been performed in previous experiments. Data are mean +/- SD 
calculated on experiments performed in triplicate. * significantly different from the 
control (No inhibitor), P < 0.05 relative to control. 
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Figure 3.12.2 Paclitaxel efflux assay in HL-60. The control, T0, represents HL-60 cells 
exposed to 10 μM paclitaxel for 90 minutes. The T40 values represent the mass of 
paclitaxel remaining in the cells 40 minutes after the paclitaxel was removed and the P-gp 
inhibitors elacridar, cyclosporin A or verapamil were added. Cyclosporin A, elacridar and 
verapamil were dissolved in ethanol, DMSO and water, respectively. Vehicle controls 
have been performed in previous experiments. Data are mean +/- SD calculated on 
experiments performed in triplicate. * significantly different from the control (T40 
Medium), P < 0.05 relative to control. 
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Figure 3.12.3 Comparison of docetaxel and paclitaxel accumulation in the MRP-1 
over-expressing HL-60ADR cell line. HL-60ADR cells were incubated with 10 μM 
docetaxel or 10 μM paclitaxel alone and in combination with the P-gp modulators 
elacridar, cyclosporin A and verapamil and the MRP-1 inhibitor sulindac for 90 
minutes. Elacridar and sulindac were dissolved in DMSO. Ethanol was the cyclosporin 
A delivery vehicle. Verapamil was dissolved in water. Data are mean +/- SD calculated 
on experiments performed in triplicate. 
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3.13 Summary of HPLC-based method for taxane measurement 
 
The HPLC assay proved a number of points. A greater mass of docetaxel than 
paclitaxel was accumulated in all cell lines examined, corresponding to the more 
cytotoxic effect of docetaxel in growth assays, although this ratio varied significantly 
between cell lines. The P-gp inhibitors and the MRP-1 inhibitor, sulindac had no effect 
on taxane transport in the non-P-gp-expressing cell lines A549 and DLKP. ATP 
depletion decreased docetaxel accumulation in DLKP but had no significant effect in 
A549. 
 
In the P-gp-expressing DLKP-A, elacridar was the most potent inhibitor of taxane 
transport (in accumulation and efflux studies), followed by cyclosporin A. Verapamil 
did not inhibit docetaxel but did inhibit paclitaxel accumulation and efflux in DLKP-A. 
Verapamil did, however, exhibit synergistic toxicity with both taxanes in cytotoxicity 
assays, suggesting an ability to modulate P-gp. ATP depletion increased docetaxel 
accumulation in this cell line. This effect is examined further in Chapter 6.  
 
DLKP-TXT also expresses P-gp but at lower levels than DLKP-A. The increase in 
docetaxel accumulation caused by cyclosporin A and elacridar in this cell line was not 
as dramatic as that seen in DLKP-A. Verapamil had no effect. Combinations of 
elacridar and verapamil with the taxanes showed equally dramatic synergy in 
proliferation assays. Verapamil, elacridar and cyclosporin A did not significantly affect 
paclitaxel accumulation. Interestingly, sulindac decreased paclitaxel levels in this cell 
line through an unknown mechanism. 
 
The levels of docetaxel and paclitaxel accumulated in HL-60 and HL-60ADR were 
more similar compared to the other cell lines examined. The decrease in HL-60 
docetaxel accumulation related to verapamil was unexpected. Verapamil had a similar 
effect on paclitaxel accumulation in this cell line. Elacridar treatment resulted in a 
minor, but significant, increase in paclitaxel efflux from HL-60. None of the inhibitors 
had a significant effect on docetaxel or paclitaxel accumulation in the MRP-1-over-
expressing HL-60ADR. 
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The studies utilising the HPLC technique for measurement of the taxanes highlighted a 
number of limitations of the method, generally related to the docetaxel and paclitaxel 
levels required in the assays.   
 
• 10 µM of docetaxel or paclitaxel is supraphysiological, limiting extrapolation of 
in vitro data to the in vivo setting. 
• The high concentrations of the taxanes may mask the effects of weaker 
competitive inhibitors. 
• The high concentrations of taxanes may mask the influence of putative uptake 
mechanisms by saturating any such mechanism. Higher taxane concentrations 
also increase the contribution of passive diffusion to taxane accumulation.  
• The assay protocol was not conducive to high through-put of results. 
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Chapter 4. Analysis of epirubicin transport in DLKP-A 
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4.1 Laser scanning confocal microscopy imaging of epirubicin and 
paclitaxel. 
 
The anthracycline epirubicin is a P-gp and MRP-1 substrate and therefore P-gp 
modulators affect epirubicin transport in P-gp-expressing cell lines. Epirubicin is 
naturally fluorescent and its localisation within cells can be observed by laser confocal 
microscopy. Taking exposure time (120 minutes) and epirubicin concentration (2 µM) 
from the anthracycline accumulation assay, a spectral scan was performed on DLKP 
cells exposed to epirubicin for 120 minutes to determine the optimal absorbance (514 
nm) and emission (Em Max. 600 nm) wavelengths (Section 2.11). These values were 
then fixed and used in all epirubicin laser confocal imaging.  
Figure 4.1.1 shows detailed laser confocal images of epirubicin accumulation in the 
DLKP cell line. A single cross section scan revealed epirubicin is not uniformly 
distributed throughout the nucleus but localises at the nuclear envelope and internal 
nuclear structures (Figure 4.1.1A). The combination of a number of cross sections (Z-
plane stack) provides greater detail on the cytoplasmic epirubicin localisation (Figure 
4.1.1B). Numerous, distinct intercellular epirubicin deposits are visible with a definite 
concentration of drug occurring at the plasma membrane. The plasma membrane and 
subcellular localisation are displayed with greater clarity in the further magnified image 
in Figure 4.1.1C. 
Figures 4.1.2, 4.1.3 and 4.1.4 are laser confocal microscope images of DLKP, DLKP-A 
and DLKP-TXT, respectively,  exposed to epirubicin alone (A), or in combination with 
the P-gp modulators elacridar (B), cyclosporin A (C), verapamil (D) or the MRP-1 
inhibitor sulindac (E).  
The compounds had no effect on epirubicin fluorescence in DLKP at the concentrations 
used in HPLC-based taxane accumulation and efflux assays (Figure 4.1.2). 
In the P-gp over-expressing DLKP-A, all three P-gp modulators increased nuclear 
epirubicin fluorescence while the MRP-1 inhibitor sulindac had no effect on nuclear 
epirubicin fluorescence after a two hour exposure period (Figure 4.1.3). 
DLKP-TXT expresses lower levels of P-gp than DLKP-A. The three P-gp modulators 
do not affect nuclear epirubicin fluorescence compared to the control, Figure 4.1.4. The 
MRP-1 inhibitor sulindac decreased nuclear fluorescence of epirubicin. Of note with 
respect to this result is that sulindac also decreased accumulation of paclitaxel, but not 
docetaxel, in DLKP-TXT (Figure 3.10.1). 
 145
 
LSCM images of the microtubulin-labelling Oregon-green paclitaxel were obtained in 
DLKP and A549-Taxol. Over 120 minutes, incubation with 1 µM oregon-green 
paclitaxel gave adequate labelling for visualisation. Tubulin in DLKP had a more 
localised, centralised distribution (Figure 4.1.5) than the more disperse and 
homogenous distribution of tubulin in A549-Taxol (Figure 4.1.6). A wide field view of 
Oregon-green paclitaxel uptake in A549-Taxol revealed inconsistent levels of 
accumulation within the population (Figure 4.1.7). The nuclei of A549-Taxol cells were 
devoid of oregon-green paclitaxel fluorescence and a number of cells contained 
fluorescent oregon-green paclitaxel containing vesicles (Figure 4.1.7). An A549-Taxol 
cell undergoing mitosis was imaged (Figure 4.1.8). The polarised centromeres and 
mitotic spindles are clearly visible.  
Additional three dimensional imaging of epirubicin and paclitaxel in NSCLC cell lines 
is provided in Appendix B. 
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A)         B) 
 
 
 
 
C) 
  
 
Figure 4.1.1 DLKP cells were exposed to a 
concentration of 2 µM epirubicin for 2 hours. 
The drug-containing medium was removed and 
replaced with drug- free medium. Epirubicin 
fluorescence was then imaged using a laser 
confocal microscope. A) A single confocal 
scan through the Z plane, B) Full projection 
combining all Z plane scans, C) high 
magnification single scan of DLKP cell.  
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(A) 2 μM epirubicin                                       (B) 2 μM epirubicin + 0.25 µM elacridar      (C) 2 μM epirubicin + 10 µM cyclosporin A  
 
                     
 
 
             
   (D) 2 µM epirubicin + 100 µM verapamil     (E) 2 µM epirubicin + 10 µM sulindac 
Figure 4.1.2 DLKP cells were exposed to 
a concentration of 2 μM epirubicin alone 
or 2 μM epirubicin in combination with 
0.25 μM elacridar, 10 μM cyclosporin A, 
100 μM verapamil or 10 μM sulindac for 2 
hours. The drug-containing medium was 
then removed and replaced with drug-free 
medium. A single scan of epirubicin 
fluorescence was then imaged using a laser 
scanning confocal microscope. 
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(A) 2 μM epirubicin control                         (B) 2 μM epirubicin + 0.25 μM elacridar   (C) 2 μM epirubicin + 10 µM cyclosporin A    
 
                 
                  
 (D) 2 μM epirubicin + 100 µM verapamil   (E) 2 μM epirubicin + 10 µM sulindac                           
              
       
Figure 4.1.3 DLKP-A cells were 
exposed to a concentration of 2 μM 
epirubicin alone or 2 μM epirubicin in 
combination with 0.25 μM elacridar, 10 
μM cyclosporin A, 100 μM verapamil 
or 10 μM sulindac for 2 hours. The 
drug-containing medium was then 
removed and replaced with drug-free 
medium. A single scan of epirubicin 
fluorescence was then imaged using a 
laser scanning confocal microscope.
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 (A) 2 μM epirubicin control              (B) 2 μM epirubicin + 0.25 μM elacridar  (C) 2 μM epirubicin + 10 μM cyclosporin A   
                          
                
 
(D) 2 μM epirubicin  + 100 μM verapamil    (E) 2 μM epirubicin + 10 μM sulindac 
        
                 
Figure 4.1.4 DLKP-TXT cells were 
exposed to a concentration of 2 µM 
epirubicin alone or 2 µM epirubicin in 
combination with 0.25 µM elacridar, 10 
µM cyclosporin A, 100 µM verapamil or 
10 µM sulindac for 2 hours. The drug- 
containing medium was removed and 
replaced with drug-free medium. A single 
scan of epirubicin fluorescence was then 
imaged using a laser scanning confocal 
microscope. 
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Figure 4.1.5 DLKP cells were incubated with 1 µM Oregon-green paclitaxel for 3 hours. 
The drug- containing medium was removed and replaced with drug-free medium. 
Oregon-green paclitaxel fluorescence was then imaged using a laser scanning confocal 
microscope. 3-D animations of this image can be found in Appendix B. 
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Figure 4.1.6 A549-Taxol cells were incubated with 1 µM Oregon-
green paclitaxel for 2 hours. The drug- containing medium was 
removed and replaced with drug-free medium. Oregon-green 
paclitaxel fluorescence was then imaged using a laser scanning 
confocal microscope. 
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Figure 4.1.7 A549-Taxol cells were incubated with 1 µM Oregon-green 
paclitaxel for 2 hours. The drug- containing medium was removed and 
replaced with drug-free medium. Oregon-green paclitaxel fluorescence was 
then imaged using a laser scanning confocal microscope. 
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Figure 4.1.8 A549-Taxol cells were incubated with 1 µM Oregon-green 
paclitaxel for 2 hours. The drug- containing medium was removed and 
replaced with drug-free medium. Oregon-green paclitaxel fluorescence 
was then imaged using a laser scanning confocal microscope. 
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4.2 Epirubicin accumulation and efflux in the multi-drug resistant 
cell line DLKP-A. 
 
 
A previously developed HPLC method for measurement of epirubicin (Materials and 
Methods) was used to quantify epirubicin levels in DLKP-A in the presence of 
cyclosporin A, verapamil and elacridar, Figure 4.2.1. All three inhibitors increased 
epirubicin levels significantly relative to the control. Figure 4.2.2 shows the results of 
an epirubicin efflux assay in DLKP-A. All three compounds significantly inhibited 
epirubicin efflux from DLKP-A.  
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Figure 4.2.1 Epirubicin accumulation in DLKP-A over 120 minutes. The DLKP-A cell 
line was exposed to 2 μM epirubicin alone or in the presence of the P-gp modulators, 
elacridar, cyclosporin A and verapamil. Ethanol is the cyclosporin A delivery vehicle. 
Verapamil and elacridar were dissolved in water and DMSO respectively. Vehicle 
controls have been performed in previous experiments. Data are mean +/- SD 
calculated on experiments performed in triplicate.* significantly different from the 
control (2μM epirubicin alone), P < 0.05 relative to control. 
 
 
 
 
*
*
* 
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Figure 4.2.2 Epirubicin efflux assay in DLKP-A. The control, T0, represents DLKP-A 
cells exposed to 2 μM epirubicin for 120 minutes. The T180 values represent the mass 
of epirubicin remaining in the cells 180 minutes after epirubicin was removed and the 
P-gp inhibitors elacridar, cyclosporin A or verapamil were added. DLKP-A over-
expresses P-gp. Cyclosporin A, elacridar and verapamil were dissolved in ethanol, 
DMSO and water, respectively. Vehicle controls have been performed in previous 
experiments. Data are mean +/- SD calculated on experiments performed in triplicate. 
* significant, P < 0.05 relative to T180 medium control. 
T 0 T 180 
*
* 
*
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4.3 Summary 
 
Laser scanning confocal imaging showed: 
 
• The P-gp inhibitors elacridar, cyclosporin A and verapamil and the MRP-1 
inhibitor sulindac failed to affect fluorescence of the P-gp substrate, 
epirubicin, in DLKP.  
• Elacridar, cyclosporin A and verapamil, but not sulindac, markedly 
increased epirubicin fluorescence in DLKP-A.  
• There was no change in nuclear epirubicin fluorescence in DLKP-TXT due 
to elacridar, cyclosporin A or verapamil. Although a subjective observation, 
fluorescence levels were lower in the presence of sulindac. 
• Oregon-green paclitaxel is suitable for visualisation of tubulin in the NSCLC 
cell lines A549-Taxol and DLKP. 
 
Using a HPLC-based method for quantification, elacridar, cyclosporin A and verapamil 
increased epirubicin accumulation and inhibited epirubicin efflux in DLKP-A.  
 
The laser scanning confocal microscopy and HPLC results with epirubicin revealed that 
transport of epirubicin, at the assay concentration of 2 µM, was more sensitive to 
verapamil and cyclosporin A modulation than docetaxel, at the assay concentration of 
10µM. 
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Chapter 5. Development of a radiolabelled-based assay for 
determination of docetaxel accumulation and efflux 
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5.1 Introduction 
To address the limitations ascribed to the HPLC method for taxane measurement (Section 
3.13), a more sensitive and efficient analytical technique was required to examine 
docetaxel transport at pharmacologically relevant concentrations. Two techniques were 
considered, detection of radiolabelled docetaxel by scintillation counting and mass 
spectrometry. Circumstances dictated that the mass spectrometry technique would require 
a lengthy optimisation process and the protocol would be of a similar timespan as the 
HPLC method. 14C docetaxel was readily available commercially, relatively safe, stable 
and able to provide the levels of sensitivity required to confidently assess docetaxel influx 
and efflux mechanisms. 
Once the taxanes are radiolabelled, a liquid scintillation counter can detect much lower 
taxane amounts than the HPLC method previously employed. To develop this assay, a 
number of parameters had to optimised including cell number, medium serum 
concentration, the minimum drug concentration the cells could to be exposed to and the 
length of time the cells should be exposed to the drug. The scintillation counter efficiency 
was also determined. 
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5.2 Optimisation of radiolabelled 14C docetaxel transport assays 
5.2.1 Scintillation Counter Efficiency 
 
A scintillation counter gives results as counts per minute (C.P.M.). D.P.M., 
disintegrations per minute, is the theoretical rate of decay of a substance and is always 
higher than the reported C.P.M. The efficiency depends on the type of counter being used 
and can be calculated from the following formula: 
 
            C.P.M. – Background 
            --------------------------   X  100 
                        D.P.M.  
 
A counting device will always give a reading even if there is no radioactivity added to the 
sample being measured. Natural radiation, cosmic rays and electronic noise all contribute 
to background radioactivity. The D.P.M. of a radiochemical can be calculated from its 
specific radioactivity, the number of curies (Ci) or D.P.M. per unit weight. One curie 
represents 3.7 X 1010 disintegrations per second (D.P.S.) or 2.22 X 1012  D.P.M.  
The C.P.M. of a range of 14C radiolabelled docetaxel concentrations in 0.1M NaOH were 
measured and the D.P.M. for each calculated to give the % efficiency of the counter for 
14C isotopes, Table 5.2.1.1. 
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Table 5.2.1.1 The C.P.M. for a range of docetaxel concentrations were determined and 
the counter efficiency expressed as a percentage of the theoretical disentegrations per 
minute. 
 
14C Docetaxel (µM) C.P.M 
(counts 
per 
minute) 
Minus 
Background 
(20 C.P.M.) 
Theoretical D.P.M. 
(disintegrations per 
minute) 
% 
Efficiency 
 
0.05 1550 1530 3330 45.95 
0.1  3172 3152 6660 47.33 
0.2  6458 6438 13320 48.33 
0.5 15798 15778 33300 47.38 
0.75 23898 23878 49950 47.80 
1 31715 31695 66600 47.59 
2 63778 63758 133200 47.87 
5 159885 159865 333000 48.01 
7.5 240250 240230 499500 48.09 
10 318026 318006 666000 47.75 
 
Average % 
Efficiency 
Average 
Error 
 
47.61 0.66
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5.2.2 Influence of cell number 
 
From previous laboratory practice and literature values, a concentration of 1X105 cells 
per ml per 24-well plate well provides a confluent monolayer for the cell lines used after 
twenty four hours. Maximising the cell number per well is important as it affects the 
maximum amount of drug that can be accumulated and therefore the minimum drug 
concentration the cells can be exposed to. Cells were exposed to 14C docetaxel for 90 
minutes, concurrent with the taxane exposure time in the HPLC-based assays (Figure 
5.2.2.1). DLKP-A was chosen as it accumulated the lowest levels of docetaxel of the cell 
lines to be examined because of P-gp over-expression. Increasing the cell seeding density 
from 1 X 105 to 2 X 105 cells per ml had no effect on the amount of docetaxel 
accumulated at the concentrations of 14C docetaxel tested. A cell seeding density of 
1X105 resulted in a confluent cell monolayer after 24 hours. 
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Figure 5.2.2.1 14C docetaxel accumulation assay in DLKP-A. DLKP-A were seeded at 1 
X 105 or 2 X 105 cells per ml in a 24-well plate twenty four hours prior to drug exposure. 
1 X 105 cells resulted in a confluent monolayer in each well for the assay. Cells were 
exposed to stated docetaxel concentrations for 90 minutes. Data are mean +/- SD 
calculated on experiments performed in duplicate. 
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5.2.3 Influence of cell debris 
 
The samples to be measured contained cell debris that could interfere with counting 
efficiency. In Figure 5.2.3.1A, the volume of cells added to each sample was equal to the 
amount present under accumulation/efflux assay conditions. The results indicate that 
there was negligible quenching of the radiolabelled 14C docetaxel signal by cell debris. 
 
The C.P.M. values recorded by the liquid scintillation counter are an average of the 
C.P.M. taken at set intervals over a minute. The lower the C.P.M. of a sample, then the 
greater the % error. Figure 5.2.3.1B graphs the % error (as calculated by the scintillation 
counter) for each result against the concentration of docetaxel in the presence and absence 
of cell debris. The % error is below 5% for concentrations above 0.05 µM and this was 
deemed acceptable. 
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Figure 5.2.3.1A Comparison of 14C docetaxel standard curves in the presence and 
absence of cells. The blue curve (-▲-) represents the observed C.P.M. for a range of 
docetaxel concentrations in 0.1M NaOH. The pink curve (-■-) is the same concentrations 
measured in the presence of cell debris and 0.1M NaOH. Data are mean experiments 
performed in duplicate. 
 
 
 
 
 
 
 
 
 166
 
 
 
 
 
 
 
 
Comparison Of % Error Of C.P.M. Reading
0
2
4
6
8
10
12
14
16
18
0.01 0.1 1 10
Concentration 14C docetaxel (uM)
%
 E
rr
or
No Cells Cells
 
 
 
 
Figure 5.2.3.1B The % error in C.P.M. readings plotted against log concentration for the 
docetaxel standard curves in Figure 5.2.3.1A. % error values were produced by the 
scintillation counter for each reading. Data are mean experiments performed in duplicate. 
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5.2.4 Influence of drug adsorption onto plate wells 
 
A number of wash steps were included in each assay to remove excess drug in the 
medium and attached to the tissue culture treated plates. To ensure the recorded C.P.M. 
readings reflected accumulated drug within the cells, a control assay was carried out. 
In Figure 5.2.4.1A, the upper trend is the C.P.M. reading of the mass of docetaxel 
accumulated in 90 minutes over a range of docetaxel concentrations. The lower trend is 
the drug adsorption control in which the same concentrations of docetaxel were incubated 
in wells for 90 minutes in the absence of cells. Both experiments were carried out using 
the same procedure, all data points in duplicate.  14C docetaxel accumulation was 
saturable in DLKP. 100 nM applied to the cells for 90 minutes gave a measurable mass of 
14C docetaxel that allowed for increases and decreases in accumulation.  The scintillation 
counter error was also acceptably low. As the values of the registered C.P.M. decrease 
(Figure 5.2.4.1A), the relatively constant C.P.M. count error acquires a higher % value 
(Figure 5.2.4.1B). There was negligible loss of docetaxel due to drug adsorption. 100 nM 
docetaxel is 100 times less than the 10µM used in the HPLC assays.  
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Figure 5.2.4.1A Drug adsorption control assay performed with a docetaxel saturation 
assay in DLKP. The upper trend (-■-) represents a saturation assay carried out in DLKP 
in a 24 well-plate. Increasing concentrations of 14C docetaxel were incubated with DLKP 
for 90 minutes. The lower trend (-▲-) is the same assay carried out in an empty 24-well 
plate to account for drug adsorption to the plate. Data are mean +/- SD calculated on 
experiments performed in triplicate. 
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Figure 5.2.4.1B A comparison of the C.P.M. error readings for the accumulation assay in 
Figure 5.1.4.1A.  The control (upper trend) demonstrated much higher errors due to lower 
C.P.M. being registered as there were no cells to retain the 14C docetaxel within the wells.  
The lower trend is the error from the accumulation assay performed in the presence of 
cells. The reading error of 5% for 100 nM is deemed acceptable for this assay. Data are 
mean +/- SD calculated on experiments performed in duplicate. 
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5.2.5 Influence of alterations in medium serum concentration 
 
The A549 and DLKP cell lines are generally cultured in 5% foetal calf serum and 
DMEM/Ham’s F12. To investigate the influence of serum concentration on docetaxel 
accumulation, both A549 (Figure 5.2.5.1) and DLKP cells (Figure 5.2.5.2) were exposed 
to 100 nM 14C docetaxel for time periods of 30 to 120 minutes in the presence of a range 
of serum concentrations. For both cell lines, the higher concentrations of 100% and 50% 
serum decreased docetaxel accumulation significantly. The lower concentrations of 5, 1 
and 0% serum showed little influence on docetaxel accumulation in either cell line.  
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Figure 5.2.5.1 Effect of medium serum concentration on docetaxel accumulation in 
A549. Cells were incubated with 100 nM 14C docetaxel in the presence of 100, 50, 5, 1 
and 0% foetal calf serum in DMEM/Ham’s F12. 14C docetaxel accumulation was 
measured at 30, 60, 90 and 120 minutes for each serum concentration. Data are mean +/- 
SD calculated on experiments performed in triplicate. 
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Figure 5.2.5.2 Effect of medium serum concentration on docetaxel accumulation in 
DLKP. Cells were incubated with 100 nM 14C docetaxel in the presence of 100, 50, 5, 1 
and 0% foetal calf serum in DMEM/Ham’s F12. 14C docetaxel accumulation was 
measured at 30, 60, 90 and 120 minutes for each serum concentration. Data are mean +/- 
SD calculated on experiments performed in triplicate. 
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5.3 Comparison of radiolabelled assay and HPLC method for 
docetaxel measurement. 
 
For a direct comparison to be made between the radiolabelled assay and the HPLC 
method, the radiolabelled results (C.P.M.) have to be converted to mass per number of 
cells. Figure 5.3.1 is a standard curve generated by measuring the C.P.M. values 
associated with different concentrations of 14C docetaxel. The concentration values of 14C 
docetaxel in the presence of cell debris from Figure 5.2.3.1A were converted to mass 
docetaxel (250 µl of each concentration was read) and plotted against C.P.M. The curve 
intercepted through zero because a blank was subtracted from all samples. The equation 
of this curve (y=0.0061x) can be applied to all subsequent assays using radiolabelled drug 
of the same specific activity. 
Figure 5.3.2 shows the docetaxel saturation assay in DLKP (Figure 5.2.4.1A) when 
converted to mass docetaxel per 10,000 cells. A concentration of 100 nM 14C docetaxel 
applied to DLKP in a 24 -well plate for 90 minutes results in 1 ng docetaxel per ten 
thousand cells being accumulated. This translates to 100 ng per million cells. 
A major anomaly with the HPLC method was the ineffectiveness of cyclosporin A and 
particularly verapamil, in inhibiting docetaxel efflux in P-gp over-expressing cell lines, 
Sections 3.8 and 3.10. 
500 nM 14C radiolabelled docetaxel was applied to DLKP-A cells in the presence of 
elacridar, cyclosporin A and verapamil (Figure 5.3.3). This concentration of docetaxel is 
20-times less than the 10 µM docetaxel employed in the HPLC assays. All three 
inhibitors increased docetaxel accumulation approximately 11-fold. The concentrations of 
each inhibitor used are the same as used in the HPLC-based assay (Figure 3.4.1) but in 
this case, cyclosporin A and verapamil exhibit P-gp reversal activity as indicated by the 
increased drug accumulation. 
Verapamil and cyclosporin A had a minor effect on docetaxel accumulation in the 
docetaxel-selected DLKP variant DLKP-TXT when employing the HPLC analysis 
method, Section 3.10. The MRP-1 inhibitor sulindac also caused a minor increase in 
docetaxel accumulation. The lower concentration of 14C docetaxel (500 nM) applied to 
this cell line in a radiolabel-based assay produced the same result but the effectiveness of 
verapamil increased (Figure 5.3.4). Cyclosporin A increased docetaxel accumulation 1.5 
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times while verapamil and elacridar increased docetaxel accumulation 1.4 and 1.3 times, 
respectively. Interestingly, sulindac caused a 1.2 fold increase in docetaxel accumulation, 
although this did not prove statistically significant. 
The docetaxel accumulation and efflux profiles vary greatly between cell lines, depending 
on the presence or absence of drug transporters. These profiles are therefore a defining 
characteristic for a cell line. Figure 5.3.5 shows the docetaxel accumulation profiles in the 
non-P-gp expressing A549 and the P-gp-expressing A549-Taxol cell lines, as measured 
by radiolabel assay. At 100 nM docetaxel the accumulation profiles of both cell lines are 
almost identical up to 190 minutes. The accumulation profile of docetaxel in A549 was 
previously determined using the HPLC method (Figure 3.2.1). Apart from a very different 
profile shape, a much larger mass of docetaxel was accumulated in 90 minutes using the 
HPLC assay, approximately 250 ng docetaxel per million cells. The radiolabel based 
assay, using 100 nM docetaxel instead of 10 µM to determine the profile, only 
accumulated the equivalent of 50 ng per million cells after 90 minutes. 
 
Differences between HPLC and radiolabel-determined results were also evident in the 
docetaxel efflux profile in A549 (Section 3.2). The efflux profiles of cell lines are 
possibly more informative than the accumulation profiles, especially in those cell lines 
expressing drug efflux pumps. The previous efflux profile studies in A549 utilising the 
HPLC method (Figure 3.2.2) and 10 µM of docetaxel to load up the cells, showed a 
marked decrease in the amount of docetaxel retained within the first 50 minutes, a profile 
that would fit a drug transporter-expressing cell line. A similar assay carried out in A549 
using the radiolabel based method can be seen in Figure 5.3.6. The efflux profiles 
resulting from incubation with 0.1, 1 and 10 µM docetaxel showed a concentration related 
effect on docetaxel efflux. The comparison of mass docetaxel accumulated at T10 
between each method in A549 showed the equivalent of 20 ng per million cells retained 
using the radiolabel method (incubated with 0.1 µM 14C docetaxel) and approximately 60 
ng per million cells using the HPLC procedure ( incubated with 10 µM docetaxel). 
Figure 5.3.7 represents the docetaxel efflux profile in the non-Pgp-expressing DLKP cell 
line. The profile was similar to that obtained in A549 (Figure 5.3.6) with no significant 
decrease in the mass of docetaxel retained after 100 minutes. Approximately one third 
more docetaxel was retained within DLKP compared to A549, 0.32 ng/10,000 cells and 
0.22 ng/10,000 cells, respectively.  
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An accumulation assay examining the levels of docetaxel accumulated in DLKP-A when 
exposed to 100 and 500 nM docetaxel in the absence and presence of cyclosporin A is 
shown in Figure 5.3.8. 500 nM docetaxel was chosen as the incubation concentration for 
radiolabelled efflux assays in DLKP-A. 
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Figure 5.3.1 The C.P.M. of the standard curve in Figure 5.3.1 was plotted against the 
mass of docetaxel each standard contained. The resulting plot gave the equation 
y=0.0061x. All data points determined in duplicate +/− SD. 
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Figure 5.3.2 The curve calculated in Figure 5.3.1 (y=0.0061x) was used to convert 
C.P.M./10,000 cells to mass docetaxel/10,000 cells. The curve represents mass docetaxel 
accumulated. Data are mean +/- SD calculated on experiments performed in triplicate. 
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Figure 5.3.3 14C docetaxel accumulation assay in DLKP-A. Cells were incubated with 
500 nM 14C docetaxel alone or in combination with 0.25 µM elacridar, 10 µM 
cyclosporin A or 100 µM verapamil for 90 minutes. Data are mean +/- SD calculated on 
experiments performed in triplicate. 
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Figure 5.3.4 14C docetaxel accumulation assay in DLKP-TXT. Cells were incubated with 
500 nM 14C docetaxel alone or in combination with 0.25 µM elacridar, 10µM cyclosporin 
A, 100 µM verapamil or 10 µM sulindac for 90 minutes. Data are mean +/- SD calculated 
on experiments performed in triplicate. * significant relative to 500 nM docetaxel control, 
P< 0.05. 
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Figure 5.3.5 Comparison of 14C docetaxel accumulation profiles in A549 and A549-
Taxol. Cells were exposed to 100 nM 14C docetaxel for various timepoints up to 190 
minutes. Data are mean +/- SD calculated on experiments performed in duplicate. 
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Figure 5.3.6 14C docetaxel efflux profile in the A549 cell line. Cells were incubated with 
0.1 µM, 1 µM or 10 µM 14C docetaxel for 90 minutes. The drug was then removed, the 
cells washed and fresh drug-free medium applied. The amount of 14C docetaxel retained 
was measured at intervals up to 80 minutes. Data are mean +/- SD calculated on 
experiments performed in triplicate. 
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Figure 5.3.7 14C docetaxel efflux profile in the DLKP cell line. Cells were incubated with 
100 nM 14C docetaxel for 90 minutes. The drug was then removed, the cells washed and 
fresh drug-free medium applied. The amount of 14C docetaxel retained was measured at 
intervals up to 100 minutes. Data are mean +/- SD calculated on experiments performed 
in triplicate. 
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Figure 5.3.8 Determination of loading concentration for 14C docetaxel efflux assays in 
DLKP-A. DLKP-A cells were exposed to 100 nM or 500 nM 14C docetaxel alone or in 
combination with 5 µM or 10 µM cyclosporin A for 90 minutes. Cyclosporin A was 
dissolved in ethanol. The ethanol control corresponds to the 500 nM 14C docetaxel and 10 
µM cyclosporin A. Data are mean +/- SD calculated on experiments performed in 
triplicate. 
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5.4 Summary 
 
Optimal conditions for the 14C radiolabelled docetaxel assay were determined: 
 
• Cells were seeded 24 hours prior to assay in a 24-well plate at a concentration  
 of 1 X 105 cells/ml. 
• Assays were carried out under normal growth conditions, 5% FCS in   
 DMEM/Ham’s F12. 
• 100 nM 14C docetaxel is sufficient for examining drug accumulation in all cell 
 lines to be examined. 500 nM 14C docetaxel is required for 14C docetaxel efflux 
 assays  in DLKP-A. 
• Direct extraction of 14C docetaxel using 0.1M NaOH is possible as cell debris  
 does not cause signal quenching. 
 
 
The 14C radiolabelled docetaxel assay proved able to address the limitations of the HPLC 
based method for taxane measurement: 
 
• 100 nM 14C docetaxel is within the physiological exposure levels of docetaxel. 
• The efflux profile of docetaxel in A549 and DLKP is consistent with a non- 
 MDR cell line. 
• Inhibition of 14C docetaxel transport by verapamil is detectable in the P-gp over-
 expressing cell lines DLKP-A and DLKP-TXT. 
• The assay protocol is considerably less time consuming. 
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Chapter 6. Docetaxel influx in the human lung cancer cell 
lines DLKP and A549 
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6.1 Introduction 
 
There are no known energy-dependent influx mechanisms for the taxanes in lung cancer 
cells. An energy-dependent taxane transport mechanism would be saturable, temperature- 
dependent and ATP-dependent. Saturation occurs when the concentration of a substrate 
reaches such a level that all the available transporters for that substrate are utilised and no 
increase in the rate of accumulation is possible. Inhibition of activity due to decreasing 
temperature is another characteristic of active transport-mediated movement. A reduction 
in the levels of cellular ATP would be expected to reduce the effectiveness of an ATP-
dependent transporter. All three characteristics were examined in the DLKP and A549 
lung cancer cell lines. 
The OATP (SLC21, SLCO, organic anion transporter polypeptides) family of transporters 
have recently been implicated in the transport of taxanes in the liver. The OATP family 
are classified as anion exchangers that do not rely directly on ATP for functionality. The 
OATP1B3 (OATP8/SLC21A8) transporter has been identified as an important 
hepatocellular transporter of paclitaxel [192]. DNA microarray analysis carried out on the 
DLKP and A549 cell lines revealed RNA expression levels for many of the OATP family 
in A549 but not in DLKP (Appendix A, Table A1). To investigate the possible 
involvement of the OATP family in docetaxel accumulation in the A549 cell line, initial 
docetaxel accumulation assays were carried out in the presence of bromosulfophthalein 
(BSP) and digoxin. BSP is an OATP inhibitor of broad specificity (OATP1A2 (OATP-
A), OATP2B1 (OATP-B), OATP1B1 (OATP-C) and OATP1B3) while digoxin is a 
selective transport substrate for OATP1B3 [263]. Based on initial BSP results, other 
OATP inhibitors were tested including indocyanine green, OATP-1B1 specific and not 
transported by OATP1B3 [264] and  cyclosporin A, reported to be an OATP1B1 and 
OATP1B3 inhibitor [265]. Digoxin, indocyanine green and cyclosporin A were examined 
as they interact with OATPs that are inhibited by BSP but are not necessarily OATPs that 
are known to be specific to lung tissue. OATP2B1 is found in lung tissue and BSP is a 
substrate [266]. More specific to this research, Northern blot analysis has detected 
OATP3A1 (OATP-D) at the mRNA level in A549 [267]. 
OATP2B1, -3A1 and –4A1 (OATP-E) and prostaglandin transporter (PGT) expression 
have been found in lung tissue by RT-PCR in a study by Tamai et al. [268]. OATP1A2 
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and OATP-1B1 were not detected in lung tissue. The most specific substrates that could 
potentially inhibit OATP2B1, -3A1 and –4A1 competitively are DHEAS [263], 
prostaglandin E2 [267] and thyroid hormone (T3) [269]. The effect of these three 
compounds on docetaxel accumulation was also examined in A549. 
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6.2 Saturation 
 
Saturation assays looking at the accumulation of a range of increasing docetaxel 
concentrations at a 90 minute timepoint were carried out in A549, DLKP, A549-Taxol 
and DLKP-Mitox. Saturation is a result of capacity limited drug transport. Docetaxel 
concentrations up to 500 nM did not reach saturation in A549 (Figure 6.2.1). Saturation 
of docetaxel transport occurred in DLKP within the range of drug concentrations 
examined (Figure 6.2.2). In the P-gp-expressing A549-Taxol, docetaxel accumulation 
does not reach saturation up to 400 nM but then starts to decrease at 500 nM, Figure 
6.2.3. Accumulation of docetaxel does not reach saturation in DLKP-Mitox despite a 
decrease in rate of accumulation at 200 nM, Figure 6.1.4. 
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Figure 6.2.1 14C docetaxel accumulation assay examining saturation in the A549 cell 
line. Cells were exposed to a range of 14C docetaxel concentrations (5, 15, 25, 50, 75, 
100, 200, 300, 400 and 500 nM) for 90 minutes. Data are mean +/- SD calculated on 
experiments performed in duplicate. 
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Figure 6.2.2 14C docetaxel accumulation assay examining saturation in the DLKP cell 
line. Cells were exposed to a range of 14C docetaxel concentrations (5, 15, 25, 50, 75, 
100, 200, 300 and 500 nM) for 90 minutes. Data are mean +/- SD calculated on 
experiments performed in duplicate. 
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Figure 6.2.3 14C docetaxel accumulation assay examining saturation in the A549-Taxol 
cell line. Cells were exposed to a range of 14C docetaxel concentrations (5, 15, 25, 50, 75, 
100, 200, 300, 400 and 500 nM) for 90 minutes. Data are mean +/- SD calculated on 
experiments performed in duplicate. 
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Figure 6.2.4 14C docetaxel accumulation assay examining saturation in DLKP-Mitox. 
Cells were exposed to a range of 14C docetaxel concentrations (5, 15, 25, 50, 75, 100, 
200, 300, 400 and 500 nM) for 90 minutes. Data are mean +/- SD calculated on 
experiments performed in duplicate. 
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6.3 Temperature 
 
Accumulation of 100 nM 14C docetaxel was examined at 30, 60, 90 and 120 minutes at a 
range of temperatures in A549 and DLKP. 
In the A549 cell line, the transport of 14C docetaxel was found to be temperature- 
dependent, Figure 6.3.1. Reduced temperatures (40C and 270C) decreased docetaxel 
accumulation significantly. At 40C accumulation was almost eliminated but at 270C 
docetaxel accumulation reached equivalent levels to the mass accumulated after 120 
minutes at 370C. At 410C drug accumulation increased and at 460C a further increase was 
observable until the 60 minute timepoint when docetaxel accumulation levels then began 
to drop. 
In the DLKP cell line (Figure 6.3.2), decreasing temperature once again reduced 
docetaxel accumulation but in this cell line the difference in accumulation between 370C 
and 270C was more pronounced than in A549, never attaining parity. Drug accumulation 
was almost eliminated at 40C. The accumulation profile for 14C docetaxel at 410C and 
460C in DLKP was similar to A549 but a complete reduction in accumulation after 60 
minutes at 460C was evident. 
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Figure 6.3.1 The effect of temperature on accumulation of 14C docetaxel in A549. Cells 
were exposed to 100 nM 14C docetaxel for 30, 60, 90 and 120 minutes at 4, 27, 37, 41 and 
460C. Data are mean +/- SD calculated on an experiment performed in triplicate. 
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Figure 6.3.2 The effect of temperature on accumulation of 14C docetaxel in DLKP. Cells 
were exposed to 100 nM 14C docetaxel for 30, 60, 90 and 120 minutes at 4, 27, 37, 41 and 
460C. Data are mean +/- SD calculated on experiments performed in triplicate. 
 
 
 
 196
6.4 ATP depletion 
 
ATP depletion by sodium azide (mitochondrial metabolic inhibitor), 2-deoxyglucose 
(glycolysis inhibitor) and antimycin A (electron transport chain inhibitor) was quantified 
over 15, 30 and 45 minutes using a bioluminescent luciferase-based assay (Section 2.17) 
in the DLKP and A549 cell lines. The level of ATP in glucose-free medium containing 
5% FCS was also determined at these timepoints. 
In DLKP, glucose-free medium alone reduced ATP levels by 21.5% after 30 minutes and 
the three inhibitors reduced ATP levels further at the three concentrations studied, Figure 
6.4.1. 10 mM 2-deoxyglucose proved the most effective at reducing ATP levels in DLKP. 
At the 30 minute timepoint, 10 mM sodium azide reduced ATP levels by 44.1%, 5 mM 2-
deoxyglucose by 60.6% and 10 µM antimycin A by 36%. Similar results were found in 
the A549 cell line (Figure 6.4.2). Glucose-free medium alone had a less substantial 
impact on ATP levels (18.6% reduction after 30 minutes) compared to 10 mM sodium 
azide (48.1%), 2-deoxyglucose (56.2%) and 10 µM sodium azide (49.8%). 
Two combinations of inhibitors in glucose-free medium were then tested in DLKP and 
A549, Figure 6.4.3. 10 mM sodium azide and 5 mM 2-deoxyglucose (treatment A) 
caused a 90.3% and 90.1% reduction in cellular ATP levels in DLKP and A549, 
respectively. 10 mM sodium azide, 5 mM 2-deoxyglucose and 10 µM antimycin A 
(treatment B) depleted ATP levels by 93.5% in DLKP and 95.2% in A549. A standard 
curve was used to generate values for the mass of ATP (ng) per 10,000 cells for the two 
treatments, Table 6.4.1. DLKP contains 2.1 times the amount of ATP found in A549. 
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Figure 6.4.1 The effects of glucose-free medium (DMEM/Ham’s F12) supplemented with 5% FCS alone (A) and in combination with sodium 
azide (B), 2-deoxyglucose (C) and antimycin A (D) on ATP levels in DLKP. Results are expressed as a percentage of control. Data are mean +/- 
SD calculated on experiments performed in duplicate.
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Figure 6.4.2 The effects of glucose-free medium (DMEM/Ham’s F12) supplemented with 5% FCS alone (A) and in combination with  sodium 
azide (B), 2-deoxyglucose (C) and antimycin A (D) on ATP levels in A549. Results are expressed as a percentage of control. Data are mean +/- 
SD calculated on experiments performed in duplicate. 
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Figure 6.4.3 The effects of two combinations of ATP-depleting agents on ATP levels in DLKP and A549. Treatment A consisted of 10 mM 
sodium azide and 5 mM 2-deoxyglucose. Treatment B consisted of 10 mM sodium azide, 5 mM 2-deoxyglucose and 10 µM sodium azide. Both 
assays were undertaken in the presence of glucose -free medium (DMEM/Ham’s F12) supplemented with 5% FCS. Results are expressed as a 
percentage of a control representing ATP levels under normal glucose containing conditions. Data are mean +/- SD calculated on an experiment 
performed in duplicate. 
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Table 6.4.1 The effects of glucose-free medium (DMEM/Ham’s F12) supplemented with 5% FCS (medium control), 10 mM sodium azide and 5 
mM 2-deoxyglucose (treatment A) and 10 mM sodium azide, 5 mM 2-deoxyglucose and 10 µM antimycin A (treatment B) in DLKP and A549. 
A standard curve was used to determine the nanograms of ATP per 10,000 cells (Section 2.17.2). Data are mean +/- SD calculated on an 
experiment performed in duplicate.  
 
 
DLKP T0 
(ng ATP/10,000 cells) 
T15 
(ng ATP/10,000 cells) 
T30 
(ng ATP/10,000 cells) 
T45  
(ng ATP/10,000 cells) 
Medium control 8.6 +/- 0.27 
 
7.12 +/- 0.02 7.43 +/- 0.25 8.17 +/- 0.52 
Treatment A 8.6 +/- 0.27 
 
1.36 +/- 0.08 0.92 +/- 0.03 0.90 +/- 0.05 
Treatment B 8.6 +/- 0.27 
 
1.28 +/- 0.12 0.66 +/- 0.08 0.71 +/- 0.03 
A549 
 
 
Medium control 4.19 +/- 0.04 
 
3.92 +/- 0.28 3.58 +/- 0.09 3.71 +/- 0.23 
Treatment A 4.19 +/- 0.04 
 
0.53 +/- 0.15 0.44 +/- 0.05 0.63 +/- 0.08 
Treatment B 4.19 +/- 0.04 
 
0.30 +/- 0.06 0.19 +/- 0.01 0.15 +/- 0.01 
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6.5 The effect of ATP depletion on docetaxel accumulation 
 
Treatment B (10mM sodium azide, 5 mM 2-deoxyglucose and 10 µM antimycin A) was 
used to deplete ATP levels when examining the accumulation of 100 nM 14C docetaxel in 
DLKP and A549. A decrease in docetaxel accumulation would be indicative of an ATP-
dependent influx mechanism while an increase in docetaxel levels would be suggestive of 
an ATP-dependent efflux mechanism. Accumulation of 100 nM 14C docetaxel was 
studied directly in the presence of normal medium (glucose-containing DMEM/Ham’s 
F12 supplemented with 5% FCS), glucose free-medium alone (glucose-free DMEM 
supplemented with 5% FCS) and glucose-free medium containing ATP inhibitors 
(treatment B).  The same assay was also carried out after cells had been pre-treated with 
ATP inhibitors in glucose-free medium for 30 minutes. Figure 6.5.1A shows docetaxel 
accumulation in DLKP cells pre-treated and not pre-treated with ATP inhibitors. In both 
instances accumulation in normal medium and glucose-free medium was similar. In 
DLKP, in the presence of ATP inhibitors, there was a significant decrease in the amount 
of docetaxel accumulated after 120 minutes in both pre-treated and non-pre-treated cells. 
Comparing the non-pre-treated and pre-treated cells under each medium condition 
directly revealed a strong decrease in docetaxel accumulation in pre-treated cells under all 
medium circumstances, Figure 6.5.1B. The decreases were significant at 60, 90 and 120 
minutes under the various assay conditions.  
Accumulation of 100 nM 14C docetaxel was also similar in the A549 cell line irrespective 
of ATP inhibitor pre-treatment, Figure 6.5.2 A. Converse to the DLKP results, the 
presence of ATP inhibitors resulted in an increase in the amount of docetaxel 
accumulated in both assay conditions but the trend was more prominent in the pre-treated 
cells. Pre-treatment did not result in differences in accumulation of docetaxel in A549 
when the pre-treated and non-pre-treated conditions were compared in A549, Figure 
6.5.2B. 
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Figure 6.5.1A Effects of energy depletion on accumulation of 10nM 14C docetaxel in DLKP. Accumulation of 100 nM 14C docetaxel was 
examined in normal medium (DMEM/Ham’s F12 supplemented with 5% FCS), glucose-free medium (glucose-free DMEM supplemented with 
5% FCS) and glucose-free medium and ATP inhibitors (glucose-free DMEM supplemented with 5% FCS, 10 mM sodium azide, 5 mM 2-
deoxyglucose and 10 µM antimycin A).  Pre-treatment involved pre-incubation of cells with 10 mM sodium azide, 5 mM 2-deoxyglucose and 10 
µM antimycin A in glucose-free medium supplemented with 5% FCS for 30 minutes. Cells were washed once with warm PBS and accumulation 
of 100 nM 14C docetaxel measured. Data are mean +/- SD calculated on an experiment performed in triplicate. * significant, P<0.05 at 120 
minutes relative to the normal medium control. 
*
*
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Figure 6.5.1B Comparison of the effects of pre-treatment and 
no pre-treatment on 100 nM 14C docetaxel accumulation in 
DLKP under individual assay conditions. Normal medium 
consisted of DMEM/Ham’s F12 supplemented with 5% FCS. 
Glucose-free medium consisted of glucose-free DMEM 
supplemented with 5% FCS. ATP inhibitors utilised were 10 
mM sodium azide, 5 mM 2-deoxyglucose and 10 µM 
antimycin A. Data are mean +/- SD calculated on an 
experiment performed in triplicate. * significant, P<0.05 at 
60, 90 and120 minutes relative to cells receiving no pre-
treatment.
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Figure 6.5.2A Effects of energy depletion on accumulation of 100 nM 14C docetaxel in A549. Accumulation of 100 nM 14C docetaxel was 
examined in normal medium (DMEM/Ham’s F12 supplemented with 5% FCS), glucose-free medium (glucose-free DMEM supplemented with 
5% FCS) and glucose-free medium and ATP inhibitors (glucose-free DMEM supplemented with 5% FCS, 10 mM sodium azide, 5 mM 2-
deoxyglucose and 10 µM antimycin A).  Pre-treatment involved pre-incubation of cells with 10 mM sodium azide, 5 mM 2-deoxyglucose and 10 
µM antimycin A in glucose-free medium supplemented with 5% FCS for 30 minutes. Cells were washed once with warm PBS and accumulation 
of 100 nM 14C docetaxel measured. Data are mean +/- SD calculated on an experiment performed in triplicate. * significant, P<0.05 at 90 and 
120 minutes relative to the normal medium control. ** significant, P<0.05 at 60, 90 and 120 minutes relative to the normal medium control. 
***
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Figure 6.5.2 B Comparison of the effects of pre-treatment and 
no pre-treatment on 100 nM 14C docetaxel accumulation in 
A549 under individual assay conditions. Normal medium 
consisted of DMEM/Ham’s F12 supplemented with 5% FCS. 
Glucose-free medium consisted of glucose-free DMEM 
supplemented with 5% FCS. ATP inhibitors utilised were 10 
mM sodium azide, 5 mM 2-deoxyglucose and 10 µM 
antimycin A. Data are mean +/- SD calculated on an 
experiment performed in triplicate. 
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6.6 OATP inhibitors 
 
To investigate the possible involvement of OATP (organic anion transporter 
polypeptides) in docetaxel accumulation in the A549 and DLKP cell lines, a number of 
14C docetaxel accumulation assays were carried out in the presence of OATP inhibitors.  
The effects of bromosulfophthalein (BSP) on 14C docetaxel accumulation in A549 and 
DLKP are shown in Figure 6.6.1. BSP is an OATP inhibitor of broad specificity. BSP 
concentrations of 1, 5, and 10 µM had no effect on docetaxel accumulation in A549. 50 
µM BSP, however, reduced docetaxel accumulation significantly, contrary to the increase 
in accumulated 14C docetaxel observed in A549 in the presence of ATP depleting agents 
(Figure 6.5.2A). BSP had no effect on docetaxel accumulation in DLKP at any of the 
concentrations used. 
A comparison of the effects of digoxin on 14C docetaxel accumulation in A549 and DLKP 
is shown in Figure 6.6.2. Digoxin is a selective transport substrate for OATP1B3. 10, 50, 
and 100 µM digoxin had no effect on docetaxel accumulation but the presence of 150 µM 
digoxin produced a significant decrease in drug accumulation in the A549 cell line.  
In the DLKP cell line, 50 µM digoxin decreased docetaxel accumulation and 10 µM had 
no effect on drug accumulation. The 0.8% DMSO control renders the decrease associated 
with 50 µM digoxin insignificant, however. 
A wide range of indocyanine green (ICG) concentrations were examined in A549, Figure 
6.6.3. Unexpectedly, the highest concentrations of ICG (10-100 µM) increased docetaxel 
levels by up to 1.8 times (100 µM for 120 minutes). The highest concentration assayed, 
150 µM, increased docetaxel accumulation but to a lesser extent than 100 µM. The lower 
range of ICG concentrations examined (0.05- 1 µM) had no effect on 14C docetaxel 
accumulation. 10-150 µM ICG was also studied in the DLKP cell line, Figure 6.6.4. 50 
µM ICG resulted in a 1.47 fold increase in docetaxel accumulated after 120 minutes 
relative to the control. 100 and 150 µM also resulted in changes to docetaxel 
accumulation levels but the high levels of DMSO (up to 5.8%) countered the effects of 
ICG, ultimately reducing docetaxel levels.  
The effect of a further four OATP inhibitors of varying specificity were examined in the 
A549 cell line. Dehydroepiandrosterone (DHEAS) produced significant increases in 14C 
docetaxel accumulation across all timepoints in a concentration dependent manner, Figure 
6.6.5. Cyclosporin A had no major effect on 14C docetaxel accumulation, Figure 6.6.6. 
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Treatment with 150 µM prostaglandin E2 (PGE2) did result in a minor but significant 
decrease in docetaxel levels but this corresponded with a significant decrease associated 
with the DMSO control, Figure 6.6.7. 50 µM thyroid hormone (tri-iodothyronine, T3) 
resulted in a significant increase in 14C docetaxel accumulation up to 90 minutes in A549, 
Figure 6.6.8. 
High DMSO concentrations decrease 14C docetaxel accumulation in A549 and DLKP. 
DLKP was more susceptible to this effect than A549, Figures 6.6.3 and 6.6.4. 
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Figure 6.6.1 The effect of bromosulfophthalein (BSP) on 14C docetaxel accumulation in the A549 and DLKP cell lines. Cells were incubated 
with 100 nM 14C docetaxel alone (Control) or 100 nM 14C docetaxel and BSP (1, 5, 10, 50 µM) for 30, 60, 90 and 120 minutes. A 2% DMSO 
control was also included that corresponded to the amount of DMSO present in 50 µM BSP. Data are mean +/- SD calculated on experiments 
performed in triplicate. * significant, P<0.05 at 30, 60 and 90 minutes relative to the control. † not significant, P>0.05 for all timepoints relative 
to the control. 
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Figure 6.6.2 The effect of digoxin on 14C docetaxel accumulation in the A549 and DLKP cell lines. Cells were incubated with 100 nM 14C 
docetaxel alone or 100 nM 14C docetaxel and digoxin (1, 5, 10, 50µM) for 30, 60, 90 and 120 minutes. 2.4% and 0.8% DMSO control were also 
included that correspond to the amount of DMSO present in 150 µM and 50 µM digoxin respectively. Data are mean +/- SD calculated on 
experiments performed in triplicate. * significant, P<0.05 at 90 and 120 minutes relative to the control. ** significant, P<0.05 at 60 minutes 
relative to the control.† not significant, P>0.05 for all timepoints relative to the control. 
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Figure 6.6.3 The effect of indocyanine green (ICG) on 14C docetaxel accumulation in the A549 cell line. Cells were incubated with 100 nM 14C 
docetaxel alone (Control) or 100 nM 14C docetaxel and ICG (A -0.05, 0.1, 0.5, 1 and B- 10, 50, 100, 150 µM ) for 30, 60, 90 and 120 minutes. A 
2% and 0.1% DMSO control was included that correspond to the amount of DMSO present in 50 µM and 1µM ICG respectively. Data are mean 
+/- SD calculated on experiments performed in triplicate. * significant, P<0.05 for all timepoints relative to the control. 
**  significant, P<0.05 for 30, 60 and 120 minutes relative to the control. ***  significant, P<0.05 for 30, 60 and 90 minutes relative to the 
control. The 6% DMSO control is significant at the 30 minute timepoint only, P<0.05. 
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Figure 6.6.4 The effect of indocyanine green (ICG) on 14C docetaxel accumulation in the 
DLKP cell line. Cells were incubated with 100 nM 14C docetaxel alone (Control) or 100 
nM 14C docetaxel and ICG (10, 50, 100, 150 µM) for 30, 60, 90 and 120 minutes. A 5.8% 
DMSO control was included that corresponded to the amount of DMSO present in 150 
µM ICG. Data are mean +/- SD calculated on experiments performed in triplicate.  
* significant, P<0.05 for all timepoints relative to the control.** significant, P<0.05 for 
30, 60 and 90 minutes relative to the control. *** significant, P<0.05 for 30 and 60 
minutes relative to the control. 
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Figure 6.6.5 The effect of dehydroepiandrosterone (DHEAS) on 14C docetaxel 
accumulation in the A549 cell line. Cells were incubated with 100 nM 14C docetaxel 
alone (Control) or 100 nM 14C docetaxel and DHEAS (10, 50, 100, 150 µM) for 30, 60, 
90 and 120 minutes. A 0.9% DMSO control was included that corresponded to the 
amount of DMSO present in 150 µM DHEAS. Data are mean +/- SD calculated on 
experiments performed in triplicate. * significant, P<0.05 for all timepoints relative to the 
control. **  significant, P<0.05 for 30, 90 and 120 minutes relative to the control. 
 
A549 
* 
*
**
 213
 
 
 
 
 
 
Cyclosporin A
0
20
40
60
80
100
120
30 60 90 120
Time (Minutes)
C
.P
.M
./1
0,
00
0 
C
el
ls
Control
10 µM
50 µM
75 µM
100 µM
2.4% Ethanol Control
 
 
 
 
Figure 6.6.6 The effect of cyclosporin A on 14C docetaxel accumulation in the A549 cell 
line. Cells were incubated with 100 nM 14C docetaxel alone (Control) or 100 nM 14C 
docetaxel and cyclosporin A (10, 50, 75, 100 µM) for 30, 60, 90 and 120 minutes. A 
2.4% DMSO control was included that corresponded to the amount of DMSO present in 
100 µM cyclosporin A. Data are mean +/- SD calculated on experiments performed in 
triplicate. 
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Figure 6.6.7 The effect of prostaglandin E2 on 14C docetaxel accumulation in the A549 
cell line. Cells were incubated with 100 nM 14C docetaxel alone (Control) or 100 nM 14C 
docetaxel and prostaglandin E2 (10, 50, 100, 150 µM) for 30, 60, 90 and 120 minutes. A 
0.5% DMSO control was included that corresponded to the amount of DMSO present in 
150 µM prostaglandin E2. Data are mean +/- SD calculated on experiments performed in 
triplicate. * significant P<0.05 at 120 minutes relative to the control. 
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Figure 6.6.8 The effect of tri-iodothyronine (T3) on 14C docetaxel accumulation in the 
A549 cell line. Cells were incubated with 100 nM 14C docetaxel alone (Control) or 100 
nM 14C docetaxel and T3 (10, 50, 100, 150 µM) for 30, 60, 90 and 120 minutes. A 1% 
DMSO control was included that corresponded to the amount of DMSO present in 150 
µM T3. Data are mean +/- SD calculated on experiments performed in triplicate.   
* significant P<0.05 at 30, 60 and 90 minutes relative to the control. 
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6.7 Summary 
 
A number of important differences were found when comparing the transport of 14C 
docetaxel in DLKP and A549.  
 
Accumulation of 14C docetaxel in DLKP was: 
 
• Saturated at 500 nM. 
• Temperature-dependent. 
• Energy –dependent. ATP-depletion led to a decrease in 14C docetaxel levels in 
  DLKP. 
• Not dependent on bromosulfophthalein and digoxin. 
 
Accumulation of 14C docetaxel in A549 was: 
 
• Unsaturated at 500 nM. 
• Temperature-dependent (but the accumulation levels at 270C returned to 370C 
  levels with time). 
• Energy –dependent. ATP-depletion led to an increase in 14C docetaxel levels 
  in A549. 
• Dependent on bromosulfophthalein and digoxin. Bromosulfophthalein and 
  digoxin decreased the levels of 14C docetaxel accumulated. 
• Dependent on DHEAS, and tri-iodothyronine (thyroid hormone, T3). DHEAS, 
  T3 increased the levels of 14C docetaxel accumulated. 
 
 
Indocyanine green markedly increased docetaxel levels in A549 and DLKP. The ICG 
effect was concentration dependent, occurred in A549 or DLKP and was of a greater 
magnitude than any other of the changes in 14C docetaxel levels observed in this study. 
High DMSO concentrations decreased 14C docetaxel accumulation in A549 and DLKP 
but DLKP was more susceptible than A549 to the DMSO-related changes in docetaxel 
accumulation.
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Chapter 7. TKIs as modulators of Multi-Drug Resistance 
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7.1 Introduction 
 
The ability of the tyrosine kinase inhibitors gefitinib and erlotinib to modulate P-gp 
activity has been described previously [107], [270]. This body of work endeavoured to 
compare and assess the ability of erlotinib, gefitinib and the dual tyrosine kinase inhibitor, 
lapatinib to act as P-gp modulators in lung cancer cell models with varying EGFR status. 
The effects of the TKIs on P-gp ATPase activity, docetaxel accumulation and efflux, 
epirubicin accumulation and cell proliferation were studied to provide a broad basis of 
evidence for the potential of these compounds as plausible MDR modulators. 
An increase in P-gp levels due to TKI exposure might contribute to an increase in 
resistance, limiting the effectiveness of P-gp substrate cytotoxics and TKIs. Changes in 
EGFR levels could also affect TKI efficacy. The consequences of TKI treatment on the 
protein levels of P-gp and EGFR were examined by Western blot and ELISA in the 
EGFR- and P-gp-over-expressing, A549-Taxol cell line. 
The transport proteins, MRP-1 and BCRP, are also major contributors to drug resistance 
in cancer. The effects of the three TKIs on MRP-1 and BCRP ATPase activity were 
examined. Sulindac and its metabolite sulindac sulfide were also examined for activity in 
the MRP-1 and BCRP ATPase assays. 
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7.2 Modulation of P-gp by TKIs 
7.2.1 P-gp, EGFR and Her-2 status of the cell lines 
 
The EGFR and Her-2 status of DLKP, DLKP-A, A549 and A549-Taxol cell lines were 
determined by ELISA (Figure 7.2.1.1). The parent DLKP and A549 cell lines do not 
express detectable levels of P-gp but the adriamycin-selected, DLKP-A, and paclitaxel 
(®Taxol)-selected, A549-Taxol, cell lines over-express P-gp (Figure 3.1.1). An ELISA 
was required to detect the low levels of EGFR and Her-2 in the lung cancer cell lines. All 
four cell lines expressed low Her-2 levels. DLKP was EGFR- negative while DLKP-A 
showed EGFR expression. A549 and A549-Taxol both expressed higher EGFR levels 
than DLKP-A. 
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Figure 7.2.1.1 Detection of EGFR and Her-2 by ELISA in DLKP, DLKP-A, A549 and 
A549-Taxol. Values were determined by two independent experiments each carried out in 
duplicate. Data are mean +/- SD. 
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7.2.2 Effects of TKIs on P-gp ATPase activity 
 
We compared all three TKIs, and the classic P-gp inhibitor cyclosporin A, in P-gp 
ATPase inhibition (Figure 7.2.2.1A) and activation (Figure 7.2.2.1B) assays to determine 
the ability of lapatinib to interact with P-gp and to find the exact method of P-gp 
modulation employed by erlotinib and gefitinib. P-gp uses ATP as the energy source for 
substrate transport. The ATPase function of P-gp converts ATP to ADP and Pi in order to 
transport substrates. The ATPase activation assay measured the amount of Pi released by 
P-gp ATPase in the presence of a test compound while the inhibition ATPase assays 
measured the decrease a test compound produced in Pi released from fully substrate 
(verapamil)-activated P-gp. In the inhibition assays, lapatinib displayed direct inhibition 
of verapamil-activated P-gp ATPase activity at 5 µM. Cyclosporin A demonstrated the 
greatest inhibitory effect at low concentrations. Erlotinib and gefitinib did not reduce 
verapamil-induced P-gp ATPase activity even though gefitinib stimulated P-gp ATPase 
activity above control levels. 
All three TKIs displayed activation of P-gp ATPase activity at low concentrations. At 
higher concentrations (10-40 µM), gefitinib and erlotinib were strong activators of P-gp 
ATPase activity. Lapatinib activation activity did not increase above 5 µM. Cyclosporin 
A was the weakest activator of P-gp. Baseline P-gp ATPase activity and the maximum 
verapamil-stimulated P-gp ATPase activity was within expected parameters (Section 
2.18.9). These results and the implications are discussed in Section 8.6. 
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Figure 7.2.2.1 The effects of lapatinib, gefitinib, erlotinib and cyclosporin A on vanadate-sensitive P-gp ATPase inhibition (A) and activation 
(B). For (A) the control represents the ATPase activity measured in the presence of 45 µM verapamil (P-gp substrate) but in the absence of 
added test compounds. For (B), the control represents the ATPase activity measured in the absence of added test compounds. Each concentration 
was determined in duplicate. All compounds were dissolved in DMSO except cyclosporin A which was dissolved in ethanol. Each concentration 
was determined in duplicate. Data are mean +/- SD. 
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7.2.3 TKI-related increase in docetaxel accumulation in the P-gp-
positive DLKP-A cell line 
 
A 14C docetaxel accumulation assay was employed to examine the P-gp-modulatory 
abilities of gefitinib, erlotinib and lapatinib compared with the classic MDR modulator 
cyclosporin A and the third generation P-gp inhibitor elacridar, in the P-gp over-
expressing DLKP-A cell line.  
Gefitinib and erlotinib increased docetaxel accumulation in a concentration-dependent 
manner comparable to cyclosporin A (Figure 7.2.3.1) while lapatinib proved more 
effective at increasing docetaxel levels than cyclosporin A. The non-competitive P-gp 
inhibitor, elacridar, was the most potent compound. Lapatinib, erlotinib, gefitinib, 
cyclosporin A and elacridar (1 μM) each increased docetaxel accumulation 4.2, 1.6, 1.6, 
2.1, and 6.3 fold respectively. 
Neither gefitinib, lapatinib nor erlotinib (10 µM) increased docetaxel accumulation over 
90 minutes in the P-gp negative DLKP cell line, Figure 7.2.3.2. These results and their 
implications are discussed in Section 8.6. 
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Figure 7.2.3.1 Accumulation of 100 nM 14C radio-labelled docetaxel in DLKP-A over 90 minutes. Values represent the average of 
three determinations. All inhibitors were dissolved in DMSO, except cyclosporin A (ethanol). Data are mean +/- SD calculated on 
experiments performed in triplicate.† not significant relative to control, P > 0.05 
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Figure 7.2.3.2 Accumulation of 100 nM 14C docetaxel in DLKP over 90 minutes. All 
inhibitors were dissolved in DMSO. Data are mean +/- SD calculated on experiments 
performed in triplicate. 
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7.2.4 Inhibition of docetaxel efflux from the P-gp-positive DLKP-A 
cell line 
 
The accumulation studies displayed changes in docetaxel levels in the presence of 
continuous docetaxel influx. To isolate the effect of the TKIs on docetaxel efflux, DLKP-
A cells were exposed to 500 nM docetaxel for 90 minutes. The concentration of 500 nM 
was determined previously in Section 5.3. Once loaded with drug, the effects of the TKIs 
and elacridar on docetaxel efflux were examined. Gefitinib and erlotinib effectively 
decreased docetaxel efflux from DLKP-A (Figure 7.2.4.1). Lapatinib and elacridar were 
the most potent compounds decreasing docetaxel efflux at all concentrations tested. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 227
 
Lapatinib
0
10
20
30
40
50
60
0 10 20 30 40 50 60
Time (Minutes)
C
.
P
.
M
.
/
1
0
,
0
0
0
 
C
e
l
l
s
 
Gefitinib 
0
10
20
30
40
0 10 20 30 40 50 60
Time (Minutes)
C
.
P
.
M
.
/
1
0
,
0
0
0
 
C
e
l
l
s
  
Erlotinib
0
10
20
30
40
50
0 10 20 30 40 50 60
Time (Minutes)
C
.
P
.
M
.
/
1
0
,
0
0
0
 
C
e
l
l
s
Elacridar
0
10
20
30
40
50
60
0 10 20 30 40 50 60
Time (Minutes)
C
.
P
.
M
.
/
1
0
,
0
0
0
 
C
e
l
l
s
     
 
 
Figure 7.2.4.1 Efflux of 14C docetaxel from DLKP-A. Cells were exposed to 500 nM 14C docetaxel for 90 minutes, the drug removed and 
replaced with medium or a concentration of tyrosine kinase inhibitor (TKI) or elacridar for 20, 40 and 60 minutes. (● – medium, ○ – 1 µM, ▲- 5 
µM, □ – 10 µM, ■ – DMSO control). All inhibitors dissolved in DMSO. Data are mean +/- SD calculated on experiments performed in 
triplicate. 
DLKP-A 
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7.2.5 Increased epirubicin accumulation in the DLKP-A cell line 
 
Accumulation of the naturally fluorescent P-gp substrate chemotherapeutic, epirubicin, 
was examined in DLKP-A. Quantitative analysis of the effect of lapatinib on epirubicin 
accumulation over 120 minutes was carried out using the mass spectrometry-based 
method described in Section 2.14.8 (Figure 7.2.5.1 A). Lapatinib increased the mass of 
epirubicin accumulated in DLKP-A in a concentration-dependent manner. Laser confocal 
imaging was utilised to visualise the increase in epirubicin accumulation in DLKP-A 
(Figure 7.2.5.1 B-G). After 120 minutes exposure to 2 µM epirubicin, only minute 
cytoplasmic levels of the drug were visible (B), similar results to the DMSO control (C). 
Due to lapatinib-mediated P-gp inhibition, there was a dose-dependent increase in 
fluorescence visible in the presence of 1 µM (E), 5 µM (F) and 10 µM (G) lapatinib, 
especially in the level of nuclear fluorescence. Mass spectrometric quantification 
confirmed the increased level of drug present at these concentrations.  
The effects of erlotinib and gefitinib on epirubicin accumulation in DLKP-A were also 
examined by laser confocal microscopy at a concentration of 5 µM, but over a 90 minute 
time period, Figure 7.2.5.2. Elacridar treatment resulted in epirubicin detection in all cells 
within the field of view (Figure 7.2.5.2B). Both gefitinib (Figure 7.2.5.2C) and erlotinib 
(Figure 7.2.5.2D) increased nuclear and cytoplasmic epirubicin localisation in DLKP-A 
by inhibition of plasma membrane and nuclear localised P-gp. Interestingly a number of 
the control cells displayed intercellular levels of epirubicin (Figure 7.2.5.2C) suggesting 
the resistance mechanism is not uniformly distributed in the cell population.
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Figure 7.2.5.1 The effect of lapatinib on epirubicin accumulation in DLKP-A. A) 
Epirubicin (EPI) accumulation in DLKP-A in the presence of lapatinib over 120 minutes 
was quantified by mass spectrometry. Data are mean +/- SD calculated on experiments 
performed in triplicate. Laser confocal imaging of epirubicin in DLKP-A is shown for B) 
2 µM EPI, C) 2 µM EPI + DMSO, D) 2 µM EPI + 0.25 µM lapatinib, E) 2 µM EPI + 1 
µM lapatinib, F) 2 µM EPI + 5 µM lapatinib, and G) 2 µM EPI + 10 µM lapatinib. Each 
panel consists of a polarised contrast image on the left, the fluorescence image in the 
middle and an overlay of the fluorescence on the polarised image on the right.  
* significant, P < 0.05
* 
* 
* 
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A. 2  µM epirubicin                                                      B. 2 µM epirubicin + 5 µM elacridar 
    
 
 
 
 
 
 
 
 
 
 
 
 
C. 2 µM epirubicin + 5 µM gefitinib                                    D. 2 µM epirubicin + 5 µM erlotinib 
   
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.2.5.2 Laser Confocal Microscope imaging of epirubicin accumulation in the P-gp over-expressing DLKP-A cell line over 90 minutes 
(A) and in the presence of elacridar (B), gefitinib (C) and erlotinib (D) A polarised contrast image is included on the right of each image. 
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7.2.6 The implications of P-gp modulation by TKIs on cell survival 
 
IC50 values for the chemotherapy agents docetaxel, paclitaxel, epirubicin and cisplatin 
and the TKIs, lapatinib, gefitinib and erlotinib are provided in Table 7.2.6. 
P-gp over-expression in DLKP-A resulted in a 228, 153 and 123-fold resistance to 
docetaxel, paclitaxel and epirubicin, respectively, compared to the parent cell line. 
Resistance to the non-P-gp substrate, cisplatin, was 1.9-fold in comparison. The lower 
level of P-gp expression in A549-Taxol resulted in a lower fold increases in resistance to 
docetaxel (5.6) and paclitaxel (3.6). Interestingly, there was no increase in epirubicin 
(0.8) resistance. P-gp expression in DLKP-A lead to minor resistance to the TKIs 
gefitinib and erlotinib compared to DLKP. There was no significant difference in 
sensitivity to lapatinib between the DLKP and DLKP-A cell lines. A549-Taxol exhibited 
minor resistance to lapatinib and erlotinib but not gefitinib compared to A549.
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Drug DLKP DLKP-A A549 A549-Taxol 
Docetaxel 0.00038 +/- 0.000015 0.087 +/- 0.0067 (228) 0.00025 +/- 0.000021 0.0014 +/- 0.00054 (5.6) 
Paclitaxel 0.002 +/- 0.0001 0.31 +/- 0.013 (153) 0.0027 +/- 0.00057 0.0098 +/- 0.00066 (3.6) 
Epirubicin 0.017 +/- 0.0008 2.1 +/- 0.24 (123) 0.038 +/- 0.0045 0.03 +/- 0.0047 (0.8†) 
Cisplatin 1.1 +/- 0.24 2.0 +/- 0.17 (1.9) 2.4 +/- 0.44 2.6 +/- 0.23 (1.1†) 
Lapatinib 2.7 +/- 0.1 2.4 +/- 0.2 (0.9†) 2.8 +/- 0.1 3.7 +/- 0.1 (1.3) 
Gefitinib 6.1 +/- 0.02 8.5 +/- 0.36 (1.4) 7.3 +/- 0.33 7.4 +/- 0.23 (1†) 
Erlotinib 8.8 +/- 0.5 11.1 +/- 0.5 (1.3) 3.1 +/- 0.2 9.3 +/- 1.8 (3) 
 
Table 7.2.6 IC50 values (µM) determined from 7-day proliferation assays. Values represent the average of three independent 
determinations +/- SD. Fold increase in resistance compared to the parent cell line is given in brackets. All fold increases are significant 
unless otherwise denoted. (†values, not significant, P>0.05) 
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7.2.7 Combination proliferation assays 
 
Peak serum concentration values for standard or near standard doses of gefitinib (225 
mg), erlotinib (150 mg) and lapatinib (1200 mg) have been determined at approximately 
0.7 µM, 4 µM, and 2 µM, respectively [271], [272], [273]. TKI concentrations close to 
physiological levels and providing low cytotoxicity were selected for combination 
studies. A supra-additive decrease in cell survival resulted from co-treatment with the 
TKIs and the P-gp substrates docetaxel, paclitaxel and epirubicin in the P-gp positive 
DLKP-A (Figure 7.2.7.2) and A549-Taxol (Figure 7.2.7.1) cell lines. No potentiation of 
toxicity was observed when the TKIs were combined with the non-P-gp substrate 
cisplatin. Lapatinib exhibited the greatest potentiation of docetaxel, paclitaxel and 
epirubicin toxicity, followed by gefitinib and then erlotinib. 
DLKP (Figure 7.2.7.2) and A549 (Figure 7.2.7.1) cells exhibited only additive 
potentiation of TKI- taxane toxicity due to the absence of P-gp. However, epirubicin 
toxicity was potentiated most notably by lapatinib and erlotinib. Of note, a minor increase 
in cell survival was observed when combining the TKIs with higher concentrations of 
cisplatin in DLKP-A (Appendix A, Figure A1). 
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Figure 7.2.7.1 Proliferation assays combining the TKIs lapatinib, gefitinib and erlotinib 
with docetaxel, paclitaxel, epirubicin and cisplatin in A549 (▲- inhibitor only, ■ - 20 nM 
epirubicin, □ – 0.2 nM docetaxel, ○ – 1 nM paclitaxel, ● – 1500 nM cisplatin) and A549 
–Taxol (▲- inhibitor only, ■ - 30 nM epirubicin, □ – 0.75 nM docetaxel, ○ – 2 nM 
paclitaxel, ● – 1000 nM cisplatin). Points represent the average of three independent 
determinations +/- SD. 
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Figure 7.2.7.2 Proliferation assays combining the TKIs lapatinib, gefitinib and erlotinib 
with docetaxel, paclitaxel, epirubicin and cisplatin in DLKP(▲- inhibitor only, ■ - 15 nM 
epirubicin, □ – 0.25 nM docetaxel, ○ – 1 nM paclitaxel, ● – 1500 nM cisplatin)  and 
DLKP-A (▲- inhibitor only, ■ - 750 nM epirubicin, □ – 50 nM docetaxel, ○ – 250 nM 
paclitaxel, ● – 1500 nM cisplatin). Points represent the average of three independent 
determinations +/- SD. 
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7.2.8 Effects of the P-gp substrate erlotinib and P-gp inhibitor 
lapatinib on docetaxel accumulation in A549-Taxol 
 
In order to examine docetaxel transport in a cell line expressing levels of P-gp closer to 
that expected physiologically, A549-Taxol cells were exposed to 500 nM 14C docetaxel 
in the presence of 0.25, 1, 2.5, and 5 µM erlotinib (Figure 7.2.8.1A) or lapatinib (Figure 
7.2.8.1B) for 90, 135, and 180 minutes. 5 µM elacridar was included to represent 
maximal P-gp inhibition. Erlotinib was chosen as it displayed the highest P-gp ATPase 
activation and was most likely to be a transported substrate and competitive inhibitor. 
Lapatinib was the only TKI examined that inhibited verapamil-stimulated P-gp ATPase 
activity. Both TKIs increased 14C docetaxel accumulation in a time- and concentration-
dependent manner. 2.5 µM erlotinib was required to generate near maximal docetaxel 
accumulation. 0.25 µM of lapatinib produced an increased docetaxel accumulation with 1 
µM generating maximum docetaxel accumulation at the 135 and 180 minute timepoints. 
At maximum concentrations (5 µM), lapatinib was more effective than erlotinib, 
significantly increasing docetaxel accumulation by 45.1, 27.9 and 30.3% over 90, 135 
and 180 minutes respectively.  
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Figure 7.2.8.1 The effects of erlotinib (A) and lapatinib (B) on accumulation of 500 nM 14C 
docetaxel in the A549-Taxol cell line over 90, 135 and 180 minutes. A 1% DMSO control 
representing the amount of DMSO present in 5 µM TKI concentrations was also included. 
Each value represents the average of three determinations. All inhibitors dissolved in DMSO. 
(* significant, P < 0.05 relative to 500 nM docetaxel control). 
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7.3 The effects of TKI exposure on P-gp expression in A549-Taxol 
The EGFR- and P-gp- over-expressing A549-Taxol cell line was utilised to examine 
the effects of TKI treatment on P-gp protein expression. Cells were exposed to 
epidermal growth factor (EGF) at concentrations of 10, 50 and 100 ng/ml and varying 
concentrations of lapatinib and erlotinib (2.5, 5 and 10 µM) and gefitinib (5, 10 and 
20 µM) for 48 hours. Treatment with increasing levels of EGF resulted in a decrease 
in P-gp protein expression, Figure 7.3.1. Conversely, lapatinib, erlotinib and gefitinib 
treatment resulted in an increase in P-gp protein expression, Figure 7.3.2, Figure 7.3.3 
and Figure 7.3.4, respectively.  
 
 
 239
 
 
 
 
 
 
 
 
 
                                        
 
                                                
 
 
 
 
 
Figure 7.3.1 Western blot showing the effect of EGF treatment on P-gp expression 
(170 kDa) in A549-Taxol after 48 hours. Cells were treated with 10, 50 and 100 
ng/ml EGF in DMEM/Ham’s F12 in serum-free conditions. The control represents P-
gp expression after 48 hours in serum-free conditions. 
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Figure 7.3.2 Western blot showing the effect of lapatinib treatment on P-gp 
expression (170 kDa) in A549-Taxol after 48 hours. Cells were treated with 2.5, 5 
and 10 µM lapatinib in DMEM/Ham’s F12 supplemented with 5% FCS. The control 
represents P-gp expression after 48 hours in DMEM/Ham’s F12 supplemented with 
5% FCS. DMSO represents P-gp expression after 48 hours in DMEM/Ham’s F12 
supplemented with 5% FCS and DMSO equivalent to the amount present in 10 µM 
lapatinib. 
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Figure 7.3.3 Western blot showing the effect of erlotinib treatment on P-gp 
expression (170 kDa) in A549-Taxol after 48 hours. Cells were treated with 2.5, 5 
and 10 µM erlotinib in DMEM/Ham’s F12 supplemented with 5% FCS. The control 
represents P-gp expression after 48 hours in DMEM/Ham’s F12 supplemented with 
5% FCS. DMSO represents P-gp expression after 48 hours in DMEM/Ham’s F12 
supplemented with 5% FCS and DMSO equivalent to the amount present in 10 µM 
erlotinib. 
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Figure 7.3.4 Western blot showing the effect of gefitinib treatment on P-gp 
expression (170 kDa) in A549-Taxol after 48 hours. Cells were treated with 2.5, 5 
and 10 µM gefitinib in DMEM/Ham’s F12 supplemented with 5% FCS. The control 
represents P-gp expression after 48 hours in DMEM/Ham’s F12 supplemented with 
5% FCS. DMSO represents P-gp expression after 48 hours in DMEM/Ham’s F12 
supplemented with 5% FCS and DMSO equivalent to the amount present in 10 µM 
gefitinib. 
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7.4 The effects of TKIs on EGFR levels 
 
EGFR protein levels were too low to be measured by Western blot and were instead 
measured through ELISA. Two ELISA kits were used to measure total EGFR in 
samples. One detected the extracellular domain, the other the intracellular domain. 
The intracellular domain is preferred as it is independent of EGFR dimerisation 
status. Initial experiments were carried out using the ELISA kit with an antibody 
developed against the extracellular domain of EGFR. The effects of EGF treatment 
on EGFR expression in A549-Taxol over 48 hours are shown in Figure 7.4.1. The 
control revealed a decrease in EGFR expression from 15.18 pg/µg to 5.18 pg/µg at 
the 48 hour timepoint. EGF treatment dramatically decreased EGFR expression to 
2.76 pg/µg from 15.18 pg/µg after 12 hours compared to 11.2 pg/µg for the control. 
Treatment of A549-Taxol with 2.5, 5 and 10 µM lapatinib resulted in an increase in 
EGFR expression at all timepoints and concentrations relative to the control, Figure 
7.4.2. The largest increase in expression occurred at the 24-hour timepoint following 
treatment with 10 µM lapatinib (12.3 pg/µg to 20.27 pg/µg). The 48 hour timepoint 
saw a decrease in EGFR expression relative to the 24 – hour timepoint for all 
concentrations but still remained above the 48 hour control levels. 
Subsequent experiments examining the effects of the TKIs on EGFR levels utilised 
both ELISA protocols, detecting the intracellular domain of EGFR as well as the 
extracellular domain at the 48 hour timepoint. Targetting the intracellular region of 
the EGFR protein resulted in detection of minutely higher levels of EGFR protein 
than when the extracellular domain was targetted in the control, Figure 7.4.4. 
Treatment with 10, 50 and 100 ng/ml EGF reduced EGFR expression levels as 
measured by both assay systems but the reduction was more pronounced in the results 
obtained from detection of the EGFR intracellular domain (Figure 7.4.4). 10 ng/ml 
EGF reduced EGFR levels from 5.18 pg/µg to 4.24 pg/µg (extracellular domain 
detection) and 6.67 pg/µg to 3.46 pg/µg (detection of intracellular domain). 
Treatment with each of the TKIs, lapatinib, erlotinib and gefitinib had the same effect 
on EGFR expression in A549-Taxol, Figures 7.4.5, 7.4.6 and 7.4.7, respectively. The 
TKIs increased EGFR expression. Once again, higher EGFR levels were detected 
using the ELISA detecting the intracellular domain of EGFR. A DMSO control was 
not included in the gefitinib assay as the same control was carried out in the erlotinib 
experiment.
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Figure 7.4.1 The effects of EGF on EGFR protein expression in A549-Taxol over 48 
hours. An ELISA recognising the extracellular domain of EGFR was utilised. Cells 
were treated with 10, 50 and 100 ng/ml EGF in DMEM/Ham’s F12 in serum-free 
conditions. The control represents EGFR expression in serum-free conditions over 48 
hours. Data are mean +/- SD for each concentration determined in duplicate. 
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Figure 7.4.2 The effects of lapatinib on EGFR protein expression in A549-Taxol over 
48 hours. An ELISA recognising the extracellular domain of EGFR was utilised. 
Cells were treated with 2.5, 5 and 10 µM lapatinib in DMEM/Ham’s F12 
supplemented with 5% FCS. The control represents EGFR expression in 
DMEM/Ham’s F12 supplemented with 5% FCS. The DMSO control represents 
EGFR expression in DMEM/Ham’s F12 supplemented with 5% FCS and DMSO 
equivalent to the amount present in 10 µM lapatinib. Data are mean +/- SD for each 
concentration determined in duplicate. 
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Figure 7.4.3 The effects of EGF on EGFR protein expression in A549-Taxol at 48 
hours. Two ELISA kits were utilised to determine EGFR levels. Extracellular refers 
to the kit that used an antibody recognising an extracellular domain of EGFR while 
intracellular refers to the kit that used an antibody recognising an intracellular EGFR 
domain. Cells were treated with 10, 50 and 100 ng/ml EGF in DMEM/Ham’s F12 in 
serum-free conditions. The control represents EGFR expression after 48 hours in 
serum-free conditions.  Data are mean +/- SD for each concentration determined in 
duplicate. * significant, P<0.05 relative to Control. 
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Figure 7.4.4 The effects of lapatinib on EGFR protein expression in A549-taxol at 48 
hours. Two ELISA kits were utilised to determine EGFR levels. Extracellular refers 
to the kit that used an antibody recognising an extracellular domain of EGFR while 
intracellular refers to the kit that used an antibody recognising an intracellular EGFR 
domain. Cells were treated with 2.5, 5 and 10 µM lapatinib in DMEM/Ham’s F12 
supplemented with 5% FCS. The control represents EGFR expression after 48 hours 
in DMEM/Ham’s F12 supplemented with 5% FCS. The DMSO control represents 
EGFR expression after 48 hours in DMEM/Ham’s F12 supplemented with 5% FCS 
and DMSO equivalent to the amount present in 10 µM lapatinib. Data are mean +/- 
SD for each concentration determined in duplicate. * significant, P<0.05 relative to 
Control. 
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Figure 7.4.5 The effects of erlotinib on EGFR protein expression in A549-Taxol at 
48 hours. Two ELISA kits were utilised to determine EGFR levels. Extracellular 
refers to the kit that used an antibody recognising an extracellular domain of EGFR 
while intracellular refers to the kit that used an antibody recognising an intracellular 
EGFR domain. Cells were treated with 2.5, 5 and 10 µM erlotinib in DMEM/Ham’s 
F12 supplemented with 5% FCS. The control represents EGFR expression after 48 
hours in DMEM/Ham’s F12 supplemented with 5% FCS. The DMSO control 
represents EGFR expression after 48 hours in DMEM/Ham’s F12 supplemented with 
5% FCS and DMSO equivalent to the amount present in 10 µM erlotinib.  Data are 
mean +/- SD for each concentration determined in duplicate. * significant, P<0.05 
relative to Control 
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Figure 7.4.6 The effects of gefitinib on EGFR protein expression in A549-Taxol at 
48 hours. Two ELISA kits were utilised to determine EGFR levels. Extracellular 
refers to the kit that used an antibody recognising an extracellular domain of EGFR 
while intracellular refers to the kit that used an antibody recognising an intracellular 
EGFR domain. Cells were treated with 2.5, 5 and 10 µM gefitinib in DMEM/Ham’s 
F12 supplemented with 5% FCS. The control represents EGFR expression after 48 
hours in DMEM/Ham’s F12 supplemented with 5% FCS. The DMSO control 
represents EGFR expression after 48 hours in DMEM/Ham’s F12 supplemented with 
5% FCS and DMSO equivalent to the amount present in 10 µM gefitinib.  Data are 
mean +/- SD for each concentration determined in duplicate. * significant, P<0.05 
relative to Control. 
A549-Taxol 
Gefitinib 
* 
* * * 
* 
* 
 250
7.5 The Effects of TKIs on MRP-1 and BCRP ATPase activity 
 
Following examination of the effect of the three TKIs lapatinib, erlotinib and gefitinib 
on P-gp ATPase activity, their interaction with BCRP and MRP-1 ATPase activity 
was studied.  The MRP-1 modulator sulindac, previously studied in taxane transport 
assays, Section 3, and its metabolite sulindac sulfide were also included. Classic 
modulators of each pump were included for reference purposes. Elacridar and 
mitoxantrone in the case of BCRP, and vincristine and MK571, in the case of MRP-1.  
The BCRP ATPase assay is based on the same principle as the P-gp ATPase 
activation assay (Section 7.2.2). BCRP uses ATP as the energy source for substrate 
transport. The ATPase function of BCRP converts ATP to ADP and Pi in order to 
transport substrates. The ATPase activation assay measured the amount of Pi released 
by BCRP ATPase in the presence of a test compound. The high activity levels of the 
BCRP ATPase allow both activation and inhibition to be measured directly, Figure 
7.5.1. Results showed gefitinib to be the most potent stimulator of BCRP ATPase 
activity, followed by erlotinib and then lapatinib. All three TKIs greatly stimulated 
ATPase activity at low concentrations (0.25 – 5 µM for gefitinib and erlotinib, 0.25 – 
2.5 µM for lapatinib). Above these concentrations the stimulatory effect begins to 
decrease and in the case of lapatinib, to inhibit ATPase activity above 5 µM. Sulindac 
has a limited ability to stimulate BCRP ATPase activity above 15 µM. Sulindac 
sulfide, and the BCRP-substrate mitoxantrone to a greater degree, decreased BCRP 
ATPase below baseline levels at all concentrations. Elacridar decreased BCRP 
ATPase activity below the maximal inhibited value achieved by 0.1 mM Hoechst 
33342 at all concentrations examined. Baseline BCRP ATPase activity, the maximum 
sulfasalazine-stimulated and Hoechst 33342 inhibited BCRP ATPase activity were 
slightly elevated when compared to expected parameters (Section 2.18.9) 
The MRP-1 ATPase assays were also based on the same principle as the P-gp ATPase 
activation and inhibition assays. Sulindac proved to be the tested compound that 
stimulated MRP-1 ATPase activity the most, followed by sulindac sulfide, Figure 
7.5.2. Of the TKIs examined erlotinib exhibited most activity, continuously 
increasing MRP-1 ATPase activity with increasing concentration. Gefitinib followed 
a similar trend to erlotinib but to a lesser degree. Lapatinib stimulated MRP-1 ATPase 
activity at low concentrations but this effect decreases above 15 µM. The MRP-1 
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substrate vincristine has a minor stimulatory effect at the lowest concentrations (0.25 
and 1 µM) but tends towards ATPase inhibition towards higher concentrations. 
Stimulation of MRP-1 ATPase activity by N-ethylmaleimide glutathione (NEM-GS) 
was employed to test the MRP-1 ATPase inhibitory activity of test compounds, 
Figure 7.5.3. The MRP-1 inhibitor MK571 proved to have the strongest ATPase 
inhibitory effect, followed by sulindac sulfide. Gefitinib and erlotinib had no effect on 
stimulated ATPase activity while lapatinib at low concentrations (0.25-15 µM) and 
sulindac at higher concentrations (5-30 µM) stimulated MRP-1 ATPase activity 
above the maximal level. Baseline MRP-1 ATPase activity and the maximum NEM-
GS-stimulated MRP-1 ATPase activity was within expected parameters (Section 
2.18.9). 
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Figure 7.5.1 The effects of a range of compounds, including the TKIs, on vanadate-
sensitive BCRP ATPase activity. Compounds were tested at 0.25, 1, 2.5, 5, 15 and 30 
µM.  The baseline activity represents the ATPase activity measured in the absence of 
added test compounds. The maximal activity represents the ATPase activity measured 
in the presence of 0.1 mM sulfasalazine. Inhibited activity is the BCRP ATPase 
activity in the presence of 0.1 mM of the BCRP inhibitor Hoechst 33342.   All 
compounds were dissolved in DMSO. Data are mean +/- SD for each concentration 
determined in duplicate. 
 
 
 
 
 
 
 253
 
 
 
MRP-1 ATPase Activation Assay
0
2
4
6
8
10
12
14
16
0 5 10 15 20 25 30
Concentration (uM)
Pi
 li
be
ra
te
d 
(n
m
ol
/m
g 
m
em
br
an
e 
pr
ot
ei
n/
m
in
) Gefitinib
Erlotinib
Lapatinib
Sulindac
Sulindac Sulfide
Vincristine
Baseline Activity
Maximal Activity
 
 
 
Figure 7.5.2 The effects of a range of compounds, including the TKIs, on vanadate-
sensitive MRP-1 ATPase activation. Compounds were tested at 0.25, 1, 2.5, 5, 15 and 
30 µM. The baseline activity represents the ATPase activity measured in the absence 
of added test compounds. The maximal activity represents the ATPase activity 
measured in the presence of 10 mM NEM-GS. All compounds were dissolved in 
DMSO. Data are mean +/- SD for each concentration determined in duplicate. 
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Figure 7.5.3 The inhibitory effects of a range of compounds, including the TKIs, on 
activated vanadate-sensitive MRP-1 ATPase activity. Compounds were tested at 0.25, 
1, 2.5, 5, 15 and 30 µM.  The compounds were assayed in the presence of 10 mM N-
ethylmaleimide gluthathione (NEM-GS). The baseline activity represents the ATPase 
activity measured in the absence of added test compounds. The maximal activity 
represents the ATPase activity measured in the presence of 10 mM NEM-GS only. 
All compounds were dissolved in DMSO. Data are mean +/- SD for each 
concentration determined in duplicate. 
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7.6 Summary 
 
The ability of the tyrosine kinase inhibitors lapatinib, erlotinib and gefitinib to 
modulate P-gp-mediated taxane resistance in lung cancer cell models, P-gp and 
EGFR expression levels and MRP-1 and BCRP ATPase activity was assessed. 
 
Lapatinib:  
 
• Interacted with P-gp in a distinct manner to erlotinib and gefitinib. 
• Was more potent than erlotinib and gefitinib at increasing docetaxel 
accumulation and inhibiting docetaxel efflux from the P-gp over-expressing 
DLKP-A cell line. 
• Increased epirubicin accumulation in DLKP-A. 
• Was more effective than erlotinib and gefitinib in cell proliferation studies. 
• Produced synergistic potentiation of epirubicin toxicity in the absence of P-gp 
in DLKP and A549, along with erlotinib and gefitinib. 
• Was more effective than erlotinib at increasing docetaxel accumulation at 
clinically relevant concentrations in the P-gp-expressing A549-Taxol cell line. 
 
Studies in the A549-Taxol cell line showed epidermal growth factor (EGF)-treatment: 
 
•  Reduced P-gp protein levels. 
•  Reduced EGFR protein levels. 
 
Conversely, lapatinib, erlotinib and gefitinib treatment in A549-Taxol: 
 
•  Increased P-gp protein levels. 
•  Increased EGFR protein levels. 
 
The three TKIs proved to be poor activators and inhibitors of MRP-1 ATPase 
activity. Sulindac emerged as a strong activator of MRP-1 ATPase activity while its 
metabolite sulindac sulfide proved to be an MRP-1 ATPase activator and a weak 
MRP-1 ATPase inhibitor. 
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Studies showed gefitinib to be the most potent of the TKIs at activating BCRP 
ATPase activity followed by erlotinib and then lapatinib. Sulindac had no effect on 
basal activity but sulindac sulfide had a minor inhibitory effect.  
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Chapter 8. Discussion 
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8.1 HPLC- determined taxane accumulation and efflux in sensitive 
and MDR human lung and leukemic cell lines 
 
To accomplish the main objectives of this project, a reproducible method of 
measuring changes in docetaxel transport due to drug pump inhibition was required. 
This method would not only have to be sufficiently sensitive to detect alterations in 
drug levels due to pump inhibition but also provide a range of measurement broad 
enough to accommodate cell types and inhibitors of varying P-gp expression and 
potency, respectively. The following section discusses the results presented in Chapter 
3 and Chapter 4, including decisions on the cell types to be utilised, exploration of a 
HPLC-based method for taxane measurement and live cell laser scanning confocal 
microscopy of epirubicin in cells. 
 
8.1.1 Cell lines 
 
Analysis of P-gp expression in a set of NSCLC cell lines established A549 and DLKP 
as P-gp negative, A549-Taxol and DLKP-TXT as P-gp over-expressing and DLKP-A 
as highly P-gp over-expressing (Figure 3.2.1). P-gp expression was also examined in 
the SK-MES-1 cell line, its taxane-selected variants, SK-Taxol and SK-Taxotere and 
in the DMS-53 cell line and its two taxane-selected variants, DMS-Taxol and DMS-
Taxotere (Appendix A, Figure A2). While the taxane-selected variants both exhibited 
increased levels of P-gp expression, the parent DMS-53 cell line constitutively 
expressed P-gp making it unsuitable as a negative control and both cell lines exhibited 
slow growth rates in comparison to the A549 and DLKP cell lines. Employing A549 
and DLKP as the main cell lines studied provided a variation in physiological source 
(adenomatous derived vs. squamous cell derived, respectively), and a combination of 
a recognised standard cell line for comparison with the in-house developed DLKP cell 
lines. DNA microarray data sets existed for both A549 and DLKP, a tool that was of 
use when searching for putative docetaxel uptake transporters. The EGFR and Her-2 
status of all the lung cancer cell lines considered was also examined (Figure 7.2.1.1, 
Appendix A Table A6 and Appendix A Table A7). For studies involving TKIs the 
A549 and DLKP cell lines provided a positive and negative EGFR model, 
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respectively, while A549, DLKP, A549-Taxol and DLKP-A all expressed similar 
levels of Her-2 (Figure 7.2.1.1, Appendix A Figure A4). 
 
8.1.2 Optimisation of HPLC timepoints 
 
The HPLC method employed for docetaxel detection was adapted by Dr. Robert 
O’Connor from that described by Ciccolini et al. [274]. The same procedure was 
utilised for detection of paclitaxel. The accumulation and efflux timepoints for the 
A549 cell line were analysed (Section 3.3). 90 minutes was chosen for the docetaxel 
accumulation assay, a timepoint that provided sufficient accumulated drug to detect 
changes in transport. While accumulation increased gradually over time (Figure 
3.3.1), study of the efflux profile revealed a sharp decline in docetaxel levels in the 
initial 40 minutes following drug removal (Figure 3.3.2). This is not consistent with a 
cell line that is P-gp negative (Figure 3.2.1). The 40 minute timepoint chosen for 
docetaxel efflux assays placed the assay stop-point at the beginning of a stable phase 
in the docetaxel efflux profile at which changes in efflux could readily be observed. A 
number of reasons for the rapid efflux of docetaxel in A549 were considered. The 
presence of an efflux mechanism, cell necrosis or a concentration-dependent effect 
related to non-specific binding was considered. MRP-2 protein expression localised to 
the plasma membrane has been reported in A549 [275], [276]. Huisman et al., showed 
MRP-2 transports docetaxel in MRP-2 transduced epithelial MDCKII cells but this 
was examined over four hours [132]. It was unclear if the inherent level of MRP-2 
expressed in A549 would be capable of such rapid docetaxel efflux within 40 minutes, 
a hypothesis supported by docetaxel transport studies involving sulindac (discussed in 
Section 8.3). A study of cell death over the chosen time periods in DLKP revealed 
little direct toxic insult to the cells, ruling out necrosis as a contributing factor (Table 
3.7.1). The decrease in retained docetaxel was presumed to be concentration-related. 
It was most likely that the high docetaxel concentration saturated the high affinity 
intercellular binding sites leading to non-specific, low affinity docetaxel binding. The 
rapid decrease in retained docetaxel observed in the efflux assay (Figure 3.3.2) was 
likely due to dissociation of docetaxel from the low affinity binding sites.  This was 
supported by radiolabelled 14C docetaxel assays (Section 5.3) and is discussed further 
in Section 8.4.3.  
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8.1.3 Docetaxel accumulation and efflux in A549 
 
With the timepoints for monitoring drug levels characterised in A549, a set of 
experiments to establish accumulation and efflux assay protocols, examine the effects 
of sulindac on docetaxel transport in A549 and confirm the P-gp-negative status of 
A549 were carried out.  
The docetaxel accumulation and efflux assays employed clinically relevant 
concentrations of sulindac, an MRP-1 inhibitor with some ability to modulate MRP-2, 
having been shown capable of inhibiting methotrexate transport in MRP-2-expressing 
membrane vesicles [277], [160], [137]. Sulindac had no effect on docetaxel transport 
in A549 (Figures 3.4.1. and 3.4.2). Elacridar, a compound used extensively in this 
project as a P-gp inhibitor, also had no effect on docetaxel accumulation in A549 
(Figure 3.5.1). While Harris and Jeffery  provide evidence for MRP-2 and P-gp 
protein expression in the A549 cell line (using a different P-gp antibody to that used 
in this thesis), it is clear from the docetaxel transport assays that the expression levels 
of P-gp and MRP-2 did not influence docetaxel transport in A549 as measured using 
the HPLC method [275]. Further docetaxel transport assays utilising the HPLC 
method in A549 can therefore be interpreted with the assumption that MRP-2 and P-
gp had no influence on the outcome. 
 
8.1.4 The Effects of ATP-depletion on docetaxel accumulation in 
A549 
 
A major project aim was to examine docetaxel uptake specifically to elucidate the 
possible existence of an energy-dependent transport mechanism. Sodium azide and 2-
deoxyglucose are compounds long established and widely used as ATP-depleting 
agents in cell systems to compromise drug transport mechanisms such as MRP-1 
[278], [156]. Depletion of ATP levels should also affect a putative energy-dependent 
influx mechanism. Literature-derived concentrations of sodium azide and 2-
deoxyglucose were used in all ATP-depletion experiments involving the HPLC-based 
taxane measurement protocol as an initial exploration of the effects of such 
compounds on taxane transport [278], [156]. Sodium azide treatment in glucose-free 
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medium had no significant effect on docetaxel transport in A549 (Figure 3.6.1). 
Taking the 10 mM sodium azide concentration, an accumulation and efflux assay 
were carried out. Sulindac was included in both assays for comparative purposes with 
previous identical experiments in A549 carried out under normal conditions (Figures 
3.6.2 and 3.6.3). The comparable nature of the docetaxel transport assays in the 
presence or absence of sodium azide suggest no energy-dependent taxane transport 
system in this cell line. However, the exact reduction in ATP levels caused by sodium 
azide in these assays was not quantified, a determination critical to guarantee a 
sufficient decrease in ATP levels to impact docetaxel transport.  
 
8.1.5 Docetaxel and paclitaxel accumulation in DLKP 
 
The DLKP cell line was the second sensitive cell line chosen for study. Sulindac has 
been examined in DLKP in the past as an MRP-1 inhibitor, potentiating the toxicity of 
doxorubicin, vincristine and VP-16 [160]. Characterisation of the cell line by Liang et 
al. indicated that DLKP did not express P-gp (consistent with previous results 
discussed) or MRP-2 at the protein level but did express MRP-1 [260]. Docetaxel and 
paclitaxel transport was examined in DLKP to provide a control for subsequent taxane 
transport assays in the P-gp-expressing DLKP variants, DLKP-A and DLKP-TXT. 
Taxane transport assays had not previously been carried out in the DLKP cell line. 
The effect of three P-gp modulators on docetaxel accumulation and efflux and 
paclitaxel accumulation was examined in DLKP (Section 3.7). As expected, elacridar, 
cyclosporin A or verapamil had no influence on docetaxel or paclitaxel accumulation 
or efflux in this cell line due to the absence of P-gp (Figures 3.7.1, 3.7.2 and 3.7.3). 
Comparison of docetaxel and paclitaxel accumulation did lead to a number of 
interesting observations (Figure 3.7.1). The disparity observed between the mass of 
docetaxel and paclitaxel accumulated in DLKP was unexpected. Documented 
differences in lipophilicity, membrane permeability and tubulin affinity between 
paclitaxel and docetaxel may contribute to this effect but comparisons in the HL-60 
and HL-60ADR cell lines reveal more similar levels of accumulation (Section 3.12) in 
these leukemic cell models [31].  
The DLKP cell line accumulated higher levels of docetaxel on average than the A549 
cell line, 466 +/- 110 ng/million cells versus 280 +/- 42 ng/million cells, respectively. 
When combined with the HPLC assay results in Figure 3.8.1 (sodium azide reduced 
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docetaxel accumulation in DLKP) and the radiolabelled docetaxel ATP-depletion 
assays in Section 6.4 (a combination of sodium azide, 2-deoxyglucose and antimycin 
A reduced docetaxel accumulation in DLKP), a strong body of evidence was mounted 
to suggest an ATP-dependent mechanism is responsible for docetaxel uptake in 
DLKP. The results in Section 6 and Section 3.4 also allude to the absence of an active 
influx mechanism in A549. The argument in support of this hypothesis is continued 
later in this discussion in Section 7.4. It will be important, and of great interest, to 
ascertain if the disparity in accumulation between docetaxel and paclitaxel is 
maintained in DLKP at lower concentrations. A comparison of the taxanes 
(accumulation, temperature-dependency and ATP-dependency) at pharmacological 
levels would determine if the putative uptake mechanism is docetaxel specific. It 
would also examine if the disparity in accumulation levels in DLKP and its drug-
selected variants (Sections 3.7, 3.9 and 3.11) was due solely or partially to the 
physical properties of the compounds. 
 
8.1.6 Docetaxel and paclitaxel transport in DLKP-A 
 
Examination of docetaxel transport in the drug-sensitive cell lines was necessary to 
establish experimental parameters and control conditions. A major objective for 
developing the HPLC-based method for taxane measurement was to establish a cell 
system model to compare and assess putative modulators of P-gp-mediated docetaxel 
transport. The adriamycin-selected DLKP-A cell line is an example of a highly 
resistant cell line. The resistance conferred through P-gp expression in DLKP-A is 
clearly illustrated in Table 7.2.6 in Section 7, presenting IC50 values for docetaxel, 
paclitaxel and epirubicin that are 228-, 153- and 123-fold greater than the parent 
DLKP cell line.  
There was a distinct difference between the interaction of paclitaxel and docetaxel 
with P-gp modulating agents at the concentrations examined in DLKP-A. 
The specific potency of elacridar as an irreversible P-gp inhibitor allowed a 
physiologically relevant concentration of it to be employed in DLKP-A accumulation 
and efflux studies. Supra-physiological levels of cyclosporin A and verapamil were 
chosen to increase the likelihood of inhibition of taxane efflux [279]. Despite greatly 
reduced cellular levels of docetaxel and paclitaxel due to P-gp over-expression, a 
relative difference in the mass of each taxane accumulated was once again evident in 
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this DLKP variant (Figure 3.9.1). Taxane accumulation was greatly increased by P-gp 
inhibition. Elacridar proved the most effective compound for reversal of P-gp-
mediated resistance in DLKP-A. Cyclosporin A had a lesser, but significant, effect on 
accumulation of both taxanes. This is expected as cyclosporin A, along with 
verapamil, is classed as a first generation P-gp inhibitor [280].While elacridar and 
cyclosporin A behaved in an expected fashion, verapamil did not. Verapamil 
increased cellular paclitaxel accumulation to a similar extent as cyclosporin A but 
failed to affect docetaxel accumulation (Figure 3.9.1). The taxane efflux assays 
followed a similar trend. Paclitaxel levels were maintained at the 90 minute control 
level by cyclosporin A, verapamil and elacridar after 40 minutes in paclitaxel-free 
medium (Figure 3.9.2). Elacridar was the only compound to inhibit docetaxel efflux 
from DLKP-A (Figure 3.9.2).  
 
8.1.7 Taxane and verapamil proliferation assays in DLKP-A 
 
The ability of verapamil to modulate P-gp activity is well documented [95]. To 
determine if verapamil was truly unable to modulate P-gp-mediated docetaxel 
transport in DLKP-A, a number of proliferation assays combining docetaxel and 
paclitaxel with verapamil were carried out.  The drug concentrations used in the 
transport assays could not be used in the seven-day proliferation assays (Section 
2.7.2) due to toxicity from the high taxane levels employed. Non-toxic concentrations 
of all drugs were chosen to emphasise any potentiation of toxicity. The P-gp 
inhibitory effects of verapamil were clearly evident through increased docetaxel and 
paclitaxel toxicity (Figures 3.9.3 and 3.9.4). A proliferation assay exposing DLKP-A 
to the transport assay conditions (drug concentrations and exposure time) also resulted 
in potentiation of docetaxel cytotoxicity. The discrepancy between transport and 
proliferation assays can be explained. The ratio of docetaxel to verapamil in the 
docetaxel accumulation assays is 1:10, while in the proliferation assays it is 1:27. The 
higher ratio of verapamil in the proliferation assays inhibited docetaxel transport in 
DLKP-A. This concentration-dependent effect suggests that docetaxel has a higher 
affinity for P-gp than paclitaxel. This is supported by observations made by 
Shirakawa et al., that 100 µM verapamil was capable of inhibiting apical to basal 
transport of 860 nM 14C docetaxel in P-gp over-expressing porcine kidney epithelial 
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cells [281].This was the first indication that the HPLC-based method for taxane 
detection may not be sensitive enough for the ultimate purposes of the project.  
8.1.8 Effect of ATP inhibitors on docetaxel transport in DLKP-A 
 
The reduced levels of docetaxel in the DLKP cell line due to treatment with ATP 
depletion agents was unexpected but could largely be attributed to an effect on 
docetaxel influx, due to the absence of major drug efflux mechanisms (Section 3.8). 
ATP depletion in DLKP-A would be expected to reduce P-gp efficacy and increase 
docetaxel accumulation levels. It should also be considered that the expression status 
of any energy-dependent influx mechanism is unknown in this cell line. 
Approximately three times more docetaxel was accumulated in the DLKP-A ATP 
depletion assay compared to previous DLKP-A transport experiments (Figure 3.10.1). 
It was intended to carry out all comparable cell-based experiments within fifteen 
passages of each other but even within this range a drop in resistance was observable. 
The docetaxel accumulation assay in Figure 3.10.1 provided tentative evidence that a 
putative energy-dependent mechanism may also be present in DLKP-A. The addition 
of sodium azide and 2-deoxyglucose in glucose-free medium reduced docetaxel 
accumulation to below control levels, although the reductions were not significant. 
One explanation of the observed results may be the inhibition of docetaxel influx in 
the absence of active P-gp. The failure of elacridar to restore the mass of docetaxel 
accumulated to control levels in the presence of sodium azide and 2-deoxyglucose 
supports the belief that all P-gp is inhibited and the decrease in docetaxel 
accumulation was attributable to inhibition of a putative energy-dependent influx 
mechanism (Figure 3.10.1). 
 
8.1.9 Docetaxel and paclitaxel transport in DLKP-TXT 
 
P-gp expression in DLKP-TXT is much lower than in DLKP-A (Section 3.2). The 
fold-resistance of DLKP-TXT and indeed A549-Taxol to the taxanes is much lower 
and closer to in vivo levels of resistance [111]. The discrepancy between docetaxel 
and paclitaxel accumulation was once again evident in this cell line (Figure 3.11.1). 
The mass of both drugs accumulated is comparable to that accumulated in DLKP 
(Section 3.7), highlighting the lower resistance levels conferred by P-gp in DLKP-
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TXT (Appendix A, Table A5). The presence of active P-gp was indicated by the 
increase in docetaxel accumulation associated with cyclosporin A and elacridar. 
Verapamil does not affect docetaxel levels, consistent with DLKP-A results (Section 
3.9). However, proliferation assays confirmed dose-dependent potentiation of 
docetaxel toxicity by verapamil at higher docetaxel/verapamil ratios (Figures 3.11.2). 
Elacridar also potentiated docetaxel toxicity concurrent with the docetaxel 
accumulation results (Figures 3.11.4). The minor increases in paclitaxel accumulation 
due to elacridar and verapamil also translated to potentiation of toxicity in 
proliferation assays (Figures 3.11.3 and 3.11.5).  
 
8.1.10 Docetaxel and paclitaxel transport in HL-60 
 
The anthracyclines are mainstay treatment for acute myeloid leukaemia (AML) [282]. 
Anthracycline transport has been studied in leukaemia cell lines such as the AML-
derived HL-60 cell line [283]. Nagasawa et al., have suggested the nucleoside 
transport system is involved in doxorubicin uptake in HL-60 [283]. Taxane transport, 
in contrast, has not been examined in the HL-60 and HL-60 ADR cell lines as the 
taxanes are not used in the treatment of leukaemia. The HL-60 cell line provides an 
ideal model for the comparison of docetaxel and paclitaxel transport as it is lacking in 
expression of the drug transporters P-gp, BCRP, MRP-2, MRP-3, MRP-5 with only 
minor expression levels of MRP-1[284]. 
Contrary to previous taxane accumulation assays in DLKP, DLKP-A and DLKP-
TXT, the mass of docetaxel and paclitaxel accumulated in HL-60 are similar (Figure 
3.12.1). Given the number of general differences between HL-60 and the DLKP 
variants (size/physiological source/adherent vs. non-adherent), it would be impossible 
to draw any conclusions on the contribution of drug uptake mechanisms to this 
observation but it may be a point notable for further investigation.  
Docetaxel or paclitaxel accumulation was not affected significantly by elacridar, 
cyclosporin A or sulindac treatment, to be expected in a cell line that does not express 
P-gp (Figure 3.12.1). Of most interest is the significant reduction in both docetaxel 
and paclitaxel accumulation evident with co-incubation with verapamil. This effect is 
not without precedent. Verapamil inhibited 14C paclitaxel uptake in the adriamycin-
selected NCI/ADR RES breast cancer cell line through suggested inhibition of active 
inward transport [285]. The exact mechanism was not identified. The same study also 
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reported that verapamil increased the efflux of 14C paclitaxel in the adriamycin-
sensitive MDA-MB-435 breast cancer cell line [285]. The decrease in retained 
paclitaxel is unlikely to be accounted for by stimulation of efflux in HL-60 as 
verapamil had no effect on paclitaxel efflux (Figure 3.12.2). Elacridar caused a 
significant increase in paclitaxel efflux (Figure 3.12.2) but did not produce a 
corresponding decrease in paclitaxel accumulation (Figure 3.12.1) that was significant 
and therefore did not provide supporting evidence of an elacridar stimulated efflux 
mechanism. The large decrease in paclitaxel levels observed in HL-60 over 40 
minutes in the absence of major taxane transporters is most likely the same effect 
previously seen in A549 (Figure 3.3.2) compounded by the smaller size of the HL-60 
cells. This effect is discussed in greater detail in Section 8.4.3.   
 
8.1.11 Docetaxel and paclitaxel transport in HL-60 ADR 
 
The HL-60ADR cell line over-expresses MRP-1 conferring significant resistance to 
MRP-1 substrate drugs including adriamycin [286] (Appendix A, Table A5). As 
mentioned previously, it has been reported that adriamycin selection of HL-60 cells 
has led to resistance to anthracyclines and vinca alkaloids but also low level cross-
resistance to paclitaxel [287]. A study involving HL-60 ADR-derived MRP-1 vesicles 
showed little or no transport of paclitaxel [288]. Inclusion of sulindac in the HL-60 
ADR taxane accumulation experiments supports the findings that the taxanes are not 
MRP-1 substrates (Figure 3.12.3). It also confirmed the absence of functional P-gp 
expression from the HL-60ADR cell line as none of the P-gp modulators tested 
significantly altered docetaxel or paclitaxel accumulation. 
 
8.1.12 Assessment of the HPLC method for taxane quantification 
 
The HPLC-based method for taxane quantification is reliable and reproducible but 
was ultimately unsuitable for fulfilment of the project goals. The supra-physiological 
taxane levels required for detection meant the effects of potential competitive 
inhibitors could be missed, extrapolation of clinical relevancy would not be possible 
and changes in accumulation in cell lines expressing low levels of P-gp would be 
difficult. Assay logistics such as required cell number and overall experiment duration 
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contribute to the weaknesses of this method.  However, the HPLC-based protocol did 
provide valuable results including identifying a disparity in docetaxel and paclitaxel 
accumulation, a decrease in docetaxel accumulation in DLKP and HL-60 due to 
sodium azide and sulindac, respectively, and a decrease in paclitaxel and epirubicin 
(discussed in Section 8.2.3)  levels observed in DLKP-TXT related to sulindac.  
 
8.2 LSCM imaging of epirubicin 
 
The anthracycline, epirubicin, is a P-gp and MRP-1 substrate chemotherapy drug that 
is naturally fluorescent, allowing it to be imaged directly through laser confocal 
microscopy [289]. It was initially envisaged that the laser confocal imaging of 
epirubicin in sensitive and drug-resistant cell lines could provide additional 
quantitative information on the effects of P-gp modulators on chemotherapy 
compounds. Direct epirubicin measurement by HPLC (Section 4.2) was deemed more 
advantageous than confocal methods for quantifying epirubicin because of the varied 
distribution of epirubicin within cells and the subjective nature of determining 
concentrations through fluorescence. It became apparent that confocal imaging was 
more useful in a qualitative capacity, defining cellular localisation and changes 
therein due to transporter inhibition.  
 
8.2.1 LSCM imaging of epirubicin in DLKP 
 
Epirubicin was shown to be localised to the nucleus and plasma membrane of DLKP 
cells with minimal cytoplasmic presence (Figure 4.1.1). This is consistent with the 
slow permeability of epirubicin through the plasma membrane, the intercalation of 
epirubicin with DNA and previous confocal observations in non-MDR tumour cells 
by other groups [290], [291]. Elacridar, cyclosporin A, verapamil or sulindac 
treatment caused no visible change in the level of epirubicin fluorescence or 
localisation in the DLKP cell model (Figure 4.1.2). Sulindac treatment might have 
been expected to increase epirubicin levels through MRP-1 inhibition. It was unlikely, 
however, that increases in epirubicin mass would have been visibly detectable through 
microscopy given the limited exposure time and the low MRP-1 expression levels in 
DLKP [160]. High over-expression of drug pumps is required to detect epirubicin 
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changes using the confocal method. A comparison of the DLKP-TXT and DLKP-A 
confocal results clearly illustrates this point (Figures 4.1.3 and 4.1.4). Cyclosporin A, 
elacridar and verapamil increased epirubicin accumulation and fluorescence through 
P-gp inhibition in DLKP-A but did not produce observable changes in lower P-gp 
expressing DLKP-TXT. 
8.2.2 LSCM of epirubicin in DLKP-A 
 
In contrast to the results obtained in DLKP, there is a complete absence of nuclear 
localised epirubicin in DLKP-A due to P-gp over-expression (Figure 4.1.3). This is 
consistent with LSCM anthracycline results in MDR bladder and myeloid cancer cell 
lines [291], [292]. All three P-gp modulators, elacridar, cyclosporin A and verapamil, 
increased intracellular epirubicin accumulation, and affect nuclear localisation 
through P-gp inhibition. There is no preferential increase in epirubicin levels accorded 
to a particular modulator implying a similar ability for each compound to modulate 
epirubicin transport in DLKP-A at the concentrations used. Anthracycline selection 
has been shown to increase cytoplasmic vesicle and nuclear membrane-localised P-gp 
in MCF-7/DX breast cancer cells leading to increased resistance [293]. The confocal 
images suggest an increase in cytoplasmic vesicle-localised P-gp may have occurred 
through adriamycin selection in DLKP-A. No cytoplasmic epirubicin-containing 
vesicles were observed in DLKP treated with P-gp modulators (Figure 4.1.2, 
Appendix B) but epirubicin containing cytoplasmic vesicles were clearly visible in the 
inhibitor-treated DLKP-A cells.  
 
8.2.3 LSCM of epirubicin in DLKP-TXT 
 
The reduction in accumulated paclitaxel levels due to sulindac in DLKP-TXT, as 
measured by HPLC, was not observed with docetaxel (Figure 4.1.4). The epirubicin 
confocal studies show that while the three P-gp modulators do not increase epirubicin 
levels sufficiently to be observable within the parameters of the experiment (Figure 
4.1.4), there is a decrease in nuclear epirubicin fluorescence in the presence of 
sulindac that is congruent with the decrease in paclitaxel accumulation seen in the 
HPLC accumulation assay. Further study is needed to establish if sulindac is 
selectively inhibiting uptake of epirubicin and paclitaxel in DLKP-TXT. 
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8.2.4 Laser confocal imaging of Oregon-green paclitaxel in DLKP 
and A549-Taxol 
 
The taxanes are not naturally fluorescent and require conjugation with fluorophores to 
allow visualisation by laser confocal microcopy [294]. These bulky additions (MW 
paclitaxel = 854 g/mol / MW Oregon-green 488 paclitaxel = 1319 g/mol) most likely 
alter a number of paclitaxel kinetic characteristics such as drug transport and 
permeability but in the case of Oregon-green-tagged paclitaxel allowed visualisation 
of the tubulin network in A549-Taxol and DLKP (Figures 4.1.5, 4.1.6, 4.1.7 and 
Appendix B). Marcus et al., have recently published similar images of the tubulin 
structure of A549 in which they were using fluorescently-tagged paclitaxel to probe 
the mechanistic basis for farnesyl transferase-mediated reversal of taxane resistance 
[294]. By observing the levels of Oregon-green paclitaxel bound to cellular 
microtubules, Marcus et al., found that farnesyl transferase inhibitors could reverse 
paclitaxel resistance by increasing the levels of paclitaxel bound to microtubules in 
paclitaxel-sensitive and paclitaxel-resistant cell lines [294]. This technique could be 
employed to examine tubulin structure after exposure to tubulin –targetted cytotoxics 
like the taxanes or during mitotic events in tumour cell lines as shown in Figure 4.1.8. 
There appears to be distinctive variations in tubulin distribution between DLKP 
(Figure 4.1.5) and A549-Taxol (Figure 4.1.6). The variation in uptake of Oregon-
green paclitaxel in the A549-Taxol cells could be due to P-gp over-expression but a 
control experiment in A549 would be needed to verify this. A comparison of taxane 
cytotoxicity values between A549-Taxol and DLKP revealed differences in sensitivity 
levels to the taxanes in these cell lines (Table 7.2.6) but this is most likely due to P-gp 
expression levels. 
 
8.2.5 HPLC-based quantification of epirubicin in DLKP-A 
 
The transport of epirubicin was examined to provide a quantitative result to 
complement the confocal studies in Section 4.2 and to compare the P-gp-mediated 
transport of a member of the anthracyline family with that of the taxanes, docetaxel 
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and paclitaxel. In addition, epirubicin/docetaxel and epirubicin/paclitaxel are used in 
combination for the treatment of advanced breast cancer [295], [296]. HPLC-
detection of the anthracycline, doxorubicin (adriamycin), was optimised by Dr. 
Robert O’Connor and later adapted for epirubicin measurement [160]. The epirubicin 
assays employed extended accumulation (2 hours) and efflux (3 hours) timepoints 
compared to the taxane transport assays. This is presumably due to epirubicin 
requiring increased time to reach and bind its high affinity nuclear target (DNA) in 
contrast to the cytoplasmic microtubule target of the taxanes [25]. Unlike the taxane 
transport studies reported herein, the HPLC-based epirubicin measurement protocol 
required 2 µM of drug for accumulation and efflux assays, a concentration that is 
below reported pharmacological Cmax (peak plasma concentration) values for 
epirubicin (Section 2.14) [297], [298].  
 
Elacridar, cyclosporin A and verapamil increased the mass of epirubicin accumulated 
in DLKP-A (Figure 4.2.1) and not only maintained levels of epirubicin in the efflux 
assay, they also increased drug levels after three hours in epirubicin-free medium 
(Figure 4.2.2). P-gp has been found localised in the nuclear membrane of 
doxorubicin-selected cells [293]. Although counterintuitive, the increase in epirubicin 
levels produced by P-gp modulators in the DLKP-A efflux assay may be due to 
inhibition of nuclear localised P-gp. The control set of cells were exposed to 
epirubicin for two hours but there was no nuclear localisation and some cytoplasmic 
localisation as gleaned from the confocal data (Figure 4.1.3).  The cytoplasmic 
epirubicin could possibly be sequestered in expanded lysosomal compartments as has 
been shown previously for anthracyclines in the doxorubicin-selected U-937 leukemic 
cell line [292]. With no access to its nuclear targets, this cytoplasmic pool of 
epirubicin would be quickly depleted by lysosomal sequestration and extrusion by 
active P-gp, even in the time between assay washes. In the presence of the P-gp 
modulators however, with inhibited plasma membrane, vesicle and nuclear membrane 
localised P-gp, the cytoplasmic epirubicin pool is stabilised and allowed access to the 
nucleus. DNA intercalated epirubicin would not be easily effluxed leading to the 
higher levels of epirubicin retained than in the control cells. 
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8.3 Development of a radiolabelled-based assay for determination 
of docetaxel accumulation and efflux 
 
Radiolabelled-based drug assays have achieved levels of detection in the picomolar 
range [143]. 14C radiolabelled drugs are relatively safe and extremely stable (half life 
~ 5000 years). As an alternative to the HPLC method of taxane detection, 14C-
radiolabelled docetaxel was chosen as the basis for the development of a more 
efficient detection method. A quick throughput protocol for the detection of 14C 
docetaxel in multi-drug resistant cells was not found in the literature. Given the 
importance of developing an accurate and reliable assay, a number of optimisation 
steps were undertaken. The optimisation process resulted in a method for docetaxel 
measurement that was of greater sensitivity than the HPLC-based technique, which 
utilised lower cell numbers, less consumables, and improved results throughput. 
 
8.3.1 Scintillation counter efficiency and seeding density 
 
Scintillation counter efficiency remained stable over a range of 14C docetaxel 
concentrations from 0.05 to 10 µM averaging 47.6% (Table 5.2.1.1). Counter 
efficiency can be used for calculation of disintegrations per minute (D.P.M.) along 
with background levels to calculate the actual mass of docetaxel present in a sample if 
required. DLKP-A were seeded at 1 X 105 cells/ml and 2 X 105 cells/ml for 24 hours 
prior to 14C docetaxel exposure (Figure 5.2.2.1). DLKP-A was chosen for this step as 
it accumulates the lowest levels of docetaxel of the cell lines being examined due to 
P-gp over-expression. Both seeding densities resulted in similar uptake levels at the 
14C docetaxel concentrations examined. This supported visual evidence that 1 X 105 
cells/ml provided a confluent monolayer and the excess cells present by seeding 2 X 
105 cells/ml did not attach to the well surface but were removed at various wash steps 
in the procedure. 
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8.3.2 The presence of cell debris does not quench radioactivity signal 
 
The samples to be read on the scintillation counter would not contain pure radio-
labelled drug but a mixture of 14C docetaxel, cell debris and 0.1 M NaOH. To quantify 
any cell debris-related quenching of 14C signal, an experiment was designed to 
compare the counts per minute (C.P.M.) for a range of 14C docetaxel concentrations in 
the presence or absence of cell debris. Cell debris was found to have negligible affect 
on detection levels (Figure 5.2.3.1A). The quantity of cell debris included with each 
sample was equivalent to that present in an assay sample. Assay reproducibility was 
increased due to the fact that cell debris does not affect readings. A representation of 
the scintillation count error as reported by the scintillation counter for the assay in 
Figure 5.2.3.1A revealed that the internal error associated with 14C docetaxel 
concentrations of 50 nM (0.05 µM) and above was below 5% (Figure 5.2.3.1B).  
 
8.3.3 Drug adsorption has negligible effect on assay error 
 
The capacity of the cell culture-treated 24-well plates to adsorp drug was a potential 
source of assay error. Song et al., have shown rapid and non-specific adsorption of 
paclitaxel to glass and plastic surfaces, such as glass vials and polystyrene tissue 
culture plates [299]. Retention of 14C docetaxel by 24-well tissue culture plates would 
lead to falsely elevated and unpredictable accumulation readings. The accumulation 
of a range of 14C docetaxel concentrations was measured in a 24-well plate containing 
DLKP and mirrored in an empty 24-well plate (Figure 5.2.4.1A). The readings 
reflecting drug adsorption in the empty 24-well plate were nominal and proved to be a 
negligible source of error compared to the large values recorded in the DLKP cell 
line. A representation of the internal scintillation counter error for this experiment 
reveals the higher error levels associated with lower radiation counts (Figure 
5.2.4.1B). While the internal % error is not of critical importance due to replicate data 
sets, maintaining error levels below 5% improves confidence in the assay. The % 
error levelled out below 5% at 100 nM in DLKP. 100 nM was chosen as the standard 
concentration for accumulation assays. 100 nM (0.1 µM) is a hundred times lower 
than the 10 µM employed previously in the HPLC based studies. 100 nM is  a value 
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that is also within the pharmacologically relevant range of docetaxel exposure (~0.01 
to 6 µM), therefore making findings more therapeutically relevant [300]. 
 
8.3.4 5% FCS has no effect on 14C docetaxel accumulation 
 
The presence of plasma proteins such as those found in foetal calf serum (FCS) within 
transport assays could have a major impact on drug accumulation. Urien et al., 
reported that docetaxel was extensively bound to plasma proteins (>98%) in vivo, the 
main carriers being lipoproteins, albumin and alpha 1-acid glycoprotein at clinically 
relevant concentrations [301]. FCS has also been shown to bind paclitaxel in vitro 
[299]. A549 and DLKP and their drug-selected variants are maintained in 5% FCS in 
DMEM/Ham F12. Accumulation of 100 nM 14C docetaxel was examined in A549 and 
DLKP in the presence of increasing concentrations of FCS (Section 5.2.5). 
Maintaining the cells in 5% FCS was deemed acceptable in all 14C docetaxel assays. 
50 and 100% FCS lead to huge reductions in 14C docetaxel accumulation, highlighting 
the influence of FCS on drug transport due to drug binding reducing the quantity of 
drug available for uptake into cells.  
 
8.3.5 Choice of a standard concentration of 14C docetaxel for use in 
DLKP-A efflux assays 
 
It was established that the pharmacologically relevant 100 nM 14C docetaxel was the 
optimum concentration for accumulation assays in A549, DLKP and their variants 
and, by default, for efflux assays in A549 and DLKP. It remained unclear if 100 nM 
14C docetaxel would provide sufficient accumulated 14C docetaxel for the purposes of 
an efflux assay in DLKP-A, an important factor when the effectiveness of TKIs as P-
gp inhibitors was examined (Section 7). A comparison of 100 nM and 500 nM 14C 
docetaxel accumulation alone and in the presence of cyclosporin A revealed 500 nM 
14C docetaxel provided a level of drug accumulation adequate for efflux assays in 
DLKP-A (Figure 5.3.8). Although 100 nM 14C docetaxel gave a measurable signal in 
DLKP-A , 500 nM 14C docetaxel provided a higher signal allowing detection of a 
wider range of potential effects. 500 nM is still within therapeutically relevant 
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concentrations [300]. Including cyclosporin A resulted in higher levels of drug 
retention but the effects of residual cyclosporin A on 14C docetaxel efflux in an assay 
would have needed further examination. 
 
8.3.6 Calculation of the mass of docetaxel in cells 
 
To directly compare the radiolabelled 14C docetaxel assay to the HPLC based method 
for taxane measurement, C.P.M. were converted to mass docetaxel (ng). This was 
achieved by generating a standard curve, plotting C.P.M. against mass docetaxel 
(Figure 5.3.1). The 14C docetaxel accumulation assay in DLKP (Section 5.2.4.1A) 
was then converted from C.P.M. to ng docetaxel/10,000 cells (Figure 5.3.2). The 
standard concentration of 14C docetaxel chosen for accumulation studies (100 nM) 
resulted in 1 ng docetaxel accumulated per 10,000 cells or 100 ng docetaxel 
accumulated per million cells. This is lower than the mass of docetaxel retained in 
DLKP on average on exposure to 10 µM docetaxel (466 +/- 110 ng/million cells) 
(Section 3.7).  
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8.4 Comparison of accumulation assays using radiolabel and 
HPLC techniques 
 
A major limitation of the HPLC-based method was the difficulty in identifying 
competitive inhibitors of P-gp-mediated docetaxel efflux because of the 
supraphysiological extracellular concentration employed (Section 3.13). The efflux 
profile of docetaxel in A549 was also inconsistent with the absence of taxane 
transporters (Section 3.3.2). The radiolabelled-based assay overcame these 
limitations. 
 
8.4.1 Verapamil increased 14C docetaxel accumulation in DLKP-A 
and DLKP-TXT 
 
Co-treatment of DLKP-A with verapamil and a concentration of 100 nM 14C 
docetaxel resulted in an increase in docetaxel accumulation (Figure 5.3.3).  
All three P-gp modulators produced similar levels of drug resistance reversal in 
DLKP-A (Figure 5.3.3). Inhibition of P-gp by verapamil resulting in an increase in 
docetaxel accumulation was apparent, contrary to the same experiment carried out 
using the HPLC method, Figure 3.9.1, in which the same concentration (100 µM) of 
verapamil did not affect docetaxel accumulation.  
A corresponding comparison of 14C docetaxel accumulation in the presence of P-gp 
inhibitors in DLKP-TXT also uncovered the P-gp inhibitory effects of verapamil 
(Figure 5.3.4), an effect absent when the HPLC-based system was used to quantify 
docetaxel levels (Figure 3.11.1). This showed the suitability of the 14C docetaxel 
assay for examination of docetaxel transport in cell lines expressing lower levels of P-
gp. Cyclosporin A and elacridar also illicited relatively large increases in 14C 
docetaxel accumulation in DLKP-TXT. Sulindac was shown to have no influence on 
14C docetaxel accumulation in DLKP-TXT. These results confirmed the 14C docetaxel 
assay was superior to the HPLC method for docetaxel measurement. 
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8.4.2 Comparison of the accumulation profiles of 100 nM 14C 
docetaxel in A549 and A549-Taxol 
 
It was unexpected that the accumulation of 100 nM 14C docetaxel was similar 
between the P-gp over-expressing A549-Taxol and the non-P-gp expressing A549 
(Figure 5.3.5). An accumulation assay in A549-Taxol examining a range of 14C 
docetaxel concentrations revealed that the decrease in accumulation only initiated at 
400 nM 14C docetaxel (Figure 6.2.3). This would suggest a minimum concentration 
threshold for activation and/or detection of P-gp-mediated docetaxel efflux in A549-
Taxol over the 90 minute time period examined. The lipophilic nature of docetaxel 
may mean a higher docetaxel concentration (500 nM) is required to increase the rate 
of passive docetaxel influx to a rate where the influence of P-gp-mediated docetaxel 
efflux can be observed. Analysis of the major factors affecting the intracellular 
pharmacokinetics of paclitaxel (extracellular concentration, intracellular binding 
capacity, intracellular binding affinity and P-gp expression) by computational model 
analysis predicted that extracellular drug concentration was the most important factor 
at pharmacological drug levels (100-1000 nM) [302]. Figures 5.3.5 and 6.2.3 may be 
in vitro evidence for the complexity of the intracellular pharmacokinetics of docetaxel 
in low P-gp-expressing cells at pharmacologically relevant concentrations. Lapatinib 
and erlotinib increased the accumulation of 14C docetaxel in A549-Taxol (Figure 
7.2.8.1) but this occurred using a concentration of 500 nM 14C docetaxel, above the 
threshold value observed in A549-Taxol (Figure 6.2.3). Furthermore, the TKI-related 
increases in 14C docetaxel accumulation only became significant at later timepoints 
for the lower concentrations of lapatinib (Figure 7.2.8.1). These observations indicate 
that maximising the concentration of the chemotherapeutic agent that the tumour is 
exposed to is a priority if pursuing the TKI/cytotoxic combinations to circumvent 
MDR, as suggested in Section 8.6.8. 
 
8.4.3 The effects of high extracellular concentrations of docetaxel on 
efflux profiles in A549 and DLKP 
 
The influence of the extracellular docetaxel concentration on drug binding was 
apparent in the HPLC-determined docetaxel efflux profile in A549 in which a 
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significant reduction in cellular docetaxel was evident 45 minutes after drug removal 
(Figure 3.3.2). The efflux profile of docetaxel was re-examined with the radiolabel-
based assay at three concentrations, 0.1, 1 and 10 µM (Figure 5.3.6). This revealed 
that the efflux profile was dependent on the concentration of 14C docetaxel employed 
to load the cells. Saturation of intracellular and extracellular binding sites and a 
constant accumulation pressure due to the extracellular/intracellular drug gradient 
may be an explanation for the HPLC results (Figure 3.3.2) and the docetaxel efflux 
profile at 10 µM in Figure 5.3.6. Once the docetaxel containing medium is removed, 
the drug concentration gradient is reversed and excess docetaxel diffuses from the 
cell. Sang et al., provide evidence of triphasic changes in intracellular to extracellular 
paclitaxel ratios in MCF-7 breast cancer cells [303]. They postulate that low 
extracellular paclitaxel concentrations (<100 nM) result in a linear increase in 
intracellular concentrations before saturation of the high affinity intracellular binding 
sites (tubulin) while the second phase, between 100 nM and a 1000 nM, exhibit a non-
linear relationship between extracellular and intracellular drug concentrations as the 
intracellular binding sites become saturated [303]. In the third phase, above 1000nM 
(1 µM), once the high affinity binding sites are saturated, the relationship returns to a 
linear function as non-saturable binding becomes the major mode of intracellular drug 
binding [303]. Docetaxel has a higher affinity for tubulin than paclitaxel and may 
therefore be expected to be more effective at saturating the high affinity intracellular 
binding sites [31].  Exposure to 100 nM 14C docetaxel resulted in an A549 (Figure 
5.3.6) and DLKP (Figure 5.3.7) efflux profile that would be expected in cell lines that 
do not express major levels of taxane efflux mechanisms and retain accumulated drug 
at the high affinity intracellular binding sites.  
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8.4.4 Assessment of the radiolabel-based method for docetaxel 
quantification 
 
The radiolabel-based transport assay addressed the major disadvantages of the HPLC 
method: 
 
• Pharmacological levels of docetaxel could be examined. 
• The effects of competitive inhibitors are easier to detect. 
• The docetaxel efflux profile in A549 and DLKP is consistent with the absence 
of detectable levels of P-gp.  
• Improvement of assay efficiency. 
 
Similar variations of the developed method have been used to detect other 
radiolabelled drugs such as tritium-labelled [3H] paclitaxel and OATP substrates like 
17ß-D-glucuronide [143], [304]. The extensive optimisation process should mean the 
developed protocol could easily be adapted for the detection of other radiolabelled 
drugs. 
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8.5 A docetaxel uptake mechanism in lung cancer  
 
There are a number of reasons why a docetaxel transporter would be of interest in the 
treatment of lung cancer. A specific docetaxel uptake mechanism could: 
 
• Increase sensitivity to and concentrations of substrate drugs in tissues with 
expression of the transporter 
• Be useful in predicting chemotherapeutic drug response  
• Be a potential therapeutic target 
• Lead to drug:drug interactions between substrate compounds 
 
 
8.5.1 Docetaxel influx in the human lung cancer cell lines DLKP and 
A549 
 
It is widely believed that many MDR-type drugs (e.g. taxanes, anthracyclines) enter 
cells by passive diffusion through the plasma membrane [305]. Active systems of 
influx and efflux for other agents such as anti-folate therapies like methotrexate and 
the platinum-based drugs cisplatin, carboplatin and oxaliplatin have been described 
[306]. Smith et al., reported that OATP1B3 (SLCO1B3, OATP8) is capable of 
stimulating uptake of paclitaxel and docetaxel, using oocyte injection experiments, an 
artificial in vitro method for determining transporter affinity for substrates [307]. 
Xenopus laevis oocytes were injected with OATP1B3 cRNA and incubated with 
radiolabelled docetaxel or paclitaxel and the intracellular taxane concentration of the 
oocytes determined [307]. Kobayashi et al., reported similar findings for OAT2 
(SLC22A7)-expressing oocytes with respect to paclitaxel [193]. 
The discovery that members of the SLCO and SLC22 families of transporters are 
involved in the hepatic transport of the taxanes has raised the possibility of the 
existence of further tissue-specific docetaxel transporters. OATP1B3 and OAT2 do 
not utilise ATP directly but do rely on the concentration gradients of co-transported 
compounds that may be maintained through energy-dependent means  [308], [201]. A 
number of studies have recently shown that the SLCO family members transport a 
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wide range of amphipathic compounds in a sodium-independent manner accepting 
glutathione in exchange for an organic anion while the SLC22 family are passive 
diffusion organic cation transporters [308], [201].  
There is no evidence in the literature for an energy-dependent docetaxel, or indeed 
paclitaxel, transport mechanism responsible for drug uptake in lung tissue. The study 
of docetaxel influx in this project was divided into exploration of two areas, energy-
dependent docetaxel transport and OATP-mediated docetaxel transport. All the 14C 
docetaxel accumulation studies carried out utilised the protocol developed in Section 
5. 
8.5.2 Energy-dependent docetaxel transport 
 
Energy-dependent drug transport has a number of characteristics: 
 
• Energy-dependent drug transport is saturable, that is, it reaches a maximum 
rate. Saturation is the point at which all transporters present are being utilised 
and transport is capacity limited. 
• It is temperature-dependent. Changes in temperature affect the enzymatic 
processes, such as ATPase function, involved in active drug transport. 
• It is ATP-dependent.  ATPase conversion of ATP to ADP provides the energy 
required for drug transport. 
 
Each of these factors were examined and compared in the adenomatous NSCLC cell-
derived A549 and squamous cell-derived DLKP to determine if an energy-dependent 
docetaxel influx mechanism is present.  
 
8.5.3 14C docetaxel accumulation is saturable in DLKP but not A549 
 
The linear trend observed for 14C docetaxel accumulation in A549 is indicative of 
transport that is not saturable up to 500 nM (Figure 6.2.1). In contrast, 14C docetaxel 
accumulation was saturable in DLKP (Figure 6.2.2). Saturation alone is not 
conclusive evidence of an energy-dependent transport mechanism but it does imply 
the presence of a rate-limiting transport step. 
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14C docetaxel saturation was also studied in A549-Taxol and DLKP-Mitox cells. The 
over-expression of P-gp in A549-Taxol would have been expected to reduce the 
accumulation of 14C docetaxel compared to the A549 parent cell line (Figure 6.2.3). 
As expected, the levels of 14C docetaxel accumulated were indeed lower for all 
concentrations measured except for 300 nM and 400 nM, but these values were within 
the standard deviation range for the A549 values. The 14C docetaxel accumulation 
profile in DLKP-Mitox was markedly different from the parent DLKP cell line 
(Figure 6.2.4). The reduced accumulation of 14C docetaxel relative to DLKP could be 
due to increased efflux due to expression of a docetaxel efflux pump other than P-gp. 
DLKP-Mitox does not express P-gp (Figure 3.2.1) and the BCRP it is known to 
express does not transport docetaxel [260]. Another possibility is decreased 
accumulation due to down-regulation of an unknown influx mechanism.  
 
8.5.4 14C docetaxel accumulation is temperature-dependent in A549 
and DLKP 
 
The use of temperature change (0-370C) to affect drug accumulation in order to 
demonstrate the presence of an active transport mechanism is an established technique 
[309], [310]. Lower temperatures would be expected to reduce the rates of reaction 
and catalytic activities of proteins associated with transport. Accumulation of 14C 
docetaxel was reduced at 40C and 270C in both A549 (Figure 6.3.1) and DLKP 
(Figure 6.3.2), indicative of a temperature-dependent accumulation rate. Temperatures 
above 370C have not generally been examined in the literature. This is presumably 
due to the unreliable integrity of the cell membrane above a temperature of 37.20C. 
The rapid decrease in 14C docetaxel accumulation occurring after 60 minutes at 460C 
was accompanied by visual changes in cell morphology, including poorly defined 
outlines and morphological homogenisation (observation). It could be presumed that 
increased levels of accumulation observed at 410C and in the first 60 minutes at 460C 
are similarly related to changes in membrane state but further work would be needed 
to confirm this. The difference between 14C docetaxel accumulation at 270C and 370C 
in DLKP is consistently greater than the difference observed in A549. This suggests 
14C docetaxel accumulation is more temperature sensitive in DLKP than A549. 
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The temperature-dependent changes in 14C docetaxel accumulation alone are not 
definitive evidence of the existence of an ATP-dependent transport mechanism as 
anion exchangers such as the OATP family are also affected by temperature changes 
as well as membrane fluidity and flux. A fuller picture of the effect of temperature on 
14C docetaxel accumulation in DLKP and A549 could be gained by examining 
accumulation at varying temperatures and concentrations. 
8.5.5 Depletion of ATP levels by sodium azide, 2-deoxyglucose and 
antimycin A in A549 and DLKP 
 
A decrease in cellular ATP levels affects the efficiency of ATP-dependent 
transporters. Previous studies carried out involving ATP-depletion agents assumed 
ATP levels were reduced (Section 3). The extent of ATP depletion caused by glucose-
free medium alone and in combination with sodium azide, 2-deoxyglucose and 
antimycin A was measured in A549 and DLKP using a bioluminescent luciferase- 
based assay (Figures 6.4.1 and 6.4.2). Although a source of ATP, it was decided to 
include 5% FCS in the assays to maintain uniformity between saturation temperature 
and ATP depletion assays. While none of the compounds alone completely eliminated 
ATP, a combination of sodium azide, 2-deoxyglucose and antimycin A in glucose-
free medium achieved 92 % and 96 % reductions in ATP levels for DLKP and A549, 
respectively (Figure 6.4.3, Table 6.4.1). These reductions are comparable to those 
achieved in other breast and lung cancer cell lines [311], [312]. 
 
8.5.6 ATP depletion reduced 14C docetaxel accumulation in DLKP 
and increased 14C docetaxel accumulation in A549 
 
Pre-treatment of DLKP with the ATP inhibitors resulted in a decrease in 14C 
docetaxel accumulation (Figure 6.5.1 A). The decrease in 14C docetaxel accumulation 
was visible directly when comparing medium conditions within pre-treated and non- 
pre-treated cells, but only at the 120 minute timepoint (Figures 6.5.1 A). Comparison 
of each individual condition (normal medium, glucose-free medium and glucose-free 
medium and ATP inhibitors) under pre-treated and non-pre-treated conditions defined 
the reduced 14C docetaxel accumulation clearly (Figure 6.5.1 B).  This representation 
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of the data revealed that the 30 minute pre-treatment with the ATP inhibitors in DLKP 
subsequently resulted in lowered levels of  14C docetaxel accumulated under all 
conditions (Figure 6.5.1 B).  
 
The ATP inhibitor study in A549 revealed an increase in 14C docetaxel accumulation, 
concomitant with inhibition of an efflux mechanism or stimulation of a non-active 
uptake mechanism by one of the ATP inhibitors used. While 2-deoxyglucose is taken 
into the cell through the glucose uptake system, there is no evidence that sodium 
azide, 2-deoxyglucose or antimycin A are substrates for an influx mechanism that 
could be associated with docetaxel accumulation. A549 is reported to express MRP-2 
and the presence of OATP family members capable of bi-directional transport cannot 
be discounted [276], [195]. Pre-treatment with ATP inhibitors did not affect 14C 
docetaxel accumulation in normal and glucose-free medium (Figure 6.5.2 B). Pre-
treatment with ATP inhibitors produced an initial minor increase in 14C docetaxel 
accumulation compared to the non-pre-treated cells but produced comparable results 
at later timepoints (Figure 6.5.2 B).  
The recovery rate of the ATP levels in DLKP and A549 after ATP inhibitor exposure 
has not been studied, so it may be that A549 has a quicker response and recovery time 
to ATP inhibitors than DLKP. The rate of ATP recovery could be determined 
experimentally by exposing cells to ATP depleting agents for a set period then 
incubating cells in medium, and determining ATP levels at set intervals thereafter. 
 
In summary, 14C docetaxel accumulation in DLKP is saturable (Figure 6.2.2), 
temperature-dependent (Figure 6.3.2) and ATP-dependent (Figures 6.5.1 A and 6.5.1 
B) fulfilling the criteria expected for an energy-dependent influx mechanism.  
 
8.5.7 Possible docetaxel transport mechanisms in DLKP 
 
Speculation based on current results for possible uptake mechanisms in DLKP is 
difficult for a number of reasons. Saturation and temperature-dependence are 
characteristic of all carrier-mediated transport mechanisms. ATP-dependence may be 
a result of transporters being directly dependent on ATP (contain an ATPase 
component) or indirectly relying on ATP to maintain electrochemical gradients 
(secondary active transport). The ability of anion exchangers such as the OATP 
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transporters to translocate drugs in a bi-directional manner further complicates the 
situation. Bi-directional transport can be dependent on the site of protein localisation 
and/or changes in substrate concentrations [195].  
The two available sources of information for speculation on the possible transporters 
in the NSCLC cell line DLKP are the literature and microarray data generated from 
the cell line. Studies on uptake mechanisms for the taxanes in tissues other than the 
liver are in short supply as it was generally assumed that taxane tumour uptake is 
passive in nature. Ehrhlichova et al., studied 14C paclitaxel in adriamycin-sensitive (P-
gp-negative) MDA-MB-435 and adriamycin-resistant (P-gp-positive) NCI/ADR-RES 
breast cancer cell lines [285]. They found that 14C paclitaxel accumulation (20-500 
nM) was saturable in MDA-MB-435. Additionally, SB-T-1214, a novel taxane analog 
was found to cause dose-dependent inhibition of 14C paclitaxel uptake in both MDA-
MB-435 and NCI/ADR-RES. The authors suggested that these effects could be due to 
an active inward transport mechanism. It is also worth noting that 14C paclitaxel efflux 
was stimulated by high concentrations of verapamil (100 – 400 µM) in the MDA-MB-
435 cell line. MDA-MB-435 was shown to express MRP-2 and the authors discussed 
the possibility that stimulation of MRP-2 could be responsible for the increased 14C 
paclitaxel efflux.  
Ehrhlichova et al., provided circumstantial evidence for a taxane uptake mechanism 
in a breast cancer cell line but others have found members of the SLC superfamily of 
transporters that mediate taxane transport. The SLC family of transporters are the 
subject of intense interest at present due to advances in identification of family 
members and their recently appreciated importance in vectorial drug transport. Drug 
vectoring occurs in polarised tissues involved in drug disposition (liver, kidney) and 
restricted distribution to protected sites (blood-brain barrier) and so plays a vital role 
in drug absorption, disposition, metabolism and excretion. Polarised cells 
asymmetrically express a variety of drug transporters on the apical (e.g. MRP-2) and 
basolateral sides (e.g. SLCO1B1), resulting in transcellular drug transport in a specific 
direction.  
Smith et al., found that OATP1B3 (SLC01B3) was able to stimulate uptake of 
radiolabelled paclitaxel and docetaxel. OAT2 (SLC22A7) is a sodium-independent 
multi-specific organic anion/dimethyldicarboxylate exchanger expressed 
predominantly in the liver that has been shown to mediate transport of 
dehydroepiandrosterone sulfate (DHEAS), prostaglandin E2, 5-fluorouracil and 
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paclitaxel [193]. OATP1B3 and OAT2 expression has not been reported in normal 
lung tissue in previous studies [203], [313].  
A search of microarray data obtained from DLKP, DLKP-A, A549 and A549-Taxol 
and analysed by Genespring software, indicated SLC22A3 (OCT3, EMT), SLC22A5 
(OCTN2) and SLC22A18 (HET, ITM, BWR1A, IMPT1, TSSC5, ORCTL2, 
BWSCR1A, p45-BWR1A) mRNA transcripts to be present (Appendix A, Table A2). 
The presence of SLC22A3 and SLC22A5 mRNA is consistent with previous studies 
reporting expression of these transporters in the lung [201]. SLC22A3 is a passive 
diffusion organic cation transporter, while SLC22A5 is a sodium-dependent carnitine 
co-transporter that can also function as a sodium-independent organic cation 
transporter [201]. SLC22A18 may be associated with tumorigenesis in Wilm’s 
disease, breast and lung cancers as well as the transport of chloroquine- and 
quinidine-related compounds in the kidney [314], [315], [316]. At this point, it is 
important to note that the microarray data was only used as an exploratory tool to 
provide a starting point to indicate which SLC family members were most likely to be 
expressed in A549 and DLKP. mRNA levels do not necessarily correlate directly to 
protein expression. Protein detection techniques are the only way to positively 
confirm the presence of identified transporters. This applies to all references to the 
microarray data in this discussion.  
 
Expression of all members of the OATP/SCLO family was absent according to the 
DLKP microarray data (Appendix A, Table A1). This was unusual as studies have 
shown expression of a number of OATP members in normal lung tissue [268]. The 
broad specificity OATP inhibitor bromosulfophthalein (BSP) had no effect on 
docetaxel accumulation in DLKP (Figure 5.5.1), offering confirmatory evidence that 
OATP family members were absent. Interestingly, digoxin did reduce docetaxel 
accumulation in DLKP, (Figure 5.5.2). It is possible that DLKP expresses a protein 
that transports digoxin and not BSP but there is insufficient data to provide evidence 
for this. The mRNA for the digoxin transporter OATP1B3 is absent from DLKP 
according to microarray results and there is no evidence for the ability of SLC22A3 or 
SLC22A18 to transport digoxin. Digoxin has been shown to have no effect on 
SLC22A5-mediated carnitine transport [317].  Investigation of the effects of digoxin 
on docetaxel accumulation in DLKP warrants futher investigation.  
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Taking the results at face value, none of the transporters discussed fit the saturable, 
temperature-dependent and ATP-dependent nature of 14C docetaxel accumulation 
observed in DLKP. In order to identify the likely mechanism involved, future studies 
should examine putative inhibitors of ATP-dependent transporters that are known to 
be expressed in lung tissue. These target transporters could be prioritised according to 
the DLKP microarray data. The involvement of anion exchangers should also be 
explored by examining docetaxel transport in combination with anion exchange-
associated substrates such as glutathione, carnitine, carboxylate and sodium. These 
assays would also function to narrow down possible candidate transporters. Rather 
than looking at total cellular docetaxel accumulation, the use of monolayer transport 
assays that distinguish between apical and basolateral transport may also be helpful in 
identifying transporters that may have polarised expression on one cell membrane 
surface. 
 
8.5.8 OATP-mediated docetaxel transport in A549 
 
As mentioned previously, members of the OATP/SLCO transporter family are 
expressed in the lung (Section 6.1). With the knowledge that OATP1B3 can transport 
docetaxel, a study of the affects of various OATP inhibitors on 14C docetaxel 
accumulation in A549 and DLKP was designed [192]. Alterations in 14C docetaxel 
accumulation due to treatment with such inhibitors could be indicative of OATP-
mediated docetaxel transport in these cell lines. 
Exploratory examination of DNA microarray analysis carried out on the A549 cell 
line revealed RNA expression levels for OATP3A1 and OATP4A1 and particularly 
high levels of OATP1B3 (Appendix A, Table A1).  
Initial experiments involving OATP inhibitors revealed that BSP and digoxin reduced 
14C docetaxel accumulation in A549 (Figure 6.6.1 and Figure 6.6.2).  For this reason 
and the absence of OATP mRNA expression in DLKP according to the microarray 
data, the A549 cell line was chosen for the assays involving the more specific OATP 
inhibitors (indocyanine green, DHEAS, prostaglandin E2, tri-iodo thyroxine (T3).  
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8.5.9 Indocyanine green increases 14C docetaxel accumulation in 
A549 and DLKP 
 
Indocyanine green (ICG, cardiogreen) is used intravenously as a diagnostic aid in the 
determination of blood volume, cardiac output and hepatic function, and as a tissue 
stain for imaging retinal and choroidal vasculatures [318], [319]. Indocyanine green 
had unexpected effects on 14C docetaxel accumulation in A549 and DLKP.  Its uptake 
is mediated by OATP1B1 in the liver and BSP is also an OATP1B1 substrate [320]. 
The effect of ICG on 14C docetaxel accumulation was examined to determine if 
OATP1B1 was involved in the initial BSP-related decrease in 14C docetaxel 
accumulation levels observed in A549 (Figure 6.6.1). The increased amount of 14C 
docetaxel accumulated in A549 due to ICG is most likely not OATP-related. A 
similar increase was shown in DLKP (Figure 6.6.4), a cell line in which the 
OATP1B1 inhibitor BSP had no effect on 14C docetaxel accumulation (Figure 6.6.1). 
The diminished increase in drug accumulation at the highest concentrations of ICG in 
A549 and DLKP are most likely due to the high DMSO levels (Section 8.5.13). 
The mechanism of the ICG effect may merit investigation for the possibility that ICG 
could have the potential to increase tumour docetaxel levels in vivo. ICG uptake in 
HaCaT keratinocytes was saturable, highly cumulative and inhibited by BSP [321]. A 
study to determine if the ICG 14C docetaxel accumulation effect in A549 and DLKP is 
reversible by BSP would provide evidence for the involvement of the OATP family in 
the effect. ICG is amphiphilic and has been shown to interact strongly with 
phospholipids, the main constituent of cellular plasma membrane bi-layers [319]. 
There is evidence that ICG can bind both the hydrophilic and lipophilic structures of 
phospholipids at the same time [319]. Such interactions could alter the structure and 
permeability of phospholipid bi-layers and may be an explanation for the increased 
14C docetaxel levels observed in A549 and DLKP. 
Photoactivation of ICG by irradiation has been shown to effectively kill human 
keratinocytes, fibroblasts and squamous cell carcinoma cells in vitro [321]. 
Identification of a possible carrier, other than OATP1B1, could further the potential of 
phototherapies in suitable cancers.  
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8.5.10 T3 and DHEAS increase 14C docetaxel accumulation in A549 
 
The BSP and digoxin-related decrease in 14C docetaxel accumulation in A549 
suggested involvement of the OATP family in docetaxel uptake. The subsequent 
results for indocyanine green, the OATP1B1 modulator and cyclosporin A (Figure 
6.6.6), a reported OATP1B1 and OATP1B3 modulator, suggest that OATP1B3 or 
OATP1B1 are not involved in 14C docetaxel accumulation in A549 [264],[265].  
Digoxin, indocyanine green and cyclosporin A interact with OATPs that are inhibited 
by BSP, but are not necessarily OATPs whose expression has been reported in lung 
tissue.  OATP2B1 (OATP-B) is found in lung tissue and BSP is a substrate [266]. 
More specific to this research, Northern blot analysis has detected OATP3A1 (OATP-
D) at the mRNA level in A549 [267]. OATP2B1, 3A1 and 4A1 (OATP-E) and 
prostaglandin transporter (PGT) expression has been found in lung tissue by RT-PCR 
in a study by Tamai et al. [268]. OATP1A2 (OATP-A) and OATP1B1 were not 
detected in lung tissue [268]. Microarray analysis reported mRNA presence for 
OATP1B3, 3A1 and 4A1 in A549 (Appendix A, Table A1). Although cyclosporin A 
had no effect on 14C docetaxel accumulation in A549 (Figure 6.6.6), further 
examination of this transporters influence on docetaxel transport in A549 is 
warranted. OATP1B3 is still the only documented member of the SLCO family to 
transport the taxanes. BSP, a broad specificity inhibitor capable of modulating 
OATP1B3, reduced docetaxel accumulation in A549 (Figure 6.6.1) and the protein 
levels of OATP1B3 expressed in A549 are still unknown [307]. It is possible that 
cyclosporin A was not present at the optimum conditions necessary for inhibition of 
OATP1B3 transport. 
The most specific substrates that could potentially inhibit OATP2B1, -3A1  and –4A1 
competitively are dehydroepiandrosterone sulfate (DHEAS) [263], prostaglandin E2 
(PGE2) [267] and thyroid hormone (Tri-iodothyronine, T3) [269]. BSP is a substrate 
for both OATP2B1 and OATP4A1, and considering the decrease in 14C docetaxel 
uptake associated with BSP, these transporters are candidates for the inhibition of 
docetaxel accumulation in A549. OATP3A1 has a similar drug transport profile to 
PGT. The fact that PGE2 did not affect 14C docetaxel accumulation would suggest that 
OATP3A1 is not involved in 14C docetaxel uptake in A549 (Figure 6.6.7). DHEAS 
and T3 did affect 14C docetaxel accumulation (Figures 6.6.5 and 6.6.8). Both produced 
minor but significant increases in 14C docetaxel accumulation. Combined with the 
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increase in accumulation due to ATP inhibition (Figure 6.4.2), the most plausible 
explanation is the existence of an ATP-dependent docetaxel efflux mechanism that 
can be inhibited by DHEAS and T3. The indocyanine green-related increases in 14C 
docetaxel accumulation are most likely not due to OATP or any putative efflux 
mechanism. The reduction in 14C docetaxel accumulation due to BSP and digoxin, 
however, may still be down to inhibition of an influx mechanism other than OATP. 
The possibility that OATP bi-directional transport is responsible is plausible given the 
small 14C docetaxel increase observed.  
 
8.5.11 ATP-dependent docetaxel transporter in A549 
 
MRP-2 is the best candidate to explain the ATP-dependent (Figure 6.5.2A) and 
DHEAS-dependent (Figure 6.6.5) increases in 14C docetaxel accumulation in A549. 
A549 expresses detectable levels of MRP-2 protein but not P-gp (Figure 3.2.1) [276]. 
DNA microarray data also provides corroborative evidence of this MRP-2 expression 
(Appendix A, Table A3). There are conflicting reports over the ability of MRP-2 to 
transport DHEAS. Zelcer et al., have reported no direct transport of DHEAS in 
membrane vesicles containing MRP-2 or MRP-3 [322]. On the other hand, Spears et 
al., suggest that OATP1B1 and MRP-2 are mediators of DHEAS and rifampicin 
directional trans-epithelial transport in porcine LLC-PK1 [323]. Spears et al., do 
acknowledge that similar work carried out in canine MDCKII-derived cell models by 
Sasaki et al., found no increase in the basolateral to apical transport of DHEAS [323], 
[324]. An examination of DHEAS transport and MRP-2 ATPase activity would 
elucidate the involvement of MRP-2 in docetaxel transport in A549. The other 
compound to increase 14C docetaxel accumulation in A549 was tri-iodothyroxine (T3) 
(Figure 6.6.8). T3 has been shown to be involved in the regulation of MRP-2 protein 
and mRNA expression [325]. An exploration of the ability of MRP-2 to transport T3 
would be of interest. Future work to ascertain if MRP-2 is a mediator of 14C docetaxel 
efflux in A549 would include the determination of MRP-2 protein levels in A549, the 
study of DHEAS and T3 transport in A549 and MRP-2 ATPase assays and a study of 
the protein levels of the other known energy-dependent docetaxel transporter, MRP-7 
[143]. DNA microarray data suggests the presence of MRP-7 mRNA in A549 
(Appendix A, Table A3). 
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8.5.12 Future investigation of cisplatin transport by SLC family 
members in A549 and DLKP 
 
Two members of the SLC superfamily, SLC7A11 (xCT) and SLC31A (Ctr1, copper 
transporter 1) have been implicated in chemosensitivity to cisplatin [306]. mRNA for 
both these transporters was present in DLKP and A549 according to microarray data 
(Appendix A Table A4). Given the importance of cisplatin in NSCLC, investigation 
of the expression and possible involvement of these transporters in sensitivity to 
cisplatin and cisplatin resistance in platinum-selected variants of NSCLC cell lines 
(A549 and DLKP) would be of merit. 
 
8.5.13 DMSO decreases 14C docetaxel accumulation 
 
In the 14C docetaxel transport assays, high DMSO concentrations were associated 
with decreased 14C docetaxel accumulation in DLKP (Figure 6.6.2 and 6.6.4). DMSO 
caused no significant changes in 14C docetaxel accumulation in A549 at the 
concentrations examined (Section 6.6). Of the two cell lines, DLKP was more 
sensitive to the presence of DMSO (Figure 6.6.4). DMSO increases the permeability 
of cell membranes, the basis for its use in the treatment of vesicant chemotherapeutic 
extravasation in the clinic [326]. Extravasation occurs when chemotherapeutic drug 
leaks from a vein or an I.V. catherer into surrounding tissue. Studies on the molecular 
mechanism of action of DMSO reveal that DMSO causes thinning of phospholipid 
membranes at low concentrations and pore formation and membrane disintegration at 
high concentrations [327]. The evidence suggests that increasing DMSO 
concentration should increase membrane fluidity and permeability and increase 
docetaxel accumulation. This is contrary to the observed results. Disruption of plasma 
membrane integrity could affect the function of a specific drug uptake mechanism.  
This is a possible explanation for the decrease in 14C docetaxel accumulation in 
DLKP that is consistent with the evidence for an energy-dependent uptake mechanism 
in this cell line. 
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8.6 Modulation of P-gp-mediated docetaxel transport 
 
Having considered the mediation of docetaxel uptake in NSCLC, modulators of P-gp-
mediated docetaxel efflux, the second major aim of the project, was considered. The 
ability of a number of P-gp modulators to overcome tumour resistance has been tested 
in vivo [280]. Many of these first (cyclosporin A, verapamil) and second generation 
(PSC833) drugs failed in attempts to circumvent MDR due to intolerable toxicity, 
poor bioavailability and lack of specificity [280]. In a different strategy, that takes 
advantage of pharmacokinetic interactions, cyclosporin A and PSC833 have proved 
useful in increasing the oral bioavailability and brain penetration of the taxanes when 
so utilised in clinical and pre-clinical studies [328]. Tariquidar is the third generation 
inhibitor considered to have the most potential, having successfully completed Phase I 
and II trials but there is little information on its pharmacokinetic interactions with 
cytotoxic agents as yet [329]. Recent reports of the ability of tyrosine kinase inhibitors 
to interact with mediators of MDR raise new potential for this class of drug [253]. In 
addition to their primary function of c-ErbB inhibition, the low toxicity tyrosine 
kinase inhibitors, gefitinib, erlotinib and lapatinib may provide the balance between 
bioavailability and P-gp inhibition at pharmacologically achievable doses necessary to 
circumvent MDR.  
 
8.6.1 Distinct manner of lapatinib’s interaction with P-gp  
 
Results indicate that lapatinib interacts with P-gp in a manner distinct from that of 
gefitinib and erlotinib. Lapatinib is an effective inhibitor of verapamil-stimulated P-gp 
ATPase activity while erlotinib and gefitinib have very little direct P-gp ATPase 
inhibitory activity even at elevated concentrations (Figure 7.2.2.1A). The energy 
released from ATP hydrolysis is used to drive drug movement. A strong substrate will 
stimulate P-gp ATPase activity resulting in increased levels of ATP hydrolysis. P-gp 
ATPase studies showed erlotinib to be a strong P-gp substrate while gefitinib was 
transported at a slower rate (Figure 7.2.2.1B). The gefitinib results were consistent 
with previous findings by Ozvegy-Laczka et al. [251]. In contrast to gefitinib and 
erlotinib, lapatinib was a poor activator of P-gp ATPase activity which suggests, when 
combined with the ATPase inhibition assay results, that it is a slowly transported 
 292
substrate with a high affinity for a P-gp binding site (Figure 7.2.2.1). Lapatinib may 
therefore be more effective at overcoming P-gp-mediated resistance to 
chemotherapeutic agents than erlotinib and gefitinib at equal concentrations.  
 
ATPase assays alone do not definitively classify compounds as P-gp substrates or 
inhibitors. Verapamil, for instance, is a strong P-gp ATPase activator but it is not 
transported in monolayer efflux assays [330]. Direct measurement of compound 
transport using sensitive techniques such as mass spectrometry or radiolabelled drug 
transport assays would provide the best verification for a substrate or inhibitor. In 
order to evaluate the three TKIs as possible MDR modulators, the effects of the TKIs 
in cytotoxic drug transport and combination proliferation assays were examined to 
complement the ATPase findings. 
 
8.6.2 Potency of lapatinib in docetaxel combination proliferation and 
transport assays 
 
In vitro docetaxel transport assays confirmed lapatinib as the most potent P-gp 
modulator of the TKIs tested. Using a physiologically-relevant concentration of 
radiolabelled docetaxel, it was shown that each of the TKIs increased the net 
accumulation of docetaxel in the P-gp-over-expressing DLKP-A cell line (Figure 
7.2.3.1). Lapatinib produced near maximal P-gp inhibition and very significantly 
increased the accumulation of docetaxel at concentrations of 1-2.5 µM. This 
observation is particularly noteworthy as lapatinib serum levels peaked at 
approximately 2-4 µM when patients received a 1250 -1,600 mg dose [273]. 
 
Although cyclosporin A was a better inhibitor of verapamil-stimulated P-gp activity 
in the purified ATPase assay (Figure 7.2.2.1), lapatinib was more effective at 
increasing P-gp-mediated docetaxel accumulation in DLKP-A (Figure 7.2.3.1). This 
observation possibly reflects differences in transport rates between the purified insect 
vesicle preparation and live human cancer cell P-gp models, a point discussed in 
further detail later with relation to the BCRP ATPase assays (Section 8.8). A greater 
affinity of lapatinib over cyclosporin A for binding site of docetaxel on P-gp is 
another possibility. A control experiment in the parent DLKP cell line confirmed the 
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P-gp specific nature of the TKIs in DLKP-A (Figure 7.2.3.2). The effect of gefitinib, 
erlotinib and lapatinib on docetaxel efflux was also tested, with lapatinib, predictably, 
proving to be the most potent inhibitor of docetaxel efflux in DLKP-A at the 
concentrations tested (Figure 7.2.4.1). 
 
8.6.3 Lapatinib potentiates epirubicin toxicity and accumulation 
through inhibition of P-gp 
 
Using direct quantitation assays and confocal microscopy in DLKP-A cells, it was 
found that concurrent incubation with lapatinib increased the net accumulation of 
another P-gp substrate, epirubicin, in a concentration-dependent manner (Figure 
7.2.5.1). Concentrations of 1 µM lapatinib and above increased the concentration of 
the anthracycline, particularly in the nucleus of the cells, while higher levels increased 
both nuclear and cytoplasmic levels of epirubicin. Erlotinib and gefitinib also proved 
capable of inhibiting epirubicin efflux in DLKP-A at a concentration of 5 µM (Figure 
7.2.5.2).  
P-gp detected in the plasma membrane, nuclear membrane and intracellular organelles 
of cancer cells has been associated with acquired and intrinsic drug resistance [293], 
[331]. P-gp protects the cell by extruding epirubicin and lowering intracellular drug 
concentrations. Given the nuclear primary target of epirubicin action, inhibition of P-
gp, allowing the drug to permeate to the nucleus, is likely the major source of the 
observed potentiation in epirubicin toxicity.  
 
8.6.4 IC50 Determinations in DLKP, DLKP-A, A549 and A549-Taxol  
 
IC50 determinations in the NSCLC cell lines revealed little influence of P-gp on TKI 
efficacy (Table 7.2.6), consistent with previous findings by Kitazaki et al. [107]. The 
sizable taxane and anthracycline resistance conferred by P-gp over-expression in 
DLKP-A did not translate to similar levels of TKI resistance. This is most likely due 
to the low tyrosine kinase receptor levels in these cell lines. The amount of drug in the 
cells was of no consequence due to low level expression of target receptors. Lapatinib 
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proved to be the most potent TKI in all NSCLC cell lines, irrespective of EGFR and 
Her-2 status.  
The high concentrations of TKIs that were needed to produce toxicity in these cells 
were also likely to be due to the low tyrosine kinase receptor expression levels (Figure 
7.2.1.1). The observed toxicity at high concentrations may be generated by a more 
non-specific toxic effect.  
Unexpectedly, P-gp expression in the taxane-selected A549-Taxol did not result in 
resistance to epirubicin. The existence of genetic P-gp polymorphisms may offer an 
explanation for this observation although the influence they have on substrate 
disposition is controversial [332].  
 
8.6.5 Implications of combination proliferation assays  
 
Combination toxicity assays of cytotoxic P-gp substrates plus TKIs in the resistant 
A549-Taxol and DLKP-A cell lines yielded strong cytotoxic synergy (Figure 7.2.7.1 
and Figure 7.2.7.2). This was not evident with the non-P-gp substrate, cisplatin. 
Further observations, employing higher cisplatin concentrations, suggest that all three 
TKIs may partially antagonise the actions of cisplatin in DLKP-A (Appendix A, 
Figure A1). Other pre-clinical studies of gefitinib and cisplatin have yielded 
conflicting observations of synergy or antagonism [333]. Two clinical studies utilising 
chemotherapy regimens containing cisplatin and carboplatin in combination with 
gefitinib, failed to to meet either the primary end point of survival or the secondary 
end points of time to disease progression or response rates [334]. Further investigation 
is required to identify the cause of the cisplatin antagonism in our system and the 
possible clinical implications, particularly in NSCLC treatment, where the platinum 
drugs are a mainstay treatment. Potentiation of epirubicin toxicity by the TKIs in the 
non-P-gp-expressing A549 and DLKP cell lines was not anticipated (Figure 7.2.7.1 
and Figure 7.2.7.2). Inhibition of other putative epirubicin efflux mechanisms and 
interactions between pathways associated with tyrosine kinase-mediated signalling 
pathways and epirubicin toxicity may play a role. The effect is unlikely to be EGFR-
related due to presence of the phenomenon in the EGFR-negative DLKP cell line 
(Figure 7.2.1.1). 
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8.6.6 Docetaxel accumulation in A549-Taxol 
 
While DLKP-A is an ideal model in which to study the effects of putative P-gp 
inhibitors, the extreme levels of P-gp present confer significant resistance to a number 
of important chemotherapeutic agents. The level of docetaxel resistance present in the 
A549-Taxol cell line may be closer to that observed in vivo [111] (Table 7.2.6). The 
ability of erlotinib and lapatinib to increase accumulation of a physiologically relevant 
concentration of docetaxel (500 nM) in the A549-Taxol cell line over a time period 
within the exposure profile of both docetaxel [300] and each TKI is indicative of a 
feasible therapeutic strategy for P-gp inhibition (Figure 7.2.8.1). Erlotinib and 
lapatinib were selected as they represented the most effective ATPase activator and 
inhibitor, respectively, of the three TKIs examined. Lapatinib was more effective than 
erlotinib at the clinically relevant concentrations of 0.25 µM and 1 µM. 
 
8.6.7 Negative effects of TKI P-gp inhibiton 
 
The anatomical localisation (luminal surface of intestinal epithelium, bile canalicular 
membrane of hepatocytes, placenta, blood-brain barrier) and its broad substrate 
specificity means P-gp plays a major role in drug absorption and disposition [335]. P-
gp inhibitors such as cyclosporin A, PSC833, imatinib and elacridar have been shown 
to increase the bioavailability and central nervous system penetration of paclitaxel and 
docetaxel in clinical and pre-clinical studies [328]. Lapatinib-mediated P-gp inhibition 
could partly reduce the clearance of P-gp substrate cytotoxics to a greater degree than 
gefitinib and erlotinib, affecting the pharmacokinetics and pharmacodynamics of 
concurrently administered P-gp substrate cytotoxics. This effect would be most 
pronounced in compartments in the body which are especially dependent on P-gp to 
provide protection from the toxic effects of drugs, e.g. certain stem cell populations 
[336], [337]. Clinical studies of docetaxel, paclitaxel and epirubicin with lapatinib 
may provide a better insight. To date, no adverse interactions have been observed 
between the taxane, paclitaxel, and lapatinib [338], [339]. A phase I study of 
docetaxel and lapatinib has been completed (NCT00148902). A number of phase I, II 
and III trials are planned combining both docetaxel and paclitaxel with lapatinib in 
Her-2-positive breast cancer (NCT00450892 and NCT00356811). A Phase I clinical 
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study (NCT00313599) examining paclitaxel and lapatinib treatment in a broad range 
of tumours, including lung cancer, is currently recruiting patients. Two clinical trials 
involving lapatinib in the treatment of advanced metastatic breast cancer are currently 
recruiting in Ireland. These trials are a Phase IV trial combining lapatinib and 
capecitabine in patients whose breast cancer has progressed on other therapies 
(NCT00338247), and a phase I/II trial involving lapatinib in combination with 
docetaxel and trastuzamab in Her-2 overexpressing, and previously untreated, 
metastatic breast cancer  (NCT00251433). 
 
8.6.8 Applications of TKIs in combination chemotherapy regimen 
and as P-gp modulators in the clinic 
 
The results presented suggest an application for the TKIs, particularly lapatinib, as 
MDR modulators in P-gp-positive tumours in combination with P-gp substrate 
chemotherapy agents such as docetaxel and epirubicin, irrespective of EGFR and Her-
2 status (Section 7). Anthracycline/TKI combinations may be capable of additional 
anti-cancer actions, due to potentiation of toxicity, as observed in our study, even in 
the cell lines with little or no P-gp. Lapatinib mono- and combination therapies may 
be useful in the treatment of NSCLC, where a taxane/platinum combination is a 
standard first line therapy for advanced NSCLC [340]. Gefitinib and erlotinib have 
achieved most clinical success in a sub-population of NSCLC patients with mutated 
forms of EGFR [341]. Lapatinib has been shown to bind the inactive form of EGFR 
rather than the active form bound by erlotinib [250]. A slower off-rate than gefitinib 
and erlotinib from bound EGFR has also been reported.  Additional in vitro studies in 
mutated and wild type EGFR-over-expressing cell lines may be useful to model if 
there is a greater efficacy of lapatinib than erlotinib in those patients whose tumours 
over-express EGFR but do not contain the sensitising mutation. 
 
Gefitinib and erlotinib most likely interact with P-gp as substrates rather than 
inhibitors. At high concentrations these agents can reduce the P-gp-mediated efflux of 
substrate cytotoxics in a competitive manner. There is a possibility that P-gp could 
become a resistance factor for gefitinib and erlotinib. The distinct manner of lapatinib 
interaction with P-gp when compared to gefitinib and erlotinib combined with the 
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transport and proliferation data suggest P-gp over-expression is unlikely to generate 
resistance to this agent. Lapatinib, at readily achievable serum concentrations, 
effectively inhibits P-gp-mediated efflux, leading to an increased toxicity of P-gp 
substrate cytotoxics. Lapatinib-mediated P-gp inhibition provides potential for A) 
MDR circumvention and B) drug pharmacokinetic interactions between lapatinib and 
potent P-gp substrate cytotoxics. These results would suggest that the combination of 
lapatinib with a taxane or an anthracycline warrants clinical investigation in cancer.  
 
8.7 Possible link between EGFR signalling and P-gp expression 
 
A change in P-gp expression or activity due to inhibition of the EGFR signalling 
cascade would have important consequences for the efficacy of P-gp substrate EGFR-
TKIs and co-administered P-gp substrate chemotherapeutic agents. 
The EGFR, Her-2 and P-gp-positive, A549-Taxol cell line was the ideal candidate to 
investigate possible links between EGFR and P-gp (Figure 7.2.1.1). 
Studies have shown a link between EGFR and P-gp activity and expression. Results 
published by Yang et al., indicate that EGF exposure can modulate the 
phosphorylation and function of P-gp, suggesting that the effect may be initiated 
through the activation of phospholipase C (PLC) in MCF-7/AdrR drug resistant breast 
cancer cell lines [342]. Wartenberg et al., report that EGF-mediated signal 
transduction pathways negatively regulate P-gp expression in a process that may 
involve reactive oxygen species (ROS) as second messengers in DU-145 tumour 
spheroids [343]. Maximum expression of P-gp was found to correlate with a number 
of factors including reduced ROS levels and minor activity of the MAPK members, c-
JNK and the EGF-regulated ERK1, 2 and p38 MAPK. The down-regulation of P-gp 
expression due to EGF treatment (activation of the ERK1, 2 and p38 MAPK 
pathways) reported by Wartenberg et al. is consistent with the down-regulation of P-
gp expression seen in A549-Taxol due to EGF treatment (Figure 7.3.1). Furthermore, 
the ROS-mediated downregulation of P-gp by buthionine sulfoximine (BSO) 
treatment was completely abolished upon inhibition of the Ras-mediated tyrosine 
kinase signalling pathway, clearly indicating that EGF-mediated signal transduction 
pathways are negatively regulating P-gp expression [343]. This would support the 
increases in P-gp expression observed in A549-Taxol on inhibition of the EGFR 
pathway by gefitinib, erlotinib and lapatinib (Figures 7.3.2, 7.3.3, 7.3.4). The 
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involvement of ROS in this up-regulation was not examined in A549-Taxol or the 
phosphorylation state of P-gp, two factors that would be of interest given the evidence 
in the literature. It is also of interest to note that the lowest concentration of erlotinib 
and lapatinib used (2.5 µM) can be considered pharmacologically relevant. To further 
examine the link between EGFR and P-gp, measurement of total and phosphorylated 
EGFR was planned. Total EGFR levels were determined but unfortunately pEGFR 
levels remain uncharacterised because of time constraints. 
To ascertain if the link between EGFR and P-gp is merely a general stress response to 
TKI insult or a specific connection, further studies are needed. To this purpose, 
analysis of pEGFR and the total and phosphorylated levels of members of the major 
EGFR signalling pathways (Akt, MAPK, JNK) under TKI treatment in A549-Taxol, 
and indeed other P-gp and EGFR-positive cell lines, is required. 
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8.7.1 EGF treatment reduced EGFR protein levels 
 
Endocytic removal of active ligand-receptor complexes from the cell surface is the 
major process that regulates the amplitude and kinetics of signal transduction by 
tyrosine kinase receptors [344]. Following internalisation of the activated tyrosine 
kinase receptor, regulation of EGFR levels is a balance between degradation, within 
intercellular lysosomes, and recycling to the plasma membrane. Internalised receptors 
are generally recycled from early endosomes back to the plasma membrane [219]. 
Treatment of the A549-Taxol cell line with EGF had dramatic effects on the levels of 
detectable EGFR protein (Figure 7.4.1). This is consistent with the knowledge that the 
total number of surface EGFR declines in response to EGF treatment within a short 
time period (30 minutes) [345]. The continuous activation and internalisation by 
excess EGF pushes the regulated balance towards degradation. It is possible, that 
similar to prolonged VEGFR exposure to VEGF in HUVEC cells, the EGFR levels 
remain depleted until newly synthesised receptors arrive at the surface with recovery 
of three quarters of the original VEGFR occurring within 5 hours [346]. The fact that 
EGFR levels do not start to recover within the 48 hour time frame examined may be 
related to the serum-free conditions. The control reveals that abrogation of all ligand 
stimulation initiates a slow overall reduction of detectable EGFR protein levels in the 
control.  
 
8.7.2 TKIs increase EGFR levels in A549-Taxol  
 
The TKI lapatinib produces the opposite effect to treatment with EGF (Figure 7.4.2). 
There are a number of possibilities as to how lapatinib produces this increase in 
EGFR protein levels. Lapatinib binds the inactive (monomer) conformation of EGFR 
as opposed to the active conformation (dimer) bound by erlotinib and gefitinib. 
Although this has little overall consequence for signalling as gefitinib-bound EGFR 
dimers have been shown to exist as inactive receptor/ligand complexes, it is unknown 
if lapatinib bound EGFR is internalised [250], [347]. It is possible that lapatinib 
treatment produces a build-up of inactive EGFR at the cell surface. Gefitinib 
treatment has been shown to exert a strong inhibitory effect on the endocytosis of 
EGFR and the internalisation rate of EGFR from the plasma membrane via the early 
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endosomes to the late endosomes/lysosomes was delayed in the NSCLC PC-9 cell 
line [348]. Internalised ligand-bound and active EGFR on endosomes can continue to 
signal and recruit proteins [219]. Presumably such signalling contributes to regulation 
of degradation pathways and any TKI bound EGFR is non-active. The similar effects 
of lapatinib, erlotinib and gefitinib on EGFR levels (Figures 7.4.4, 7.4.5 and 7.4.6), at 
least at the 48 hour timepoints, would suggest that eradication of the active EGFR 
signal by all the TKIs increases EGFR protein levels. This process could involve an 
increase in recycling, an inhibition of endocytosis or an increase in newly synthesised 
protein. The decrease in EGFR protein observed post 24 hours of lapatinib exposure 
would suggest a restoration of the mechanisms of EGFR degradation or a reduction in 
protein synthesis. It is unlikely to be related to cell mortality as control levels of 
EGFR remain relatively constant between 24 and 48 hours of exposure (Figure 7.4.2). 
It is interesting to note that in the presence of serum, EGFR levels do not decrease as 
rapidly as in serum starved conditions (Figure 7.4.1). The presence of ligands is 
required to maintain EGFR protein levels. 
 
An investigation to discern any differences between the effects of lapatinib, erlotinib 
and gefitinib on EGFR trafficking in A549 and A549-Taxol would be of interest. 
A549 express WT-EGFR that has been associated with constitutively impaired 
endocytic machinery and gefitinib resistance in NSCLC cell lines [348]. A 
comparison with A549-Taxol would determine any changes associated with paclitaxel 
resistance and P-gp expression. Her-2 interactions could also be studied, particularly 
in the presence of lapatinib and in Her-2 over-expressing cell lines. Shorter timepoints 
should be employed as EGFR trafficking events occur rapidly as approximately 40% 
of surface EGFR in A549 is internalised within 15 minutes of EGF exposure [349]. 
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8.7.3 Comparison of ELISAs utilising detection antibodies to 
intercellular and extracellular EGFR epitopes 
 
Total EGFR protein was initially measured using an ELISA (DY231, Section 2.16.1) 
that utilised a detection antibody recognising an extracellular EGFR epitope (Figures 
7.4.1 and 7.4.2). It was unknown if this detection antibody could detect ligand bound 
EGFR. A second ELISA was carried out on the 48 hour timepoints of EGF, lapatinib, 
gefitinib and erlotinib treatments in A549-Taxol, which employed a detection 
antibody raised to an intracellular region of EGFR (DYC1854, Section 2.16.1) 
(Figures 7.4.3, 7.4.4, 7.4.5 and 7.4.6). The intracellular ELISA detected higher levels 
of EGFR protein than the extracellular ELISA. This disparity is most likely due to 
differences in overall sensitivity of the ELISAs rather than a real increase in detected 
EGFR as the magnitude of the TKI-associated increase (and decrease in the case of 
EGF) is similar between the two ELISAs. Taking just the magnitudes of TKI-induced 
augmentation of EGFR protein levels, lapatinib and gefitinib produce greater 
increases in EGFR levels than erlotinib. 
A549 has been shown to express wild-type EGFR [348]. Examination of the EGFR 
phenotype in A549-Taxol or the same treatments carried out in A549 would be 
needed to confirm that lapatinib and gefitinib produce a greater increase than erlotinib 
on WT-EGFR protein levels. 
 
8.7.4 c-ErbB receptors and P-gp: A more direct association? 
 
EGFR signalling is associated with a number of processes implicated in cancer 
development including cell cycle control, apoptosis, angiogenesis and metastasis 
[350]. A number of recent studies have started to reveal connections between EGFR 
signalling, invasion and multi-drug resistance. Over-expression of EGFR and/or 
ligands, as well as several metalloproteinases (MMPs), is associated with an invasive 
phenotype in NSCLC lines, with EGFR levels correlated directly to invasive potential 
[350]. Motogenic activation by EGF has recently been shown to require the 
concomitant functionality of EGFR and the hyaluronan receptor, CD44, in fibroblasts 
[351]. This is of particular interest when considered in conjunction with two papers 
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that relate CD44 with P-gp and Her-2. Miletti-Gonzalez et al. report that A) the 
expression of CD44 and P-gp are coregulated, B) CD44 and P-gp co-
immunoprecipitate and are co-localised in the plasma membrane and C) drugs that 
interfere with P-gp function (trans-flupenthixol and vinblastine) also interfere with 
invasion and metastasis in the drug resistant breast cancer cell line MCF-7/Adr [352]. 
Results obtained by Misra et al., also from the MCF-7/Adr cell line, led them to 
propose that hyaluronan constitutively induces assembly of a Her-2-containing 
signalling complex that stimulates the PI3K/Akt pathway (and others) through 
interaction with CD44 [353]. P-gp and MRP-2 are induced by PI3K in MCF7/Adr 
cells [353]. These studies suggest complex interplay between motogenic and drug 
resistance pathways involving members of the c-ErbB family and P-gp at the plasma 
membrane. It would be interesting to investigate if lapatinib had any effect on the 
invasion levels of the NSCLC lines used in this thesis. It may provide further impetus 
for the use of lapatinib in P-gp expressing NSCLC.  
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8.8 TKIs and BCRP and MRP-1 
 
The investigation of the capability of the TKIs to modulate multi-drug resistance has 
to this point concentrated solely on P-gp. Along with P-gp, MRP-1 and BCRP are 
considered the key ABC proteins involved in multi-drug resistance. A full description 
of these transporters and their substrates can be found in the Section 1.3.2.  
 
The interaction of gefitinib with BCRP has been well established [354], [108], [251], 
[355], [255]. Results indicate that gefitinib is a BCRP substrate at low micromolar 
concentrations, activating ATPase activity and exhibiting decreased accumulation in 
BCRP-transfected SaOS2 cell lines [251], [354]. Gefitinib has been shown to inhibit 
BCRP ATPase activity at higher concentrations (10 µM) [251]. The evidence for the 
interaction of erlotinib with BCRP is less abundant [356], [357].  A similar situation 
exists for lapatinib. Lapatinib has been shown to inhibit P-gp and BCRP with IC50 
values of 4 µM and 1.85 µM respectively [358]. Due to the limited information 
available, the nature of the interaction between erlotinib and lapatinib and BCRP is 
unknown. 
 
The interaction of gefitinib with MRP-1 has not been tested extensively. Gefitinib has 
been found to inhibit MRP-1 ATPase activity, but not stimulate it, and inhibit calcein 
AM extrusion from HL-60-MRP1 cells [251]. There is no data available for the 
interaction of erlotinib and lapatinib with MRP-1. 
 
There is evidence linking various elements of the EGFR signalling cascade to MRP-1 
and BCRP expression levels. Garcia et al., have shown that EGF treatment in the 
absence of other growth factors induced MRP-1, 3, 5, and 7 gene expression and lead 
to an increase in MRP-1 promoter activity in MCF-7 breast cancer cells [359]. The 
same study reported activation of ERK and Akt by EGF in MCF-7. Takada et al., 
have found evidence that the relative expression of BCRP on the cell surface is 
regulated by the PI3K-Akt pathway with a positive correlation in polarised LLC-PK1 
cells [360]. 
Considering these findings, the abrogation of EGFR signalling by MRP-1 or BCRP 
substrate TKIs could lead to changes in the resistance phenotype of cancer cells 
affecting the efficacy of chemotherapeutic cytotoxics and TKIs. 
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Any interaction of the TKIs with MRP-1 or BCRP would also have pharmacokinetic 
implications. Additionally, patients expressing naturally occurring BCRP 
polymorphic variants may be more sensitive to BCRP substrate TKIs. These BCRP 
variants have been shown to have differences in their activities and substrate 
recognition and it has been suggested that they may play a role in the increased 
sensitivity to gefitinib in the Japanese population, who express the BCRP variant 
Q141K with a high frequency [361]. 
 
To further investigate the scope of TKI/ABC interactions gefitinib, erlotinib and 
lapatinib were examined in MRP-1 and BCRP ATPase assays. Sulindac and its active 
metabolite sulindac sulfide were also assayed. As mentioned earlier, ATPase assays 
do not provide definitive answers as to the nature of drug: transporter interactions but 
are useful indicators of substrates or inhibitors. When a number of drugs are assayed 
simultaneously, they can be ranked relative to one another based on their ability to 
modulate ATPase activity. 
 
8.8.1 BCRP ATPase activity as measured using SB-MXR-
M-ATPase membrane preparations 
 
Test compounds were examined in membrane preparations obtained from mammalian 
cells expressing wild-type BCRP (WT-482R) rather than from the Spodoptera 
frugiperda ovarian (Sf9) cell membrane preparations used in the P-gp and MRP-1 
ATPase assays. The advantages of the mammalian cell based membrane preparations 
were recently extolled by Glavinas et al., [362]. Sf9 membranes expressing the wild 
type (WT) BCRP transporter (482R) exhibit high baseline vanadate –sensitive 
ATPase activity that cannot be further stimulated by known BCRP substrates [363]. 
BCRP characterisation could still be carried out in Sf9 membranes expressing the 
R482G variant of BCRP that also had very high baseline vanadate-sensitive ATPase 
activity but could be stimulated by a number of known BCRP substrates [364]. 
Glavinas et al., showed that membranes prepared from human cell lines selected with 
cytotoxic substrates for BCRP are more suitable for the detection of WT BCRP 
substrates in ATPase assays. The baseline vanadate-sensitive ATPase level in the 
mammalian cell membrane preparations is also high enough to detect both activators 
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and inhibitors of BCRP ATPase activity without need of a stimulating agent like 
verapamil in the P-gp ATPase inhibition assays. This is of considerable advantage as 
it reveals direct transporter ATPase inhibition. The existence of more than one 
binding site for substrates and inhibitors, as reported for BCRP and P-gp, can mean 
complex interaction profiles when a stimulatory agent is utilised [361], [365].  
It is noticeable that control BCRP ATPase activity levels (baseline, maximal and 
inhibited) as measured in this project using the SB-MXR-M-ATPase membrane 
preparations (Figure 7.5.1) are considerably lower than those reported for the MXR-
M-ATPase membrane preparations by Glavinas et al. [362]. This is probably due to 
differences in protocol. BCRP ATPase activity was assayed at 320C for this project as 
described in the supplied protocol (Section 2.18) but at 370C by Glavinas et al. The 
range of SB-MXR-M-ATPase membrane preparations is still of a magnitude to 
distinguish activators and inhibitors of baseline BCRP ATPase activity (Figure 7.5.1).  
 
8.8.2 Gefitinib, erlotinib and lapatinib stimulate BCRP ATPase 
activity at low, pharmacologically-relevant, levels 
 
The stimulation of BCRP ATPase activity by gefitinib is consistent with the results of 
Ozvegy-Laczka et al. although direct comparison is not possible due to the use of Sf9 
membranes in their work, rather those of mammalian cell origin (Figure 7.5.1) [251]. 
Low gefitinib concentrations stimulated BCRP ATPase activity while higher 
concentrations started to reduce the maximum BCRP ATPase activity achieved. There 
is a variation of the concentration at which gefitinib reduced ATPase activity below 
the baseline level between our results (not achieved at 30 µM) and Ozvegy-Laczka et 
al. (10 µM) but this once again could be attributable to assay parameters. The 
concentration at which the TKIs inhibit the baseline ATPase activity is the point they 
become true inhibitors of BCRP ATPase activity. Lapatinib (5 µM) inhibits the 
baseline BCRP ATPase activity at lower concentrations than gefitinib and does not 
achieve similar levels of ATPase stimulation (Figure 7.5.1). Erlotinib may inhibit 
baseline BCRP ATPase activity at concentrations above 30 µM. The analysis of 
BCRP ATPase activity suggests gefitinib and erlotinib have a greater affinity for 
BCRP at low concentrations than lapatinib (Figure 7.5.1). It is interesting to note that 
the maximum BCRP ATPase inhibition for each TKI, irrespective of its magnitude, 
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falls within the same range (~ 2.5 – 5 µM). Further work is required to confirm if the 
TKIs are transported substrates at low concentrations.  
 
Sulindac had no significant effect on BCRP activity but its metabolite sulindac sulfide 
displayed minor inhibition of the baseline ATPase activity. It is unlikely that the 
inhibition levels observed could be of therapeutic benefit against BCRP-mediated 
drug resistance but what is of interest is its similarity to the effects of mitoxantrone, 
the prototypical BCRP substrate [364], [366] (Figure 7.5.1). It may be of interest to 
examine sulindac sulfide further as a BCRP substrate. Past studies involving Sf9 
BCRP ATPase assays showed stimulation of BCRP ATPase activity by mitoxantrone 
[364]. There is no comparable study of mitoxantrone in mammalian cell membranes 
to ascertain if this is a phenomenon associated with membrane preparations from 
differing origins. 
Elacridar confirms that it is a better BCRP inhibitor than Hoechst 33342, the lowest 
concentration (0.25 µM) reducing the BCRP ATPase activity below that produced by 
an excess of Hoechst 33342.  
 
Results confirm that the TKIs interact with BCRP at lower concentrations than P-gp, 
when considering stimulation of ATPase. Direct inhibition of BCRP ATPase activity 
occurs at higher concentrations of the TKIs with lapatinib producing inhibition of 
baseline BCRP ATPase activity at 5 µM followed by erlotinib and gefitinib. The 
ability of the TKIs to modulate BCRP ATPase activity in the presence of a 
stimulating agent was not conducted. Lapatinib is the poorest activator of BCRP 
ATPase activity as it was the poorest activator of P-gp ATPase activity. Although the 
TKIs show no direct inhibition of BCRP ATPase alone, this study is concerned with 
the ability of the TKIs to modulate transport of other drugs. It would be interesting to 
compare the capabilities of the TKIs to inhibit drug stimulated BCRP ATPase activity 
to see if there is a difference in the ability of lapatinib, and gefitinib and erlotinib, to 
modulate it, as in the verapamil stimulated P-gp ATPase inhibition assays. This also 
brings up another factor, the choice of stimulating agent. Future work may consider 
studying the effects of the TKIs on P-gp and BCRP ATPase activity when stimulated 
using the cytotoxic compound of interest, in the case of this project, docetaxel. The P-
gp modulator cyclosporin A proved a better inhibitor of verapamil stimulated P-gp 
ATPase activity than lapatinib (Figure 7.2.2.1) but lapatinib increased docetaxel 
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levels to a greater degree than cyclosporin A in vitro (Figure 7.2.3.1). A comparison 
of lapatinib and cyclosporin A inhibition of docetaxel-stimulated P-gp ATPase 
activity may have provided a better prediction of the in vitro result. 
A BCRP ATPase inhibition assay would be required to assess the TKIs as modulators 
of BCRP-mediated drug transport. Low TKI concentrations could be subject to 
BCRP-mediated resistance in tumours and the profiles of TKIs in combination with 
BCRP substrate cytotoxics should be studied carefully in vitro and in vivo. There are 
recent clinical indications that lapatinib may alter the pharmacokinetic profiles of SN-
38, the active metabolite of the BCRP substrate drug irinotecan [358]. 
 
8.8.3 Gefitinib, erlotinib and lapatinib have a minor stimulatory 
effect on MRP-1 ATPase activity 
 
The effects of gefitinib on MRP-1 ATPase have been studied in Sf9 cells previously 
by Ozvegy-Laczka et al. [251]. Our findings that gefitinib has a minor stimulatory 
effect on MRP-1 ATPase activity and no inhibitory effect on NEM-GS stimulated 
ATPase activity are contrary to their findings (Figures 7.5.2 and 7.5.3). MRP-1 
sometimes requires the presence of free glutathione to transport uncharged or mildly 
cationic compounds such as vincristine and etoposide [125]. It is possible that the 
conflicting results may be attributable to the presence of glutathione (2 mM) in the 
MRP-1 ATPase activation assay carried out in this project but not in the published 
study. There are no comparable results for lapatinib and erlotinib. Both TKIs exhibit 
minor ATPase activation suggesting possible interaction with MRP-1 as weak 
substrates in the presence of glutathione (Figure 7.5.2).  
None of the three TKIs inhibited NEM-GS stimulated MRP-1 ATPase activity up to a 
concentration of 30 µM (Figure 7.5.3). Gefitinib has been shown to inhibit NEM-GS 
stimulated MRP-1 ATPase activity [251]. This effect occurred above 10 µM but there 
were no intermediate data points between 10 µM and 50 µM, the next concentration 
assayed. It is possible that the inhibition of MRP-1 ATPase activity may have 
occurred at a concentration above 30 µM in this situation. Exploration of higher 
gefitinib concentrations in our system would confirm this. 
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8.8.4 The MRP-1 substrate vincristine does not stimulate MRP-1 
ATPase activity 
 
The effect of vincristine on MRP-1 ATPase activity highlights the caution needed 
when extrapolating the transport characteristics of a compound from ATPase activity 
alone. Vincristine is a transported MRP-1 substrate but, consistent with the MRP-1 
ATPase activation results in Figure 7.5.2, it does not increase MRP-1 ATPase activity 
[367]. In the same study, Hooijberg et al., have shown that glutathione alone 
stimulates the ATPase activity of MRP-1 in a dose dependent manner up to 5 mM. 
The baseline ATPase activity of MRP-1 was not examined in the absence of 
glutathione in this thesis. A working hypothesis consistent with literature data and the 
thesis results has been suggested by Salerno et al. [368]. They imagine MRP-1 to be 
composed of two components, an active, ATP-dependent “G” unit and an inert “D” 
unit, dependent on the G unit for transport. Each unit has its profile substrate drugs 
(G-class and D-class). G-class substrates include glutathione and LTC4. Vincristine 
and daunorubicin are considered D-class substrates. D-class substrates are essentially 
co-transported in the presence of G-class substrates without additional ATP 
hydrolysis. Salerno et al., also envisage two types of MRP-1 inhibitor, Class I and 
Class II. A class I inhibitor (e.g. MK571) affects the G unit, therefore abrogating 
transport of both G and D class substrates. A class II inhibitor (e.g. verapamil) affects 
the D unit only. Free of the dependent D unit, the transport of G class substrates is 
actually stimulated by class II inhibitors. Taking this model, it could be argued that 
the minor increases the TKIs and vincristine could be Class II MRP-1 inhibitors 
(Figure 7.5.3). 
 
8.8.5 Sulindac is an activator but not an inhibitor of MRP-1 ATPase 
activity 
 
Sulindac is a reported MRP-1 modulator and the subject of a clinical trial to determine 
its efficacy in this role [369], [161]. The nature of the effect of sulindac on MRP-1 
ATPase activity has not been explored to date. The strong concentration-dependent 
increase in MRP-1 ATPase activation and little inhibitory effect on n-ethylmaleimide 
(NEM) stimulated MRP-1 ATPase activity would suggest that sulindac is a substrate 
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of MRP-1 (Figures 7.5.2 and 7.5.3). The classification of sulindac sulfide is harder to 
predict from the MRP-1 ATPase results. Sulindac sulfide stimulates MRP-1 ATPase 
activity in a concentration-dependent manner that levels off at 15 µM but also inhibits 
NEM-GS stimulated MRP-1 ATPase activity from 15 µM. This suggests that sulindac 
sulfide is an MRP-1 substrate at low concentrations (sub 15 µM) and an MRP-1 
inhibitor at higher levels. To further elucidate the transport characteristics of sulindac 
and sulindac sulfide, it would be useful to examine the drugs in an MRP-1 ATPase 
activation assay in the absence of glutathione to determine if ATPase activation is 
glutathione dependent. In combination with a comparison with the effects of the class 
II inhibitor verapamil, a hypothesis based on the Salerno model could then be 
postulated.  Transport assays involving MRP-1 substrates and ideally direct sulindac 
and sulindac sulfide measurement would complete the picture.  
 
8.8.6 The possibility of TKI influx mechanisms 
 
This thesis has examined the influx characterisitics of docetaxel in NSCLC lung 
cancer cell lines but with regard to the TKIs, has concentrated on the processes of 
efflux. Thomas et al., have reported active transport of the TKI imatinib, in the 
chronic myeloid leukaemia cell line CEM, most probably mediated by human organic 
cation transporter 1 (hOCT1, SLC22A1) [310]. Given the similar profiles of P-gp-
mediated inhibition of docetaxel by imatinib and gefitinib in DLKP-A (Appendix A, 
Figure A3), it may be plausible that hOCT1 or another influx mechanism could 
facilitate active influx of lapatinib, gefitinib and erlotinib in normal tissue and tumour 
cells. hOCT1 expression has been reported in normal breast and lung tissues and 
tumour cells [201]. Microarray data indicates low hOCT1 mRNA expression in A549 
and A549-Taxol but does not indicate mRNA expression in DLKP or DLKP-A 
(Appendix A, Table A2). However, other members of the SLC22 family including 
SLC22A3, A4 and A5, do show expression in the microarray sets. Examination of 
TKI influx in a range of breast and lung cancer cell lines could reveal additional 
markers for TKI sensitivity and kinetics. 
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Chapter 9. Conclusions 
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• The HPLC method for taxane measurement was insensitive. The results 
involving 10 µM of taxane may bear little relevance to real pharmacological 
effects. 
 
• Use of the 14C-labelled docetaxel permitted analysis of transport at 
pharmacologically achievable levels (100-500 nM). 
 
• Docetaxel uptake was found to be saturable, temperature-dependent and ATP-
dependent in DLKP. The decrease in accumulated docetaxel in the presence of 
ATP depleting agents is consistent with the existence of an ATP-dependent 
docetaxel uptake mechanism in DLKP. This is the first evidence of a 
docetaxel uptake mechanism in a NSCLC cell line. Further work is required to 
identify the docetaxel uptake mechanism involved. 
 
• Docetaxel transport in A549 was shown to be temperature-dependent and non-
saturable up to 500 nM. ATP depletion resulted in an increase in accumulated 
docetaxel levels. These observations suggested the existence of an energy-
dependent efflux mechanism in A549. MRP-2 is the most likely candidate 
based on the ability of DHEAS and T3 to increase docetaxel accumulation and 
its reported expression levels in A549. 
 
• A study of the involvement of the SLCO/OATP family in docetaxel uptake in 
A549 was not conclusive. The docetaxel accumulation studies involving 
bromosulfophthalein and digoxin, general modulators of the OATP family, 
resulted in a decrease in docetaxel accumulation in A549 but studies with 
more specific OATP modulators such as DHEAS and T3 led to increases in 
docetaxel levels, possibly through inhibition of the putative energy-dependent 
transport mechanism described above. The possibility that the bi-directional 
transport capabilities of the OATP family may be involved still has to be 
determined.   
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• The ability of the OATP1B1 substrate, indocyanine green, to increase the 
accumulation of docetaxel in A549 and DLKP, in a concentration-dependent 
manner, warrants further investigation. The effect is unlikely to be OATP-
mediated given the magnitude of the increase and the fact it was not confined 
to A549, the cell line in which the general OATP inhibitor 
bromosulfophthalein decreased docetaxel accumulation, unlike DLKP. 
Indocyanine green could be altering cell membrane permeability through 
phospholipid binding.  
 
• The ability of known OATP substrates to modulate docetaxel transport in the 
NSCLC cell line A549 indicates that further study of the role of the OATP 
family in tumour cell taxane transport is warranted. 
 
• The mechanisms of interaction between the TKIs examined and P-gp is 
distinctly different. Lapatinib inhibited verapamil-stimulated P-gp ATPase 
activity while being a poor activator of P-gp ATPase itself. Conversely, 
erlotinib and gefitinib displayed less verapamil-stimulated P-gp ATPase 
inhibitory activity but greatly increased P-gp ATPase activation. Lapatinib is 
most likely a slowly transported substrate with high affinity for P-gp while 
erlotinib and gefitinib are likely transported P-gp substrates.  These results 
provide evidence that P-gp may contribute to resistance to gefitinib and 
erlotinib at low concentrations but is unlikely to impact on lapatinib resistance. 
 
• In combination proliferation assays, gefitinib, erlotinib and lapatinib enhanced 
response to the P-gp substrate chemotherapy drugs, docetaxel, paclitaxel and 
epirubicin in our P-gp-positive MDR cell line models at low, physiologically 
relevant, levels. Lapatinib proved the most potent of the TKIs. 
 
• Drug transport studies in the P-gp over-expressing cell lines A549-Taxol and 
DLKP-A showed lapatinib to be the most effective of the three TKIs at 
increasing docetaxel accumulation and decreasing P-gp-mediated docetaxel 
efflux in cell lines. 
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• Taken together, the ATPase assay, proliferation assay and docetaxel transport 
assay results suggest the three TKIs, particularly lapatinib, have significant 
potential to augment the cytotoxic activity of P-gp substrate chemotherapeutic 
agents, particularly docetaxel, in P-gp positive tumours. 
 
• On a cautionary note, concurrent administration of gefitinib, erlotinib or 
lapatinib with P-gp substrate chemotherapeutics will require further 
investigation to assess if such combinations may generate possible alterations 
in cytotoxic pharmacokinetics.  
 
• Preliminary results of combination proliferation assays between the TKIs and 
cisplatin indicate such combinations require further investigation to determine 
their efficacy and possible antagonism in NSCLC.  
 
• Lapatinib and erlotinib demonstrated an ability to potentiate the action of 
epirubicin in cells with no P-gp activity. The potentiation of epirubicin toxicity 
by lapatinib occurred in the EGFR and Her-2 expressing A549 but it is all the 
more noteworthy as it also occurred in the DLKP cell line that does not 
express EGFR and only expresses minor levels of Her-2. Anthracycline/TKI 
combinations may be capable of additional anti-cancer actions, due to 
potentiation of toxicity, even in the cell lines with little or no P-gp.  
 
• When assessed in the BCRP ATPase assays, gefitinib and erlotinib proved 
more effective at stimulating BCRP ATPase activity than lapatinib. A 
comparison of the effects of the TKIs on drug-stimulated BCRP ATPase 
activity is required to provide a definitive answer as to the which of the TKIs 
examined is the best candidate for the modulation of BCRP activity in vivo. 
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•  MRP-1 ATPase studies suggest that the NSAID, sulindac and its active 
metabolite, sulindac sulfide, have potential as modulators of MRP-1 activity, 
supporting previous findings from our group. Gefitinib, erlotinib and lapatinib 
displayed a minor increase in MRP-1 ATPase activity but had no inhibitory 
effect on NEM-GS stimulated MRP-1 ATPase activity, suggesting they are 
weak substrates in the presence of GSH.  
 
• A specific link between EGFR inhibition and the levels of P-gp protein 
expression would have important consequences for the use of TKIs in cancer 
treatment and the development of resistance for TKIs that are transported P-gp 
substrates. Although a general link between EGFR stimulation and P-gp 
protein expression was established in the A549-Taxol cell line, the specific 
mechanism involved was not elucidated. 
 
• The EGF stimulated decrease in EGFR protein expression correlated with a 
decrease in P-gp protein expression while abrogation of the EGFR signal by 
TKIs increased EGFR and P-gp protein levels. Further work is required to 
explain the pathways involved in the link between EGFR signalling and P-gp 
expression and to determine if there is a specific relationship between TKI 
inhibition of EGFR and P-gp expression or if it is a general stress response. 
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Chapter 10. Future work 
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The section in which the point is discussed is presented in brackets where relevant. 
 
10.1 Docetaxel transport in lung cancer cell lines 
 
• Perform comparative paclitaxel transport experiments in DLKP to further 
examine the disparity in the levels of paclitaxel and docetaxel accumulated in 
this cell line (Section 8.1.6). 
 
• Examine the ability of sulindac to modulate paclitaxel and epirubicin uptake in 
DLKP-TXT (Section 8.2.3). 
 
• Further explore the temperature-dependence of docetaxel uptake in A549 and 
DLKP by comparing uptake of different docetaxel concentrations (Section 
8.5.4). 
 
• Identification of the ATP-dependent transporter in DLKP using DNA 
microarray data as a starting point (Section 8.5.7). Monolayer efflux studies 
may be useful to determine apical/basal localisation of the transporter in 
DLKP. 
 
• Examine the effects of digoxin/BSP/T3 and DHEAS on taxane movement in 
A549 using a system that can distinguish apical to basal/basal to apical 
transport monolayer efflux studies. Such studies would determine the cellular 
localisation of transporters. Immunodetection of the putative docetaxel 
transporters MRP-2 and MRP-7 in A549 (Section 8.5.11). 
 
• Immunodetection of the OATP family in A549 to determine expression levels 
and contribution to docetaxel uptake (Section 8.5.8). 
 
• Examine the possibilities of carrier-mediated cisplatin transport in A549 and 
DLKP (Section 8.5.12). 
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• Expanding the studies of docetaxel uptake to a number of NSCLC cell lines 
would help determine the prevalence and relative importance of influx 
mechanisms in NSCLC. 
 
10.2 Tyrosine kinase inhibitors 
 
• The effects of lapatinib on the ATPase activity of other drug transporters, i.e. 
MRP-2, 3 and 4, to a develop a transporter profile. 
 
• To get a definitive answer as to the ability of P-gp to transport the TKIs and 
therefore confer resistance, direct measurement of TKI transport by mass 
spectrometry or radiolabelled techniques (Section 8.6.1). 
 
• Compare the ability of lapatinib to modulate P-gp-mediated paclitaxel 
transport to docetaxel transport in combination proliferation and transport 
assays. 
 
• The ability of lapatinib to potentiate epirubicin toxicity via a non-P-gp 
mediated mechanism in NSCLC lung cancer cell lines warrants further 
investigation in all cancer cell lines of varying EGFR and Her-2 status in order 
to uncover the contributions of these receptors to the phenomenon (Section 
8.6.5).  
 
• The existence of antagonism between cisplatin/carboplatin and TKIs would 
have important implications for concurrent administration of TKIs and a 
taxane as part of a platinum/taxane doublet in NSCLC. The extent and 
mechanism of this effect requires further investigation (Section 8.6.5). 
 
• Determine if the link between EGFR and P-gp expression found in A549-
Taxol is a general stress response or a specific cell signalling pathway (Section 
8.7). 
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• Investigation of the effects of lapatinib, gefitinib and erlotinib on EGFR 
trafficking in wild type and EGFR variant-expressing cell lines (Section 
8.7.2). 
 
• Examine the effects of lapatinib, in any, on the invasive properties of A549, 
A549-Taxol, DLKP, DLKP-A and other sensitive and drug resistant NSCLC 
cell lines (Section 8.7.4). 
 
• A BCRP ATPase assay examining the effects of the TKIs on drug-stimulated 
BCRP ATPase activity (Section 8.8.3). 
 
• Examination of the effects of sulindac and sulindac sulfide on MRP-1 ATPase 
in the absence of GSH (Section 8.8.5). 
 
• Determine if the uptake of lapatinib, gefitinib and erlotinib is carrier-mediated 
in NSCLC cell lines (Section 8.8.6). 
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Figure A1 Proliferation assay combining 1500 nM cisplatin and lapatinib in DLKP-A. The combination of 1500 nM cisplatin and lapatinib 
display antagonism. Data are mean +/- SD calculated on experiments performed in triplicate. 
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The NSCLC squamous cell lung carcinoma cell line SK-MES-1 (Lane 4) does not express 
P-gp. The taxane selected variants of this cell line, SK-MES-Taxol (Lane 3) and SK-MES-
Taxotere (Lane 1) do express P-gp. The SCLC squamous cell line DMS-53 (Lane 8) does 
express P-gp as does its taxane selected variants DMS-Taxol (Lane 7) and DMS-Taxotere 
(Lane 6). 
A      
                                                                                                          
 
 
 
 
 
B 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A2   Western blot for P-gp (A) in a NSCLC and a SCLC cell line and their drug 
selected variants. DMS-Taxotere and SKMES-Taxotere were selected with docetaxel while 
SKMES-Taxol and DMS-Taxol were selected with paclitaxel. Lanes 1-5 required a 20 
minute exposure to visualise the P-gp bands while the higher P-gp levels in the DMS cell 
line and its variants required a five minute exposure. Samples were also blotted for alpha-
tubulin expression (B) 
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Figure A3 Accumulation of 100 nM 14C docetaxel in DLKP-A over 90 minutes. Values represent the average of three determinations. All 
inhibitors were dissolved in DMSO. Data are mean +/- SD calculated on experiments performed in triplicate.* significant relative to control, P < 
0.05.
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Figure A4 EGFR immunoprecipitation in two NSCLC cell lines (A549 and DLKP) and 
drug selected variants. A549-Taxol was selected with paclitaxel (Taxol®), DLKP-Mitox 
was selected with mitoxantrone, DLKP-TXT was selected with docetaxel (Taxotere ®), 
DLKP-A was selected with adriamycin, BT-20 was the EGFR positive control. High levels 
of EGFR were detected in A549 and the paclitaxel-selected A549-Taxol. DLKP show no 
EGFR expression.  DLKP-A, DLKP-TXT and DLKP—MITOX exhibit minute expression 
levels. 
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Table A1 DNA microarray data analysis for members of the SLCO (OATP) gene 
family. P = Present, A=Absent, M= Marginal, P,A=Borderline.  
 
 
 
 
GENE EST DLKP DLKP-A A549 A549-
Taxol 
SLCO      
1A2 207308_at A A P, A P, A 
 211480_s_at A M,A A A 
 211481_at A A A P, A 
1B1 210366_at A A P, A P 
1B3 206354_at A A P P 
1C1 220460_at A A P, A P, A 
2A1 204368_at A A A M, A 
2B1 203472_s_at A A P, A A 
 203473_at A A P, A P, A 
 211557_x_at A A A A 
3A1 210542_s_at A A P P 
 229776_at A A P P 
 227367_at P,A P,A P P 
 219229_at A A P P 
4A1 219911_s_at P,A A P P 
 229239_x_at A A A A 
4C1 222071_s_at P,A A P, A P, A 
5A1 220984_s_at A A A A 
6A1 1552745_at A A A A 
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Table A2 DNA microarray data analysis for members of the SLC22 gene family. P 
= Present, A=Absent, M= Marginal, P, A=Borderline.  
 
 
GENE EST DLKP DLKP-A A549 A549-
Taxol 
SLC22      
A1 207201_s_at A A P, A P, A 
A2 207429_at A A A A 
A3 205421_at A A P P 
 242578_x_at P P P P 
A4 205896_at P,A P,A P P 
A5 205074_at P P P P 
A6 210343_s_at A A A A 
 216599_x_at A A A A 
A7 1555553_a_at A A A A 
 220554_at A A A P, A 
 221661_at A A A A 
 221662_s_at A A A A 
 231398_at A A A A 
A8 221298_s_at A A A A 
 231352_at A A A A 
A9 231625_at A A A A 
A11 220100_at A A A A 
A12 237799_at A A A A 
A13 207444_at A A A A 
A14 207408_at P,M P,A P, M P, A 
A15 228497_at A P A P 
A16 232232_s_at A A A A 
 232233_at A A A A 
A17 218675_at P,M P P, A A 
 221106_at A A A A 
A18 204981_at P P P P 
A1LS 206097_at A A P P, A 
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Table A3 DNA microarray data analysis for select members of the ABC gene 
family related to taxane resistance. P = Present, A=Absent, M= Marginal, P, 
A=Borderline.  
 
GENE EST DLKP DLKP-A A549 A549-
Taxol 
ABC      
B1 (P-gp) 209994_s_at A P A P 
 243951_at A P A P 
 209993_at A P P P 
C2 
(MRP2) 206155_at 
A A P P 
C10 
(MRP7) 
213485_s_at 
 
P P P P 
 215873_x_at P P P P 
G2(BCRP) 209735_at A P, A P P 
 
 
Table A4 DNA microarray data analysis for select members of the SLC gene 
family related to platinum drug resistance. P = Present, A=Absent, M= Marginal, P, 
A=Borderline.  
 
GENE EST DLKP DLKP-A A549 A549-
Taxol 
SLC      
7A1 (xCT) 207528_s_at M, A P P P 
 209921_at P P P P 
 217678_at P P P P 
31A1(CTR1) 236217_at P M, A P P 
 203971_at P P P P 
 235013_at P P P P 
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Table A5 IC50 values for docetaxel, paclitaxel, adriamycin, elacridar, verapamil and 
sulindac in NSCLC and human leukemic cell lines. + represents the number of 96-
well plate replicates carried out. Results were calculated using Calcusyn Software. 
 
 
Drug Cell line IC50 (µM) 
Docetaxel DLKP-TXT ++ 0.0097 +/- 0.0009 
 DLKP-A2B mdr 1C7 + 0.0002827 
 HL-60s +++ 0.0114 +/- 0.0021  
 HL-60ADR +++ 0.0046 +/- 0.0008  
Paclitaxel DLKP-TXT ++ 0.018 +/- 0.0006  
 HL-60s +++ 0.0059 +/- 0.0012 
 HL-60ADR+++ 0.0064 +/- 0.0032 
Adriamycin HL-60s +++ 0.1024 +/- 0.0056  
 HL-60ADR +++ 11.3 +/- 2.8  
Elacridar DLKP-A +++ 24.8 +/- 1.5  
 DLKP-TXT ++++ 54.9 +/- 11.03  
 DLKP-A2B mdr 1C7 + 16.3  
 A549 +++ 16.3 +/- 1.2  
Verapamil DLKP-A ++ 114.5 +/- 9.9  
 DLKP-TXT ++ 135.7 +/- 0.1  
Sulindac DLKP +++ 89.9  
 A549 +++ Non-toxic at 40  
 HL-60s +++ Non-toxic at 20  
 HL-60ADR +++ Non-toxic at 15 
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Table A6 EGFR levels in NSCLC cell lines. EGFR levels were quantified using two 
different ELISA kits, each utilising a different detection antibody that recognised an 
intracellular or extracellular epitope of EGFR. Values were determined in duplicate 
for each cell line +/- SD. DMS and taxane selected variants of DMS express no 
EGFR or in the case of DMS and DMS-Taxol, levels that are minute, approaching the 
limits of detection for these ELISAs. DLKP-Txt and DLKP-Mitox express extremely 
low levels of EGFR but more than the EGFR-negative DLKP parent cell line. 
SKMES-1 and its taxane selected variants express EGFR levels comparable to the 
A549 cell line (Figure 6.1.1.1) 
 
Cell line Extracellular  Intracellular 
DLKP-TXT 1.67 +/- 0.01 1.74 +/- 0.4 
DLKP-Mitox 2.8 +/- 0.003 2.78 +/- 0.04 
SKMES-1 25.7 +/- 0.96 32.31 +/- 0.89 
SK-Taxotere 19.16 +/- 2.27 27.24 +/- 0.5 
SK-Taxol 30.1 +/- 0.29 37.44 +/- 0.09 
DMS 0.42 +/- 0.024 0 
DMS-Taxotere 0 0 
DMS-Taxol 0.32 +/- 0.36 0 
 
 
 
Table A7 Her-2 levels in NSCLC cell lines. Values were determined in duplicate for 
each cell line +/- SD. All cell lines express extremely low levels of Her-2. The levels 
of Her-2 in the DLKP variants are consistent with the parent cell line (Figure 6.1.1.1).  
 
Cell line Her-2 (pg/µg total 
protein) 
DLKP-TXT 1.12 +/- 0.01 
DLKP-Mitox 0.83 +/- 0.03 
SKMES-1 0.21 +/- 0.0076 
SK-Taxotere 0.2 +/- 0.02 
SK-Taxol 0.22 +/- 0.004 
DMS 0.12 +/- 0.015 
DMS-Taxotere 0.11 +/- 0.015 
DMS-Taxol 0.11 +/- 0.0 
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Appendix B 
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Appendix B (CD) contains additional LSCM images and 3-dimensional animations of 
epirubicin and Oregon-green paclitaxel localisation in NSCLC cell lines.  
 
Epirubicin LSCM studies 
 
1) Appendix B\Epirubicin\A549\A54910microMepirubicinANM.avi 
A549 cells were exposed to 10 µM epirubicin for 120 minutes and imaged as in Section 
2.11. A Z-stack comprising of single scans taken at 0.24 µm was compiled and turned 
into a 3-D animation. Cytoplasmic vesicles containing epirubicin were clearly visible. 
2) Appendix B\Epirubicin\A549\A54910microMepirubicin OP.avi 
The Z-stack comprising of single scans taken at 0.24 µm in 1) was shown in orthographic 
projection. Cytoplasmic vesicles containing epirubicin were clearly visible. 
3) Appendix B\Epirubicin\DLKP\DLKP10microMepirubicinANM.avi 
DLKP cells were exposed to 10 µM epirubicin for 120 minutes and imaged as in Section 
2.11. A Z-stack comprising of single scans taken at 0.24 µm was compiled and turned 
into a 3-D animation. Cytoplasmic vesicles containing epirubicin were NOT visible 
(discussed in Section 8.2.2). 
4) Appendix B\Epirubicin\DLKP-A\DLKPA 2microM epirubicin Control .tif 
DLKP-A cells were exposed to 2 µM epirubicin for 120 minutes and imaged as in 
Section 2.11. A single scan was obtained. There was little cytoplasmic or nuclear 
localisation of epirubicin. 
5) Appendix B\Epirubicin\DLKP-A\DLKPA 2microM epirubicin 10 microM 
Cyclosporin A Zm.tif 
DLKP-A cells were exposed to 2 µM epirubicin and 10 µM cyclosporin A for 120 
minutes and imaged as in Section 2.11. A single scan was obtained. Cytoplasmic and 
nuclear localisation of epirubicin was increased. Cytoplasmic vesicles containing 
epirubicin were clearly visible (discussed in Section 8.2.2). 
6) Appendix B\Epirubicin\DLKP-A\DLKPA 2microM epirubicin 100 microM 
Verapamil Zm.tif 
DLKP-A cells were exposed to 2 µM epirubicin and 100 µM verapamil for 120 minutes 
and imaged as in Section 2.11. A single scan was obtained. Cytoplasmic and nuclear 
localisation of epirubicin was increased. Cytoplasmic vesicles containing epirubicin were 
clearly visible (discussed in Section 8.2.2). 
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Oregon-green paclitaxel LSCM studies 
 
7) Appendix B\Oregon green paclitaxel\DLKP\DLKP 90 min exposure to 1 microM 
Oregon green paclitaxel 3D ANM.avi 
DLKP cells were exposed to 1 µM Oregon-green paclitaxel for 90 minutes and imaged as 
in Section 2.11. A Z-stack comprising of single scans taken at 0.24 µm was compiled and 
turned into a 3-D animation. 
8) Appendix B\Oregon green paclitaxel\DLKP\DLKP 90 min exposure to 1 microM 
Oregon green paclitaxel OP.avi 
The Z-stack comprising of single scans taken at 0.24 µm in 7) was shown in orthographic 
projection.  
9) Appendix B\Oregon green paclitaxel\DLKP\ DLKP 180 min exposure to 1 
microM Oregon green paclitaxel 3D ANM.avi 
DLKP cells were exposed to 1 µM Oregon-green paclitaxel for 180 minutes and imaged 
as in Section 2.11. A Z-stack comprising of single scans taken at 0.24 µm was compiled 
and turned into a 3-D animation. This is a 3-D animation of Figure 4.1.5 in Section 4.1. 
10) Appendix B\Oregon green paclitaxel\DLKP\ DLKP 180 min exposure to 1 
microM Oregon green paclitaxel CS ANM.avi 
The single scans taken at 0.24 µm intervals comprising the Z-stack in 9) were shown in 
sequence as an animation. This is an animation of Figure 4.1.5 in Section 4.1. 
 
 
 332
Abbreviations 
 
5-Fu   5-Fluorouracil 
ABC   ATP-binding Cassette 
ADP   Adenosine Diphosphate 
ADR   Adriamycin 
ATCC   American Tissue Culture Collection 
ATP   Adenosine Triphosphate 
BCA  ` Bicinchoninic Acid 
BCRP   Breast Cancer Resistance Protein 
BSA   Bovine Serum Albumin 
BSP   Bromosulfophthalein 
cDNA   Complementary DNA 
C.P.M.   Counts Per Minute 
CYP   Cytochrome P450 
DHEAS  Dehydroepiandosterone 
DMEM   Dulbecco’s Minimum Essential Medium 
DMSO   Dimethyl Sulfoxide 
DNA    Deoxyribonucleic Acid 
DOX   Doxorubicin (adriamycin) 
DTT   Dithiothreitol 
E17BG   Estradiol 17-ß-D-Glucuronide 
ECACC  European Collection of Animal Cell Culture 
EDTA   Ethylene diamine tetracetic acid 
ELISA   Enzyme-linked Immunosorbant Assay 
ERK   Extracellular signal-Regulated Kinase 
FCS   Fetal Calf Serum 
GSH   Glutathione 
HCL   Hydrochloric Acid 
HEPES   4-(2-hydroxyethyl)-piperazine ethane sulphonic acid 
HPLC   High Performance Liquid Chromatography 
IC50   Inhibitory Concentration 50% 
ICG   Indocyanine Green 
IgG   Immunoglobulin 
IMS   Industrial Methylated Spirits 
JNK   Jun N-terminal Kinase 
kDa   Kilo Daltons 
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MAPK   Mitogen Activated Protein Kinase 
MDR   Multi-Drug Resistance 
MEM   Minimum Essential Medium 
MgCl2   Magnesium Chloride 
Mitox   Mitoxantrone 
MRP   Multidrug Resistance-associated Protein 
mRNA   Messenger RNA 
MW   Molecular Weight 
NaCl   Sodium Chloride 
NaHCO3  Sodium Bicarbonate 
NaOH   Sodium Hydroxide 
NEAA   Non-Essential Amino Acids 
NSAID   Nonsteroidal anti-inflammatory drug 
NSCLC Non-small cell lung cancer 
OATP Organic Anion Transporting Peptide 
OD   Optical Density 
P450   Cytochrome P450 
PAGE   Polyacrylamide Gel Eletrophoresis 
PBS   Phosphate Buffered Saline 
PCR   Polymerase Chain Reaction 
P-gp   P-glycoprotein 
Pi   Inorganic Phosphate 
PMSF   Phenylmethanesulphonyl Fluoride 
RNA   Ribonucleic Acid 
r.p.m.   Revolution(s) Per Minute 
RT-PCR  Reverse Transcriptase-PCR 
SCLC   Small cell lung cancer 
SD   Standard Deviation 
SDS   Sodium Dodecyl Sulphate 
SLC   Solute Carrier 
siRNA   Small interfering RNA 
T3   Tri-iodo-L-thyronine 
TBS   Tris Buffered Saline 
TEMED  N, N, N’, N’-Tetramethyl-Ethylenediamine 
THF   Tetrahydrofuran 
Tris   Tris(hydroxymethyl)aminomethane 
UHP   Ultra high purity water 
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